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e60PreambleThe medical profession should play a central role in
evaluating evidence related to drugs, devices, and pro-
cedures for detection, management, and prevention of
disease. When properly applied, expert analysis of avail-
able data on the beneﬁts and risks of these therapies and
procedures can improve the quality of care, optimize
patient outcomes, and favorably affect costs by focusing
resources on the most effective strategies. An organized
and directed approach to a thorough review of evidence
has resulted in the production of clinical practice guide-
lines that assist clinicians in selecting the best manage-
ment strategy for an individual patient. Moreover, clinical
practice guidelines can provide a foundation for other
applications, such as performance measures, appropriate
use criteria, and both quality improvement and clinical
decision support tools.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged
in the production of guidelines in the area of cardiovascular
disease since 1980. The ACC/AHA Task Force on
Practice Guidelines (Task Force) directs this effort by
developing, updating, and revising practice guidelines for
cardiovascular diseases and procedures.
Experts in the subject under consideration are selected
from both ACC and AHA to examine subject-speciﬁc
data and write guidelines. Writing committees are specif-
ically charged with performing a literature review; weighing
the strength of evidence for or against particular tests,
treatments, or procedures; and including estimates of ex-
pected health outcomes where such data exist. Patient-
speciﬁc modiﬁers, comorbidities, and issues of patient
preference that may inﬂuence the choice of tests or ther-
apies are considered, as well as frequency of follow-up
and cost effectiveness. When available, information from
studies on cost is considered; however, a review of data on
efﬁcacy and outcomes constitutes the primary basis for
preparing recommendations in this guideline.
In analyzing the data and developing recommendations
and supporting text, the writing committee uses evidence-
based methodologies developed by the Task Force (1).
The Class of Recommendation (COR) is an estimate of
the size of the treatment effect, with consideration given
to risks versus beneﬁts, as well as evidence and/or agree-
ment that a given treatment or procedure is or is
not useful/effective or in some situations may cause harm.
The Level of Evidence (LOE) is an estimate of the cer-
tainty or precision of the treatment effect. The writing
committee reviews and ranks evidence supporting each
recommendation, with the weight of evidence ranked
as LOE A, B, or C, according to speciﬁc deﬁnitions.
The schema for the COR and LOE is summarized
in Table 1, which also provides suggested phrases for
writing recommendations within each COR. Studies are
identiﬁed as observational, retrospective, prospective, orrandomized, as appropriate. For certain conditions for
which inadequate data are available, recommendations are
based on expert consensus and clinical experience and are
ranked as LOE C. When recommendations at LOE C
are supported by historical clinical data, appropriate ref-
erences (including clinical reviews) are cited if available.
For issues with sparse available data, a survey of current
practice among the clinician members of the writing
committee is the basis for LOE C recommendations and
no references are cited.
A new addition to this methodology is separation of
the Class III recommendations to delineate whether the
recommendation is determined to be of “no beneﬁt” or is
associated with “harm” to the patient. In addition, in view
of the increasing number of comparative effectiveness
studies, comparator verbs and suggested phrases for writing
recommendations for the comparative effectiveness of one
treatment or strategy versus another are included for COR
I and IIa, LOE A or B only.
In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
(GDMT) to represent optimal medical therapy as deﬁned
by ACC/AHA guideline (primarily Class I)-recommended
therapies. This new term, GDMT, is used herein and
throughout subsequent guidelines.
Because the ACC/AHA practice guidelines address
patient populations (and clinicians) residing in North
America, drugs that are not currently available in North
America are discussed in the text without a speciﬁc COR.
For studies performed in large numbers of subjects outside
North America, each writing committee reviews the po-
tential impact of different practice patterns and patient
populations on the treatment effect and relevance to the
ACC/AHA target population to determine whether the
ﬁndings should inform a speciﬁc recommendation.
The ACC/AHA practice guidelines are intended to
assist clinicians in clinical decision making by describing
a range of generally acceptable approaches to the diag-
nosis, management, and prevention of speciﬁc diseases
or conditions. The guidelines attempt to deﬁne practices
that meet the needs of most patients in most circum-
stances. The ultimate judgment about care of a particular
patient must be made by the clinician and patient in
light of all the circumstances presented by that patient.
As a result, situations may arise in which deviations
from these guidelines may be appropriate. Clinical de-
cision making should involve consideration of the quality
and availability of expertise in the area where care is
provided. When these guidelines are used as the basis
for regulatory or payer decisions, the goal should be
improvement in quality of care. The Task Force recog-
nizes that situations arise in which additional data are
needed to inform patient care more effectively; these
areas are identiﬁed within each respective guideline
when appropriate.
Table 1. Applying Classiﬁcation of Recommendations and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial infarction, history of
heart failure, and prior aspirin use.
yFor comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments
or strategies being evaluated.
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e61Prescribed courses of treatment in accordance with these
recommendations are effective only if followed. Because
lack of patient understanding and adherence may adversely
affect outcomes, clinicians should make every effort to
engage the patient’s active participation in prescribed
medical regimens and lifestyles. In addition, patients
should be informed of the risks, beneﬁts, and alternatives
to a particular treatment and should be involved in shared
decision making whenever feasible, particularly for COR
IIa and IIb, for which the beneﬁt-to-risk ratio may be lower.
The Task Force makes every effort to avoid actual, po-
tential, or perceived conﬂicts of interest that may arise as a
result of relationships with industry and other entities
(RWI) among the members of the writing committee. Allwriting committee members and peer reviewers of the
guideline are required to disclose all current healthcare-
related relationships, including those existing 12 months
before initiation of the writing effort.
In December 2009, the ACC and AHA implemented
a new RWI policy that requires the writing committee
chair plus a minimum of 50% of the writing committee to
have no relevant RWI (Appendix 1 includes the ACC/
AHA deﬁnition of relevance). The Task Force and all
writing committee members review their respective RWI
disclosures during each conference call and/or meeting of
the writing committee, and members provide updates to
their RWI as changes occur. All guideline recommenda-
tions require a conﬁdential vote by the writing committee
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e62and require approval by a consensus of the voting mem-
bers. Authors’ and peer reviewers’ RWI pertinent to this
guideline are disclosed in Appendixes 1 and 2. Members
may not draft or vote on any recommendations pertaining
to their RWI. Members who recused themselves from
voting are indicated in the list of writing committee
members with speciﬁc section recusals noted in Appendix 1.
In addition, to ensure complete transparency, writing
committee members’ comprehensive disclosure informa-
tiondincluding RWI not pertinent to this documentdis
available as an online supplement.
Comprehensive disclosure information for the Task
Force is also available online at http://www.cardiosource.org/
en/ACC/About-ACC/Who-We-Are/Leadership/Guidelines
-and-Documents-Task-Forces.aspx. The ACC and AHA
exclusively sponsor the work of the writing committee with-
out commercial support. Writing committee members vol-
unteered their time for this activity. Guidelines are ofﬁcial
policy of both the ACC and AHA.
In an effort to maintain relevance at the point of care for
clinicians, the Task Force continues to oversee an ongoing
process improvement initiative. As a result, several changes
to these guidelines will be apparent, including limited
narrative text, a focus on summary and evidence tables
(with references linked to abstracts in PubMed), and more
liberal use of summary recommendation tables (with ref-
erences that support LOE) to serve as a quick reference.
In April 2011, the Institute of Medicine released 2 re-
ports: Finding What Works in Health Care: Standards for
Systematic Reviews and Clinical Practice Guidelines We Can
Trust (2,3). It is noteworthy that the Institute of Medicine
cited ACC/AHA practice guidelines as being compliant
with many of the proposed standards. A thorough review
of these reports and of our current methodology is under
way, with further enhancements anticipated.
The recommendations in this guideline are considered
current until they are superseded by a focused update,
the full-text guideline is revised, or until a published
addendum declares it out of date and no longer ofﬁcial
ACC/AHA policy.Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines1. Introduction
1.1. Methodology and Evidence Review
The recommendations listed in this document are,
whenever possible, evidence based. An extensive review
was conducted on literature published through November
2012, and other selected references through October
2013 were reviewed by the guideline writing committee.
Searches were extended to studies, reviews, and other ev-
idence conducted on human subjects and that were pub-
lished in English from PubMed, EMBASE, Cochrane,
Agency for Healthcare Research and Quality Reports, andother selected databases relevant to this guideline. Key
search words included but were not limited to the
following: valvular heart disease, aortic stenosis, aortic
regurgitation, bicuspid aortic valve, mitral stenosis, mitral
regurgitation, tricuspid stenosis, tricuspid regurgitation, pul-
monic stenosis, pulmonic regurgitation, prosthetic valves,
anticoagulation therapy, infective endocarditis, cardiac surgery,
and transcatheter aortic valve replacement. Additionally, the
committee reviewed documents related to the subject
matter previously published by the ACC and AHA. The
references selected and published in this document are
representative and not all-inclusive.
1.2. Organization of the Writing Committee
The committee was composed of clinicians, who included
cardiologists, interventionalists, surgeons, and anesthesi-
ologists. The committee also included representatives from
the American Association for Thoracic Surgery, American
Society of Echocardiography (ASE), Society for Cardio-
vascular Angiography and Interventions, Society of Car-
diovascular Anesthesiologists, and Society of Thoracic
Surgeons (STS).
1.3. Document Review and Approval
This document was reviewed by 2 ofﬁcial reviewers each
nominated by both the ACC and the AHA, as well as 1
reviewer each from the American Association for Thoracic
Surgery, ASE, Society for Cardiovascular Angiography
and Interventions, Society of Cardiovascular Anesthesiol-
ogists, and STS and 39 individual content reviewers
(which included representatives from the following ACC
committees and councils: Adult Congenital and Pediatric
Cardiology Section, Association of International Gover-
nors, Council on Clinical Practice, Cardiovascular Section
Leadership Council, Geriatric Cardiology Section Lead-
ership Council, Heart Failure and Transplant Council,
Interventional Council, Lifelong Learning Oversight
Committee, Prevention of Cardiovascular Disease Com-
mittee, and Surgeon Council). Reviewers’ RWI informa-
tion was distributed to the writing committee and is
published in this document (Appendix 2).
This document was approved for publication by the
governing bodies of the ACC and AHA and endorsed by
the American Association for Thoracic Surgery, ASE,
Society for Cardiovascular Angiography and Interventions,
Society of Cardiovascular Anesthesiologists, and STS.
1.4. Scope of the Guideline
The focus of this guideline is the diagnosis and manage-
ment of adult patients with valvular heart disease (VHD).
A full revision of the original 1998 VHD guideline was
made in 2006, and an update was made in 2008 (4). Some
recommendations from the earlier VHD guidelines have
been updated as warranted by new evidence or a better
understanding of earlier evidence, whereas others that
were inaccurate, irrelevant, or overlapping were deleted
Table 2. Associated Guidelines and Statements
Title Organization
Publication Year/
Reference
Recommendations for Evaluation of the
Severity of Native Valvular Regurgitation
With Two-Dimensional and Doppler
Echocardiography
ASE 2003 (5)
Guidelines for the Management of
Adults With Congenital Heart Disease
ACC/AHA 2008 (7)
Echocardiographic Assessment of Valve
Stenosis: EAE/ASE Recommendations
for Clinical Practice
EAE/ASE 2009 (8)
Recommendations for Evaluation of
Prosthetic Valves With Echocardiography
and Doppler Ultrasound
ASE 2009 (9)
Guideline for the Diagnosis and Treatment
of Hypertrophic Cardiomyopathy
ACCF/AHA 2011 (10)
Guidelines on the Management of
Cardiovascular Diseases During
Pregnancy
ESC 2011 (11)
Antithrombotic and Thrombolytic Therapy
for Valvular Disease: Antithrombotic
Therapy and Prevention of Thrombosis
ACCP 2012 (12)
Guidelines on the Management of Valvular
Heart Disease
ESC/EACTS 2012 (13)
Guideline for the Management of
Heart Failure
ACCF/AHA 2013 (14)
Guideline for the Management of
Patients With Atrial Fibrillation
AHA/ACC/HRS 2014 (15)
ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foun-
dation; ACCP, American College of Chest Physicians; AF, atrial ﬁbrillation; AHA, American
Heart Association; ASE, American Society of Echocardiography; EACTS, European Association
for Cardio-Thoracic Surgery; EAE, European Association of Echocardiography; ESC, European
Society of Cardiology; and VHD, valvular heart disease.
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e63or modiﬁed. Throughout, our goal was to provide the
clinician with concise, evidence-based, contemporary rec-
ommendations and the supporting documentation to
encourage their use.
This guideline was created in a different format from
prior VHD guidelines to facilitate access to concise, rele-
vant bytes of information at the point of care when clinical
knowledge is needed the most. Thus, each COR is fol-
lowed by a brief paragraph of supporting text and refer-
ences. Where applicable, sections were divided into
subsections of 1) diagnosis and follow-up, 2) medical
therapy, and 3) intervention. The purpose of these sub-
sections was to categorize the COR according to the
clinical decision-making pathways that caregivers use in
the management of patients with VHD. New recom-
mendations for assessment of the severity of valve lesions
have been proposed, based on current natural history
studies of patients with VHD.
The present document applies to adult patients with
VHD. Management of patients with congenital heart
disease and infants and children with valve disease are not
addressed here. The document recommends a combination
of lifestyle modiﬁcations and medications that constitute
GDMT. Both for GDMT and other recommended drug
treatment regimens, the reader is advised to conﬁrm dos-
ages with product insert material and to carefully evaluate
for contraindications and drug–drug interactions. Table 2
is a list of associated guidelines that may be of interest
to the reader. The table is intended for use as a resource
and obviates the need to repeat extant guideline
recommendations.
2. General Principles
2.1. Evaluation of the Patient With
Suspected VHD
Patients with VHD may present with a heart murmur,
symptoms, or incidental ﬁndings of valvular abnormalities
on chest imaging or noninvasive testing. Irrespective of the
presentation, all patients with known or suspected VHD
should undergo an initial meticulous history and physical
examination. A careful history is of great importance in the
evaluation of patients with VHD, because decisions about
treatment are based on the presence or absence of symp-
toms. Due to the slow, progressive nature of many valve
lesions, patients may not recognize symptoms because they
may have gradually limited their daily activity levels. A
detailed physical examination should be performed to di-
agnose and assess the severity of valve lesions based on a
compilation of all ﬁndings made by inspection, palpation,
and auscultation. The use of an electrocardiogram (ECG)
to conﬁrm heart rhythm and use of a chest x-ray to assess
the presence or absence of pulmonary congestion and
other lung pathology may be helpful in the initial assess-
ment of patients with known or suspected VHD. Acomprehensive transthoracic echocardiogram (TTE) with
2–dimensional (2D) imaging and Doppler interrogation
should then be performed to correlate ﬁndings with initial
impressions based on the initial clinical evaluation. The
TTE will also be able to provide additional information,
such as the effect of the valve lesion on the cardiac
chambers and great vessels, and to assess for other
concomitant valve lesions. Other ancillary testing such as
transesophageal echocardiography (TEE), computed to-
mography (CT) or cardiac magnetic resonance (CMR)
imaging, stress testing, and diagnostic hemodynamic car-
diac catheterization may be required to determine the
optimal treatment for a patient with VHD. An evaluation
of the possible surgical risk for each individual patient
should be performed if intervention is contemplated, as
well as other contributing factors such as the presence and
extent of comorbidities and frailty. Follow-up of these
patients is important and should consist of an annual
history and physical examination in most stable patients.
An evaluation of the patient may be necessary sooner than
annually if there is a change in the patient’s symptoms. In
some valve lesions, there may be unpredictable adverse
consequences on the left ventricle in the absence of
symptoms necessitating more frequent follow-up. The
frequency of repeat testing, such as echocardiography, will
Table 3. Stages of Progression of VHD
Stage Deﬁnition Description
A At risk Patients with risk factors for development
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effect on the left or right ventricle, coupled with the
known natural history of the valve lesion.of VHD
B Progressive Patients with progressive VHD (mild-to-moderate
severity and asymptomatic)
C Asymptomatic
severe
Asymptomatic patients who have the criteria for
severe VHD:
C1: Asymptomatic patients with severe VHD
in whom the left or right ventricle remains
compensated
C2: Asymptomatic patients with severe VHD
with decompensation of the left or right
ventricle
D Symptomatic severe Patients who have developed symptoms as a
result of VHD
VHD indicates valvular heart disease.2.2. Deﬁnitions of Severity of Valve Disease
Classiﬁcation of the severity of valve lesions should be
based on multiple criteria, including the initial ﬁndings on
the physical examination, which should then be correlated
with data from a comprehensive TTE. Intervention should
primarily be performed on patients with severe VHD in
addition to other criteria outlined in this document.
This document provides a classiﬁcation of the progres-
sion of VHD with 4 stages (A to D) similar to that pro-
posed by the “2013 ACCF/AHA Guideline for the
Management of Heart Failure.” Indication for intervention
in patients with VHD is dependent on 1) the presence or
absence of symptoms; 2) the severity of VHD; 3) the
response of the left and/or right ventricle to the volume or
pressure overload caused by VHD; 4) the effect on the
pulmonary or systemic circulation; and 5) a change in heart
rhythm. The stages take into consideration all of these
important factors (Table 3). The criteria for the stages
of each individual valve lesion are listed in Section 3
(Table 8), Section 4.2 (Table 11), Section 6.1 (Table 13),
Section 7.2 (Tables 15 and 16), and Section 8.1 (Table 19),
Section 8.3 (Table 20), Section 9.1 (Table 21), and Section 9.2
(Table 22).
The purpose of valvular intervention is to improve
symptoms and/or prolong survival, as well as to minimize
the risk of VHD-related complications such as asymp-
tomatic irreversible ventricular dysfunction, pulmonary
hypertension, stroke, and atrial ﬁbrillation (AF). Thus, the
criteria for “severe” VHD are based on studies describing
the natural history of patients with unoperated VHD, as
well as observational studies relating the onset of symptoms
to measurements of severity. In patients with stenotic le-
sions, there is an additional category of “very severe” ste-
nosis based on studies of the natural history showing that
prognosis becomes poorer as the severity of stenosis
increases.
Supporting References: (14).2.3. Diagnosis and Follow-Up
Diagnostic testing is very important for the diagnosis and
treatment of patients with VHD. TTE provides
morphological and hemodynamic information for diag-
nosis and quantitation of VHD, as well as for determining
optimal timing for intervention. In selected patients,
additional testing such as stress testing, TEE, cardiac
catheterization, and CT or CMR imaging might be
indicated. However, both the performance and interpre-
tation of these diagnostic tests require meticulous attention
to detail as well as expertise in cardiac imaging and eval-
uation of hemodynamics.2.3.1. Diagnostic Testing–Initial Diagnosis:
Recommendation
CLASS I
1. TTE is recommended in the initial evaluation of patients with
known or suspected VHD to conﬁrm the diagnosis, establish
etiology, determine severity, assess hemodynamic conse-
quences, determine prognosis, and evaluate for timing of
intervention (17–32). (Level of Evidence: B)
TTE is now the standard diagnostic test in the initial
evaluation of patients with known or suspected VHD.
Echocardiographic imaging can accurately assess the
morphology and motion of valves and can usually deter-
mine the etiology of the VHD. TTE can also assess for
concomitant disease in other valves and associated abnor-
malities such as aortic dilation. Left ventricular (LV)
chamber size and function can be reliably assessed. It is the
LV linear dimensions from echocardiography, either from
2D images or 2D-directed M-mode, that have been used
in studies to determine timing of valve operation. Until
further studies are available using LV volumes, the rec-
ommendations in this guideline will refer to LV di-
mensions. It is also important to understand the variability
in measurements of LV dimensions so that decisions on
intervention are based on sequential studies rather than a
single study, especially in asymptomatic patients. A semi-
quantitative assessment of right ventricular (RV) size and
function is usually made by a visual subjective analysis.
Doppler TTE is used for noninvasive determination of
valve hemodynamics. In stenotic lesions, measurements of
the peak velocity, as well as calculation of valve gradients
and valve area, characterize the severity of the lesion. He-
modynamic measurements can be performed at rest and
during provocation. The quantitation of the severity of
valve regurgitation is based on multiple hemodynamic
parameters using color Doppler imaging of jet geometry,
continuous wave Doppler recordings of the regurgitant
ﬂow, and pulsed wave Doppler measures of transvalvular
volume ﬂow rates and ﬂow reversals in the atria and great
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pulmonary circulation can be determined using tricuspid
regurgitation (TR) velocity to provide a noninvasive mea-
surement of RV systolic pressure. TTE quantitation of
valve stenosis and valve regurgitation has been validated
against catheterization data, in animal models with direct
measures of disease severity, and in prospective clinical
studies using valve replacement and mortality as the pri-
mary endpoint. On the basis of their value in predicting
clinical outcomes, these echocardiographic parameters are
now used to determine timing of valve intervention in
conjunction with symptom status.
Supporting References: (17–32)
2.3.2. DiagnosticTestingdChangingSignsorSymptoms:
Recommendation
CLASS I
1. TTE is recommended in patients with known VHD with any
change in symptoms or physical examination ﬁndings. (Level of
Evidence: C)
Patients with VHD should be instructed to always
report any change in symptomatic status. Patients with
known VHD who have a change in symptoms should
undergo a repeat comprehensive TTE study to determine
whether the etiology of the symptoms is due to a pro-
gression in the valve lesion, deterioration of the ventricular
response to the volume or pressure overload, or another
etiology. New signs on physical examination also warrant a
repeat TTE. The ﬁndings on TTE will be important in
determining the timing of intervention.
Supporting References: (33–40)
2.3.3. Diagnostic TestingdRoutine Follow-Up:
Recommendation
CLASS I
1. Periodic monitoring with TTE is recommended in asymptom-
atic patients with known VHD at intervals depending on valve
lesion, severity, ventricular size, and ventricular function.
(Level of Evidence: C)
After initial evaluation of an asymptomatic patient with
VHD, the clinician may decide to continue close follow-
up. The purpose of close follow-up is to prevent the irre-
versible consequences of severe VHD that primarily affect
the status of the ventricles and pulmonary circulation and
may also occur in the absence of symptoms. At a mini-
mum, the follow-up should consist of a yearly history
and physical examination. Periodic TTE monitoring also
provides important prognostic information. The frequency
of a repeat 2D and Doppler echocardiogram is based on
the type and severity of the valve lesion, the known rate
of progression of the speciﬁc valve lesion, and the effect of
the valve lesion on the affected ventricle (Table 4). This
table does not refer to patients with stage D VHD, who
will usually undergo intervention, as will other select
patient populations with stage C VHD.
Supporting References: (22,29,32–35,37–41)2.3.4. Diagnostic TestingdCardiac Catheterization:
Recommendation
CLASS I
1. Cardiac catheterization for hemodynamic assessment is rec-
ommended in symptomatic patients when noninvasive tests are
inconclusive or when there is a discrepancy between the ﬁnd-
ings on noninvasive testing and physical examination regarding
severity of the valve lesion. (Level of Evidence: C)
Although TTE (and in some instances TEE) is now
able to provide the required anatomic and hemodynamic
information in most patients with VHD, there is still a
subset of patients in whom hemodynamic catheterization is
necessary to ensure that the proper decision about treat-
ment is made. TTE may provide erroneous or inadequate
information in some patients. Severity of stenosis may be
underestimated when imaging is difﬁcult or when the
Doppler beam is not directed parallel to the valvular jet
velocities. TTE quantitation of valve regurgitation shows
considerable variability in measurement, and severity of
disease may be overestimated or underestimated if image or
Doppler data quality is suboptimal. If there are inconclu-
sive, noninvasive data, particularly in the symptomatic
patient, or if there is a discrepancy between the noninvasive
tests and clinical ﬁndings, a hemodynamic cardiac cathe-
terization is indicated. The measurements of valve gradients
and cardiac output are important for assessing valve stenosis.
Contrast angiography is still useful for a semiquantitative
assessment of the severity of regurgitation in those instances
in which the noninvasive results are discordant with the
physical examination. A major advantage of cardiac cathe-
terization is the measurement of intracardiac pressures and
pulmonary vascular resistance, which may further aid in
decision making about valve intervention. Diagnostic in-
terventions that can be performed in the catheterization
laboratory include the use of dobutamine in low-ﬂow states,
pulmonary vasodilators in pulmonary hypertension, and
exercise hemodynamics in patients with discrepant symp-
toms. It must be emphasized that there is no longer a
“routine” cardiac catheterization. Patients who come to the
catheterization laboratory present complex diagnostic
challenges because the noninvasive testing in these patients
has not provided all pertinent information. Thus, hemo-
dynamic catheterization needs to be done with meticulous
attention to detail and performed by persons with knowl-
edge and expertise in assessing patients with VHD.
Supporting References: (42,43)
2.3.5. Diagnostic TestingdExercise Testing:
Recommendation
CLASS IIa
1. Exercise testing is reasonable in selected patients with
asymptomatic severe VHD to 1) conﬁrm the absence of symp-
toms, or 2) assess the hemodynamic response to exercise, or
3) determine prognosis (44–48). (Level of Evidence: B)
In a subset of patients, exercise stress testing will be of
additional value in determining optimal therapy. Because
Table 4. Frequency of Echocardiograms in Asymptomatic Patients With VHD and Normal Left Ventricular Function
Stage Valve Lesion
Stage Aortic Stenosis* Aortic Regurgitation Mitral Stenosis Mitral Regurgitation
Progressive
(stage B)
Every 3–5 y
(mild severity Vmax 2.0–2.9 m/s)
Every 3–5 y (mild severity)
Every 1–2 y (moderate severity)
Every 3–5 y
(MVA >1.5 cm2)
Every 3–5 y (mild severity)
Every 1–2 y (moderate severity)
Every 1–2 y
(moderate severity Vmax 3.0–3.9 m/s)
Severe
(stage C)
Every 6–12 mo
(Vmax 4 m/s)
Every 6–12 mo
Dilating LV: more frequently
Every 1–2 y
(MVA 1.0–1.5 cm2)
Once every year
(MVA <1.0 cm2)
Every 6–12 mo
Dilating LV: more frequently
Patients with mixed valve disease may require serial evaluations at intervals earlier than recommended for single valve lesions.
*With normal stroke volume.
LV indicates left ventricle; MVA, mitral valve area; VHD, valvular heart disease; and Vmax, maximum velocity.
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valve lesions, patients may deny symptoms as they grad-
ually limit their activity level over years to match the
gradual limitation imposed by the valve lesion. In pa-
tients with an equivocal history of symptoms, exercise
testing helps identify those who are truly symptomatic.
There may be patients in whom resting hemodynamics
do not correlate with symptoms. In these patients, exer-
cise hemodynamics may be helpful in determining the
etiology of the symptoms, speciﬁcally in patients with
mitral VHD. Exercise stress testing is of prognostic value
in patients with asymptomatic severe aortic stenosis
(AS) and provides further information about timing of
intervention. Exercise testing in patients with severe
VHD should always be performed by trained operators
with continuous monitoring of the ECG and blood
pressure (BP).
Supporting References: (44–48)
2.4. Basic Principles of Medical Therapy
All patients being evaluated for VHD should also undergo
GDMT for other risk factors associated with cardiac dis-
ease. These include hypertension, diabetes mellitus, and
hyperlipidemia. The safety and efﬁcacy of an exercise
program for patients with VHD has not been established,
but patients will beneﬁt from an exercise prescription in
which a regular aerobic exercise program is followed to
ensure cardiovascular ﬁtness. Although heavy isometric
repetitive training will increase the afterload on the LV,
resistive training with small free weights or repetitive iso-
lated muscle training may be used to strengthen individual
muscle groups.
Most patients with LV systolic dysfunction and severe
VHD should undergo intervention for the valve itself.
However, if the decision has been made for medical
therapy, these patients should receive the GDMT drug
therapy for LV systolic dysfunction, including angiotensin-
converting enzyme (ACE) inhibitors or angiotensin-
receptor blockers (ARBs) and beta-adrenergic blockers.
Care must be taken to not abruptly lower BP in patients
with stenotic lesions.Rheumatic fever prophylaxis and infective endocarditis
(IE) prophylaxis should be given to appropriate groups
of patients as outlined in Sections 2.4.1 and 2.4.2.
The maintenance of optimal oral health remains the
most important component of an overall healthcare pro-
gram in preventing IE. Inﬂuenza and pneumococcal vac-
cinations should be given to appropriate patient groups
with VHD.
Supporting Reference: (49)
2.4.1. Secondary Prevention of Rheumatic Fever:
Recommendation
Rheumatic fever is an important cause of VHD. In the
United States, acute rheumatic fever has been uncommon
since the 1970s. However, there has been an increase in
the number of cases of rheumatic fever since 1987. Un-
derstanding of the causative organism, group A Strepto-
coccus, has been enhanced by the development of kits that
allow rapid detection of this organism. Prompt recognition
and treatment of streptococcal pharyngitis constitute pri-
mary prevention of rheumatic fever. For patients with
previous episodes of well-documented rheumatic fever or
in those with evidence of rheumatic heart disease, long-
term antistreptococcal prophylaxis is indicated for sec-
ondary prevention.
Supporting Reference: (50)
CLASS I
1. Secondary prevention of rheumatic fever is indicated in patients
with rheumatic heart disease, speciﬁcally mitral stenosis (MS)
(Tables 5 and 6) (50). (Level of Evidence: C)
Recurrent rheumatic fever is associated with a wors-
ening of rheumatic heart disease. However, infection
with group A Streptococcus does not have to be symp-
tomatic to trigger a recurrence, and rheumatic fever can
recur even when the symptomatic infection is treated.
Prevention of recurrent rheumatic fever requires long-
term antimicrobial prophylaxis rather than recognition
and treatment of acute episodes of group A Streptococcus
pharyngitis. The recommended treatment regimens and
duration of secondary prophylaxis are shown in Tables 5
and 6. In patients with documented VHD, the duration
Table 5. Secondary Prevention of Rheumatic Fever
Agent Dosage
Penicillin G benzathine 1.2 million units IM every 4 wk*
Penicillin V potassium 250 mg orally BID
Sulfadiazine 1 g orally once daily
Macrolide or azalide antibiotic (for patients
allergic to penicillin and sulfadiazine)y
Varies
*Administration every 3 wk is recommended in certain high-risk situations.
yMacrolide antibiotics should not be used in persons taking other medications that inhibit cy-
tochrome P450 3A, such as azole antifungal agents, HIV protease inhibitors, and some se-
lective serotonin reuptake inhibitors.
Adapted from Gerber et al. (50).
BID indicates twice daily; HIV, human immunodeﬁciency virus; and IM, intramuscularly.
Table 6. Duration of Secondary Prophylaxis for
Rheumatic Fever
Type Duration After Last Attack
Rheumatic fever with carditis
and residual heart disease
(persistent VHD*)
10 y or until patient is 40 y of age
(whichever is longer)
Rheumatic fever with carditis
but no residual heart disease
(no valvular disease*)
10 y or until patient is 21 y of age
(whichever is longer)
Rheumatic fever without carditis 5 y or until patient is 21 y of age
(whichever is longer)
*Clinical or echocardiographic evidence.
Adapted from Gerber et al. (50).
VHD indicates valvular heart disease.
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or until the patient is 40 years of age (whichever is
longer).
2.4.2. IE Prophylaxis: Recommendations
Because of the lack of published evidence on the use of
prophylactic antibiotics to prevent IE, the value of anti-
biotic prophylaxis has been questioned by several national
and international medical societies. Antibiotic prophylaxis
is now indicated for only a subset of patients who are at
high risk for developing IE and at highest risk for an
adverse outcome if IE occurs. The maintenance of optimal
oral health care remains the most effective intervention to
prevent future valve infection.
Supporting References: (51–53)
CLASS IIa
1. Prophylaxis against IE is reasonable for the following patients
at highest risk for adverse outcomes from IE before dental
procedures that involve manipulation of gingival tissue, manip-
ulation of the periapical region of teeth, or perforation of the oral
mucosa (54–56) (Level of Evidence: B):
 Patients with prosthetic cardiac valves;
 Patients with previous IE;
 Cardiac transplant recipients with valve regurgitation due to
a structurally abnormal valve; or
 Patients with congenital heart disease with:
B Unrepaired cyanotic congenital heart disease, including
palliative shunts and conduits;
B Completely repaired congenital heart defect repaired with
prosthetic material or device, whether placed by surgery
or catheter intervention, during the ﬁrst 6 months after
the procedure; or
B Repaired congenital heart disease with residual defects
at the site or adjacent to the site of a prosthetic patch or
prosthetic device.The risk of IE is signiﬁcantly higher in patients with a
history of prosthetic valve replacement. Even in those
patients at high risk for IE, the evidence for signiﬁcant
reduction in events with prophylaxis is conﬂicting. This
lack of supporting evidence along with the risk of
anaphylaxis and increasing bacterial resistance to anti-
microbials led to a signiﬁcant revision in the AHA rec-
ommendations for prophylaxis so that only those patients
at the highest risk of developing IE (e.g., those withprosthetic valves) should be treated. Furthermore, evi-
dence for prophylaxis has only been found to be
reasonable in dental procedures that involve manipula-
tion of gingival tissue, manipulation of the periapical
region of teeth, or perforation of the oral mucosa. In the
case of other prosthetic material (excluding surgically
created palliative systemic-pulmonary shunts or conduits)
such as annuloplasty rings, neochords, Amplatzer de-
vices, and MitraClips, there have been only sporadic case
reports of infected devices. Given the low infection rate
and scarcity of data, there is no deﬁnitive evidence that
prophylaxis in these patients is warranted in the absence
of the patient having other high risks of intracardiac
infection.
There are no randomized controlled trials (RCTs) or
large observational cohort studies for prophylaxis in pati-
ents with a previous episode of IE, but given the cumulative
risks of mortality with repeated infection, the potentially
disabling complications from repeated infections, and the
relatively low risk of prophylaxis, prophylaxis for IE has
been recommended in this high-risk group of patients. IE
is substantially more common in heart transplant recipi-
ents than in the general population. The risk of IE is
highest in the ﬁrst 6 months after transplantation due to
endothelium disruption, high-intensity immunosuppres-
sive therapy, frequent central venous catheter access, and
endomyocardial biopsies. If there is a structurally abnormal
valve, IE prophylaxis should be continued indeﬁnitely,
given the high risk of IE in post-transplant patients.
In patients in whom IE prophylaxis is reasonable, give
prophylaxis before dental procedures that involve manip-
ulation of gingival tissue or the periapical region of teeth
or cause perforation of the oral mucosa. Bacteremia com-
monly occurs during activities of daily living such as
routine brushing of the teeth or chewing. Persons at risk
for developing bacterial IE should establish and maintain
the best possible oral health to reduce potential sources of
bacterial seeding. Optimal oral health is maintained
through regular professional dental care and the use of
appropriate dental products, such as manual, powered, and
ultrasonic toothbrushes; dental ﬂoss; and other plaque-
removal devices. There is no evidence for IE prophylaxis
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absent known enterococcal infection.
Multiple epidemiological studies show no increase in
the rate of IE since adoption of the AHA and European
Society of Cardiology guidelines recommending more
restrictive use of IE prophylaxis. The NICE (National
Institute for Health and Clinical Excellence, United
Kingdom) guidelines took an even more radical departure
from the previous prophylaxis standards in not recom-
mending antibiotic prophylaxis for dental or nondental
procedures (e.g., respiratory, gastrointestinal, and genito-
urinary). Similarly, subsequent epidemiological studies
performed in the wake of the NICE guideline revisions
have demonstrated no increase in clinical cases or
deaths from IE. For the recommended choice of antibi-
otic regimen when IE prophylaxis is recommended, see
http://www.heart.org/idc/groups/heart-public/@wcm/@hcm/
documents/downloadable/ucm_307644.pdf.
Supporting References: (50–59)
CLASS III: No Beneﬁt
1. Prophylaxis against IE is not recommended in patients with
VHD who are at risk of IE for nondental procedures (e.g., TEE,
esophagogastroduodenoscopy, colonoscopy, or cystoscopy) in
the absence of active infection (60). (Level of Evidence: B)
The incidence of IE following most procedures in pa-
tients with underlying cardiac disease is low, and there is a
lack of controlled data supporting the beneﬁt of antibiotic
prophylaxis. Furthermore, the indiscriminate use of anti-
biotics can be associated with the development of resistant
organisms, Clostridium difﬁcile colitis, unnecessary expense,
and drug toxicity. The risk of IE as a direct result of a
ﬂexible endoscopic procedure is small. Transient bacter-
emia may occur during or immediately after endoscopy;
however, there are few reports of IE attributable to
endoscopy. For most gastrointestinal endoscopic pro-
cedures, the rate of bacteremia is 2% to 5%, and organisms
typically identiﬁed are unlikely to cause IE. The rate of
bacteremia does not increase with mucosal biopsy, poly-
pectomy, or sphincterotomy. There are no data to indicate
that deep biopsy, such as that performed in the rectum or
stomach, leads to a higher rate of bacteremia. The rate of
transient bacteremia is more commonly seen in routine
activities such as brushing teeth and ﬂossing (20% to 68%),
using toothpicks (20% to 40%), and simply chewing food
(7% to 51%). Some gastrointestinal procedures, such as
esophageal dilation (as high as 45%), sclerotherapy (31%),
and endoscopic retrograde cholangiopancreatography (6%
to 18%) have higher rates of bacteremia than simple
endoscopy. However, no studies indicate reduced rates of
IE with antibiotic prophylaxis.
Surgery, instrumentation, or diagnostic procedures
that involve the genitourinary tract may cause bacteremia.
The rate of bacteremia following urinary tract procedures
is high in the presence of urinary tract infection. Sterili-
zation of the urinary tract with antimicrobial therapy inpatients with bacteriuria should be attempted before elec-
tive procedures, including lithotripsy. Results of a pre-
procedure urine culture will allow the clinician to choose
antibiotics appropriate for the recovered organisms.
Supporting References: (61–73)
2.5. Evaluation of Surgical and
Interventional Risk
The decision to intervene, as well as the type of inter-
vention for a patient with severe VHD, should be based on
an individual risk–beneﬁt analysis. The risk of the proce-
dure and intermediate-term mortality must be weighed
against the beneﬁts of the procedure in altering the natural
history of the disease and acknowledging the long-term
consequences of the intervention. Operative mortality can
be estimated from a number of different scoring systems
by using a combination of risk factors such as the STS
risk estimate or Euroscore (http://www.euroscore.org/).
There are limitations to these scores, including that they
derive only from surgical patients and that they do not
take into consideration procedure-speciﬁc impediments,
major organ system compromise, comorbidities, or the
frailty of the patient. A risk-assessment scheme com-
bining these factors is presented in Table 7. The STS
risk estimate is an accepted tool to predict the risk of a
surgical operation. In an analysis of aortic valve operations
in the STS database from 2002 to 2010, 80% of patients
had a predicted risk of mortality (PROM) of <4% and an
actual mean mortality rate of 1.4%. Fourteen percent had
a PROM of 4% to 8% and an actual mean mortality rate
of 5.1%, and 6% of patients had a PROM of >8% and an
actual mortality rate of 11.1%. Other factors such as the
frailty of the patient, major organ system compromise,
and procedure-speciﬁc impediments must be taken into
consideration. A number of mechanisms to evaluate
frailty assess the ability to perform activities of daily living
(independence in feeding, bathing, dressing, transferring,
toileting, urinary continence, etc.) and measurements of
gait speed, grip strength, and muscle mass. Published
frailty scores are available, but a limited evaluation may
use the following: no frailty (able to perform all activities
of daily living and perform a 5–meter walk in <6 sec-
onds), mild degree of frailty (unable to perform 1 activity
of daily living or unable to perform a 5–meter walk in <6
seconds), and moderate-to-severe degree of frailty (unable
to perform 2 activities of daily living). Further research
is required to enhance the predictive accuracy of current
risk scores, particularly in patients undergoing trans-
catheter therapy. The overall risks versus beneﬁts should
then be discussed with the patient and family using a
shared decision-making process.
In addition to the risk classiﬁcation in Table 7, it is
appropriate to defer any type of intervention in patients
who will not beneﬁt in terms of symptoms or improved life
span from the procedure. This group of patients in whom
surgical or transcatheter intervention for severe VHD is
Table 7. Risk Assessment Combining STS Risk Estimate, Frailty, Major Organ System Dysfunction, and
Procedure-Speciﬁc Impediments
Low Risk
(Must Meet ALL Criteria
in This Column)
Intermediate Risk
(Any 1 Criterion
in This Column)
High Risk
(Any 1 Criterion
in This Column)
Prohibitive Risk
(Any 1 Criterion
in This Column)
STS PROM* <4%
AND
4%–8%
OR
>8%
OR
Predicted risk with surgery
of death or major morbidity
(all-cause) >50% at 1 y
OR
Frailtyy None
AND
1 Index (mild)
OR
2 Indices
(moderate to severe)
OR
Major organ system compromise
not to be improved postoperativelyz
None
AND
1 Organ system
OR
No more than 2 organ
systems
OR
3 Organ systems
OR
Procedure-speciﬁc
impedimentx
None Possible procedure-speciﬁc
impediment
Possible procedure-speciﬁc
impediment
Severe procedure-speciﬁc
impediment
*Use of the STS PROM to predict risk in a given institution with reasonable reliability is appropriate only if institutional outcomes are within 1 standard deviation of STS average observed/expected ratio
for the procedure in question.
ySeven frailty indices: Katz Activities of Daily Living (independence in feeding, bathing, dressing, transferring, toileting, and urinary continence) and independence in ambulation (no walking aid or assist
required or 5-meter walk in <6 s). Other scoring systems can be applied to calculate no, mild-, or moderate-to-severe frailty.
zExamples of major organ system compromise: Cardiacdsevere LV systolic or diastolic dysfunction or RV dysfunction, ﬁxed pulmonary hypertension; CKD stage 3 or worse; pulmonary dysfunction with
FEV1 <50% or DLCO2 <50% of predicted; CNS dysfunction (dementia, Alzheimer’s disease, Parkinson’s disease, CVA with persistent physical limitation); GI dysfunctiondCrohn’s disease, ulcerative
colitis, nutritional impairment, or serum albumin <3.0; cancerdactive malignancy; and liverdany history of cirrhosis, variceal bleeding, or elevated INR in the absence of VKA therapy.
xExamples: tracheostomy present, heavily calciﬁed ascending aorta, chest malformation, arterial coronary graft adherent to posterior chest wall, or radiation damage.
CKD indicates chronic kidney disease; CNS, central nervous system; CVA, stroke; DLCO2, diffusion capacity for carbon dioxide; FEV1, forced expiratory volume in 1 s; GI, gastrointestinal; INR,
international normalized ratio; LV, left ventricular; PROM, predicted risk of mortality; RV, right ventricular; STS, Society of Thoracic Surgeons; and VKA, vitamin K antagonist.
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with a successful procedure, and 2) those who have a
chance of “survival with beneﬁt” of <25% at 2 years.
Survival with beneﬁt means survival with improvement
by at least 1 New York Heart Association (NYHA) or
Canadian Cardiovascular Society class in heart failure
(HF) or angina symptoms, improvement in quality of life,
or improvement in life expectancy. Those patients with
severe frailty may fall into this category.
Supporting References: (41,74–78)
2.6. The Heart Valve Team and Heart Valve
Centers of Excellence: Recommendations
The number of patients presenting with VHD in devel-
oped countries is growing, primarily due to the increasing
age of the population. In addition, more patients with
VHD are referred to cardiovascular specialists due to
enhanced awareness of various treatments, as well as
improved noninvasive imaging tests. When patients with
VHD are referred for intervention in a timely manner,
there is an improved outcome in preservation of ventricular
function as well as enhanced survival. However, the man-
agement of patients with VHD is becoming increasingly
complex, due to the use of more sophisticated noninvasive
imaging modalities and technological advances in thera-
pies. These advances result in changing thresholds for valve
interventions. There remain a number of patients who are
referred for intervention too late in the course of their
disease or not referred at all, either of which results in poor
long-term outcomes. Alternatively, intervention in the
asymptomatic patient requires expertise in evaluation and
noninvasive imaging assessment. The advent of trans-
catheter valve therapies has transformed the treatment of
elderly high-risk patients with severe VHD but imposesdifﬁcult decision making in terms of risk–beneﬁt analysis.
Patient care should be customized to the patient’s needs,
values, and expectations.
A competent practicing cardiologist should have the
ability to diagnose and direct the treatment of most pati-
ents with VHD. For instance, otherwise healthy patients
with severe VHD who become symptomatic should nearly
always be considered for intervention. However, more
complex decision-making processes may be required in
select patient populations, such as those who have
asymptomatic severe VHD, those who are at high risk for
intervention, or those who could beneﬁt from specialized
therapies such as valve repair or transcatheter valve
intervention.
The management of patients with complex severe VHD
is best achieved by a Heart Valve Team composed pri-
marily of a cardiologist and surgeon (including a structural
valve interventionist if a catheter-based therapy is being
considered). In selected cases, there may be a multidisci-
plinary, collaborative group of caregivers, including cardi-
ologists, structural valve interventionalists, cardiovascular
imaging specialists, cardiovascular surgeons, anesthesiolo-
gists, and nurses, all of whom have expertise in the man-
agement and outcomes of patients with complex VHD.
The Heart Valve Team should optimize patient selection
for available procedures through a comprehensive under-
standing of the risk–beneﬁt ratio of different treatment
strategies. This is particularly beneﬁcial in patients in
whom there are several options for treatment, such as the
elderly high-risk patient with severe symptomatic AS being
considered for transcatheter aortic valve replacement
(TAVR) or surgical aortic valve replacement (AVR). The
patient and family should be sufﬁciently educated by the
Heart Valve Team about all alternatives for treatment so
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a shared decision-making approach.
The optimal care of the patient with complex heart
disease is best performed in centers that can provide all
available options for diagnosis and management, including
the expertise for complex aortic or mitral valve repair, aortic
surgery, and transcatheter therapies. This has led to the
development of Heart Valve Centers of Excellence. Heart
Valve Centers of Excellence 1) are composed of experi-
enced healthcare providers with expertise from multiple
disciplines; 2) offer all available options for diagnosis and
management, including complex valve repair, aortic sur-
gery, and transcatheter therapies; 3) participate in regional
or national outcome registries; 4) demonstrate adherence
to national guidelines; 5) participate in continued evalua-
tion and quality improvement processes to enhance patient
outcomes; and 6) publicly report their available mortality
and success rates. Decisions about intervention at the
Heart Valve Centers of Excellence should be dependent on
the centers’ publicly available mortality rates and operative
outcomes. It is recognized that some Heart Valve Centers
of Excellence may have expertise in select valve problems.
CLASS I
1. Patients with severe VHD should be evaluated by a multidisci-
plinary Heart Valve Team when intervention is considered.
(Level of Evidence: C)
Decisions about selection and timing of interventions
for patients with severe VHD are best done through the
Heart Valve Team. The Heart Valve Team is composed
primarily of a cardiologist and surgeon (including a
structural valve interventionist if a catheter-based therapy is
being considered). In selected cases, there may be a
multidisciplinary, collaborative group of caregivers,
including cardiologists, structural valve interventionalists,
cardiovascular imaging specialists, cardiovascular surgeons,
anesthesiologists, and nurses, many of whom have exper-
tise in the management and outcomes of patients with
complex VHD. For patients with infections of the heart,
infectious disease specialists should be involved. For
pregnant women, high-risk obstetrics should be involved.
The Heart Valve Team 1) reviews the patient’s medical
condition and valve abnormality, 2) determines the
possible interventions that are indicated, technically
feasible, and reasonable, and 3) discusses the risks and
outcomes of these interventions with the patient and
family. This approach has been used for patients with
complex coronary artery disease (CAD) and is supported
by reports that patients with complex CAD referred spe-
ciﬁcally for percutaneous coronary intervention (PCI) or
coronary artery bypass graft (CABG) surgery in concurrent
trial registries using a heart team approach have lower
mortality rates than those randomly assigned to PCI or
CABG in controlled trials.
Supporting References: (35,79–84)CLASS IIa
1. Consultationwith or referral to aHeartValveCenter of Excellence
is reasonable when discussing treatment options for 1) asymp-
tomatic patients with severe VHD, 2) patients who may beneﬁt
from valve repair versus valve replacement, or 3) patients with
multiple comorbidities for whom valve intervention is considered.
(Level of Evidence: C)
With the advent of newer surgical techniques and
lower rates of operative mortality, it is reasonable to lower
the threshold for valve intervention to prevent the adverse
consequences of severe VHD, particularly in the asymp-
tomatic patient with severe VHD. However, the overall
beneﬁt of operating on these patients requires that the
patient be evaluated by those with expertise in assessment
of VHD and that they undergo operation in a center
with low operative mortality and excellent patient out-
comes. If a “watchful waiting” approach is taken in
asymptomatic patients with severe VHD, a Heart Valve
Center of Excellence may be beneﬁcial in ensuring proper
follow-up.
Surgical outcomes depend on the expertise and expe-
rience of the surgeons, especially with highly specialized
operations such as complex mitral valve repair and surgical
treatment of aortic disease. It is well documented that
operative risks and outcomes are better for patients un-
dergoing mitral valve repair versus mitral valve replace-
ment (MVR) in patients with primary mitral regurgitation
(MR) and morphology suitable for repair. Although the
rate of mitral valve repair has increased, a number of pa-
tients with primary MR will still undergo MVR. The rate
of successful mitral valve repair in patients with primary
MR is dependent on the experience of the surgeon as well
as the surgical volume. Optimal outcomes are best ach-
ieved in Heart Valve Centers of Excellence dedicated to
the management and treatment of patients with VHD
and that offer all available treatment options, including
complex valve repair, aortic surgery, and transcatheter
therapies. At Heart Valve Centers of Excellence, health-
care providers have experience and expertise from multiple
disciplines, demonstrate adherence to national guidelines,
participate in regional or national outcome registries, and
publicly report their available mortality and success rates
with a continued quality improvement program in place.
Decisions on early operation in the asymptomatic pati-
ent can then be made based on the reported data from
the speciﬁc Heart Valve Center of Excellence, in-
cluding mortality and morbidity statistics as well as du-
rable repair rates for patients with primary MR. Heart
Valve Centers of Excellence have also been shown to in-
crease the proportion of patients managed according to
GDMT, decrease unnecessary testing, optimize timing of
intervention, and best handle other problems such as
operations for complex multivalve disease, multiple reop-
erations, and complex IE. Heart Valve Centers of
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clinician education to help ensure timely referral for
evaluation and proper protocol for follow-up.
Supporting References: (35,85–88)
3. Aortic Stenosis
See Table 8 for the stages of valvular AS andTables 9 and 10
for a summary of recommendations for choice and timing
of intervention.
3.1. Stages of Valvular AS
Medical and interventional approaches to the management
of patients with valvular AS depend on accurate diagnosis
of the cause and stage of the disease process. Table 8 shows
the stages of AS ranging from patients at risk of AS (stage
A) or with progressive hemodynamic obstruction (stage B)
to severe asymptomatic (stage C) and symptomatic AS
(stage D). Each of these stages is deﬁned by valve anatomy,
valve hemodynamics, the consequences of valve obstruction
on the left ventricle and vasculature, as well as by patient
symptoms. Hemodynamic severity is best characterized by
the transaortic maximum velocity (or mean pressure
gradient) when the transaortic volume ﬂow rate is normal.
However, some patients with AS have a low transaortic
volume ﬂow rate due to either LV systolic dysfunction with
a low LV ejection fraction (LVEF) or due to a small hy-
pertrophied left ventricle with a low stroke volume. These
categories of severe AS pose a diagnostic and management
challenge distinctly different from the challenges faced by
the majority of patients with AS, who have a high gradient
and velocity when AS is severe. These special subgroups
with low-ﬂow AS are designated D2 (with a low LVEF)
and D3 (with a normal LVEF).
The deﬁnition of severe AS is based on natural history
studies of patients with unoperated AS, which show that
the prognosis is poor once there is a peak aortic valve ve-
locity of >4 m per second, corresponding to a mean aortic
valve gradient >40 mm Hg. In patients with low forward
ﬂow, severe AS can be present with lower aortic valve
velocities and lower aortic valve gradients. Thus, an aortic
valve area should be calculated in these patients. The
prognosis of patients with AS is poorer when the aortic
valve area is <1.0 cm2. At normal ﬂow rates, an aortic valve
area of<0.8 cm2 correlates with a mean aortic valve gradient
>40 mm Hg. However, symptomatic patients who have a
calciﬁed aortic valve with reduced opening and an aortic
valve area between 0.8 cm2 and 1.0 cm2 should be closely
evaluated to determine whether they would beneﬁt from
valve intervention. Meticulous attention to detail is required
when assessing aortic valve hemodynamics, either with
Doppler echocardiography or cardiac catheterization, and the
inherent variability of the measurements and calculations
should always be considered in clinical-decision making.3.2. Aortic Stenosis
3.2.1. Diagnosis and Follow-Up
The overall approach to the initial diagnosis of VHD is
discussed in Section 2.3, and additional considerations
speciﬁc to patients with AS are addressed here.
3.2.1.1. DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS: RECOMMENDATIONS
CLASS I
1. TTE is indicated in patients with signs or symptoms of AS or a
bicuspid aortic valve for accurate diagnosis of the cause of AS,
hemodynamic severity, LV size, and systolic function, and for
determining prognosis and timing of valve intervention
(24,25,89). (Level of Evidence: B)
Most patients with AS are ﬁrst diagnosed when cardiac
auscultation reveals a systolic murmur or after a review of
TTE requested for other indications. Physical examination
ﬁndings are speciﬁc but not sensitive for evaluation of
stenosis severity. The classic ﬁndings of a loud (grade
3/6), late-peaking systolic murmur that radiates to the
carotid arteries, a single or paradoxically split second heart
sound, and a delayed and diminished carotid upstroke
conﬁrm the presence of severe AS. However, carotid up-
stroke may be normal in elderly patients because of the
effects of aging on the vasculature, and the murmur may be
soft or may radiate to the apex. The only physical exami-
nation ﬁnding that is reliable in excluding the possibility of
severe AS is a normally split second heart sound.
TTE is indicated when there is an unexplained systolic
murmur, a single second heart sound, a history of a
bicuspid aortic valve, or symptoms that might be due to
AS. Echocardiographic imaging allows reliable identiﬁca-
tion of the number of valve leaﬂets along with qualitative
assessment of valve motion and leaﬂet calciﬁcation. In
nearly all patients, the hemodynamic severity of the ste-
notic lesion can be deﬁned with Doppler echocardio-
graphic measurements of maximum transvalvular velocity,
mean pressure gradient, and continuity equation valve area,
as discussed in the European Association of Echocardi-
ography (EAE)/ASE guidelines for evaluation of valve
stenosis. Doppler evaluation of severity of AS has been well
validated in experimental and human studies compared
with direct measurements of intracardiac pressure and
cardiac output. In addition, Doppler measures of severity
of AS are potent predictors of clinical outcome. However,
Doppler may underestimate or overestimate aortic velocity
and disease severity in some patients, so clinical evaluation
should include symptoms, physical examination ﬁndings,
and results of other diagnostic testing as well.
TTE is also useful for determining the LV response to
pressure overload. Systolic function is evaluated using 2D
or 3–dimensional (3D) measurement of LVEF. LV dia-
stolic function can be evaluated using standard Doppler
approaches and an estimate of pulmonary systolic pressure
derived from the TR jet. In addition, TTE allows
Table 8. Stages of Valvular AS
Stage Deﬁnition Valve Anatomy Valve Hemodynamics Hemodynamic Consequences Symptoms
A At risk of AS  Bicuspid aortic valve
(or other congenital
valve anomaly)
 Aortic valve sclerosis
 Aortic Vmax <2 m/s  None  None
B Progressive AS  Mild-to-moderate leaﬂet
calciﬁcation of a bicuspid
or trileaﬂet valve with
some reduction in systolic
motion or
 Rheumatic valve changes
with commissural fusion
 Mild AS: Aortic Vmax
2.0–2.9 m/s or mean
DP <20 mm Hg
 Moderate AS: Aortic
Vmax 3.0–3.9 m/s
or mean DP 20–39
mm Hg
 Early LV diastolic
dysfunction may
be present
 Normal LVEF
 None
C: Asymptomatic severe AS
C1 Asymptomatic
severe AS
 Severe leaﬂet calciﬁcation
or congenital stenosis with
severely reduced leaﬂet
opening
 Aortic Vmax 4 m/s
or mean DP 40 mm Hg
 AVA typically is 1.0 cm2
(or AVAi 0.6 cm2/m2)
 Very severe AS is an aortic
Vmax 5 m/s or mean
DP 60 mm Hg
 LV diastolic dysfunction
 Mild LV hypertrophy
 Normal LVEF
 None: Exercise
testing is reasonable
to conﬁrm symptom
status
C2 Asymptomatic
severe AS with
LV dysfunction
 Severe leaﬂet calciﬁcation
or congenital stenosis with
severely reduced leaﬂet
opening
 Aortic Vmax 4 m/s or
mean DP 40 mm Hg
 AVA typically 1.0 cm2
(or AVAi 0.6 cm2/m2)
 LVEF <50%  None
D: Symptomatic severe AS
D1 Symptomatic
severe high-
gradient AS
 Severe leaﬂet calciﬁcation
or congenital stenosis with
severely reduced leaﬂet
opening
 Aortic Vmax 4 m/s or
mean DP 40 mm Hg
 AVA typically 1.0 cm2
(or AVAi 0.6 cm2/m2)
but may be larger with
mixed AS/AR
 LV diastolic dysfunction
 LV hypertrophy
 Pulmonary hypertension
may be present
 Exertional dyspnea
or decreased exercise
tolerance
 Exertional angina
 Exertional syncope or
presyncope
D2 Symptomatic severe
low-ﬂow/low-gradient
AS with reduced LVEF
 Severe leaﬂet calciﬁcation
with severely reduced leaﬂet
motion
 AVA 1.0 cm2 with
resting aortic Vmax
<4 m/s or mean DP
<40 mm Hg
 Dobutamine stress
echocardiography shows
AVA 1.0 cm2 with Vmax
4 m/s at any ﬂow rate
 LV diastolic dysfunction
 LV hypertrophy
 LVEF <50%
 HF
 Angina
 Syncope or presyncope
D3 Symptomatic severe
low-gradient AS
with normal LVEF or
paradoxical low-ﬂow
severe AS
 Severe leaﬂet calciﬁcation
with severely reduced leaﬂet
motion
 AVA 1.0 cm2 with aortic
Vmax <4 m/s or mean DP
<40 mm Hg
 Indexed AVA 0.6 cm2/m2 and
 Stroke volume index <35 mL/m2
 Measured when patient is
normotensive (systolic BP
<140 mm Hg)
 Increased LV relative
wall thickness
 Small LV chamber
with low stroke volume
 Restrictive diastolic ﬁlling
 LVEF 50%
 HF
 Angina
 Syncope or presyncope
AR indicates aortic regurgitation; AS, aortic stenosis; AVA, aortic valve area; AVAi, aortic valve area indexed to body surface area; BP, blood pressure; HF, heart failure; LV, left ventricular;
LVEF, left ventricular ejection fraction; DP, pressure gradient; and Vmax, maximum aortic velocity.
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MR being common in patients with AS.
Supporting References: (8,19,24,25,27,89–94)
CLASS IIa
1. Low-dose dobutamine stress testing using echocardiographic or
invasive hemodynamic measurements is reasonable in patients
with stage D2 AS with all of the following (95–97) (Level of
Evidence: B):
a. Calciﬁed aortic valve with reduced systolic opening;
b. LVEF less than 50%;
c. Calculated valve area 1.0 cm2 or less; and
d. Aortic velocity less than 4.0 m per second or mean pressure
gradient less than 40 mm Hg.Patients with severe AS and concurrent LV systolic
dysfunction often present with a relatively low transvalvular
velocity and pressure gradient (i.e., mean pressure
gradient <40 mm Hg) but with a small calculated valve
area. In some of these patients, severe AS is present with
LV systolic dysfunction due to afterload mismatch. In
others, primary myocardial dysfunction is present with only
moderate AS and reduced aortic leaﬂet opening due to a
low transaortic volume ﬂow rate. In these patients with
low-ﬂow/low-gradient AS and LV systolic dysfunction
(LVEF <50%), it may be useful to measure aortic velocity
(or mean pressure gradient) and valve area during a
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(i.e., dobutamine infusion) stress testing to determine
whether AS is severe or only moderate and to evaluate for
contractile or ﬂow reserve.
Dobutamine is infused in progressive stages, beginning at
5mcg/kg per minute and increasing in increments of 5mcg/
kg per minute to a maximum dose of 20 mcg/kg per minute
with appropriate clinical and hemodynamic monitoring.
Echocardiographic and Doppler data (or hemodynamic
data) are recorded at each dose of dobutamine for mea-
surement of aortic velocity, mean pressure gradient, valve
area, and LVEF. Patients who do not have true anatomically
severe AS will exhibit an increase in valve area with only a
modest increase in transaortic velocity or gradient as trans-
aortic stroke volume increases. In contrast, patients with
severe AS have a relatively ﬁxed valve area even with an in-
crease in LV contractility and transaortic volume ﬂow rate.
The document “Echocardiographic Assessment of Valve
Stenosis: EAE/ASE Recommendations for Clinical Prac-
tice” deﬁnes severe AS on low-dose dobutamine stress
testing as a maximum velocity 4.0 m per second with a
valve area1.0 cm2 at any point during the test protocol. In
addition to moderate AS and true severe AS, low-dose
dobutamine stress testing helps identify a third group of
patients who fail to show an increase in stroke volume20%
with dobutamine, referred to as “lack of contractile reserve”
or “lack of ﬂow reserve.”This subgroup of patients appears to
have a very poor prognosis with either medical or surgical
therapy. Low-dose dobutamine stress testing in patients
withAS requires center experience in pharmacological stress
testing as well as continuous hemodynamic and electrocar-
diographic monitoring with a cardiologist in attendance.
Supporting References: (8,43,95,96,98–101)
See Online Data Supplement 1 for more information on
outcomes in patients with low-ﬂow/low-gradient AS with
reduced LVEF.
3.2.1.2. DIAGNOSTIC TESTINGdCHANGING SIGNS OR SYMPTOMS
In patients with known valvular AS, repeat TTE is
appropriate when physical examination reveals a louder
systolic murmur or a change in the second heart sound or
when symptoms occur that might be due to AS because
valve obstruction may have progressed since the last eval-
uation. Repeat TTE is also appropriate in patients with AS
who are exposed to increased hemodynamic demands
either electively, such as noncardiac surgery or pregnancy,
or acutely, such as with a systemic infection, anemia, or
gastrointestinal bleeding. In these clinical settings,
knowledge of the severity of valve obstruction and LV
function is critical for optimizing loading conditions and
maintaining a normal cardiac output.
Supporting References: (24,25,89,102,103)
3.2.1.3. DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP
Timing of periodic clinical evaluation of patients with
severe asymptomatic AS depends on comorbidities andpatient-speciﬁc factors. TTE for re-evaluation of asymp-
tomatic patients with AS with normal LV systolic function
who have no change in signs or symptoms is performed at
intervals of 6 months to 1 year when aortic velocity is 4.0
m per second (stage C), 1 to 2 years when aortic velocity is
between 3.0 m per second and 3.9 m per second (stage B),
and 3 to 5 years when aortic velocity is 2.0 m per second to
2.9 m/s (stage B) (Table 4).
Valvular AS is a progressive disease, and an increase in
hemodynamic severity is inevitable once even mild AS is
present. The rate of progression of the stenotic lesion has
been estimated in a variety of invasive and noninvasive
studies. When severe AS is present (aortic velocity 4.0 m
per second), the rate of progression to symptoms is high,
with an event-free survival of only 30% to 50% at 2 years.
Therefore, patients with asymptomatic severe AS require
frequent monitoring for progressive disease because
symptom onset may be insidious and not recognized by the
patient.
Once even moderate AS is present (aortic velocity be-
tween 3.0 m per second and 3.9 m per second), the average
rate of progression is an increase in velocity of 0.3 m per
second per year, an increase in mean pressure gradient of 7
mm Hg per year, and a decrease in valve area of 0.1 cm2
per year. There is marked individual variability in the rate
of hemodynamic change. Progression of AS can be more
rapid in older patients and in those with more severe leaﬂet
calciﬁcation. Because it is not possible to predict the exact
rate of progression in an individual patient, regular clinical
and echocardiographic follow-up is mandatory in all pa-
tients with asymptomatic mild-to-moderate AS.
In patients with aortic sclerosis, deﬁned as focal areas of
valve calciﬁcation and leaﬂet thickening with an aortic
velocity <2.5 m per second, progression to severe AS oc-
curs in about 10% of patients within 5 years. Patients with
bicuspid aortic valve disease are also at risk for progressive
valve stenosis, with AS being the most common reason for
intervention in patients with a bicuspid aortic valve
(Section 5.1.1).
Supporting References: (28,104–115)
See Online Data Supplement 2 for more information on
hemodynamic progression of AS.
3.2.1.4. DIAGNOSTIC TESTINGdCARDIAC CATHETERIZATION
Diagnostic TTE and Doppler data can be obtained in
nearly all patients, but severity of AS may be under-
estimated if image quality is poor or if a parallel intercept
angle is not obtained between the ultrasound beam and
aortic jet. CMR imaging shows promise for evaluation of
severity of AS but is not widely available. Cardiac CT
imaging is useful for quantitation of valve calciﬁcation
(severe calciﬁcation is considered to be present with an
aortic valve calciﬁcation score >1,000 Agatston units) and
in patients undergoing TAVR for measurement of annulus
area, leaﬂet length, and the annular to coronary ostial
distance. However, CT imaging is less useful for evaluation
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diagnostic or if there is a discrepancy between clinical and
echocardiographic evaluation, cardiac catheterization for
determination of severity of AS is recommended. Trans-
aortic pressure gradients should be recorded for measure-
ment of mean transaortic gradient, based on simultaneous
LV and aortic pressure measurements. Aortic valve area
should be calculated with the Gorlin formula, using a Fick
or thermodilution cardiac output measurement. See
Section 14.1 for recommendations on coronary angiog-
raphy in patients with AS.
Supporting References: (42,116)
3.2.1.5. DIAGNOSTIC TESTINGdEXERCISE TESTING: RECOMMENDATIONS
CLASS IIa
1. Exercise testing is reasonable to assess physiological changes
with exercise and to conﬁrm the absence of symptoms in
asymptomatic patients with a calciﬁed aortic valve and an
aortic velocity 4.0 m per second or greater or mean pressure
gradient 40 mm Hg or higher (stage C) (25,46,47,117). (Level
of Evidence: B)
When performed under the direct supervision of an
experienced clinician, with close monitoring of BP and
ECG, exercise testing in asymptomatic patients is relatively
safe and may provide information that is not evident
during the initial clinical evaluation, particularly when the
patient’s functional capacity is unclear. Patients with
symptoms provoked by exercise testing should be consid-
ered symptomatic, even if the clinical history is equivocal.
Although it can be challenging to separate normal exercise
limitations from abnormal symptoms due to AS, particu-
larly in elderly sedentary patients, exercise-induced angina,
excessive dyspnea early in exercise, dizziness, or syncope
are consistent with symptoms of AS. In 1 series, exercise
testing brought out symptoms in 29% of patients who were
considered asymptomatic before testing; in these patients,
spontaneous symptoms developed over the next year in
51% of patients, compared with only 11% of patients who
had no symptoms on exercise testing.
Exercise testing can also identify a limited exercise ca-
pacity, abnormal BP response, or arrhythmia. An abnormal
hemodynamic response (e.g., hypotension or failure to
increase BP with exercise) in patients with severe AS is
considered a poor prognostic ﬁnding. In another series,
patients with AS who manifested symptoms, an abnormal
BP response (<20 mm Hg increase), or ST-segment ab-
normalities with exercise had a signiﬁcantly reduced
symptom-free survival at 2 years (19% compared with 85%).
However, electrocardiographic ST-segment depression is
seen in >80% of patients with AS with exercise and is
nonspeciﬁc for diagnosis of CAD. Ventricular tachycardia
was reported in early exercise studies but has not been
reported in contemporary series.
Some studies suggest additional value for measuring
changes in valve hemodynamics with exercise. In a series of
186 patients with moderate-to-severe AS, stress testingwas normal in 73% of patients; however, adverse cardiac
events occurred in 67 of these patients at a mean follow-up
interval of 2014 months. Predictors of cardiac events,
primarily symptom onset requiring AVR, were age >65
years, diabetes mellitus, LV hypertrophy, a resting mean
pressure gradient >35 mm Hg, and an increase of >20
mm Hg in mean pressure gradient with exercise. However,
a prospective study of 123 patients with asymptomatic AS
did not show additive value for exercise hemodynamics
for predicting clinical outcome when baseline measures
of hemodynamic severity and functional status were con-
sidered. Recording hemodynamics with exercise is chal-
lenging, and simpler parameters are adequate in most
patients.
Supporting References: (25,28,46,47,117–121)
See Online Data Supplement 3 for more information on
exercise testing in patients with AS.
CLASS III: Harm
1. Exercise testing should not be performed in symptomatic pa-
tients with AS when the aortic velocity is 4.0 m per second or
greater or mean pressure gradient is 40 mm Hg or higher
(stage D) (122). (Level of Evidence: B)
As reported in several prospective and retrospective
studies, the risk of exercise testing is low in asymptomatic
patients with AS. However, even in asymptomatic patients,
complications include exertional hypotension in up to 10%
of patients, exercise-induced symptoms, and ventricular
premature beats. A retrospective study of 347 patients with
AS who underwent cardiopulmonary exercise testing
showed no deaths or major complications. Most of these
patients had no (78%) or equivocal (16%) symptoms at
baseline, with only 20 symptomatic patients (6%) with
AS in this series (123).
Exercise testing should not be performed in symptom-
atic patients with AS owing to a high risk of complications,
including syncope, ventricular tachycardia, and death. In
a prospective survey of 20 medical centers in Sweden that
included 50,000 exercise tests done over an 18–month
period, the complication rate was 18.4; morbidity rate, 5.2;
and mortality rate, 0.4 per 10,000 tests. Although the
number of patients with AS was not reported, 12 of the 92
complications occurred in patients with AS: 8 had an ex-
ercise decline in BP, 1 had asystole, and 3 had ventricular
tachycardia.
Supporting References: (46,47,117–120,122,123)
3.2.2. Medical Therapy: Recommendations
CLASS I
1. Hypertension in patients at risk for developing AS (stage A) and
in patients with asymptomatic AS (stages B and C) should be
treated according to standard GDMT, started at a low dose, and
gradually titrated upward as needed with frequent clinical
monitoring (124–126). (Level of Evidence: B)
Hypertension is common in patients with AS, may be a
risk factor for AS, and adds to the total pressure overload
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Concern that antihypertensive medications might result in
a fall in cardiac output has not been corroborated in studies
of medical therapy, including 2 small RCTs, likely because
AS does not result in “ﬁxed” valve obstruction until late in
the disease process. In 1,616 patients with asymptomatic
AS in the SEAS (Simvastatin Ezetimibe in Aortic Ste-
nosis) study, hypertension (n¼1,340) was associated with a
56% higher rate of ischemic cardiovascular events and a
2-fold increased mortality rate (both p<0.01) compared
with normotensive patients with AS, although no impact
on AVR was seen. Medical therapy for hypertension
should follow standard guidelines, starting at a low dose
and gradually titrating upward as needed to achieve BP
control. There are no studies addressing speciﬁc antihy-
pertensive medications in patients with AS, but diuretics
should be avoided if the LV chamber is small, because even
smaller LV volumes may result in a fall in cardiac output.
In theory, ACE inhibitors may be advantageous due to the
potential beneﬁcial effects on LV ﬁbrosis in addition to
control of hypertension. Beta blockers are an appropriate
choice in patients with concurrent CAD.
Supporting References: (124–128)
CLASS IIb
1. Vasodilator therapy may be reasonable if used with invasive
hemodynamic monitoring in the acute management of patients
with severe decompensated AS (stage D) with NYHA class IV
HF symptoms. (Level of Evidence: C)
In patients who present with severe AS and NYHA
class IV HF, afterload reduction may be used in an effort to
stabilize the patient before urgent AVR. Invasive moni-
toring of LV ﬁlling pressures, cardiac output, and systemic
vascular resistance is essential because of the tenuous he-
modynamic status of these patients, in whom a sudden
decline in systemic vascular resistance might result in an
acute decline in cardiac output across the obstructed aortic
valve. However, some patients do beneﬁt with an increase
in cardiac output as systemic vascular resistance is slowly
adjusted downward due to the reduction in total LV
afterload. AVR should be performed as soon as feasible in
these patients.
Supporting Reference: (129)
CLASS III: No Beneﬁt
1. Statin therapy is not indicated for prevention of hemodynamic
progression of AS in patients with mild-to-moderate calciﬁc
valve disease (stages B to D) (109,130,131). (Level of
Evidence: A)
Despite experimental models and retrospective clinical
studies that suggest that lipid-lowering therapy with a
statin might prevent disease progression of calciﬁc AS, 3
large well-designed RCTs failed to show a beneﬁt either in
terms of changes in hemodynamic severity or in clinical
outcomes in patients with mild-to-moderate valve
obstruction. Thus, at the time of publication, there are no
data to support the use of statins for prevention ofprogression of AS. However, concurrent CAD is common
in patients with AS, and all patients should be screened
and treated for hypercholesterolemia using GDMT for
primary and secondary prevention of CAD.
Supporting References: (109,130–133)
See Online Data Supplement 4 for more information on
clinical trials of lipid-lowering therapy to slow progression of
AS (stage B) and prevent cardiovascular outcomes.
3.2.3. Timing of Intervention: Recommendations
See Table 9 for a summary of recommendations from this
section and Figure 1 for indications for AVR in patients
with AS. These recommendations for timing of interven-
tion for AS apply to both surgical and transcatheter AVR.
The integrative approach to assessing risk of surgical or
transcatheter AVR is discussed in Section 2.5. The speciﬁc
type of intervention for AS is discussed in Section 3.2.4.
CLASS I
1. AVR is recommended in symptomatic patients with severe AS
(stage D1) with (9,91,134,135) (Level of Evidence: B):
a. Decreased systolic opening of a calciﬁed or congenitally
stenotic aortic valve; and
b. An aortic velocity 4.0 m per second or greater or mean
pressure gradient 40 mm Hg or higher; and
c. Symptoms of HF, syncope, exertional dyspnea, angina, or
presyncope by history or on exercise testing.
Hemodynamic progression eventually leading to symp-
tom onset occurs in nearly all asymptomatic patients with
AS. However, survival during the asymptomatic phase is
similar to age-matched controls with a low risk of sudden
death (<1% per year) when patients are followed pro-
spectively and promptly report symptom onset. The rate of
symptom onset is strongly dependent on severity of AS,
with an event-free survival rate of about 75% to 80% at 2
years in those with a jet velocity <3.0 m per second
compared with only 30% to 50% in those with a jet
velocity 4.0 m per second. Patients with asymptomatic
AS require periodic monitoring for development of
symptoms and progressive disease, but routine AVR is not
recommended (Section 3.1).
However, once even mild symptoms caused by severe
AS are present, outcomes are extremely poor unless
outﬂow obstruction is relieved. Typical initial symptoms
are dyspnea on exertion or decreased exercise tolerance.
The classical symptoms of syncope, angina, and HF are
late manifestations of disease, most often seen in patients
in whom early symptom onset was not recognized and
intervention was inappropriately delayed. In patients with
severe, symptomatic, and calciﬁc AS, the only effective
treatment is surgical or transcatheter AVR, resulting in
improved survival rates, reduced symptoms, and improved
exercise capacity. In the absence of serious comorbid
conditions that limit life expectancy or quality of life, AVR
is indicated in virtually all symptomatic patients with severe
AS and should be performed promptly after onset of
symptoms. Age alone is not a contraindication to surgery,
Table 9. Summary of Recommendations for AS: Timing of Intervention
Recommendations COR LOE References
AVR is recommended for symptomatic patients with severe high-gradient AS who have symptoms
by history or on exercise testing (stage D1)
I B (9,91,134,135)
AVR is recommended for asymptomatic patients with severe AS (stage C2) and LVEF <50% I B (136,137)
AVR is indicated for patients with severe AS (stage C or D) when undergoing other cardiac surgery I B (108,138)
AVR is reasonable for asymptomatic patients with very severe AS (stage C1, aortic velocity
5.0 m/s) and low surgical risk
IIa B (139,140)
AVR is reasonable in asymptomatic patients (stage C1) with severe AS and decreased exercise
tolerance or an exercise fall in BP
IIa B (25,47)
AVR is reasonable in symptomatic patients with low-ﬂow/low-gradient severe AS with reduced LVEF
(stage D2) with a low-dose dobutamine stress study that shows an aortic velocity 4.0 m/s
(or mean pressure gradient 40 mm Hg) with a valve area 1.0 cm2 at any dobutamine dose
IIa B (43,141,142)
AVR is reasonable in symptomatic patients who have low-ﬂow/low-gradient severe AS (stage D3)
who are normotensive and have an LVEF 50% if clinical, hemodynamic, and anatomic data
support valve obstruction as the most likely cause of symptoms
IIa C N/A
AVR is reasonable for patients with moderate AS (stage B) (aortic velocity 3.0–3.9 m/s) who are
undergoing other cardiac surgery
IIa C N/A
AVR may be considered for asymptomatic patients with severe AS (stage C1) and rapid disease
progression and low surgical risk
IIb C N/A
AS indicates aortic stenosis; AVR, aortic valve replacement by either surgical or transcatheter approach; BP, blood pressure; COR, Class of Recommendation; LOE, Level of Evidence; LVEF,
left ventricular ejection fraction; and N/A, not applicable.
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matched normal subjects in the very elderly.
Severe AS is deﬁned as an aortic velocity 4.0 m per
second or mean pressure gradient 40 mm Hg based on
outcomes in a series of patients with AS of known he-
modynamic severity. Although transaortic velocity and
mean pressure gradient are redundant measures of AS
severitydwith native valve AS there is a close linear cor-
relation between velocity and mean pressure gradient
whether measured by catheterization or Doppler methodsd
both are included in this guideline so that either Doppler
or invasive measurements can be used in decision making.
There is substantial overlap in hemodynamic severity be-
tween asymptomatic and symptomatic patients, and there
is no single parameter that indicates the need for AVR.
Instead, it is the combination of symptoms, valve anatomy,
and hemodynamics (Table 8) that provides convincing
evidence that AVR will be beneﬁcial in an individual pa-
tient. Many patients with a high transaortic velocity/
pressure gradient will remain asymptomatic for several
years and do not require AVR until symptom onset.
However, if symptoms are present, a high velocity/
gradient conﬁrms valve obstruction as the cause of symp-
toms. With mixed stenosis and regurgitation, a high ve-
locity/gradient indicates severe mixed aortic valve disease.
Calculation of valve area is not necessary when a high
velocity/gradient is present and the valve is calciﬁed and
immobile; most patients will have a valve area 1.0 cm2 or
an indexed valve area 0.6 cm2/m2, but some will have
a larger valve area due to a large body size or coexisting
aortic regurgitation (AR). Thus, the primary criterion
for the deﬁnition of severity of AS is based on aortic ve-
locity or mean pressure gradient. Calculations of valve area
may be supportive but are not necessary when a high ve-
locity or gradient is present. In contrast, valve area cal-
culations are essential for patients with AS and a lowejection fraction or stroke volume as deﬁned for stages D2
and D3.
SupportingReferences: (24,25,29,89,92,94,108,109,134,135,
139,140,143–148)
See Online Data Supplements 5, 6, and 7 for more infor-
mation on clinical outcomes with asymptomatic AS (stages B
and C) of known hemodynamic severity, incidence of sudden
death in asymptomatic patients with AS (stages B and C), and
clinical outcomes with symptomatic AS of known hemodynamic
severity, respectively.
CLASS I
2. AVR is recommended for asymptomatic patients with severe AS
(stage C2) and an LVEF less than 50% with decreased systolic
opening of a calciﬁed aortic valve with an aortic velocity 4.0 m
per second or greater or mean pressure gradient 40 mm Hg or
higher (136,137). (Level of Evidence: B)
In patients with a low LVEF and severe AS, survival is
better in those who undergo AVR than in those treated
medically. The depressed LVEF in many patients is caused
by excessive afterload (afterload mismatch), and LV
function improves after AVR in such patients. If LV
dysfunction is not caused by afterload mismatch, survival is
still improved, likely because of the reduced afterload with
AVR, but improvement in LV function and resolution of
symptoms might not be complete after AVR.
Supporting References: (98,136,141,142,149–153)
See Online Data Supplement 1 for more information on
outcomes in patients with low-ﬂow/low-gradient AS with
reduced LVEF.
CLASS I
3. AVR is indicated for patients with severe AS (stage C or D)
when undergoing cardiac surgery for other indications when
there is decreased systolic opening of a calciﬁed aortic valve
and an aortic velocity 4.0 m per second or greater or mean
pressure gradient 40 mm Hg or higher (108,138). (Level of
Evidence: B)
Figure 1. Indications for AVR in Patients With AS
Arrows show the decision pathways that result in a recommendation for AVR. Periodic monitoring is indicated for all patients in whom AVR is not yet indicated, including those with
asymptomatic AS (stage D or C) and those with low-gradient AS (stage D2 or D3) who do not meet the criteria for intervention.
*AVR should be considered with stage D3 AS only if valve obstruction is the most likely cause of symptoms, stroke volume index is<35 mL/m2, indexed AVA is 0.6 cm2/m2, and
data are recorded when the patient is normotensive (systolic BP <140 mm Hg).
AS indicates aortic stenosis; AVA; aortic valve area; AVR, aortic valve replacement by either surgical or transcatheter approach; BP, blood pressure; DSE, dobutamine stress
echocardiography; ETT, exercise treadmill test; LVEF, left ventricular ejection fraction; DPmean, mean pressure gradient; and Vmax, maximum velocity.
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progression occurs in nearly all patients with severe
asymptomatic AS. Symptom onset within 2 to 5 years is
likely when aortic velocity is 4.0 m per second or mean
pressure gradient is 40 mm Hg. The additive risk of
AVR at the time of other cardiac surgery is less than the
risk of reoperation within 5 years.
Supporting References: (108,138,154,155)
CLASS IIa
1. AVR is reasonable for asymptomatic patients with very severe
AS (stage C1) with (139,140) (Level of Evidence: B):
a. Decreased systolic opening of a calciﬁed valve;
b. An aortic velocity 5.0 m per second or greater or mean
pressure gradient 60 mm Hg or higher; and
c. A low surgical risk.In patients with very severe AS and an aortic
velocity 5.0 m per second or mean pressure gradient 60
mm Hg, the rate of symptom onset is approximately 50%
at 2 years. Several observational studies have shown higher
rates of symptom onset and major adverse cardiac events in
patients with very severe, compared with severe, AS. In
addition, a study comparing early surgery with surgery at
symptom onset in 57 propensity scorematched pairs
showed a lower all-cause mortality risk with early surgery
(hazard ratio [HR]: 0.135; 95% conﬁdence interval [CI]:
0.030 to 0.597; p¼0.008). Thus, it is reasonable to
consider elective AVR in patients with very severe
asymptomatic AS if surgical risk is low rather than waiting
for symptom onset. A low surgical risk is deﬁned as an
STS PROM score of <4.0 in the absence of other
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of Excellence, this corresponds to an operative mortality
of <1.5% (Section 2.5). Patient age, avoidance of patient-
prosthesis mismatch, anticoagulation issues, and patient
preferences should be taken into account in a decision to
proceed with AVR or continue watchful waiting.
Supporting References: (115,139,140,145,156–158)
CLASS IIa
2. AVR is reasonable in apparently asymptomatic patients with
severe AS (stage C1) with (25,47) (Level of Evidence: B):
a. A calciﬁed aortic valve;
b. An aortic velocity of 4.0 m per second to 4.9 m per second or
mean pressure gradient of 40 mm Hg to 59 mm Hg; and
c. An exercise test demonstrating decreased exercise toler-
ance or a fall in systolic BP.
Exercise testing may be helpful in clarifying symptom
status in patients with severe AS. When symptoms are
provoked by exercise testing, the patient is considered
symptomatic and meets a Class I recommendation for
AVR. In patients without overt symptoms who
demonstrate 1) a decrease in systolic BP below baseline
or a failure of BP to increase by at least 20 mm Hg or 2)
a signiﬁcant decrease in exercise tolerance compared with
age and sex normal standards, symptom onset within 1
to 2 years is high (about 60% to 80%). Thus, it is
reasonable to consider elective AVR in these patients
when surgical risk is low, taking into account patient
preferences and clinical factors such as age and comorbid
conditions.
Supporting References: (25,46,47,117,119–121)
See Online Data Supplement 3 for more information on
exercise testing.
CLASS IIa
3. AVR is reasonable in symptomatic patients with low-ﬂow/low-
gradient severe AS with reduced LVEF (stage D2) with a
(43,141,142) (Level of Evidence: B):
a. Calciﬁed aortic valve with reduced systolic opening;
b. Resting valve area 1.0 cm2 or less;
c. Aortic velocity less than 4 m per second or mean pressure
gradient less than 40 mm Hg;
d. LVEF less than 50%; and
e. A low-dose dobutamine stress study that shows an aortic
velocity 4 m per second or greater or mean pressure gradient
40 mm Hg or higher with a valve area 1.0 cm2 or less at any
dobutamine dose.
Mean pressure gradient is a strong predictor of outcome
after AVR, with better outcomes with higher gradients.
Outcomes are poor with severe low-gradient AS but are
still improved with AVR compared with medical therapy
in those with a low LVEF, particularly when contractile
reserve is present. The document “Echocardiographic
Assessment of Valve Stenosis: EAE/ASE Recommenda-
tions for Clinical Practice” deﬁnes severe AS on dobut-
amine stress testing as a maximum velocity >4.0 m per
second with a valve area 1.0 cm2 at any point during the
test protocol, with a maximum dobutamine dose of20 mcg/kg per minute. On the basis of outcome data
in several prospective nonrandomized studies, AVR is
reasonable in these patients. LVEF typically increases by
10 LVEF units and may return to normal if afterload
mismatch was the cause of LV systolic dysfunction. Some
patients without contractile reserve may also beneﬁt from
AVR, but decisions in these high-risk patients must be
individualized because there are no data indicating who
will have a better outcome with surgery.
Supporting References: (43,99,137,141,142,150,151)
See Online Data Supplement 1 for more information on
outcomes in patients with low-ﬂow/low-gradient AS with
reduced LVEF.
CLASS IIa
4. AVR is reasonable in symptomatic patients with low-ﬂow/low-
gradient severe AS (stage D3) with an LVEF 50% or greater, a
calciﬁed aortic valve with signiﬁcantly reduced leaﬂet motion,
and a valve area 1.0 cm2 or less only if clinical, hemodynamic,
and anatomic data support valve obstruction as the most likely
cause of symptoms and data recorded when the patient is
normotensive (systolic BP <140 mm Hg) indicate (Level of
Evidence: C):
a. An aortic velocity less than 4 m per second or mean pressure
gradient less than 40 mm Hg; and
b. A stroke volume index less than 35 mL/m2; and
c. An indexed valve area 0.6 cm2/m2 or less.
Most patients with severe AS present with a high
transvalvular gradient and velocity. However, a subset
present with severe AS despite a low gradient and veloc-
ity due either to concurrent LV systolic dysfunction
(LVEF <50%) or a low transaortic stroke volume with
preserved LV systolic function. Studies suggest that low-
ﬂow/low-gradient severe AS with preserved LVEF oc-
curs in 5% to 25% of patients with severe AS. Some studies
suggest that even asymptomatic patients with low-ﬂow/
low-gradient severe AS with a normal LVEF have a
poor prognosis and might beneﬁt from AVR. Other
studies suggest that many of these asymptomatic patients
have only moderate AS with outcomes similar to other
patients with moderate AS and normal transaortic ﬂow
rates. However, both case-control and prospective studies
suggest that outcomes are worse in symptomatic patients
with low-ﬂow/low-gradient AS with a normal LVEF
compared with patients with high-gradient severe AS.
Although no RCTs have been done, a post hoc subset
analysis of an RCT suggests that survival may be improved
with TAVR or AVR versus medical management in the
symptomatic patient with low-ﬂow severe AS.
The clinical approach to patients with low-ﬂow AS re-
lies on integration of multiple sources of data. Low-ﬂow/
low-gradient severe AS with preserved LVEF should be
considered in patients with a severely calciﬁed aortic valve,
an aortic velocity <4.0 m per second (mean pressure
gradient <40 mm Hg), and a valve area 1.0 cm2.
However, even with low ﬂow, severe AS is unlikely with
a velocity <3.0 m per second or mean pressure gradient
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thick walls, diastolic dysfunction, and a normal LVEF
(50%). The ﬁrst diagnostic step is to ensure that data
have been recorded and measured correctly. If the patient
was hypertensive, repeat evaluation after control of BP
should be considered. Next, the valve area should be
indexed to body size because an apparent small valve area
may be only moderate AS in a small patient; an aortic valve
area index 0.6 cm2/m2 suggests severe AS. Transaortic
stroke volume should be calculated from the LV outﬂow
tract diameter and Doppler velocity time integral; a stroke
volume indexed to body surface area <35 mL/m2 is
consistent with low ﬂow. If the degree of valve calciﬁcation
cannot be adequately assessed on TTE, TEE, CT imag-
ing, or ﬂuoroscopy may be considered. The patient should
be evaluated for other potential causes of symptoms to
ensure that symptoms are most likely due to valve
obstruction. The risk of surgery and patient comorbidities
should also be taken into account.
Supporting References: (8,146,159–166)
See Online Data Supplement 8 for more information on
outcomes in patients with low-ﬂow/low-gradient AS with
preserved LVEF.
CLASS IIa
5. AVR is reasonable for patients with moderate AS (stage B) with
an aortic velocity between 3.0 m per second and 3.9 m per
second or mean pressure gradient between 20 mm Hg and 39
mm Hg who are undergoing cardiac surgery for other in-
dications. (Level of Evidence: C)
Calciﬁc AS is a progressive disease, and once moderate
AS is present, the likelihood of symptom onset within 5
years is signiﬁcant. When the risk of progressive VHD is
balanced against the risk of repeat surgery within 5 years, it
is reasonable to perform AVR at the time of other cardiac
surgery when moderate AS is present (Sections 4.3.3. and 10).
This decision must be individualized based on the speciﬁc
operative risk in each patient, clinical factors such as age and
comorbid conditions, valve durability, and patient preferences.
Supporting References: (25,92,138,154,155)Table 10. Summary of Recommendations for AS: Choice of Surgica
Recommendations
Surgical AVR is recommended in patients who meet an indication for AVR (Section 3
with low or intermediate surgical risk
For patients in whom TAVR or high-risk surgical AVR is being considered, members o
Valve Team should collaborate to provide optimal patient care
TAVR is recommended in patients who meet an indication for AVR for AS who have
surgical risk and a predicted post-TAVR survival >12 mo
TAVR is a reasonable alternative to surgical AVR in patients who meet an indication
(Section 3.2.3) and who have high surgical risk (Section 2.5)
Percutaneous aortic balloon dilation may be considered as a bridge to surgical or tra
AVR in severely symptomatic patients with severe AS
TAVR is not recommended in patients in whom existing comorbidities would preclude
expected beneﬁt from correction of AS
AS indicates aortic stenosis; AVR, aortic valve replacement; COR, Class of Recommendation; LOE, LCLASS IIb
1. AVR may be considered for asymptomatic patients with severe
AS (stage C1) with an aortic velocity 4.0 m per second or
greater or mean pressure gradient 40 mm Hg or higher if the
patient is at low surgical risk and serial testing shows an in-
crease in aortic velocity 0.3 m per second or greater per year.
(Level of Evidence: C)
Predictors of rapid disease progression include older age,
more severe valve calciﬁcation, and a faster rate of hemo-
dynamic progression on serial studies. In patients with
severe AS and predictors of rapid disease progression,
elective AVR may be considered if the surgical risk is low
and after consideration of other clinical factors and patient
preferences.
Supporting References: (115,167,168)
3.2.4. Choice of Intervention: Recommendations
See Table 10 for a summary of recommendations from this
section.
These recommendations for choice of intervention for
AS apply to both surgical and transcatheter AVR; in-
dications for AVR are discussed in Section 3.2.3. The
integrative approach to assessing risk of surgical or trans-
catheter AVR is discussed in Section 2.5. The choice of
proceeding with surgical versus transcatheter AVR is based
on multiple parameters, including the risk of operation,
patient frailty, and comorbid conditions. Concomitant
severe CAD may also affect the optimal intervention
because severe multivessel coronary disease may best be
served by AVR and CABG.
CLASS I
1. Surgical AVR is recommended in patients who meet an indica-
tion for AVR (Section 3.2.3) with low or intermediate surgical
risk (Section 2.5) (74,148). (Level of Evidence: A)
AVR is indicated for survival beneﬁt, improvement in
symptoms, and improvement in LV systolic function in
patients with severe symptomatic AS (Section 3.2.3.).
Given the magnitude of the difference in outcomes be-
tween those undergoing AVR and those who refuse AVRl or Transcatheter Intervention
COR LOE References
.2.3) I A (74,148)
f a Heart I C N/A
a prohibitive I B (169,170)
for AVR IIa B (171,172)
nscatheter IIb C N/A
the III:
No Beneﬁt
B (169)
evel of Evidence; N/A, not applicable; and TAVR, transcatheter aortic valve replacement.
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would not be appropriate in patients with a low to inter-
mediate surgical risk (Section 2.5). Outcomes after surgical
AVR are excellent in patients who do not have a high
procedural risk. Surgical series demonstrate improved
symptoms after AVR, and most patients have an im-
provement in exercise tolerance as documented in studies
with pre- and post-AVR exercise stress testing. The spe-
ciﬁc choice of prosthetic valve type is discussed in Section
11.1. Surgical AVR should be considered over TAVR in
patients who are at higher surgical risk but have severe
multivessel coronary disease.
Supporting References: (74,93,173–176)
CLASS I
2. For patients in whom TAVR or high-risk surgical AVR is being
considered, a Heart Valve Team consisting of an integrated,
multidisciplinary group of healthcare professionals with exper-
tise in VHD, cardiac imaging, interventional cardiology, cardiac
anesthesia, and cardiac surgery should collaborate to provide
optimal patient care. (Level of Evidence: C)
Decision making is complex in the patient at high sur-
gical risk with severe symptomatic AS. The decision to
perform surgical AVR, TAVR, or to forgo intervention
requires input from a Heart Valve Team. The primary
cardiologist is aware of coexisting conditions that affect risk
and long-term survival, the patient’s disease course, and the
patient’s preferences and values. Cardiac imaging special-
ists who are knowledgeable about AS and TAVR provide
evaluation of aortic valve anatomy and hemodynamic
severity, vascular anatomy, aortic annulus size, and coro-
nary anatomy, including the annular-ostial distance.
Interventional cardiologists help determine the likelihood
of a successful transcatheter procedure. The cardiac sur-
geon can provide a realistic estimate of risk with a con-
ventional surgical approach, at times in conjunction with a
cardiac anesthesiologist. An expert in VHD, typically a
cardiologist or cardiac surgeon with expertise in imaging
and/or intervention, provides the continuity and integra-
tion needed for the collaborative decision-making process.
Nurses and other members of the team coordinate care and
help with patient education. The cardiac surgeon and
interventional cardiologist are the core of the Heart Valve
Team for patients being considered for AVR or TAVR.
Supporting References: (79,177)
CLASS I
3. TAVR is recommended in patients who meet an indication for
AVR (Section 3.2.3) who have a prohibitive risk for surgical AVR
(Section 2.5) and a predicted post-TAVR survival greater than
12 months (169,170). (Level of Evidence: B)
TAVR has been studied in numerous observational
studies and multicenter registries that include large
numbers of high-risk patients with severe symptomatic
AS. These studies demonstrated the feasibility, excellent
hemodynamic results, and favorable outcomes of the pro-
cedure. In addition, TAVR was compared with standardtherapy in a prospective RCT of patients with severe
symptomatic AS who were deemed inoperable. Severe AS
was deﬁned as an aortic valve area <0.8 cm2 plus a mean
pressure gradient 40 mm Hg or a maximum aortic
velocity 4.0 m per second. All patients had NYHA class
II to IV symptoms. Patients were considered to have a
prohibitive surgical risk when predicted 30–day surgical
morbidity and mortality were 50% due to comorbid
disease or a serious irreversible condition. Patients were
excluded if they had a bicuspid aortic valve, acute myo-
cardial infarction (MI), signiﬁcant CAD, an LVEF <20%,
an aortic annulus diameter <18 mm or >25 mm, severe
AR or MR, a transient ischemic attack within 6 months, or
severe renal insufﬁciency. TAVR was performed by either
the transfemoral or transapical approach using the SA-
PIEN heart-valve system (Edwards Lifesciences LLC,
Irvine, CA). Standard therapy included percutaneous
aortic balloon dilation in 84%.
All-cause death at 2 years was lower with TAVR
(43.3%) compared with standard medical therapy (68%),
with an HR for TAVR of 0.58 (95% CI: 0.36 to 0.92;
p¼0.02). There was a reduction in repeat hospitalization
with TAVR (55% versus 72.5%; p<0.001). In addition,
only 25.2% of survivors were in NYHA class III or IV 1
year after TAVR, compared with 58% of patients receiving
standard therapy (p<0.001). However, the rate of major
stroke at 30 days was higher with TAVR (5.05% versus
1.0%; p¼0.06) and remained higher at 2 years with TAVR
compared with standard therapy (13.8% versus 5.5%;
p¼0.01). Major vascular complications occurred in 16.2%
with TAVR versus 1.1% with standard therapy (p<0.001).
Thus, in high-risk patients with severe symptomatic
AS who are unable to undergo surgical AVR due to a
prohibitive surgical risk and who have an expected survival
of >1 year after intervention, TAVR is recommended to
improve survival and reduce symptoms. This decision
should be made only after discussion with the patient
about the expected beneﬁts and possible complications of
TAVR and surgical AVR. Patients with severe AS are
considered to have a prohibitive surgical risk if they have a
predicted risk with surgery of death or major morbidity
(all cause) of >50% at 1 year; disease affecting 3 major
organ systems that is not likely to improve postoperatively;
or anatomic factors that preclude or increase the risk of
cardiac surgery, such as a heavily calciﬁed (e.g., porcelain)
aorta, prior radiation, or an arterial bypass graft adherent
to the chest wall.
Supporting References: (169,170,178)
CLASS IIa
1. TAVR is a reasonable alternative to surgical AVR in patients
who meet an indication for AVR (Section 3.2.3) and who have
high surgical risk for surgical AVR (Section 2.5) (171,172).
(Level of Evidence: B)
TAVR has been studied in numerous observational
studies and multicenter registries that include large
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AS. These studies demonstrated the feasibility, excellent
hemodynamic results, and favorable outcomes of the
procedure. In addition, TAVR was compared with stan-
dard therapy in a prospective RCT of patients with severe
symptomatic AS who were deemed high risk for surgery.
Severe symptomatic calciﬁc AS was deﬁned as aortic valve
area <0.8 cm2 plus a mean transaortic gradient 40 mm Hg
or aortic velocity 4.0 m per second with NYHA class II
to IV symptoms. Patients were deemed at high surgical
risk if risk of death was 15% within 30 days after the
procedure. An STS score 10% was used for guidance,
with an actual mean STS score of 11.8%3.3%. Exclu-
sions included bicuspid aortic valve anatomy, acute MI,
signiﬁcant CAD, an LVEF <20%, an aortic annulus
diameter <18 mm or >25 mm, severe AR or MR, tran-
sient ischemic attack within 6 months, or severe renal
insufﬁciency. On an intention-to-treat analysis, all-cause
death was similar in those randomized to TAVR
(n¼348) compared with surgical AVR (n¼351) at 30
days, 1 year, and 2 years (p¼0.001) for noninferiority of
TAVR compared with surgical AVR. The composite
endpoint of all-cause death or stroke at 2 years was 35%
with surgical AVR compared with 33.9% with TAVR
(p¼0.78). TAVR was performed by the transfemoral
approach in 244 patients and the transapical approach in
104 patients. Only limited data on long-term durability of
bioprosthetic valves implanted by the transcatheter
approach are available.
Given the known long-term outcomes and valve dura-
bility with surgical AVR, TAVR currently remains
restricted to patients with prohibitive or high surgical risk.
High surgical risk is deﬁned as an STS PROM score of 8%
to 15%, anatomic factors that increase surgical risk, or
signiﬁcant frailty (Section 14.2).
Supporting References: (171,172,179,180)
See Online Data Supplement 9 for more information on
choice of intervention.
CLASS IIb
1. Percutaneous aortic balloon dilation may be considered as a
bridge to surgical AVR or TAVR in patients with severe symp-
tomatic AS. (Level of Evidence: C)
Percutaneous aortic balloon dilation has an important
role in treating children, adolescents, and young adults with
AS, but its role in treating older patients is very limited. The
mechanism by which balloon dilation modestly reduces the
severity of stenosis in older patients is by fracture of calciﬁc
deposits within the valve leaﬂets and, to a minor degree,
stretching of the annulus and separation of the calci-
ﬁed or fused commissures. Immediate hemodynamic results
include a moderate reduction in the transvalvular pressure
gradient, but the postdilation valve area rarely exceeds
1.0 cm2. Despite the modest change in valve area, an early
symptomatic improvement usually occurs. However, serious
acute complications, including acute severe AR andrestenosis and clinical deterioration, occur within 6 to 12
months in most patients. Therefore, in patients with AS,
percutaneous aortic balloon dilation is not a substitute for
AVR.
Some clinicians contend that despite the procedural
morbidity and mortality and limited long-term results,
percutaneous aortic balloon dilation can have a temporary
role in the management of some symptomatic patients who
are not initially candidates for surgical AVR or TAVR. For
example, patients with severe AS and refractory pulmonary
edema or cardiogenic shock might beneﬁt from percuta-
neous aortic balloon dilation as a “bridge” to AVR; an
improved hemodynamic state may reduce the risks of
TAVR or surgery. In some patients, the effects of percu-
taneous aortic balloon dilation on symptoms and LV
function may be diagnostically helpful as well, but many
clinicians recommend proceeding directly to AVR in these
cases. The indications for palliative percutaneous aortic
balloon dilation in patients in whom AVR cannot be
recommended because of serious comorbid conditions are
even less well established, with no data to suggest improved
longevity; however, some patients do report a decrease in
symptoms. Most asymptomatic patients with severe AS
who require urgent noncardiac surgery can undergo surgery
at a reasonably low risk with anesthetic monitoring and
attention to ﬂuid balance. Percutaneous aortic balloon
dilation is not recommended for these patients. If preop-
erative correction of AS is needed, they should be
considered for AVR.
Supporting References: (171,172,181–183)
CLASS III: No Beneﬁt
1. TAVR is not recommended in patients in whom existing
comorbidities would preclude the expected beneﬁt from
correction of AS (169). (Level of Evidence: B)
The survival and symptom reduction beneﬁt of TAVR
is only seen in appropriately selected patients. Baseline
clinical factors associated with a poor outcome after
TAVR include advanced age, frailty, smoking or chronic
obstructive pulmonary disease, pulmonary hypertension,
liver disease, prior stroke, anemia, and other systemic
conditions. The STS estimated surgical risk score pro-
vides a useful measure of the extent of patient comor-
bidities and may help identify which patients will beneﬁt
from TAVR. In patients with a prohibitive surgical risk
for AVR in the PARTNER (Placement of Aortic
Transcatheter Valve) study, the survival beneﬁt of TAVR
was seen in those with an STS score <5% (n¼40, HR:
0.37; 95% CI: 0.13 to 1.01; p¼0.04) and in those with an
STS score between 5% and 14.9% (n¼227, HR: 0.58;
95% CI: 0.41 to 0.8; p¼0.002) but not in those with an
STS score 15% (n¼90, HR: 0.77; 95% CI: 0.46 to
1.28; p¼0.31). The relative prevalence of oxygen-
dependent lung disease was similar in all 3 groups.
However, the other reasons for inoperability were quite
different, with a porcelain aorta or prior chest radiation
Table 11. Stages of Chronic AR
Stage Deﬁnition Valve Anatomy Valve Hemodynamics Hemodynamic Consequences Symptoms
A At risk of AR  Bicuspid aortic valve (or other
congenital valve anomaly)
 Aortic valve sclerosis
 Diseases of the aortic sinuses
or ascending aorta
 History of rheumatic fever or
known rheumatic heart
disease
 IE
 AR severity: none or trace  None  None
B Progressive AR  Mild-to-moderate calciﬁcation
of a trileaﬂet valve bicuspid
aortic valve (or other congen-
ital valve anomaly)
 Dilated aortic sinuses
 Rheumatic valve changes
 Previous IE
 Mild AR:
Jet width <25% of LVOT;
Vena contracta <0.3 cm;
RVol <30 mL/beat;
RF <30%;
ERO <0.10 cm2;
Angiography grade 1þ
 Moderate AR:
Jet width 25%–64% of LVOT;
Vena contracta 0.3–0.6 cm;
RVol 30–59 mL/beat;
RF 30%–49%;
ERO 0.10–0.29 cm2;
Angiography grade 2þ
 Normal LV systolic function
 Normal LV volume or mild
LV dilation
 None
C Asymptomatic
severe AR
 Calciﬁc aortic valve disease
 Bicuspid valve (or other
congenital abnormality)
 Dilated aortic sinuses or
ascending aorta
 Rheumatic valve changes
 IE with abnormal leaﬂet
closure or perforation
 Severe AR:
Jet width 65% of LVOT;
Vena contracta >0.6 cm;
Holodiastolic ﬂow reversal in
the proximal abdominal aorta
RVol 60 mL/beat;
RF 50%;
ERO 0.3 cm2;
Angiography grade 3þ to 4þ;
 In addition, diagnosis of
chronic severe AR requires
evidence of LV dilation
C1: Normal LVEF (50%) and
mild-to-moderate LV dilation
(LVESD 50 mm)
C2: Abnormal LV systolic
function with depressed
LVEF (<50%) or severe LV
dilatation (LVESD >50 mm or
indexed LVESD >25 mm/m2)
 None; exercise
testing is
reasonable to
conﬁrm symptom
status
D Symptomatic
severe AR
 Calciﬁc valve disease
 Bicuspid valve (or other
congenital abnormality)
 Dilated aortic sinuses or
ascending aorta
 Rheumatic valve changes
 Previous IE with abnormal
leaﬂet closure or perforation
 Severe AR:
Doppler jet width 65% of
LVOT;
Vena contracta >0.6 cm,
Holodiastolic ﬂow reversal in
the proximal abdominal aorta,
RVol 60 mL/beat;
RF 50%;
ERO 0.3 cm2;
Angiography grade 3þ to 4þ;
 In addition, diagnosis of
chronic severe AR requires
evidence of LV dilation
 Symptomatic severe AR may
occur with normal systolic
function (LVEF 50%), mild-
to-moderate LV dysfunction
(LVEF 40%–50%), or severe
LV dysfunction (LVEF <40%);
 Moderate-to-severe LV
dilation is present.
 Exertional dyspnea or
angina or more severe
HF symptoms
AR indicates aortic regurgitation; ERO, effective regurgitant oriﬁce; HF, heart failure; IE, infective endocarditis; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular
end-systolic dimension; LVOT, left ventricular outﬂow tract; RF, regurgitant fraction; and RVol, regurgitant volume.
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of <5% and frailty being most common in those with an
STS score 15%. These data emphasize the importance
of evaluating the likely beneﬁt of TAVR, as well as the
risks, in weighing the risk–beneﬁt ratio of intervention in
an individual patient. TAVR is not recommended in
patients with 1) a life expectancy of <1 year, even with a
successful procedure, and 2) those with a chance of
“survival with beneﬁt” of <25% at 2 years.
Supporting References: (115,169,178,184)4. Aortic Regurgitation
4.1. Acute AR
Acute AR may result from abnormalities of the valve,
primarily IE, or abnormalities of the aorta, primarily aortic
dissection. Acute AR may also occur from iatrogenic
complications, such as following percutaneous aortic
balloon dilation or TAVR or following blunt chest trauma.
The acute volume overload on the left ventricle usually
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forward cardiac output. Urgent diagnosis and rapid inter-
vention can be lifesaving.
4.1.1. Diagnosis
TTE is indispensable in conﬁrming the presence, severity,
and etiology of AR, estimating the degree of pulmonary
hypertension, and determining whether there is rapid
equilibration of aortic and LV diastolic pressure. Short
deceleration time on the mitral ﬂow velocity curve and early
closure of the mitral valve onM-mode echocardiography are
indicators ofmarkedly elevated LV end-diastolic pressure. A
short half-time of <300 milliseconds on the AR velocity
curve indicates rapid equilibration of the aortic and LV
diastolic pressures.Assessing reversedﬂowduring diastole in
the aortic arch in comparison with the forward systolic ﬂow
provides a quick semiquantitative estimate of regurgitant
fraction.
Acute severe AR caused by aortic dissection is a surgical
emergency that requires particularly prompt identiﬁcation
and management. However, the presence of new, even
mild, AR, diagnosed by auscultation of a diastolic murmur
or ﬁndings on echocardiography, may be a sign of acute
aortic dissection. The sensitivity and speciﬁcity of TTE for
diagnosis of aortic dissection are only 60% to 80%, whereas
TEE has a sensitivity of 98% to 100% and a speciﬁcity of
95% to 100%. CT imaging is also very accurate and may
provide the most rapid approach to diagnosis at many
centers. CMR imaging is useful with chronic aortic disease
but is rarely used in unstable patients with suspected
dissection. Angiography should be considered only when
the diagnosis cannot be determined by noninvasive imag-
ing and when patients have suspected or known CAD,
especially those with previous CABG.
4.1.2. Intervention
In patients with acute severe AR resulting from IE or
aortic dissection, surgery should not be delayed, especially
if there is hypotension, pulmonary edema, or evidence of
low ﬂow (Section 12). Numerous studies have demon-
strated improved in-hospital and long-term survival in
such patients if they are treated with prompt AVR, as long
as there are no complications (such as severe embolic ce-
rebral damage) or comorbid conditions that make the
prospect of recovery remote. In a prospectively enrolled
multinational cohort of 1,552 patients with deﬁnite native
valve endocarditis (NVE), evidence of new AR was present
in 37% of patients. HF (HR: 2.33; 95% CI: 1.65 to 3.28;
p<0.001) and pulmonary edema (HR: 1.51; 95% CI: 1.04
to 2.18; p¼0.029) were associated with increased in-
hospital mortality. Early surgery was associated with
reduced in-hospital mortality (HR: 0.56; 95% CI: 0.38 to
0.82; p¼0.003). The effect of early surgery on in-hospital
mortality was also assessed by propensity-based matchingadjustment for survivor bias and by instrumental variable
analysis. Compared with medical therapy, early surgery in
the propensity-matched cohort after adjustment for survi-
vor bias was associated with an absolute risk reduction
of 5.9% (p<0.001) for in-hospital mortality.
Intra-aortic balloon counterpulsation is contraindicated
in patients with acute severe AR. Augmentation of aortic
diastolic pressure will worsen the severity of the acute
regurgitant volume, thereby aggravating LV ﬁlling pres-
sures and compromising forward output.
Beta blockers are often used in treating aortic dissection.
However, these agents should be used very cautiously, if
at all, for other causes of acute AR because they will block
the compensatory tachycardia and could precipitate a
marked reduction in BP.
Supporting References: (185–195)
4.2. Stages of Chronic AR
The most common causes of chronic AR in the United
States and other developed countries are bicuspid aortic
valve and calciﬁc valve disease. In addition, AR frequently
arises from primary diseases causing dilation of the
ascending aorta or the sinuses of Valsalva. Another cause of
AR is rheumatic heart disease (the leading cause in many
developing countries). In the majority of patients with AR,
the disease course is chronic and slowly progressive with
increasing LV volume overload and LV adaptation via
chamber dilation and hypertrophy. Management of pa-
tients with AR depends on accurate diagnosis of the cause
and stage of the disease process. Table 11 shows the stages
of AR ranging from patients at risk of AR (stage A) or
with progressive mild-to-moderate AR (stage B) to severe
asymptomatic (stage C) and symptomatic AR (stage D).
Each of these stages is deﬁned by valve anatomy, valve
hemodynamics, severity of LV dilation, and LV systolic
function, as well as by patient symptoms.
4.3. Chronic AR
See Figure 2 for indications for AVR for chronic AR.
4.3.1. Diagnosis and Follow-Up
4.3.1.1. DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS: RECOMMENDATIONS
CLASS I
1. TTE is indicated in patients with signs or symptoms of AR
(stages A to D) for accurate diagnosis of the cause of regurgi-
tation, regurgitant severity, and LV size and systolic function,
and for determining clinical outcome and timing of valve inter-
vention (32,196–205). (Level of Evidence: B)
The clinical stages that characterize the severity of
chronic AR (Table 11) are deﬁned by symptomatic status,
severity of regurgitation, and LV volume and systolic
function. TTE is an indispensable imaging test for evalu-
ating patients with chronic AR and guiding appropriate
management decisions. It provides diagnostic information
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reparability), severity of regurgitation, morphology of the
ascending aorta, and LV response to the increases in pre-
load and afterload. Quantitative measures of regurgitant
volume and effective regurgitant oriﬁce area were strong
predictors of clinical outcome in a prospective study of 251
asymptomatic patients with isolated AR and normal LV
function (stages B and C). This was conﬁrmed in a sub-
sequent study involving 294 patients. Observation of dia-
stolic ﬂow reversal in the aortic arch or more distally can
help identify patients with severe AR. Numerous studies
involving a total of >1,150 patients have consistently
shown that measures of LV systolic function (LVEF or
fractional shortening) and LV end-systolic dimension
(LVESD) or volume are associated with development
of HF symptoms or death in initially asymptomatic pa-
tients (stages B and C1). Moreover, in symptomatic pa-
tients undergoing AVR (stage D), preoperative LV systolic
function and end-systolic dimension or volume areFigure 2. Indications for AVR for Chronic AR
AR indicates aortic regurgitation; AVR, aortic valve replacement (valve repair may be appr
LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LV
regurgitant volume.signiﬁcant determinants of survival and functional results
after surgery. Symptomatic patients (stage D) with normal
LVEF have signiﬁcantly better long-term postoperative
survival than those with depressed systolic function.
Supporting References: (17,32,196–220)
See Online Data Supplement 10 for more information on
the natural history of asymptomatic AR.
CLASS I
2. TTE is indicated in patients with dilated aortic sinuses or
ascending aorta or with a bicuspid aortic valve (stages A and B)
to evaluate the presence and severity of AR (221). (Level of
Evidence: B)
A diastolic regurgitant murmur is not always audible
in patients with mild or moderate AR. TTE is more
sensitive than auscultation in detecting AR in patients
at risk for development of AR. In a series of 100
patients referred for echocardiographic evaluation of
a systolic murmur, 28 had AR on echocardiography.opriate in selected patients); ERO, effective regurgitant oriﬁce; LV, left ventricular;
ESD, left ventricular end-systolic dimension; RF, regurgitant fraction; and RVol,
JACC Vol. 63, No. 22, 2014 Nishimura et al.
June 10, 2014:e57–185 2014 AHA/ACC Valvular Heart Disease Guideline
e85Auscultation had high speciﬁcity (96%) for detecting AR
but low sensitivity (21%), and diagnostic accuracy was
only 75%.
Supporting Reference: (221)
CLASS I
3. CMR is indicated in patients with moderate or severe AR
(stages B, C, and D) and suboptimal echocardiographic images
for the assessment of LV systolic function, systolic and dia-
stolic volumes, and measurement of AR severity (222,223).
(Level of Evidence: B)
CMR imaging provides accurate measures of regurgitant
volume and regurgitant fraction in patients with AR, as
well as assessment of aortic morphology, LV volume, and
LV systolic function. In addition to its value in patients
with suboptimal echocardiographic data, CMR is useful
for evaluating patients in whom there is discordance be-
tween clinical assessment and severity of AR by echocar-
diography. CMR measurement of regurgitant severity is
less variable than echocardiographic measurement.
Supporting References: (222–228)
4.3.1.2. DIAGNOSTIC TESTINGdCHANGING SIGNS OR SYMPTOMS
Symptoms are the most common indication for AVR in
patients with AR. In patients with previous documentation
of mild or moderate AR, new-onset dyspnea or angina may
indicate that AR has progressed in severity. If AR remains
mild, further investigation for other etiologies is indicated.
In patients with previous documentation of severe AR,
onset of symptoms is an indication for surgery and repeat
TTE is indicated to determine the status of the aortic
valve, aorta, and left ventricle preoperatively.
Supporting References: (31,214,220,229,230)
4.3.1.3. DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP
Patients with asymptomatic severe AR with normal LV
systolic function are at risk for progressive increases in LV
end-diastolic and end-systolic volumes and reduction in
systolic function. In a series of asymptomatic patients with
AR and normal LV systolic function who underwent serial
echocardiograms, predictors of death or symptoms in a
multivariate analysis were age, initial end-systolic dimen-
sion, and rate of change in end-systolic dimension and rest
LVEF during serial studies. In asymptomatic patients who
do not fulﬁll the criteria for AVR, serial imaging is indi-
cated to identify those who are progressing toward the
threshold for surgery (Table 4).
Supporting Reference: (32)
4.3.1.4. DIAGNOSTIC TESTINGdCARDIAC CATHETERIZATION
When there is discordance between clinical assessment and
noninvasive tests about the severity of AR, additional
testing is indicated. Under most circumstances, another
noninvasive test such as CMR is used when TTE and
clinical ﬁndings are discordant. Invasive assessment is
indicated when CMR is not available or there are con-
traindications for CMR, such as implanted devices. In
symptomatic patients with equivocal echocardiographicevidence of severity of AR, cardiac catheterization is useful
to assess hemodynamics, coronary artery anatomy, and
severity of AR.
Supporting References: (222,224–228)
4.3.1.5. DIAGNOSTIC TESTINGdEXERCISE TESTING
Exercise stress testing can be used to assess symptomatic
status and functional capacity in patients with AR. Such
testing is helpful in conﬁrming patients’ reports that they
have no symptoms with daily life activities and in assessing
objective exercise capacity and symptom status in those
with equivocal symptoms.
4.3.2. Medical Therapy: Recommendations
CLASS I
1. Treatment of hypertension (systolic BP >140 mm Hg) is rec-
ommended in patients with chronic AR (stages B and C), pref-
erably with dihydropyridine calcium channel blockers or ACE
inhibitors/ARBs (204,209). (Level of Evidence: B)
Vasodilating drugs are effective in reducing systolic BP in
patients with chronic AR. Beta blockers may be less effective
because the reduction in heart rate is associated with an even
higher stroke volume, which contributes to the elevated
systolic pressure in patients with chronic severe AR.
Supporting References: (204,209,231–233)
CLASS IIa
1. Medical therapy with ACE inhibitors/ARBs and beta blockers
is reasonable in patients with severe AR who have symptoms
and/or LV dysfunction (stages C2 and D) when surgery is
not performed because of comorbidities (232,234). (Level of
Evidence: B)
Vasodilating drugs improve hemodynamic abnormalities
in patients with AR and improve forward cardiac output.
However, 2 small RCTs yielding discordant results did not
conclusively show that these drugs alter the natural history
of asymptomatic patients with chronic severe AR and
normal LV systolic function. Thus, vasodilator therapy is
not recommended routinely in patients with chronic
asymptomatic AR and normal LV systolic function.
In symptomatic patients who are candidates for surgery,
medical therapy is not a substitute for AVR. However,
medical therapy is helpful for alleviating symptoms in pa-
tients who are considered at very high risk for surgery
because of concomitant comorbid medical conditions. In
a cohort study of 2,266 patients with chronic AR, treat-
ment with ACE inhibitors or ARBs was associated with a
reduced composite endpoint of AVR, hospitalization for
HF, and death from HF (HR: 0.68; 95% CI: 0.54 to 0.87;
p<0.01). In that study, 45% had evidence of LV systolic
impairment. In another retrospective cohort study of 756
patients with chronic AR, therapy with beta-adrenergic
blockers was associated with improved survival (HR:
0.74; 95% CI: 0.58 to 0.93; p<0.01). Also, 33% of patients
had associated CAD, 64% had hypertension, 20% had
renal insufﬁciency, 70% had HF, and 25% had AF. Pa-
tients treated with beta blockers were more likely to also
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dihydropyridine calcium channel blockers (22% versus
16%; p¼0.03). Importantly, more patients receiving beta
blockers in that study underwent AVR (49% versus 29%;
p<0.001), but this was accounted for in the multivariate
model. When patients were censored at the time of sur-
gery, beta-blocker therapy remained associated with higher
survival rates (p<0.05).
Supporting References: (204,209,231,232,234–239)
See Online Data Supplement 11 for more information on
vasodilator therapy in AR.
4.3.3. Timing of Intervention: Recommendations
See Table 12 for a summary of recommendations from this
section.
The vast majority of patients who require surgery for
chronic severe AR will require AVR. Valve-sparing
replacement of the aortic sinuses and ascending aorta is a
possible strategy in patients with AR caused by aortic
dilation in whom a trileaﬂet or bicuspid valve is not
thickened, deformed, or calciﬁed. Despite advances in
primary aortic valve repair, especially in young patients
with bicuspid aortic valves, the experience at a few
specialized centers has not yet been replicated at the gen-
eral community level, and durability of aortic valve repair
remains a major concern. Performance of aortic valve repair
should be concentrated in those centers with proven
expertise in the procedure.
Supporting References: (244–247)
CLASS I
1. AVR is indicated for symptomatic patients with severe AR
regardless of LV systolic function (stage D) (31,229,230).
(Level of Evidence: B)
Symptoms are an important indication for AVR in pa-
tients with chronic severe AR, and the most important
aspect of the clinical evaluation is taking a careful, detailed
history to elicit symptoms or diminution of exercise ca-
pacity. Patients with chronic severe AR who develop
symptoms have a high risk of death if AVR is not per-
formed. In a series of 246 patients with severe AR followed
without surgery, those who were NYHA class III or IVTable 12. Summary of Recommendations for AR Intervention
Recommendations
AVR is indicated for symptomatic patients with severe AR regardless of LV systolic fun
AVR is indicated for asymptomatic patients with chronic severe AR and LV systolic dy
(LVEF <50%) (stage C2)
AVR is indicated for patients with severe AR (stage C or D) while undergoing cardiac
for other indications
AVR is reasonable for asymptomatic patients with severe AR with normal LV systolic
(LVEF 50%) but with severe LV dilation (LVESD >50 mm, stage C2)
AVR is reasonable in patients with moderate AR (stage B) who are undergoing other c
AVR may be considered for asymptomatic patients with severe AR and normal LV sy
(LVEF 50%, stage C1) but with progressive severe LV dilation (LVEDD >65 mm)
risk is low*
*Particularly in the setting of progressive LV enlargement.
AR indicates aortic regurgitation; AVR, aortic valve replacement; COR, Class of Recommendation; LOE,
ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; and N/A, not applicable.had a mortality rate of 24.6% per year; even NYHA class II
symptoms were associated with increased mortality (6.3%
per year). Numerous other studies indicate that survival
and functional status after AVR are related to severity of
preoperative symptoms assessed either subjectively or
objectively with exercise testing, with worse outcomes in
patients who undergo surgery after development of
moderately severe (NYHA class III) symptoms or
impaired exercise capacity. In a series of 289 patients
followed after AVR, long-term postoperative survival was
signiﬁcantly higher in patients who were in NYHA class
I or II at the time of surgery compared with those in
NYHA class III or IV (10–year survival rates 78%7%
versus 45%4%, respectively; p<0.001). The importance
of preoperative symptoms in the study was observed for
both patients with normal LV systolic function and those
with LV systolic dysfunction. Postoperative survival is
signiﬁcantly higher in symptomatic patients with normal
LVEF compared with those with impaired systolic
function, but even in symptomatic patients with severely
depressed systolic function, surgery is recommended over
medical therapy. In a postoperative series of 450 patients
undergoing AVR from 1980 to 1995, patients with
markedly low LVEF incurred high short- and long-term
mortality after AVR. However, postoperative LV func-
tion improved signiﬁcantly, and most patients survived
without recurrence of HF. This was conﬁrmed in a series
of 724 patients who underwent AVR from 1972 to
1999, in which long-term survival was signiﬁcantly
reduced in the 88 patients with severe LV dysfunction
(LVEF <30%) compared with the 636 patients with
either less severe LV dysfunction or normal LVEF (81%
versus 92% at 1 year, 68% versus 81% at 5 years, 46%
versus 62% at 10 years, 26% versus 41% at 15 years, and
12% versus 24% at 20 years, respectively; p¼0.04).
Among propensity-matched patients operated on in the
latter time frame since 1985, these trends were no longer
signiﬁcant (survival at 1, 5, and 10 years after surgery was
92%, 79%, and 51%, respectively for patients with severe
LV dysfunction and 96%, 83%, and 55% for the others,
respectively; p¼0.9).COR LOE References
ction (stage D) I B (31,229,230)
sfunction I B (211,229,
240,241)
surgery I C N/A
function IIa B (225,242,243)
ardiac surgery IIa C N/A
stolic function
if surgical
IIb C N/A
Level of Evidence; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVEF, left
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See Online Data Supplement 12 for more information on
outcome after surgery for AR.
CLASS I
2. AVR is indicated for asymptomatic patients with chronic severe
AR and LV systolic dysfunction (LVEF <50%) at rest (stage C2)
if no other cause for systolic dysfunction is identiﬁed
(211,229,240,241). (Level of Evidence: B)
After AVR, LV systolic function is an important
determinant of survival and functional status for chronic
severe AR. Optimal outcomes are obtained when surgery is
performed before LVEF decreases below 50%. However,
among patients with LV systolic dysfunction, LV function
will improve in many after surgery, especially those with
minimal or no symptoms, mild versus severe LV systolic
dysfunction, and a brief duration of LV dysfunction. A
series of 37 patients with severe AR who underwent AVR
were studied, all of whom had preoperative LV dysfunction
but preserved exercise capacity (including 8 asymptomatic
patients). In the 10 patients in whom LV dysfunction had
developed <14 months preoperatively, there was a greater
improvement in LV systolic function and regression of LV
dilatation compared with those patients who had a longer
duration of LV dysfunction. Patients with preserved ex-
ercise capacity had higher survival rates, a shorter duration
of LV dysfunction, and a persistent improvement in LV
size and systolic function at late postoperative studies
at 3 to 7 years. Thus, once LV systolic dysfunction
(LVEF <50%) is demonstrated, results are optimized by
referring for surgery rather than waiting for onset of
symptoms or more severe LV dysfunction.
SupportingReferences: (17,211–220,229,240–242,249,250)
CLASS I
3. AVR is indicated for patients with severe AR (stage C or D)
while undergoing cardiac surgery for other indications. (Level of
Evidence: C)
Patients with chronic severe AR should undergo AVR if
they are referred for other forms of cardiac surgery, such as
CABG, mitral valve surgery, or replacement of the
ascending aorta. This will prevent both the hemodynamic
consequences of persistent AR during the perioperative
period and the possible need for a second cardiac operation
in the near future.
CLASS IIa
1. AVR is reasonable for asymptomatic patients with severe AR
with normal LV systolic function (LVEF ‡50%) but with severe LV
dilation (LVESD >50 mm or indexed LVESD >25 mm/m2) (stage
C2) (225,242,243). (Level of Evidence: B)
LVESD in patients with chronic AR reﬂects both the
severity of the LV volume overload and the degree of LV
systolic shortening. An elevated end-systolic dimension
often reﬂects LV systolic dysfunction with a depressed
LVEF. If LVEF is normal, an increased LVESD indicates
a signiﬁcant degree of LV remodeling and is associatedwith subsequent development of symptoms and/or LV
systolic dysfunction. In a series of 104 initially asymp-
tomatic patients with normal LV systolic function followed
for a mean of 8 years, an LVESD >50 mm was associated
with a risk of death, symptoms, and/or LV dysfunction of
19% per year. In a second study of 101 similar patients
followed for a mean of 5 years, this risk was 7% per year.
In a third study of 75 similar patients followed for a mean
of 10 years, the risk was 7.6% per year. Among patients
undergoing AVR, a smaller LVESD is associated with
both better survival and improvement in LV systolic
function after surgery. Most studies used unadjusted LV
dimension, with more recent data suggesting that indexing
for body size may be appropriate, particularly in women or
small patients. A study of 246 patients that adjusted end-
systolic dimension for body size suggested that an end-
systolic dimension 25 mm/m2 is associated with a poor
outcome in asymptomatic patients. This has been con-
ﬁrmed by a subsequent study of 294 asymptomatic patients
in which an end-systolic dimension >24 mm/m2 was an
independent predictor of LV systolic dysfunction, symp-
toms, or death, and an earlier study of 32 patients in which
an end-systolic dimension >26 mm/m2 was associated
with persistent LV dilation after AVR. Other studies have
suggested that end-systolic volume index is a more sensi-
tive predictor of cardiac events than end-systolic dimension
in asymptomatic patients, but values of end-systolic volume
index identifying high-risk patients have varied between
35 mL/m2 and 45 mL/m2 in 2 studies. Thus, more data
are needed to determine threshold values of end-systolic
volume index with which to make recommendations for
surgery in asymptomatic patients.
Supporting References: (17,31,32,196,197,199,203–205,
208,212–216,218,242,243,249,251–254)
See Online Data Supplement 12 for more information on
AVR in asymptomatic patients.
CLASS IIa
2. AVR is reasonable in patients with moderate AR (stage B) while
undergoing surgery on the ascending aorta, CABG, or mitral
valve surgery. (Level of Evidence: C)
Because of the likelihood of progression of AR and the
need for future AVR in patients with moderate AR, it is
reasonable to replace the aortic valve in patients who have
evidence of primary aortic valve leaﬂet disease or signiﬁcant
aortic dilation if they are referred for other forms of cardiac
surgery, such as CABG, mitral valve surgery, or replace-
ment of the ascending aorta.
CLASS IIb
1. AVR may be considered for asymptomatic patients with severe
AR and normal LV systolic function at rest (LVEF ‡50%, stage
C1) but with progressive severe LV dilatation (LV end-diastolic
dimension >65 mm) if surgical risk is low. (Level of Evidence: C)
LV end-diastolic dimension is indicative of the severity
of LV volume overload in patients with chronic AR. It is
signiﬁcantly associated with development of symptoms
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but less so than LVESD. Similarly, end-diastolic volume
index is less predictive than end-systolic volume index in
asymptomatic patients. However, especially in young pa-
tients with severe AR, progressive increases in end-
diastolic dimension are associated with a subsequent need
for surgery. In a series of 104 initially asymptomatic pa-
tients with normal LV systolic function followed for a
mean of 8 years, an LV end-diastolic dimension of70mm
was associated with a risk of death, symptoms, and/or
LV dysfunction of 10% per year. In a second study of 101
patients followed for a mean of 5 years, this risk was 6.3%
per year; in a third study of 75 patients followed for a mean
of 10 years, the risk was 5.8% per year. Marked increases
in end-diastolic dimension (80 mm) have been associated
with sudden death. The writing committee thought that
AVR may be considered for the asymptomatic patient with
severe AR, normal LV systolic function, and severe LV
dilatation (LV end-diastolic dimension >65 mm) if there
is a low surgical risk and particularly if there is evidence
of progressive LV dilation.
New markers of severity of AR and its resultant LV
volume overload are under investigation. These include
measures of regurgitant fraction, regurgitant volume, and
effective regurgitant oriﬁce area; LV volume assessment
with 3D echocardiography; noninvasive measures of LV
end-systolic stress and systolic and diastolic strain rates;
and biomarkers such as brain natriuretic peptide. Further
experience with these new markers pertaining to patient
outcomes is necessary before ﬁrm recommendations can be
proposed.
Supporting References: (32,196,197,203–207)
5. Bicuspid Aortic Valve and Aortopathy
Patients with a bicuspid aortic valve may also have an
associated aortopathy consisting of aortic dilation, coarc-
tation, or even aortic dissection.
5.1. Bicuspid Aortic Valve
5.1.1. Diagnosis and Follow-Up
5.1.1.1. DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS: RECOMMENDATIONS
CLASS I
1. An initial TTE is indicated in patients with a known bicuspid
aortic valve to evaluate valve morphology, to measure the
severity of AS and AR, and to assess the shape and diameter of
the aortic sinuses and ascending aorta for prediction of clinical
outcome and to determine timing of intervention (255–260).
(Level of Evidence: B)
Most patients with a bicuspid aortic valve will develop AS
or AR over their lifetime. Standard echocardiographic ap-
proaches for measurement of stenosis and regurgitant
severity are key to optimal patientmanagement as detailed in
the recommendations for AS and AR (Sections 3 and 4).Bicuspid aortic valves are frequently associated with
aortic dilation either at the level of the sinuses of Valsalva
or, more frequently, in the ascending aorta. In some pa-
tients, severe aneurysmal aortic dilation may develop. The
incidence of aortic dilation is higher in patients with fusion
of the right and noncoronary cusps than the more common
phenotype of fusion of the right and left coronary cusps.
In a series of 191 patients with bicuspid aortic valves un-
dergoing echocardiography, those with fusion of the right
or left coronary cusp and the noncoronary cusp had a
greater prevalence of aortic dilation than those with the
fusion of the right and left coronary cusps (68% versus
40%). This was conﬁrmed in a subsequent report of 167
patients with bicuspid aortic valves studied with CT and
echocardiography. Patients with fusion involving the
noncoronary cusp are also more likely to have dilation of
the ascending aorta, rather than the sinuses, which often
extends to the transverse arch.
In nearly all patients with a bicuspid aortic valve, TTE
provides good quality images of the aortic sinuses with
accurate diameter measurements. Further cephalad seg-
ments of the ascending aorta can be imaged in many pa-
tients by moving the transducer up 1 or 2 interspaces to
view the arch from a suprasternal notch approach. The
echocardiographic report should include aortic measure-
ments at the aortic annulus, sinuses, sinotubular junction,
and mid-ascending aorta, along with an indicator of the
quality and completeness of aortic imaging in each patient
with a bicuspid aortic valve. Doppler interrogation of the
proximal descending aorta allows evaluation for aortic
coarctation, which is associated with the presence of a
bicuspid aortic valve.
In 20% to 30% of patients with bicuspid valves, other
family members also have bicuspid valve disease and/or an
associated aortopathy. A speciﬁc genetic cause has not been
identiﬁed, and the patterns of inheritance are variable, so it
is important to take a family history and inform patients
that other family members may be affected. Imaging of
ﬁrst-degree relatives is clearly appropriate if the patient has
an associated aortopathy or a family history of VHD or
aortopathy. Many valve experts also recommend screening
all ﬁrst-degree relatives of patients with bicuspid aortic
valve, although we do not yet have data addressing the
possible impact of screening on outcomes or the cost-
effectiveness of this approach.
Supporting References: (255–261)
CLASS I
2. Aortic magnetic resonance angiography or CT angiography is
indicated in patients with a bicuspid aortic valve when
morphology of the aortic sinuses, sinotubular junction, or
ascending aorta cannot be assessed accurately or fully by
echocardiography. (Level of Evidence: C)
TTE can provide accurate assessment of the presence
and severity of aortic dilation in most patients. However, in
some patients, only the aortic sinuses can be visualized,
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tissue. When echocardiographic images do not provide
adequate images of the ascending aorta to a distance
4.0 cm from the valve plane, additional imaging is
needed. TEE may be considered but requires sedation
and still may miss segments of the mid-ascending aorta.
Magnetic resonance angiography or chest CT angiography
provide accurate diameter measurements when aligned
perpendicular to the long axis of the aorta. Advantages of
magnetic resonance angiography and CT angiography
compared with TTE include higher spatial (but lower
temporal) resolution and the ability to display a 3D
reconstruction of the entire length of the aorta. Magnetic
resonance angiography and CT angiography aortic di-
ameters typically are 1 mm to 2 mm larger than echocar-
diographic measurements because of inclusion of the aortic
wall in the measurement and because echocardiographic
measurements are made at end-diastole, whereas magnetic
resonance angiography or CT angiography measurements
may represent an average value. Magnetic resonance an-
giography imaging is preferred over CT angiography im-
aging, when possible, because of the absence of ionizing
radiation exposure in patients who likely will have multiple
imaging studies over their lifetime.
Supporting References: (261–263)
5.1.1.2. DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP: RECOMMENDATION
CLASS I
1. Serial evaluation of the size and morphology of the aortic si-
nuses and ascending aorta by echocardiography, CMR, or CT
angiography is recommended in patients with a bicuspid aortic
valve and an aortic diameter greater than 4.0 cm, with the
examination interval determined by the degree and rate of
progression of aortic dilation and by family history. In patients
with an aortic diameter greater than 4.5 cm, this evaluation
should be performed annually. (Level of Evidence: C)
Patients with bicuspid aortic valves who have docu-
mented dilation of the sinuses of Valsalva or ascending
aorta should have serial assessment of aortic morphology
because the aortopathy may progress with time. In a se-
ries of 68 patients with bicuspid aortic valves, the mean
rate of diameter progression was 0.5 mm per year at the
sinuses of Valsalva (95% CI: 0.3 to 0.7), 0.5 mm per year
at the sinotubular junction (95% CI: 0.3 to 0.7), and 0.9
mm per year at the proximal ascending aorta (95% CI:
0.6 to 1.2). Others have reported mean rates of increase
of up to 2 mm per year. Aortic imaging at least annually
is prudent in patients with a bicuspid aortic valve and
signiﬁcant aortic dilation (>4.5 cm), a rapid rate of
change in aortic diameter, and in those with a family
history of aortic dissection. In patients with milder
dilation that shows no change on sequential studies and a
negative family history, a longer interval between imaging
studies is appropriate.
Supporting References: (264–266)5.1.2. Medical Therapy
There are no proven drug therapies that have been shown
to reduce the rate of progression of aortic dilation in pa-
tients with aortopathy associated with bicuspid aortic valve.
In patients with hypertension, control of BP with any
effective antihypertensive medication is warranted. Beta
blockers and ARBs have conceptual advantages to reduce
rate of progression but have not been shown to be bene-
ﬁcial in clinical studies.
5.1.3. Intervention: Recommendations
CLASS I
1. Operative intervention to repair the aortic sinuses or replace the
ascending aorta is indicated in patients with a bicuspid aortic
valve if the diameter of the aortic sinuses or ascending aorta is
greater than 5.5 cm (113,267,268). (Level of Evidence: B)
In 2 large long-term retrospective cohort studies of pa-
tients with bicuspid aortic valves, the incidence of aortic
dissection was very low. In a study of 642 patients followed
for a mean of 9 years, there were 5 dissections (3 ascending
and 2 descending). In another bicuspid aortic valve study
of 416 patients followed for a mean of 16 years, there were
2 dissections. In the latter report, the calculated incidence
of dissection was higher than the age-adjusted relative risk
of the county’s general population (HR: 8.4; 95% CI: 2.1
to 33.5; p¼0.003) but was only 3.1 (95% CI: 0.5 to 9.5)
cases per 10,000 patient-years. In patients with bicuspid
aortic valves, data are limited regarding the degree of aortic
dilation at which the risk of dissection is high enough
to warrant operative intervention in patients who do not
fulﬁll criteria for AVR on the basis of severe AS or AR.
Previous ACC/AHA guidelines have recommended sur-
gery when the degree of aortic dilation is >5.0 cm at any
level, including sinuses of Valsalva, sinotubular junction,
or ascending aorta. The current writing committee con-
siders the evidence supporting these previous recommen-
dations very limited and anecdotal and endorses a more
individualized approach. Surgery is recommended with
aortic dilation of 5.1 cm to 5.5 cm only if there is a family
history of aortic dissection or rapid progression of dilation.
In all other patients, operation is indicated if there is
more severe dilation (5.5 cm). The writing committee also
does not recommend the application of formulas to adjust
the aortic diameter for body size. Furthermore, prior rec-
ommendations were frequently ambiguous with regard
to the level to which they apply (sinus segment versus
tubular ascending aorta) and did not acknowledge the
normal difference in diameter at these levels, with the sinus
segment 0.5 cm larger in diameter than the normal
ascending aorta. In Heart Valve Centers of Excellence,
valve-sparing replacement of the aortic sinuses and
ascending aorta yields excellent results in patients who do
not have severely deformed or dysfunctional valves.
Supporting References: (113,244,245,266–273)
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1. Operative intervention to repair the aortic sinuses or replace the
ascending aorta is reasonable in patients with bicuspid aortic
valves if the diameter of the aortic sinuses or ascending aorta is
greater than 5.0 cm and a risk factor for dissection is present
(family history of aortic dissection or if the rate of increase in
diameter is ‡0.5 cm per year). (Level of Evidence: C)
In patients with bicuspid aortic valves, data are limited
regarding the degree of aortic dilation at which the risk of
dissection is high enough to warrant operative intervention
in patients who do not fulﬁll criteria for AVR on the basis
of severe AS or AR. In patients at higher risk of dissection
based on family history or evidence of rapid progression of
aortic dilation (0.5 cm per year), surgical intervention is
reasonable when the aortic diameter is >5.0 cm.
Supporting References: (266,268–270,274)
CLASS IIa
2. Replacement of the ascending aorta is reasonable in patients
with a bicuspid aortic valve who are undergoing aortic valve
surgery because of severe AS or AR (Sections 3.2.3 and 4.3.3)
if the diameter of the ascending aorta is greater than 4.5 cm.
(Level of Evidence: C)
In patients with bicuspid aortic valves, data are limited
regarding the degree of aortic dilation at which the risk of
dissection is high enough to warrant replacement of the
ascending aorta at the time of AVR. The risk of progres-
sive aortic dilation and dissection after AVR in patients
with bicuspid aortic valves has been the subject of several
studies, although deﬁnitive data are lacking. In patients
undergoing AVR because of severe AS or AR, replacement
of the ascending aorta is reasonable when the aortic
diameter is >4.5 cm. Replacement of the sinuses of Val-
salva is not necessary in all cases and should be individu-
alized based on the displacement of the coronary ostia,
because progressive dilation of the sinus segment after
separate valve and graft repair is uncommon.
Supporting References: (266,268–270,275–279)
6. Mitral Stenosis
6.1. Stages of MS
Medical and interventional approaches to the management
of patients with valvular MS depend on accurate diagnosis
of the cause and stage of the disease process. Table 13
shows the stages of mitral valve disease ranging from pa-
tients at risk of MS (stage A) or with progressive hemo-
dynamic obstruction (stage B) to severe asymptomatic
(stage C) and symptomatic MS (stage D). Each of these
stages is deﬁned by valve anatomy, valve hemodynamics,
the consequences of valve obstruction on the left atrium
(LA) and pulmonary circulation, and patient symptoms.
The anatomic features of the stages of MS are based on a
rheumatic etiology for the disease. There are patients who
have a nonrheumatic etiology of MS due to senile calciﬁc
disease (Section 6.3) in whom there is a heavily calciﬁedmitral annulus with extension of the calcium into the
leaﬂets. Hemodynamic severity is best characterized by the
planimetered mitral valve area and the calculated mitral
valve area from the diastolic pressure half-time. The deﬁ-
nition of “severe” MS is based on the severity at which
symptoms occur as well as the severity at which interven-
tion will improve symptoms. Thus, a mitral valve area
1.5 cm2 is considered severe. This usually corresponds to
a transmitral mean gradient of >5 mm Hg to 10 mm Hg
at a normal heart rate. However, the mean pressure
gradient is highly dependent on the transvalvular ﬂow and
diastolic ﬁlling period and will vary greatly with changes in
heart rate. The diastolic pressure half-time is dependent
not only on the degree of mitral obstruction but also the
compliance of the left ventricle and the LA and other
measures of mitral valve area, such as the continuity
equation or the proximal isovelocity surface area, may be
used if discrepancies exist.
Supporting References: (280–286)6.2. Rheumatic MS
SeeFigure3 for indications for intervention for rheumaticMS.
6.2.1. Diagnosis and Follow-Up
6.2.1.1. DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS: RECOMMENDATIONS
CLASS I
1. TTE is indicated in patients with signs or symptoms of MS to
establish the diagnosis, quantify hemodynamic severity (mean
pressure gradient, mitral valve area, and pulmonary artery
pressure), assess concomitant valvular lesions, and demon-
strate valve morphology (to determine suitability for mitral
commissurotomy) (8,287–295). (Level of Evidence: B)
Suspicion for MS may arise from a childhood history of
rheumatic fever or a characteristic auscultatory ﬁnding of
an opening snap after the second heart sound and subse-
quent apical diastolic murmur, but such patients often
present with nonspeciﬁc complaints of exertional dyspnea
with an unrevealing physical examination. In the vast
majority of cases, TTE can elucidate the anatomy and
functional signiﬁcance of MS but must be undertaken with
great care. Use of 2D scanning from the parasternal long-
axis window can identify the characteristic diastolic dom-
ing of the mitral valve, whereas short-axis scanning will
demonstrate commissural fusion and allow planimetry of
the mitral oriﬁce. This must be done carefully to obtain the
smallest oriﬁce in space and the largest opening in time.
3D echocardiography (either TTE or TEE) may allow
greater accuracy but is not yet routinely used. Doppler
hemodynamics are typically obtained from the apical
4–chamber or long-axis view and should include peak and
mean transvalvular gradient as calculated by the simpliﬁed
Bernoulli equation, averaged from 3 to 5 beats in sinus
rhythm and 5 to 10 beats in AF. Heart rate should always
be included in the report because it greatly affects trans-
valvular gradient due to the differential impact of
Table 13. Stages of MS
Stage Deﬁnition Valve Anatomy Valve Hemodynamics Hemodynamic Consequences Symptoms
A At risk of MS  Mild valve doming during diastole  Normal transmitral ﬂow velocity  None  None
B Progressive MS  Rheumatic valve changes with
commissural fusion and diastolic
doming of the mitral valve
leaﬂets
 Planimetered MVA >1.5 cm2
 Increased transmitral ﬂow velocities
 MVA >1.5 cm2
 Diastolic pressure half-time <150 ms
 Mild-to-moderate LA enlargement
 Normal pulmonary pressure at rest
 None
C Asymptomatic
severe MS
 Rheumatic valve changes with
commissural fusion and diastolic
doming of the mitral valve
leaﬂets
 Planimetered MVA 1.5 cm2
 (MVA 1.0 cm2 with very
severe MS)
 MVA 1.5 cm2
 (MVA 1.0 cm2 with very severe MS)
 Diastolic pressure half-time 150 ms
 (Diastolic pressure half-time 220 ms
with very severe MS)
 Severe LA enlargement
 Elevated PASP >30 mm Hg
 None
D Symptomatic
severe MS
 Rheumatic valve changes with
commissural fusion and diastolic
doming of the mitral valve
leaﬂets
 Planimetered MVA 1.5 cm2
 MVA 1.5 cm2
 (MVA 1.0 cm2 with very severe MS)
 Diastolic pressure half-time 150 ms
 (Diastolic pressure half-time 220 ms
with very severe MS)
 Severe LA enlargement
 Elevated PASP >30 mm Hg
 Decreased
exercise
tolerance
 Exertional
dyspnea
The transmitral mean pressure gradient should be obtained to further determine the hemodynamic effect of the MS and is usually >5 mm Hg to 10 mm Hg in severe MS; however, due to the variability of
the mean pressure gradient with heart rate and forward ﬂow, it has not been included in the criteria for severity.
LA indicates left atrial; LV, left ventricular; MS, mitral stenosis; MVA, mitral valve area; and PASP, pulmonary artery systolic pressure.
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Concomitant MR should be sought and quantiﬁed as
recommended, along with other valve lesions (Section
7.3.1.1). RV systolic pressure is typically estimated by
continuous wave Doppler of TR. Mitral valve morphology
and feasibility for percutaneous mitral balloon commis-
surotomy or surgical commissurotomy can be assessed in
several ways, most commonly via the Wilkins score, which
combines valve thickening, mobility, and calciﬁcation with
subvalvular scarring in a 16–point scale. Characterization
of commissural calciﬁcation is also useful. Additional
echocardiographic tools for assessment of MS include the
mitral pressure half-time, which is inversely related to
mitral valve area. However, the mitral pressure half-time is
also affected by left atrial and LV compliance. Thus, other
methods for calculation of the mitral valve area, such as the
continuity method and proximal isovelocity surface area
method, could be used if necessary. Left atrial dimension,
area, and volume index should be measured, with careful
interrogation for possible left atrial thrombus (although full
exclusion of thrombus requires TEE). As with any echo-
cardiogram, full characterization of global and regional LV
and RV function should be reported.
Supporting References: (8,287–295)
CLASS I
2. TEE should be performed in patients considered for percuta-
neous mitral balloon commissurotomy to assess the presence
or absence of left atrial thrombus and to further evaluate the
severity of MR (288,296–298). (Level of Evidence: B)
TEE offers excellent visualization of the mitral valve
and LA and is an alternative approach to assessment of
MS in patients with technically limited transthoracic
interrogation. Three-dimensional datasets may beacquired, from which optimal measurements of minimal
oriﬁce area can be obtained ofﬂine. However, in the vast
majority of patients with MS, valve morphology and lesion
severity can be obtained with TTE. A key exception is in
patients being considered for percutaneous mitral balloon
commissurotomy, in whom left atrial cavity and appendage
thrombi must be excluded. Although TTE may identify
risk factors for thrombus formation, several studies show
that TTE has poor sensitivity for detecting such thrombi,
thus mandating a TEE before percutaneous mitral balloon
commissurotomy. Although TTE is generally accurate in
grading MR, TEE may offer additional quantitation and
assurance that MR >2þ is not present, which generally
precludes percutaneous mitral balloon commissurotomy.
Supporting References: (288,296–298)
6.2.1.2. DIAGNOSTIC TESTINGdCHANGING SIGNS OR SYMPTOMS
Patients with an established diagnosis of MS may experi-
ence a change in symptoms from progressive narrowing of
the mitral valve, worsening of concomitant MR or other
valve lesions, or a change in hemodynamic state due to
such factors as AF, fever, anemia, hyperthyroidism, or
postoperative state. In such cases, a TTE examination
should be repeated to quantify the mitral valve gradient
and area, as well as other parameters that may contribute
to a change in symptoms.
6.2.1.3. DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP
Rheumatic MS is a slowly progressive disease, character-
ized by a prolonged latent phase between the initial
rheumatic illness and the development of valve stenosis.
The latent phase is an interval typically measured in de-
cades in the developed world but considerably shorter pe-
riods in the developing world, likely due to recurrent
Figure 3. Indications for Intervention for Rheumatic MS
AF indicates atrial ﬁbrillation; LA, left atrial; MR, mitral regurgitation; MS, mitral stenosis; MVA, mitral valve area; MVR, mitral valve surgery (repair or replacement); NYHA,
New York Heart Association; PCWP, pulmonary capillary wedge pressure; PMBC, percutaneous mitral balloon commissurotomy; and T 1/2, pressure half-time.
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rowing is typical, although the rate of progression is highly
variable. In 103 patients with MS followed for 3.32
years, valve area decreased at 0.09 cm2 per year, although
there was signiﬁcant interpatient variability. Larger valves
decreased in area more rapidly, although the same absolute
decrease would be expected to have greater impact in the
more stenotic valves. Importantly, progressive enlargement
in the right ventricle and rise in RV systolic pressure were
observed, even in the absence of a decrease in mitral valve
area. Accordingly, repeat TTE at intervals dictated by valve
area is an important aspect of disease management, even in
patients without symptoms. TTE should be performed to
re-evaluate asymptomatic patients with MS and stable
clinical ﬁndings to assess pulmonary artery pressure and valve
gradient (very severe MS with mitral valve area <1.0 cm2
every year, severe MS with mitral valve area 1.5 cm2 every
1 to 2 years; and progressive MS with mitral valve area
>1.5 cm2 every 3 to 5 years) (Table 4).
Supporting References: (299–301)6.2.1.4. DIAGNOSTIC TESTINGdCARDIAC CATHETERIZATION
In the contemporary era, adequate assessment of MS and
associated lesions can be obtained in the vast majority of
patients by TTE, occasionally supplemented by TEE.
However, in those few patients with nondiagnostic studies
or whose clinical and echocardiographic ﬁndings conﬂict, it
is essential to further characterize MS hemodynamics and
catheterization as the next best approach. Catheterization
is also the only method available to measure absolute
pressures inside the heart, which may be important in
clinical decision making. Such studies must be carried out
by personnel experienced with catheterization laboratory
hemodynamics with simultaneous pressure measurements
in the left ventricle and LA, ideally via transseptal cathe-
terization. Although a properly performed mean pulmo-
nary artery wedge pressure is an acceptable substitute for
mean LA pressure, the LV to pulmonary wedge gradient
will overestimate the true transmitral gradient due to phase
delay and delayed transmission of pressure changes. The
Gorlin equation is applied for calculation of mitral valve
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e93area, using cardiac output obtained via thermodilution
(when there is no signiﬁcant TR) or the Fick method.
Ideally, measured oxygen consumption should be used in
this calculation. Full right-heart pressures should be re-
ported. In cases where exertional symptoms seem out of
proportion to resting hemodynamic severity, data may be
obtained during exercise.
Supporting References: (302–304)
6.2.1.5. DIAGNOSTIC TESTINGdEXERCISE TESTING: RECOMMENDATION
CLASS I
1. Exercise testing with Doppler or invasive hemodynamic
assessment is recommended to evaluate the response of the
mean mitral gradient and pulmonary artery pressure in patients
with MS when there is a discrepancy between resting Doppler
echocardiographic ﬁndings and clinical symptoms or signs.
(Level of Evidence: C)
Exercise testing with hemodynamics yields a number of
data points to help in the management of MS when a
patient’s symptoms seem signiﬁcantly greater or less than
would be expected from TTE. Results have been published
using both exercise and dobutamine with Doppler echo-
cardiography, although exercise is preferred in general as
the more physiological test. Most experience is with
treadmill exercise, with images and Doppler obtained
immediately after stress, but bicycle exercise allows data
acquisition at various stages of exercise. Bicycle or arm
ergometry exercise testing during cardiac catheterization
can also be performed for direct measurements of pulmo-
nary artery wedge pressure and pulmonary pressures at rest
and with exercise. Simple functional capacity is important
to help quantify the patient’s symptoms and assess changes
over time. Changes in valve gradient are also helpful, as is
the presence of exercise-induced pulmonary hypertension.
Although exercise-induced pulmonary hypertension does
not have a formal place in these guidelines, a rise in RV
systolic pressure to >60 mm Hg to 70 mm Hg should
prompt the clinician to carefully consider the patient’s
symptoms. Most patients can continue to be followed
without exercise testing by careful clinical assessment and
periodic resting echocardiograms as indicated above.
Supporting References: (305–308)
6.2.2. Medical Therapy: Recommendations
CLASS I
1. Anticoagulation (vitamin K antagonist [VKA] or heparin) is
indicated in patients with 1) MS and AF (paroxysmal, persis-
tent, or permanent), 2) MS and a prior embolic event, or 3) MS
and a left atrial thrombus (309–315). (Level of Evidence: B)
In the presurgical era, patients with MS were at high
risk for arterial embolization, which was further elevated in
those with AF and prior embolic events. Anticoagulation
with VKA has long been recommended for patients
with MS with AF or prior embolism and has been so
well accepted that patients with MS have generally
been excluded from AF trials examining the utility ofanticoagulation. One exception to trials excluding patients
with MS is the NASPEAF (National Study for Prevention
of Embolism in Atrial Fibrillation) trial. Of the 495 high-
risk patients in the cohort, 316 patients had MS. Of these
316 patients, 95 had a prior embolization. Patients in the
study were randomized to standard anticoagulation with
VKA (international normalized ratio [INR] goal 2 to 3)
versus the combination of an antiplatelet agent and VKA
anticoagulation with a lower INR goal (0.10 to 2.5). The
study demonstrated a highly signiﬁcant increased risk for
embolism among those patients with VHD with prior
events versus those without (9.1% versus 2.3% over 3 years;
p<0.001). Further larger studies are required to determine
if antiplatelet agents should be used in patients with AF
and MS. Although no trial evidence exists for anti-
coagulation when LA or left atrial appendage thrombi are
incidentally found (generally by TEE), it is well docu-
mented that even in sinus rhythm, such clots are predis-
posed to embolize, and so anticoagulation with VKA is
recommended. Anticoagulation should be given indeﬁ-
nitely to patients with these indications. It is controversial
as to whether long-term anticoagulation should be given to
patients with MS in normal sinus rhythm on the basis of
left atrial enlargement or spontaneous contrast on TEE.
The efﬁcacy of the novel oral anticoagulant agents in
preventing embolic events has not been studied in patients
with MS.
Supporting References: (309–315)
CLASS IIa
1. Heart rate control can be beneﬁcial in patients with MS and AF
and fast ventricular response. (Level of Evidence: C)
Patients with MS are prone to developing atrial ar-
rhythmias. Thirty percent to 40% of patients with severe
MS will develop AF. Signiﬁcant detrimental hemody-
namic consequences may be associated with the acute
development of AF, primarily from the rapid ventricular
response, which shortens the diastolic ﬁlling period and
increases left atrial pressure. The treatment of acute AF is
anticoagulation and control of the heart rate response with
negative dromotropic agents. If the rate cannot be
adequately controlled with medications, cardioversion may
be necessary to improve hemodynamics. In the stable pa-
tient, the decision for rate control versus rhythm control is
dependent on multiple factors, including the duration of
AF, hemodynamic response to AF, left atrial size, prior
episodes of AF, and a history of embolic events. It is more
difﬁcult to achieve rhythm control in patients with MS
because the rheumatic process itself may lead to ﬁbrosis of
the intermodal and interatrial tracts and damage to the
sinoatrial node.
Supporting Reference: (316)
CLASS IIb
1. Heart rate control may be considered for patients with MS in
normal sinus rhythm and symptoms associated with exercise
(317,318). (Level of Evidence: B)
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occupied by diastole decreases with increasing heart rate,
thereby increasing the mean ﬂow rate across the mitral
valve (assuming constant cardiac output) with a consequent
rise in mean mitral gradient in MS in proportion to the
square of the ﬂow rate. A study of normal volunteers un-
dergoing bicycle exercise echocardiography demonstrated a
reduction in the diastolic interval from 604 milliseconds
to 219 milliseconds as the heart rate increased from 60
beats per minute to 120 beats per minute indicating a 63%
reduction in total diastolic time. Maintaining the same
cardiac output would require a 38% increase in mean ﬂow
rate during diastole, which, by squared relation of the
Bernoulli equation, requires an increase in mean mitral
gradient of approximately 90%. Thus, it is rational to think
that limiting tachycardia with beta blockade might be
beneﬁcial in patients with MS in normal sinus rhythm.
Nevertheless, the only RCT on the impact of beta blockade
on exercise duration in MS failed to show this salutary
effect. One study looked at 15 patients with an average
mitral area of 1.0 cm2 (NYHA class II and III) randomized
in crossover fashion to atenolol or placebo. Although the
exercise heart rate was signiﬁcantly reduced and diastolic
ﬁlling interval increased by 40%, there was no increase in
functional capacity, and maximal O2 consumption actually
fell by 11%, with cardiac index falling by 20% when pa-
tients were treated with beta blockade. One study had
more neutral results in a trial of 17 patients with NYHA
class I and II MS, and 7 patients had improvement in
maximal oxygen consumption, whereas 4 had a deteriora-
tion in symptoms. Overall, anaerobic threshold was
reduced by 11% with atenolol therapy, so these studies doTable 14. Summary of Recommendations for MS Intervention
Recommendations
PMBC is recommended for symptomatic patients with severe MS (MVA 1.5 cm2, st
favorable valve morphology in the absence of contraindications
Mitral valve surgery is indicated in severely symptomatic patients (NYHA class III/IV)
MS (MVA 1.5 cm2, stage D) who are not high risk for surgery and who are not c
for or failed previous PMBC
Concomitant mitral valve surgery is indicated for patients with severe MS (MVA 1.5
stage C or D) undergoing other cardiac surgery
PMBC is reasonable for asymptomatic patients with very severe MS (MVA 1.0 cm2,
and favorable valve morphology in the absence of contraindications
Mitral valve surgery is reasonable for severely symptomatic patients (NYHA class III/I
severe MS (MVA 1.5 cm2, stage D), provided there are other operative indication
PMBC may be considered for asymptomatic patients with severe MS (MVA 1.5 cm2
favorable valve morphology who have new onset of AF in the absence of contraind
PMBC may be considered for symptomatic patients with MVA >1.5 cm2 if there is e
hemodynamically signiﬁcant MS during exercise
PMBC may be considered for severely symptomatic patients (NYHA class III/IV) with
(MVA 1.5 cm2, stage D) who have suboptimal valve anatomy and are not candid
surgery or at high risk for surgery
Concomitant mitral valve surgery may be considered for patients with moderate MS
(MVA 1.6–2.0 cm2) undergoing other cardiac surgery
Mitral valve surgery and excision of the left atrial appendage may be considered for
severe MS (MVA 1.5 cm2, stages C and D) who have had recurrent embolic event
adequate anticoagulation
AF indicates atrial ﬁbrillation; COR, Class of Recommendation; LOE, Level of Evidence; MS, mitral sten
balloon commissurotomy.not support the general use of heart rate control in patients
with MS and normal sinus rhythm. Nevertheless, in
selected patients whose symptoms worsen markedly with
exercise, a trial of beta blockade might be considered.
Other negative chronotropic agents have not been evalu-
ated in patients with MS.
Supporting References: (317,318)
6.2.3. Intervention: Recommendations
See Table 14 for a summary of recommendations from this
section.
CLASS I
1. Percutaneous mitral balloon commissurotomy is recommended
for symptomatic patients with severe MS (mitral valve area
£1.5 cm2, stage D) and favorable valve morphology in the
absence of left atrial thrombus or moderate-to-severe MR
(280–284,286,328). (Level of Evidence: A)
Several RCTs have established the safety and efﬁcacy of
percutaneous balloon mitral commissurotomy compared
with surgical closed or open commissurotomy. The tech-
nique is generally performed by advancing 1 balloon
catheters across the mitral valve and inﬂating them, thereby
splitting the commissures. For the percutaneous approach
to have optimal outcome, it is essential that the valve
morphology be predictive of success, generally being mo-
bile, relatively thin, and free of calcium. This is usually
assessed by the Wilkins score, although other risk scores
have also shown utility. Clinical factors such as age,
NYHA class, and presence or absence of AF are also
predictive of outcome. Percutaneous mitral balloon com-
missurotomy should be performed by experiencedCOR LOE References
age D) and I A (280–284,286)
with severe
andidates
I B (319–324)
cm2, I C N/A
stage C) IIa C (293,325–327)
V) with
s
IIa C N/A
, stage C) and
ications
IIb C N/A
vidence of IIb C N/A
severe MS
ates for
IIb C N/A
IIb C N/A
patients with
s while receiving
IIb C N/A
osis; MVA, mitral valve area; NYHA, New York Heart Association; and PMBC, percutaneous mitral
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for potential complications. Percutaneous mitral balloon
commissurotomy is also useful in patients with restenosis
following prior commissurotomy if restenosis is the con-
sequence of refusion of both commissures.
SupportingReferences: (280–284,286,292,294,325,328–331)
See Online Data Supplement 13 for a summary of RCTs
that have established the safety and efﬁcacy of percutaneous
mitral balloon commissurotomy in comparison to surgical closed
or open commissurotomy.
CLASS I
2. Mitral valve surgery (repair, commissurotomy, or valve
replacement) is indicated in severely symptomatic patients
(NYHA class III to IV) with severe MS (mitral valve area £1.5
cm2, stage D) who are not high risk for surgery and who are not
candidates for or who have failed previous percutaneous mitral
balloon commissurotomy (319–324). (Level of Evidence: B)
Mitral valve surgery is an established therapy for MS,
predating percutaneous mitral balloon commissurotomy.
Surgical options may involve commissurotomy (either
closed, where the valve is opened blindly through the LA
or left ventricle, or open, which allows more extensive
surgery under direct visualization). MVR may be preferred
in the presence of severe valvular thickening and sub-
valvular ﬁbrosis with leaﬂet tethering. In addition to those
who have suboptimal valve anatomy (or failed percutaneous
mitral balloon commissurotomy), patients with moderate
or severe TR may also have a better outcome with a sur-
gical approach that includes tricuspid valve repair. Because
the natural history of MS is one of slow progression over
decades and MS does not have long-standing detrimental
effects on the left ventricle, surgery should be delayed until
the patient has severe limiting symptoms (NYHA class III
to IV).
Supporting References: (283,319–324,332–334)
CLASS I
3. Concomitant mitral valve surgery is indicated for patients with
severe MS (mitral valve area £1.5 cm2, stage C or D) undergoing
cardiac surgery for other indications. (Level of Evidence: C)
Studies of the natural history of moderate-to-severe MS
demonstrate progressive decrement in valve area of 0.09
cm2 per year. For patients with other indications for open
heart surgery, mitral intervention should be undertaken,
particularly in those patients with valves amenable to open
commissurotomy or valve repair.
Supporting Reference: (300)
CLASS IIa
1. Percutaneous mitral balloon commissurotomy is reasonable for
asymptomatic patients with very severe MS (mitral valve
area £1.0 cm2, stage C) and favorable valve morphology in the
absence of left atrial thrombus or moderate-to-severe MR
(293,325–327). (Level of Evidence: C)
Although it is a general rule in VHD not to intervene
before the onset of symptoms, there are patients who will
clearly beneﬁt from intervention while still ostensiblyasymptomatic. Most patients with mitral valve area 1.0
cm2 will manifest a true reduction in functional capacity
even if the gradual onset is not obvious. In addition,
numerous studies have demonstrated a greater likelihood of
successful percutaneous mitral balloon commissurotomy
when the valve is less thickened and calciﬁed, indicating
intervention before this state. Furthermore, it is preferable
to intervene before the development of severe pulmonary
hypertension, because those patients with near systemic
pulmonary pressure show reduced RV function and
persistent pulmonary hypertension following percutaneous
mitral balloon commissurotomy or MVR.
Supporting References: (293,325–327)
CLASS IIa
2. Mitral valve surgery is reasonable for severely symptomatic
patients (NYHA class III to IV) with severe MS (mitral valve
area £1.5 cm2, stage D), provided there are other operative
indications (e.g., aortic valve disease, CAD, TR, aortic aneu-
rysm). (Level of Evidence: C)
A situation may arise in which a patient who is other-
wise a candidate for percutaneous mitral balloon com-
missurotomy (favorable valve anatomy, no atrial thrombus
or signiﬁcant MR) has other cardiac conditions that should
be addressed surgically. These patients should undergo a
comprehensive operation to address all lesions, including
MS. However, as percutaneous intervention has evolved,
particularly that involving the coronary arteries and aortic
valve, there will be circumstances in which an all-
percutaneous approach will be favored. This decision
should take into account the local expertise at the treating
facility.
CLASS IIb
1. Percutaneous mitral balloon commissurotomy may be consid-
ered for asymptomatic patients with severe MS (mitral valve
area £1.5 cm2, stage C) and valve morphology favorable for
percutaneous mitral balloon commissurotomy in the absence of
left atrial thrombus or moderate-to-severe MR who have new
onset of AF. (Level of Evidence: C)
Patients with mild and asymptomatic MS may develop
AF as an isolated event that can be managed without
mitral valve intervention for many years. However, in many
patients, the onset of AF may be a harbinger of a more
symptomatic phase of the disease. Percutaneous mitral
balloon commissurotomy may be considered in such cases,
particularly if rate control is difﬁcult to achieve or if the
mitral valve area is 1.5 cm2. Lowering the left atrial
pressure by percutaneous mitral balloon commissurotomy
may be useful if a rhythm control approach is taken for AF.
CLASS IIb
2. Percutaneous mitral balloon commissurotomy may be considered
for symptomatic patients with mitral valve area greater than
1.5 cm2 if there is evidence of hemodynamically signiﬁcant MS
based on pulmonary artery wedge pressure greater than 25 mm
Hg or mean mitral valve gradient greater than 15 mm Hg during
exercise. (Level of Evidence: C)
Nishimura et al. JACC Vol. 63, No. 22, 2014
2014 AHA/ACC Valvular Heart Disease Guideline June 10, 2014:e57–185
e96It is recognized that there are patients with genuine
symptoms from MS, even with mitral valve area between
1.6 cm2 and 2.0 cm2, who would beneﬁt from percuta-
neous mitral balloon commissurotomy. This may occur for
several reasons. First, given the vagaries of clinical imaging,
it is possible that the valve is actually smaller than the re-
ported area. Second, for a given valve area, the transmitral
gradient will be higher in persons with a large body surface
area or those with other reasons to have an elevated cardiac
output (e.g., arteriovenous ﬁstulae). Third, there is a vari-
able relation of pulmonary vascular resistance in compari-
son to mitral valve area. Thus, patients may experience
clinical improvement in such cases. This procedure may
be performed for these indications in patients with valve
morphology suitable for percutaneous mitral balloon
commissurotomy.
Supporting Reference: (335)
CLASS IIb
3. Percutaneous mitral balloon commissurotomy may be consid-
ered for severely symptomatic patients (NYHA class III to IV)
with severe MS (mitral valve area £1.5 cm2, stage D) who have
a suboptimal valve anatomy and who are not candidates for
surgery or at high risk for surgery. (Level of Evidence: C)
Both the Wilkins score and the presence of commis-
sural calciﬁcation predict successful percutaneous mitral
balloon commissurotomy. However in all such series,
this predictive ability is not absolute, with 42% of pa-
tients with a Wilkins score >8 having an optimal
outcome (25% increase in mitral valve area to >1.5 cm2)
and 38% of patients with commissural calcium having
event-free survival at 1.8 years. Accordingly, severely
symptomatic patients who are poor surgical candidates
may beneﬁt from percutaneous mitral balloon commis-
surotomy even with suboptimal valve anatomy. Patients
who refuse surgery may also be considered for percuta-
neous mitral balloon commissurotomy after discussion
about the potential complications associated with this
procedure when performed in patients with suboptimal
valve anatomy.
Supporting References: (292–294)
CLASS IIb
4. Concomitant mitral valve surgery may be considered for pa-
tients with moderate MS (mitral valve area 1.6 cm2 to 2.0 cm2)
undergoing cardiac surgery for other indications. (Level of
Evidence: C)
Consideration of concomitant MVR at the time of other
heart surgery must balance several factors, including the
severity of MS (based on mitral valve area, mean pressure
gradient, and pulmonary arterial pressure); rate of pro-
gression; history of AF; skill of the surgeon; and perceived
risk of repeat cardiac surgery if the MS progresses to a
symptomatic state. Consideration should also include the
suitability of the valve for subsequent percutaneous mitral
balloon commissurotomy (echocardiogram score and presenceof MR), as this might be a preferable method for treating
worsening MS.
CLASS IIb
5. Mitral valve surgery and excision of the left atrial appendage
may be considered for patients with severe MS (mitral valve
area £1.5 cm2, stages C and D) who have had recurrent embolic
events while receiving adequate anticoagulation. (Level of
Evidence: C)
A large prospective study of patients with MS shows an
elevated risk of recurrent embolism among patients with
prior embolic events irrespective of the presence or absence
of AF. The risk is reduced, but not eliminated, by percu-
taneous mitral balloon commissurotomy. Another study of
205 patients who underwent mitral valve surgery, 58 with
ligation of the left atrial appendage, demonstrated that lack
of ligation was signiﬁcantly associated with future embolic
events (odds ratio [OR]: 6.7). This study also noted that in
6 of the 58 ligation patients, communication of the left
atrial appendage and LA cavity was still present. Residual
communication between the left atrial appendage and LA
cavity was noted in 60% of patients undergoing left atrial
appendage ligation in a subsequent study, suggesting that
left atrial appendage excision and not ligation may be the
preferred approach in selected patients.
Supporting References: (336,337)
See Online Data Supplements 14 and 15 for more infor-
mation on the outcomes of percutaneous mitral balloon
commissurotomy.
6.3. Nonrheumatic MS
Although the vast majority of MS in the world results
from rheumatic heart disease, senile calciﬁc MS is found
with increasing frequency in the elderly population in
North America. This is due to calciﬁcation of the mitral
annulus and calciﬁcation that extends into the leaﬂets,
which cause both a narrowing of the annulus and rigidity
of the leaﬂets without commissural fusion. Mitral annular
calciﬁcation has been associated with decreased renal
function and inﬂammatory markers like C-reactive pro-
tein; however, senile calciﬁc MS is common in the elderly
population with normal renal function and is associated
with senile AS. Data are relatively sparse on the natural
history of senile calciﬁc MS. A small study of 32 patients
observed over a mean of 2.6 years demonstrated pro-
gression in mean mitral valve gradient in only half of the
subjects. However, in those with progression, the rate of
change averaged 2 mm Hg per year and changed as
rapidly as 9 mm Hg per year. More rapid progression
was found in younger patients, but surprisingly this was
not predicted by a reduced glomerular ﬁltration rate.
Although the mean pressure gradient from Doppler
echocardiography is accurate, the use of a mitral valve
area from diastolic half-time is uncertain in this popula-
tion. Indications for intervention in patients with senile
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for the following reasons. First, because calciﬁcation in-
volves the annulus and base of the leaﬂets without
commissural fusion, there is no role for percutaneous
mitral balloon or surgical commissurotomy. Second, the
presence of severe mitral annular calciﬁcation can be quite
challenging for the surgeon because it causes problems in
securely attaching the prosthetic valve and narrowing of
the oriﬁce. Supra-annular insertion and other innovative
techniques can be used, such as placement of a felt patch
around the valve oriﬁce to anchor the prosthesis; how-
ever, this only works if the mitral oriﬁce is adequate. If
the annular calciﬁcation narrows the oriﬁce, it has to be
debrided. The other alternative is left atrial to ventricular
bypass with a valved conduit in extreme cases of calciﬁ-
cation both of the leaﬂet and the annulus. Finally, pa-
tients with calciﬁcation are often elderly and debilitated,
have multiple comorbidities, and are at high risk for
surgery. For these reasons, intervention should be delayed
until symptoms are severely limiting and cannot be
managed with diuresis and heart rate control.
A subset of patients have mitral inﬂow obstruction due
to other causes, such as congenital malformations, tumors,
or other masses. Congenital MS usually takes the form of a
parachute mitral valve, where the mitral chordae are
attached to a single or dominant papillary muscle and often
form a component of the Shone complex, which can
include supramitral rings, valvular or subvalvular AS, and
aortic coarctation. For MS caused by tumors or other
obstructive lesions, intervention is aimed at reducing or
removing the mass, with efforts made to preserve the valve.
Supporting References: (338–352)
7. Mitral Regurgitation
7.1. Acute MR
Acute MR may be due to disruption of different parts of
the mitral valve apparatus. IE may cause leaﬂet perforation
or chordal rupture. Spontaneous chordal rupture may occur
in patients with degenerative mitral valve disease. Rupture
of the papillary muscle occurs in patients who have an acute
ST-segment elevation MI usually associated with an
inferior infarction. The acute volume overload on the left
ventricle and LA results in pulmonary congestion and low
forward cardiac output. Diagnosis of the presence and
etiology of acute MR and urgent intervention may be
lifesaving.
7.1.1. Diagnosis and Follow-Up
TTE is useful in patients with severe acute primaryMR for
evaluation of LV function, RV function, pulmonary artery
pressure, and mechanism of MR. The patient with severe
acute MR, which might occur from chordal rupture, usu-
ally experiences acute decompensation with hemodynamic
embarrassment. The sudden volume overload increases leftatrial and pulmonary venous pressure, leading to pulmo-
nary congestion and hypoxia, whereas decreased blood
delivery to the aorta causes reduced cardiac output, hypo-
tension, or even shock. The rapid systolic rise in LA
pressure with a concomitant fall in LV systolic pressure
limits the pressure gradient driving MR to early systole.
Thus, the murmur may be short and unimpressive. Some
patients with severe torrential MR have no murmur due to
equalization of the LV and left atrial pressures. TTE can
usually clarify the diagnosis by demonstrating the presence
of severe MR, the mechanism causing MR, and a hyper-
dynamic instead of a depressed left ventricle as would be
present in many other causes of hemodynamic compro-
mise. Likely mechanisms of acute MR detected by TTE
include valve disruption or perforation from IE, chordal
rupture, and/or papillary muscle rupture. If the diagnosis
of IE as the cause of acute MR is made, therapy that in-
cludes antibiotic administration and early surgery must be
considered.
It may be difﬁcult to diagnose severe acute MR with
TTE due to narrow eccentric jets of MR, tachycardia, and
early equalization of LV and LA pressures. In cases where
TTE is nondiagnostic but the suspicion of severe acute
MR persists, enhanced mitral valve imaging with TEE
usually clariﬁes the diagnosis. TEE can be especially
helpful in detecting valvular vegetations and annular ab-
scesses that may further accentuate the need for a more
urgent surgical approach. In the presence of sudden acute
and hemodynamic instability after MI with hyperdynamic
LV function by TTE and no other cause for the deterio-
ration, TEE should be performed as soon as possible,
looking for severe MR due either to a papillary muscle or
chordal rupture.
7.1.2. Medical Therapy
Vasodilator therapy can be useful to improve hemody-
namic compensation in acute MR. The premise of use of
vasodilators in acute MR is reduction of impedance of
aortic ﬂow, thereby preferentially guiding ﬂow away from
the left ventricle to the left atrial regurgitant pathway,
decreasing MR while simultaneously increasing forward
output. This is usually accomplished by infusion of an
easily titratable agent such as sodium nitroprusside or
nicardipine. Use of vasodilators is often limited by systemic
hypotension that is exacerbated when peripheral resistance
is decreased.
Intra-aortic balloon counterpulsation can be helpful
to treat acute severe MR. By lowering systolic aortic
pressure, intra-aortic balloon counterpulsation decreases
LV afterload, increasing forward output while decreasing
regurgitant volume. Simultaneously, intra-aortic balloon
counterpulsation increases diastolic and mean aortic pres-
sure, thereby supporting the systemic circulation. In almost
every case, intra-aortic balloon counterpulsation is a
temporizing measure for achieving hemodynamic stability
until deﬁnitive mitral surgery can be performed. The use
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effective to stabilize a patient with acute hemodynamic
compromise before operation.
Supporting References: (353,354)
7.1.3. Intervention
Prompt mitral valve surgery is recommended for treatment
of the symptomatic patient with acute severe primary MR.
The severity of acute primary MR is variable, and some
patients with more moderate amounts of MR may develop
compensation as LV dilation allows for lower ﬁlling
pressure and increased forward cardiac output. However,
most patients with acute severe MR will require surgical
correction for re-establishment of normal hemodynamics
and for relief of symptoms. This is especially true for a
complete papillary muscle rupture that causes torrential
MR, which is poorly tolerated. Even if there is a partial
papillary muscle rupture with hemodynamic stability, ur-
gent surgery is indicated because this can suddenly progress
to complete papillary muscle rupture. In cases of ruptured
chordae tendineae, mitral repair is usually feasible and
preferred over MVR, and the timing of surgery can be
determined by the patient’s hemodynamic status. If IE is
the cause of severe symptomatic MR, earlier surgery is
generally preferred because of better outcomes over medical
therapy. However, this strategy should also be tempered
by the patient’s overall condition.
Supporting Reference: (355)7.2. Stages of Chronic MR
In assessing the patient with chronic MR, it is critical to
distinguish between chronic primary (degenerative) MR
and chronic secondary (functional) MR, as these 2 condi-
tions have more differences than similarities.
In chronic primary MR, the pathology of 1 of the
components of the valve (leaﬂets, chordae tendineae,
papillary muscles, annulus) causes valve incompetence
with systolic regurgitation of blood from the left ventricle
to the LA (Table 15). The most common cause of chronic
primary MR in developed countries is mitral valve
prolapse, which has a wide spectrum of etiology and
presentation. Younger populations present with severe
myxomatous degeneration with gross redundancy of both
anterior and posterior leaﬂets and the chordal apparatus
(Barlow’s valve). Alternatively, older populations present
with ﬁbroelastic deﬁciency disease, in which lack of con-
nective tissue leads to chordal rupture. The differentiation
between these 2 etiologies has important implications for
operative intervention. Other less common causes of
chronic primary MR include IE, connective tissue disor-
ders, rheumatic heart disease, cleft mitral valve, and radi-
ation heart disease. If the subsequent volume overload of
chronic primary MR is prolonged and severe, it causes
myocardial damage, HF, and eventual death. Correction of
the MR is curative. Thus, MR is “the disease.”In chronic secondary MR, the mitral valve is usually
normal (Table 16). Instead, severe LV dysfunction is
caused either by CAD, related MI (ischemic chronic
secondary MR), or idiopathic myocardial disease (non-
ischemic chronic secondary MR). The abnormal and
dilated left ventricle causes papillary muscle displacement,
which in turn results in leaﬂet tethering with associated
annular dilation that prevents coaptation. Because MR is
only 1 component of the disease (severe LV dysfunction,
coronary disease, or idiopathic myocardial disease are the
others), restoration of mitral valve competence is not by
itself curative; thus, the best therapy for chronic secondary
MR is much less clear than it is for chronic primary MR.
The data are limited, and there is greater difﬁculty in
deﬁning the severity of MR in patients with secondaryMR
than in those with primaryMR. In patients with secondary
MR, adverse outcomes are associated with a smaller
calculated effective regurgitant oriﬁce compared to pri-
mary MR due to multiple reasons. The MR will likely
progress because of the associated progressive LV systolic
dysfunction and adverse remodeling. In addition, there is
an underestimation of effective regurgitant oriﬁce area by
the 2D echocardiographyderived ﬂow convergence
method due to the crescentic shape of the regurgitant
oriﬁce. There are the additional clinical effects of a
smaller amount of regurgitation in the presence of
compromised LV systolic function and baseline elevated
ﬁlling pressures.7.3. Chronic Primary MR
7.3.1. Diagnosis and Follow-Up
7.3.1.1. DIAGNOSTIC TESTINGdINITIAL DIAGNOSIS: RECOMMENDATIONS
CLASS I
1. TTE is indicated for baseline evaluation of LV size and function,
RV function and left atrial size, pulmonary artery pressure, and
mechanism and severity of primary MR (stages A to D) in any
patient suspected of having chronic primary MR (5,21,39,
356–371). (Level of Evidence: B)
Images provided by TTE generate most of the diag-
nostic data needed for clinical decision making in chronic
primary MR. The outcome of the patient with chronic
primary MR is determined by lesion severity and the
presence or absence of negative prognostic features that
include the presence of symptoms, onset of LV dysfunc-
tion, and presence of pulmonary hypertension; usually only
severe MR leads to these negative sequelae. Favorable
loading conditions in MR (increased preload and usually
normal afterload) increase ejection phase indexes of LV
function, such as LVEF, but do not affect the extent of
shortening. Thus, a “normal” LVEF in MR is approxi-
mately 70%. In turn, the onset of LV dysfunction is
inferred when LVEF declines toward 60% or when the left
ventricle is unable to contract to <40 mm diameter at end
systole. It is clear that properly obtained and validated
Table 15. Stages of Primary MR
Grade Deﬁnition Valve Anatomy Valve Hemodynamics* Hemodynamic Consequences Symptoms
A At risk of MR  Mild mitral valve prolapse
with normal coaptation
 Mild valve thickening and
leaﬂet
restriction
 No MR jet or small central jet
area <20% LA on Doppler
 Small vena contracta <0.3 cm
 None  None
B Progressive MR  Severe mitral valve prolapse
with normal coaptation
 Rheumatic valve changes
with leaﬂet restriction and
loss of central coaptation
 Prior IE
 Central jet MR 20%–40% LA or
late systolic eccentric jet MR
 Vena contracta <0.7 cm
 Regurgitant volume <60 mL
 Regurgitant fraction <50%
 ERO <0.40 cm2
 Angiographic grade 1–2þ
 Mild LA enlargement
 No LV enlargement
 Normal pulmonary pressure
 None
C Asymptomatic severe MR  Severe mitral valve prolapse
with loss of coaptation or
ﬂail leaﬂet
 Rheumatic valve changes
with leaﬂet restriction and
loss of central coaptation
 Prior IE
 Thickening of leaﬂets with
radiation heart disease
 Central jet MR >40% LA or
holosystolic eccentric jet MR
 Vena contracta 0.7 cm
 Regurgitant volume 60 mL
 Regurgitant fraction 50%
 ERO 0.40 cm2
 Angiographic grade 3–4þ
 Moderate or severe
LA enlargement
 LV enlargement
 Pulmonary hypertension may
be present at rest or with exercise
 C1: LVEF >60% and LVESD
<40 mm
 C2: LVEF 60% and LVESD
40 mm
 None
D Symptomatic severe MR  Severe mitral valve prolapse
with loss of coaptation or
ﬂail leaﬂet
 Rheumatic valve changes
with leaﬂet restriction and
loss of central coaptation
 Prior IE
 Thickening of leaﬂets with
radiation heart disease
 Central jet MR >40% LA or
holosystolic eccentric jet MR
 Vena contracta 0.7 cm
 Regurgitant volume 60 mL
 Regurgitant fraction 50%
 ERO 0.40 cm2
 Angiographic grade 3–4þ
 Moderate or severe LA
enlargement
 LV enlargement
 Pulmonary hypertension present
 Decreased exercise
tolerance
 Exertional dyspnea
*Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. Categorization of MR severity as mild, moderate, or
severe depends on data quality and integration of these parameters in conjunction with other clinical evidence.
ERO indicates effective regurgitant oriﬁce; IE, infective endocarditis; LA, left atrium/atrial; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD; left ventricular end-systolic dimension; and
MR, mitral regurgitation.
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mental cardiac remodeling than simple chamber di-
mensions, as suggested by angiographically obtained
volume data. These techniques have been replaced by
newer noninvasive imaging techniques, which initially
used chamber dimensions for measurement of LV size and
function. Until more prognostic volumetric data are
available, most current prognostic data rely on chamber
dimensions. Pulmonary artery systolic pressure approach-
ing 50 mm Hg also worsens prognosis. Thus, when the
murmur of MR is ﬁrst discovered, the clinician needs to
know the severity of the MR (Table 15) and the size and
function of the left ventricle, pulmonary artery pressure,
and valve pathoanatomy from which valve reparability
can be predicted. Determination of the severity of MR
should be made on the basis of measurements of effective
oriﬁce area, regurgitant volume, and regurgitant fraction
using the proximal isovelocity surface area or quantitative
Doppler ﬂow measurements. However, there are limita-
tions to this technique, and multiple Doppler parameters,
including color jet area, vena contracta, continuous wave
Doppler intensity, and transmitral jet velocity curve should
be used to correlate with the quantitative measurements.
Once 1 of the above “triggers” is reached, indicating severeMR and LV dysfunction, the patient should be considered
for mitral valve surgery. TTE serves to give this infor-
mation in most cases and also generates baseline data that
can be used to compare the patient’s progress on subse-
quent examinations. Three-dimensional echocardiogra-
phy, strain imaging, or CMR may add more accurate
assessment of the LV response in the future. Symptom
presence is a key determinant of outcome, yet symptom
status is highly subjective. Studies have demonstrated a
correlation between B-type natriuretic peptide and
outcome in MR. Although the data are preliminary, the
ﬁnding of a rising B-type natriuretic peptide could be
helpful as another factor in deciding the optimal timing of
mitral surgery.
Supporting References: (5,21,39,356–371)
CLASS I
2. CMR is indicated in patients with chronic primary MR to assess
LV and RV volumes, function, or MR severity and when these
issues are not satisfactorily addressed by TTE (366,372,373).
(Level of Evidence: B)
In most cases, TTE provides the data needed for
adequate evaluation of the MR patient. However, in cases
where TTE image quality is poor, CMR may be of value in
Table 16. Stages of Secondary MR
Grade Deﬁnition Valve Anatomy Valve Hemodynamics* Associated Cardiac Findings Symptoms
A At risk of MR  Normal valve leaﬂets, chords,
and annulus in a patient
with coronary disease or
cardiomyopathy
 No MR jet or small central jet
area <20% LA on Doppler
 Small vena contracta
<0.30 cm
 Normal or mildly dilated LV
size with ﬁxed (infarction) or
inducible (ischemia) regional
wall motion abnormalities
 Primary myocardial disease
with LV dilation and systolic
dysfunction
 Symptoms due to coronary
ischemia or HF may be
present that respond to
revascularization and
appropriate medical therapy
B Progressive MR  Regional wall motion abnor-
malities with mild tethering
of mitral leaﬂet
 Annular dilation with mild
loss of central coaptation of
the mitral leaﬂets
 ERO <0.20 cm2y
 Regurgitant volume <30 mL
 Regurgitant fraction <50%
 Regional wall motion abnor-
malities with reduced LV
systolic function
 LV dilation and systolic
dysfunction due to primary
myocardial disease
 Symptoms due to coronary
ischemia or HF may be
present that respond to
revascularization and
appropriate medical therapy
C Asymptomatic
severe MR
 Regional wall motion abnor-
malities and/or LV dilation
with severe tethering of
mitral leaﬂet
 Annular dilation with severe
loss of central coaptation of
the mitral leaﬂets
 ERO 0.20 cm2y
 Regurgitant volume 30 mL
 Regurgitant fraction 50%
 Regional wall motion abnor-
malities with reduced LV
systolic function
 LV dilation and systolic
dysfunction due to primary
myocardial disease
 Symptoms due to coronary
ischemia or HF may be
present that respond to
revascularization and
appropriate medical therapy
D Symptomatic
severe MR
 Regional wall motion abnor-
malities and/or LV dilation
with severe tethering of
mitral leaﬂet
 Annular dilation with severe
loss of central coaptation of
the mitral leaﬂets
 ERO 0.20 cm2y
 Regurgitant volume 30 mL
 Regurgitant fraction 50%
 Regional wall motion abnor-
malities with reduced LV
systolic function
 LV dilation and systolic
dysfunction due to primary
myocardial disease
 HF symptoms due to MR
persist even after revascular-
ization and optimization
of medical therapy
 Decreased exercise tolerance
 Exertional dyspnea
*Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. Categorization of MR severity as mild, moderate, or
severe depends on data quality and integration of these parameters in conjunction with other clinical evidence.
yThe measurement of the proximal isovelocity surface area by 2D TTE in patients with secondary MR underestimates the true ERO due to the crescentic shape of the proximal convergence.
2D indicates 2-dimensional; ERO, effective regurgitant oriﬁce; HF, heart failure; LA, left atrium; LV, left ventricular; MR, mitral regurgitation; and TTE, transthoracic echocardiogram.
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LV volumes, RV volumes, and LVEF, and an estimation
of MR severity, but outcome data using CMR volumes
is pending. CMR is less helpful in establishing mitral
pathoanatomy.
Supporting References: (366,372,373)
CLASS I
3. Intraoperative TEE is indicated to establish the anatomic basis
for chronic primary MR (stages C and D) and to guide repair
(374,375). (Level of Evidence: B)
Intraoperative TEE is a standard imaging modality for
the surgical therapy of MR. Before the operative incision,
TEE may give the surgeon a better understanding of the
valve anatomy and type of repair that will likely be per-
formed, although this decision is ultimately made when
the valve is inspected visually. Three-dimensional TEE
may be helpful in further visualizing the abnormal mitral
valve anatomy. Because anesthesia lessens afterload, pre-
load, and mitral valve closing force, it is important that
decisions about severity of MR not be re-evaluated under
these artiﬁcial conditions, in which MR severity could be
underestimated.
Intraoperative TEE is especially helpful in gauging the
adequacy of repair. Because even mild residual MR
after repair increases the likelihood of later repair failurenecessitating reoperation, surgeons strive for near-perfect
operative repair. If MR is detected in the operating room
following repair, it is often an indication that the repair
should be revised. This assessment should be made during
conditions that approach those of normal physiology. The
left ventricle should be well ﬁlled and systemic BP should
be brought well into the normal range. A low preload with
underﬁlling of the left ventricle can lead to 1) systolic
anterior leaﬂet motion with outﬂow obstruction or 2) un-
derestimation of degree of residual MR. Thus, information
obtained by TEE when the ventricle is underﬁlled can lead
to an unneeded revision in the former case while over-
looking a needed revision in the latter. Intraoperative TEE
is also useful for diagnosing mitral inﬂow obstruction or
LV outﬂow obstruction as a result of the mitral valve
repair.
Supporting References: (374,375)
CLASS I
4. TEE is indicated for evaluation of patients with chronic primary
MR (stages B to D) in whom noninvasive imaging provides
nondiagnostic information about severity of MR, mechanism of
MR, and/or status of LV function. (Level of Evidence: C)
TEE is not recommended for routine evaluation and
follow-up of patients with chronic primary MR but is
indicated in speciﬁc situations. Because TEE provides
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formed when TTE images are inadequate. TEE is espe-
cially useful in cases of MR due to IE, where additional
information about other potentially infected structures can
be fully evaluated by that technique. TEE allows more
precise quantitation of regurgitant severity and provides a
better estimate of the likelihood of a successful surgical
valve repair. Three-dimensional TEE may be helpful in
further visualizing the abnormal mitral valve anatomy.
Mitral valve repair is preferable to valve replacement
because of lower operative mortality and avoidance of the
complications inherent to prosthetic valves that accrue over
time. Thus, if repair can be accomplished, it might be
performed earlier in the course of disease. Alternatively,
if replacement is likely, strategy shifts toward performing
surgery later to avoid unwanted exposure time to
prosthetic-related complications.
7.3.1.2. DIAGNOSTIC TESTINGdCHANGING SIGNS OR SYMPTOMS
TTE is indicated in patients with primary MR (stages B to
D) to evaluate the mitral valve apparatus and LV function
after a change in signs or symptoms. The onset of symp-
toms (dyspnea on exertion, orthopnea, or declining exercise
tolerance) is by itself a negative prognostic event even if
LV function is preserved. Symptoms are the culmination of
the pathophysiology of MR and may indicate changes in
LV diastolic function, left atrial compliance, LV ﬁlling
pressure and/or increases in pulmonary artery pressure,
and decreases in RV function or the coexistence of TR.
Therefore, symptoms add pathophysiological data not
readily available from imaging. Further, there is no evi-
dence that treatment with diuretics or other therapies that
might relieve symptoms changes the prognostic effect of
symptom onset. Once symptoms have occurred, the patient
should be considered for mitral valve operation even if
medication has led to improvement. Repeat TTE at the
time of symptom onset is indicated to conﬁrm that
symptoms are likely due to MR or its effect on the left
ventricle, which in turn supports surgical correction. The
new onset of AF is also an indication for repeat TTE to
look for changes in severity of MR and the status of the left
ventricle.
Supporting References: (365,376)
7.3.1.3. DIAGNOSTIC TESTINGdROUTINE FOLLOW-UP
TTE should be performed on an annual or semiannual
basis for surveillance of LV function (estimated by LVEF
and end-systolic dimension) and pulmonary artery pressure
in asymptomatic patients with severe primary MR (stage
C1). Chronic severe MR is tolerated poorly, reaching a
trigger for surgery at an average rate of about 8% per year.
Because this progression varies from patient to patient and
because prognosis worsens if correction of MR is delayed
beyond the onset of these triggers, either referral to a Heart
Valve Center of Excellence for early repair or very careful
surveillance is mandatory. If a watchful waiting approach is
pursued, periodic TTE is critical to examine the patient forchanges in LV function and pulmonary pressure in
determining the proper timing of surgery. For patients
approaching the above benchmarks, semiannual TTE is
recommended. It should be noted that echocardiographic
measurements are variable, and management decisions that
rest on these measurements should be conﬁrmed by repeat
TTE if the patient is approaching or has reached the
important triggers for surgery noted above.
In patients with chronic primary MR that is less than
severe (stages A and B), TTE is indicated periodically to
evaluate for changes in MR severity. MR is a progressive
disease. The LV volume overload induced by chronic
primary MR causes eccentric cardiac remodeling with
progressively increasing chamber volume, tending to
reduce valve leaﬂet coaptation. Advancing valve pathology
leads to further worsening of MR. This process may
develop slowly without dramatic changes in symptoms or
physical examination. Thus, MR could become severe and
even lead to LV dysfunction without the patient or clini-
cian being aware of it. Accordingly, periodic repeat TTE to
examine for changes in severity of MR and LV size and
function when baseline disease is less than severe is
advisable. For mild MR, follow-up every 3 to 5 years is
adequate unless the results of the physical examination or
symptoms change. For moderate MR, follow-up every 1 to
2 years is recommended, again unless clinical status sug-
gests a worsening in severity (Table 4).
Supporting Reference: (39)
7.3.1.4. DIAGNOSTIC TESTINGdCARDIAC CATHETERIZATION
Left ventriculography and/or hemodynamic measurements
are indicated when clinical assessment and/or noninvasive
tests are inconclusive or discordant regarding 1) severity of
MR, 2) LV function, or 3) the need for surgery. Imaging
with these techniques is adequate for evaluation of MR in
the majority of cases. However, invasive hemodynamic
evaluation may be necessary in some cases, especially when
there is a clinical discrepancy between symptomatic status
and noninvasive testing. Elevated ﬁlling pressures support
a cardiac cause for dyspnea and/or may indicate severely
abnormal pathophysiology even when the patient claims to
be asymptomatic. Conversely, a normal invasive hemody-
namic examination in a symptomatic patient with what
appears to be less than severe MR suggests a noncardiac
cause for the symptoms. Hemodynamic evaluation can be
especially helpful in patients with concomitant lung dis-
ease. Normal left atrial (or wedge) pressure and a large
transpulmonary gradient suggest pulmonary hypertension
due to lung disease rather than mitral valve disease. Pa-
tients usually complain of dyspnea with exertion, yet
noninvasive evaluation is usually made at rest. Hemody-
namic measurement made during either handgrip or dy-
namic exercise may be very revealing. Increased load with
exercise may bring out severely disordered hemodynamics
explaining the patient’s exercise-related symptoms. Left
ventriculography may also be of diagnostic beneﬁt.
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measures ﬂow velocity, ventriculography uses the density of
contrast to determine the amount of blood ﬂow from the
left ventricle to LA. Although only semiquantitative, a
carefully performed ventriculogram can add signiﬁcantly to
the diagnostic data pool.
Supporting Reference: (42)
7.3.1.5. DIAGNOSTIC TESTINGdEXERCISE TESTING: RECOMMENDATIONS
CLASS IIa
1. Exercise hemodynamics with either Doppler echocardiography
or cardiac catheterization is reasonable in symptomatic pa-
tients with chronic primary MR where there is a discrepancy
between symptoms and the severity of MR at rest (stages B
and C) (377,378). (Level of Evidence: B)
The symptoms of chronic primary MR usually occur
during exercise. Thus, evaluation during exercise may be
very informative when resting TTE and symptomatic
status are discordant or when the magnitude of LV and LA
enlargement seem out of proportion to the severity of
resting MR. In such cases, severity of MR and/or pul-
monary artery pressure may increase during exercise, both
helping to explain exercise-induced symptoms and indi-
cating that mitral surgery may be in order. The change in
pulmonary artery wedge pressure and LV diastolic pressure
during exercise can be obtained during cardiac catheteri-
zation, which may further aid in determining the etiology
of symptoms.
Supporting References: (42,377,378)
CLASS IIa
2. Exercise treadmill testing can be useful in patients with chronic
primary MR to establish symptom status and exercise tolerance
(stages B and C). (Level of Evidence: C)
The onset of symptoms represents a key development in
severe MR. However, some patients may not recognize
their symptoms, may deny them, or may alter their lifestyle
to remain asymptomatic. A formal treadmill exercise test
can establish true exercise tolerance and can also form the
baseline for future symptom assessment. Additional in-
formation about a cardiac or noncardiac limitation can be
obtained using oxygen consumption measurements during
exercise. Exercise echocardiography may add additional
prognostic value beyond conventional exercise treadmill
testing in patients with asymptomatic moderate or severe
chronic primary MR.
Supporting References: (378–381)
7.3.2. Medical Therapy: Recommendations
CLASS IIa
1. Medical therapy for systolic dysfunction is reasonable in
symptomatic patients with chronic primary MR (stage D) and
LVEF less than 60% in whom surgery is not contemplated (382–
386). (Level of Evidence: B)
Patients with MR and LV dysfunction experience
myocardial damage and HF. With onset of LV systolicdysfunction, surgery is usually indicated. However, in those
patients in whom surgery is not performed or will be
delayed, medical therapy for systolic dysfunction should be
implemented. Although there are sparse data available
speciﬁc to patients with MR with LV dysfunction, it seems
reasonable to treat such patients with the standard regimen
for HF, including beta-adrenergic blockade, ACE in-
hibitors or ARBs, and possibly aldosterone antagonists.
Perhaps the best data exist for the use of beta blockers,
which reverse LV dysfunction in experimental MR. Pa-
tients who are receiving beta blockers may have better
surgical outcomes and delayed onset of LV dysfunction
compared with those not taking these medications. ACE
inhibition has not been effective in experimental MR with
LV dysfunction but has caused reverse remodeling in a
study with a small number of patients. Because aldosterone
antagonism is thought to work in part by inhibiting
ﬁbrosis, its role in MR where little ﬁbrosis occurs is
unclear.
Supporting References: (382–386)
CLASS III: No Beneﬁt
1. Vasodilator therapy is not indicated for normotensive
asymptomatic patients with chronic primary MR (stages B
and C1) and normal systolic LV function (386–391). (Level of
Evidence: B)
Because vasodilator therapy appears to be effective in
acute severe symptomatic MR, it seems reasonable to
attempt afterload reduction in chronic asymptomatic MR
with normal LV function in an effort to forestall the need
for surgery. However, the results from the limited number
of trials addressing this therapy have been disappointing,
demonstrating little or no clinically important beneﬁt.
Conversely, because vasodilators decrease LV size and
mitral closing force, they may increase mitral valve pro-
lapse, worsening rather than decreasing severity of MR.
The foregoing does not apply to patients with concomitant
hypertension. Hypertension must be treated because of the
well-known morbidity and mortality associated with that
condition and because increased LV systolic pressure by
itself increases the systolic transmitral gradient and worsens
severity of MR.
Supporting References: (386–391)
7.3.3. Intervention: Recommendations
See Table 17 for a summary of recommendations from this
section.
Intervention for patients with primary MR consists of
either surgical mitral valve repair or MVR. Mitral valve
repair is preferred over MVR if a successful and durable
repair can be achieved. Repair success is dependent on the
mitral valve morphology as well as surgical expertise.
Percutaneous mitral valve repair provides a less invasive
alternative to surgery but is not approved for clinical use in
the United States.
Supporting Reference: (426)
Table 17. Summary of Recommendations for Chronic Primary MR
Recommendations COR LOE References
MV surgery is recommended for symptomatic patients with chronic severe primary MR (stage D) and
LVEF >30%
I B (365,376)
MV surgery is recommended for asymptomatic patients with chronic severe primary MR and LV
dysfunction (LVEF 30%–60% and/or LVESD 40 mm, stage C2)
I B (359–362,
392–394)
MV repair is recommended in preference to MVR when surgical treatment is indicated for patients
with chronic severe primary MR limited to the posterior leaﬂet
I B (87,364,
395–409)
MV repair is recommended in preference to MVR when surgical treatment is indicated for patients
with chronic severe primary MR involving the anterior leaﬂet or both leaﬂets when a successful and
durable repair can be accomplished
I B (86,407–413)
Concomitant MV repair or replacement is indicated in patients with chronic severe primary MR
undergoing cardiac surgery for other indications
I B (414)
MV repair is reasonable in asymptomatic patients with chronic severe primary MR (stage C1) with
preserved LV function (LVEF >60% and LVESD <40 mm) in whom the likelihood of a successful
and durable repair without residual MR is >95% with an expected mortality rate of <1% when
performed at a Heart Valve Center of Excellence
IIa B (39,86,
415–419)
MV repair is reasonable for asymptomatic patients with chronic severe nonrheumatic primary MR
(stage C1) and preserved LV function in whom there is a high likelihood of a successful and durable
repair with 1) new onset of AF or 2) resting pulmonary hypertension (PA systolic arterial pressure
>50 mm Hg)
IIa B (363,415,
420–425)
Concomitant MV repair is reasonable in patients with chronic moderate primary MR (stage B)
undergoing cardiac surgery for other indications
IIa C N/A
MV surgery may be considered in symptomatic patients with chronic severe primary MR and
LVEF 30% (stage D)
IIb C N/A
MV repair may be considered in patients with rheumatic mitral valve disease when surgical treatment is
indicated if a durable and successful repair is likely or if the reliability of long-term anticoagulation
management is questionable
IIb B (86,406,413)
Transcatheter MV repair may be considered for severely symptomatic patients (NYHA class III/IV) with
chronic severe primary MR (stage D) who have a reasonable life expectancy but a prohibitive surgical
risk because of severe comorbidities
IIb B (426)
MVR should not be performed for treatment of isolated severe primary MR limited to less than one
half of the posterior leaﬂet unless MV repair has been attempted and was unsuccessful
III: Harm B (87,407–409)
AF indicates atrial ﬁbrillation; COR, Class of Recommendation; LOE, Level of Evidence; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; MR,
mitral regurgitation; MV, mitral valve; MVR, mitral valve replacement; N/A, not applicable; NYHA, New York Heart Association; and PA, pulmonary artery.
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1. Mitral valve surgery is recommended for symptomatic patients
with chronic severe primary MR (stage D) and LVEF greater
than 30% (365,376). (Level of Evidence: B)
Primary MR is a mechanical problem of the leaﬂets that
has only a mechanical solutiondthat of mitral valve sur-
gery. The onset of symptoms that results from severe MR
worsens prognosis even when LV function appears to be
normal, and negative prognosis extends even to mild
symptoms. Thus, the onset of symptoms is an indication
for prompt mitral valve surgery.
Supporting References: (365,376)
CLASS I
2. Mitral valve surgery is recommended for asymptomatic patients
with chronic severe primary MR and LV dysfunction (LVEF 30%
to 60% and/or LVESD ‡40 mm, stage C2) (359–362,392–394).
(Level of Evidence: B)
The goal of therapy inMR is to correct it before the onset
of LV systolic dysfunction and the subsequent adverse
effect on patient outcomes. Ideally, mitral valve surgery
should be performed when the patient’s left ventricle ap-
proaches but has not yet reached the parameters that indi-
cate systolic dysfunction (LVEF 60% or LVESD 40
mm). Because symptoms do not always coincide with LV
dysfunction, imaging surveillance is used to plan surgerybefore severe dysfunction has occurred. If moderate LV
dysfunction is already present, prognosis is reduced
following mitral valve operation. Thus, further delay (even
though symptoms are absent) will lead to greater LV
dysfunction and a still worse prognosis. Because the loading
conditions in MR allow continued late ejection into a
lower-impedance LA, a higher cutoff for “normal” LVEF is
used in MR than in other types of heart disease. Although
it is clearly inadvisable to allow patients’ LV function to
deteriorate beyond the benchmarks of an LVEF 60%
and/or LVESD 40 mm, some recovery of LV function
can still occur even if these thresholds have been crossed.
Supporting References: (359–362,392–394)
CLASS I
3. Mitral valve repair is recommended in preference to MVR when
surgical treatment is indicated for patients with chronic severe
primary MR limited to the posterior leaﬂet (87,364,395–409).
(Level of Evidence: B)
Mitral competence is only 1 function of the mitral valve
apparatus. The mitral valve apparatus is an integral part of
the left ventricle. It aids in LV contraction and helps
maintain the efﬁcient prolate ellipsoid shape of the left
ventricle. Destruction of the mitral apparatus causes im-
mediate LV dysfunction. Mitral valve repair is favored over
MVR for 3 reasons:
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mortality rate than MVR. Although no RCTs exist,
virtually every clinical report, including data from the
STS database, indicates that operative risk (30–day
mortality) for repair is about half that of MVR.
2. LV function is better preserved following repair
preserving the integrity of the mitral valve apparatus
versus following MVR.
3. Repair avoids the risks inherent to prosthetic heart
valves, that is, thromboembolism or anticoagulant-
induced hemorrhage for mechanical valves or struc-
tural deterioration for bioprosthetic valves.
Because the success of repair increases with surgical
volume and expertise, repair (which is the preferred treat-
ment) is more likely to be accomplished in centers with
surgeons who have expertise in this type of surgery. Mitral
valve repair over MVR is indicated even in patients >65
years of age. When in doubt, MVR is preferable to a poor
repair. The results of a minimally invasive approach per-
formed via minithoracotomy/port access using direct
vision, thoracoscopic, or robotic assistance versus a con-
ventional sternotomy approach may be similar when per-
formed by highly experienced surgeons.
Surgical repair of MR has been remarkably successful in
the treatment of primary MR. When leaﬂet dysfunction is
sufﬁciently limited so that only annuloplasty and repair of
the posterior leaﬂet are necessary, repair of isolated
degenerative mitral disease has led to outcomes distinctly
superior to biological or mechanical valve replacement: an
operative mortality of <1%; long-term survival equivalent
to that of the age-matched general population; approxi-
mately 95% freedom from reoperation; and >80% freedom
from recurrent moderate or severe (3þ) MR at 15 to 20
years after operation. As much as one half of the posterior
leaﬂet may be excised, plicated, or resuspended. Posterior
leaﬂet repair has become sufﬁciently standardized so that
valve repair rather than valve replacement is the standard of
care in this situation. Execution of this procedure with a
success rate 90% should be the expectation of every
cardiac surgeon who performs mitral valve procedures.
Supporting References: (87,364,395–409,427–432)
CLASS I
4. Mitral valve repair is recommended in preference to MVR when
surgical treatment is indicated for patients with chronic severe
primary MR involving the anterior leaﬂet or both leaﬂets when a
successful and durable repair can be accomplished (86,407–
413). (Level of Evidence: B)
Degenerative mitral valve disease consisting of more
than posterior leaﬂet disease requires a more complex and
extensive repair. When the anterior leaﬂet or both leaﬂets
require repair, durability of the repair is less certain, with a
freedom from reoperation of approximately 80% and a
freedom from recurrent moderate or severe MR of 60% at
15 to 20 years. These results are superior to the results of
MVR, even in elderly patients. Repair should also beattempted if possible with other causes of severe MR, such
as papillary muscle rupture, IE, and cleft mitral valve. As
the repair becomes more complex, however, results of very
complex repair in younger patients may be matched by
results of durable mechanical MVR with careful manage-
ment of anticoagulation.
More complex repair is not well standardized and is
more surgically demanding. The Heart Valve Team should
assign complex repairs to more experienced mitral valve
surgeons with established outcomes, including acute suc-
cess rate as well as long-term durability. The probability of
mitral valve repair rather than MVR correlates with
surgeon-speciﬁc mitral volumes. In a 2007 analysis, hos-
pitals that performed <36 mitral operations per year had a
48% repair rate, whereas hospitals that performed >140
mitral operations per year had a 77% repair rate. Hospital
mortality was also 50% lower, on average, in the highest-
volume hospitals. There was, however, considerable
overlap in speciﬁc hospital outcomes, with >25% of low-
volume hospitals outperforming the median high-volume
hospitals. This overlap suggests that hospital or surgeon-
speciﬁc volumes should not be used as a surrogate for
actual surgeon-speciﬁc repair rates and outcomes.
Supporting References: (86,407–413)
CLASS I
5. Concomitant mitral valve repair or MVR is indicated in patients
with chronic severe primary MR undergoing cardiac surgery for
other indications (414). (Level of Evidence: B)
During coronary revascularization and in cases of IE or
other conditions where multiple valves may be involved, it
is prudent to correct severe primary MR at the time of
surgery. This is especially true when mitral repair can be
performed in conjunction with AVR because operative risk
is lower than that of double valve replacement.
Supporting Reference: (414)
CLASS IIa
1. Mitral valve repair is reasonable in asymptomatic patients with
chronic severe primary MR (stage C1) with preserved LV func-
tion (LVEF >60% and LVESD <40 mm) in whom the likelihood of
a successful and durable repair without residual MR is greater
than 95% with an expected mortality rate of less than 1% when
performed at a Heart Valve Center of Excellence (39,86,415–
419). (Level of Evidence: B)
The onset of symptoms, LV dysfunction, or pulmonary
hypertension worsens the prognosis for MR. Careful
intensive surveillance may result in timing of valve surgery
before these negative sequelae occur. However, an attrac-
tive alternative strategy for treating severe chronic primary
MR is to perform early mitral repair before these triggers
are reached. Early mitral repair avoids the need for
intensive surveillance and also obviates the possibility that
patients might become lost to follow-up or delay seeing
their clinician until advanced LV dysfunction has already
ensued. This strategy requires expertise in clinical evalua-
tion and cardiac imaging to ensure that MR is severe. For
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vided. An unwanted valve replacement, exposing the pa-
tient to the unneeded risks accrued from prosthetic valve
replacement, or a repair that fails, necessitating reopera-
tion, should be considered complications of this approach.
Thus, there must be a high degree of certainty that a du-
rable repair can be performed. In this regard, posterior
leaﬂet repair is usually more durable than anterior leaﬂet
repair, especially in less experienced hands, and high sur-
gical volume is also associated with better repair rates and
more durable outcomes. These operations on the asymp-
tomatic patient should be performed in Heart Valve
Centers of Excellence by experienced surgeons with
expertise in mitral valve repair. When performed by
experienced surgeons in a Heart Valve Center of Excel-
lence, there is a lower risk of patients developing HF and
lower mortality rates in patients with severe MR from ﬂail
leaﬂets who undergo early operation as opposed to
watchful waiting.
Supporting References: (39,86,415–419)
CLASS IIa
2. Mitral valve repair is reasonable for asymptomatic patients with
chronic severe nonrheumatic primary MR (stage C1) and pre-
served LV function (LVEF >60% and LVESD <40 mm) in whom
there is a high likelihood of a successful and durable repair with
1) new onset of AF or 2) resting pulmonary hypertension (pul-
monary artery systolic arterial pressure >50 mm Hg)
(363,415,420–425). (Level of Evidence: B)
In nonrheumatic MR, the onset of AF is in part due to
enlarging left atrial size, and its presence worsens surgical
outcome. Furthermore, the longer AF is present, the more
likely it is to persist. Thus, it may be reasonable to restore
mitral competence by low-risk repair with the hope that
the ensuing reduction in left atrial size will help restore and
maintain sinus rhythm. However, restoration of sinus
rhythm following valve surgery is uncertain, and concom-
itant AF ablation surgery may be warranted (Section
14.2.2). This strategy does not apply to rheumatic MR,
where active atrial inﬂammation may make restoration of
sinus rhythm less likely and valve scarring reduces the
likelihood of a successful repair. The presence of pulmo-
nary arterial hypertension due to MR is associated with
poorer outcome after valve surgery. Thus, it is reasonable to
consider surgery in these patients if there is a high likeli-
hood of a successful and durable repair.
Supporting References: (363,420–425)
CLASS IIa
3. Concomitant mitral valve repair is reasonable in patients with
chronic moderate primary MR (stage B) when undergoing car-
diac surgery for other indications. (Level of Evidence: C)
Because MR is a progressive lesion, it is reasonable to
address it at the time of other cardiac surgery. This is
especially true if the mitral valve can be repaired. However,
the added risk of mitral valve surgery must be weighed
against the potential for progression of MR. In such cases,increased operative mortality might not be justiﬁed in
treating moderate MR.
Supporting Reference: (433)
CLASS IIb
1. Mitral valve surgery may be considered in symptomatic patients
with chronic severe primary MR and LVEF less than or equal to
30% (stage D). (Level of Evidence: C)
Most patients with decompensated MR and an
LVEF 30% have secondary rather than primary MR.
However in the rare cases where valve pathology indicates a
clear primary cause in a patient with far-advanced LV
dysfunction, surgery might be beneﬁcial, especially in pa-
tients without severe comorbidities. Repair seems reason-
able in such patients because of the likelihood of continued
deterioration in LV function if surgery is not performed.
However, data regarding surgery in patients with primary
MR and a low LVEF are lacking.
CLASS IIb
2. Mitral valve repair may be considered in patients with rheumatic
mitral valve disease when surgical treatment is indicated if a
durable and successful repair is likely or when the reliability of
long-term anticoagulation management is questionable
(86,406,413). (Level of Evidence: B)
Rheumatic mitral valve disease is less suitable for mitral
repair than complex degenerative disease. Durability of the
repair is limited by thickened or calciﬁed leaﬂets, extensive
subvalvular disease with chordal fusion and shortening, and
progression of rheumatic disease. Freedom from reopera-
tion at 20 years, even in experienced hands, is in the 50%
to 60% range. In a large series from Korea, repair was
accomplished in 22% of patients operated on for rheumatic
disease. One third of these patients who underwent repair
had signiﬁcant stenosis or regurgitation at 10 years. Repair
of rheumatic mitral valve disease should be limited to pa-
tients with less advanced disease in whom a durable repair
can be accomplished or to patients in whom a mechan-
ical prosthesis cannot be used because of anticoagulation
management concerns.
Supporting References: (434,435)
CLASS IIb
3. Transcatheter mitral valve repair may be considered for severely
symptomatic patients (NYHA class III to IV) with chronic severe
primary MR (stage D) who have favorable anatomy for the repair
procedure and a reasonable life expectancy but who have a
prohibitive surgical risk because of severe comorbidities and
remain severely symptomatic despite optimal GDMT for HF
(426). (Level of Evidence: B)
An RCT of percutaneous mitral valve repair using the
MitraClip device versus surgical mitral repair was con-
ducted in the United States. The clip was found to be safe
but less effective than surgical repair because residual MR
was more prevalent in the percutaneous group. However,
the clip reduced severity of MR, improved symptoms, and
led to reverse LV remodeling. Percutaneous mitral valve
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primary MR who remain severely symptomatic with
NYHA class III to IV HF symptoms despite optimal
GDMT for HF and who are considered inoperable.
Supporting References: (426,436,437)
CLASS III: Harm
1. MVR should not be performed for the treatment of isolated se-
vere primary MR limited to less than one half of the posterior
leaﬂet unless mitral valve repair has been attempted and was
unsuccessful (87,407–409). (Level of Evidence: B)
Surgical repair of MR has been remarkably successful,
particularly in the treatment of chronic primary MR.
Repair of isolated degenerative mitral disease, when leaﬂet
dysfunction is sufﬁciently limited that only annuloplasty
and repair of the posterior leaﬂet are necessary, has led to
outcomes distinctly superior to biological or mechanical
MVR: operative mortality of <1%; long-term survival
equivalent to that of age-matched general population;
approximately 95% freedom from reoperation; and >80%
freedom from recurrent moderate or severe (3þ) MR at
15 to 20 years after operation. As much as one half of the
posterior leaﬂet may be excised, plicated, or resuspended.
Posterior leaﬂet repair has become sufﬁciently standardized
in this situation that repair rather than MVR is the stan-
dard of care. Execution of this procedure with a success
rate 90% should be the expectation of every cardiac
surgeon who performs mitral valve procedures.
Supporting References: (87,407–409)
See Online Data Supplements 16 and 17 for more infor-
mation on intervention.
7.4. Chronic Secondary MR
7.4.1. Diagnosis and Follow-Up: Recommendations
CLASS I
1. TTE is useful to establish the etiology of chronic secondary MR
(stages B to D) and the extent and location of wall motion
abnormalities and to assess global LV function, severity of MR,
and magnitude of pulmonary hypertension. (Level of Evidence: C)
In general, the presence of chronic secondary MR
worsens the prognosis of patients with LV systolic
dysfunction and symptoms of HF, and most patients with
secondary MR have severe global LV dysfunction. How-
ever, in some patients, a limited but strategically placed
wall motion abnormality may also cause chronic secondary
MR, and prognosis may be better in such patients. An
initial TTE helps establish the cause of chronic secondary
MR and also serves as a baseline for future comparisons. In
patients with secondary MR, outcome studies have shown
poorer prognosis with effective regurgitant oriﬁce 20
mm2. It is recognized that there is difﬁculty assessing
secondary MR in patients with reduced LV systolic func-
tion and low forward ﬂow.
Supporting References: (438,439)CLASS I
2. Noninvasive imaging (stress nuclear/positron emission tomog-
raphy, CMR, or stress echocardiography), cardiac CT angiog-
raphy, or cardiac catheterization, including coronary
arteriography, is useful to establish etiology of chronic sec-
ondary MR (stages B to D) and/or to assess myocardial
viability, which in turn may inﬂuence management of functional
MR. (Level of Evidence: C)
Prognosis is poor for both ischemic and nonischemic
MR, but ischemic MR lends itself to the possibility of
revascularization and potential improvement in LV func-
tion if CAD has led to large areas of hibernating viable
myocardium. CT angiography is usually adequate to rule
out signiﬁcant CAD and thus rule out ischemic MR. If
CAD is detected and noninvasive testing demonstrates
areas of viability, coronary arteriography is pursued to
better deﬁne the anatomy for potential revascularization.
Supporting Reference: (440)
7.4.2. Medical Therapy: Recommendations
CLASS I
1. Patients with chronic secondary MR (stages B to D) and HF
with reduced LVEF should receive standard GDMT therapy for
HF, including ACE inhibitors, ARBs, beta blockers, and/or
aldosterone antagonists as indicated (310,441–445). (Level of
Evidence: A)
Chronic secondary MR usually develops as a result of
severe LV dysfunction. Thus, standard GDMT for HF
forms the mainstay of therapy. Diuretics, beta blockers,
ACE inhibition or ARBs, and aldosterone antagonists
help improve symptoms and/or prolong life in HF in
general and probably do so even when HF is complicated
by chronic secondary MR.
Supporting References: (310,441–445)
CLASS I
2. Cardiac resynchronization therapy with biventricular pacing is
recommended for symptomatic patients with chronic severe
secondary MR (stages B to D) who meet the indications for de-
vice therapy (446,447). (Level of Evidence: A)
Wall motion abnormalities are a common cause of
chronic secondary MR, and their presence worsens the
condition. The presence of conduction system abnormal-
ities, especially left bundle-branch block, causes disordered
LV contraction that exacerbates or is the primary cause of
wall motion abnormalities. Electrical resynchronization
may reduce or even eliminate wall motion abnormalities.
Cardiac resynchronization therapy may also improve LV
function and mitral valve closing force, which in turn leads
to a reduction in chronic secondary MR in some cases.
Thus, cardiac resynchronization therapy should be consid-
ered in symptomatic patients with chronic secondary MR
who meet the indications for device therapy as outlined in
the ACC/AHA guidelines for device-based therapy.
Supporting References: (446,447)
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See Table 18 for a summary of recommendations for this
section and Figure 4 for indications for surgery for MR.
Chronic severe secondary MR adds volume overload to
a decompensated left ventricle and worsens prognosis.
However, there are only sparse data to indicate that cor-
recting MR prolongs life or even improves symptoms over
an extended time. The beneﬁts of performing mitral valve
repair over MVR are also unclear in this subset of patients.
Percutaneous mitral valve repair provides a less invasive
alternative to surgery but is not approved for clinical use in
the United States.
Supporting References: (426,436,459)
CLASS IIa
1. Mitral valve surgery is reasonable for patients with chronic se-
vere secondary MR (stages C and D) who are undergoing CABG
or AVR. (Level of Evidence: C)
There is no proof that correction of chronic secondary
MR at the time of AVR or CABG is effective in pro-
longing life or relieving symptoms, but it seems wise to
address the mitral valve during those operations. Although
it may be hoped that the revascularization will recruit hi-
bernating myocardium and reduce chronic secondary MR
or that LV pressure reduction from relief of AS or volume
reduction from relief of AR might improve chronic sec-
ondary MR, such hopes may not be realized. Failing to
correct chronic secondary MR may leave the patient with
severe residual MR.
CLASS IIb
1. Mitral valve repair or replacement may be considered for
severely symptomatic patients (NYHA class III to IV) with
chronic severe secondary MR (stage D) who have persistent
symptoms despite optimal GDMT for HF (439,448–458). (Level
of Evidence: B)
Although it is clear that chronic severe secondary
MR adds to the burden of HF by imposing volume
overload on an already compromised left ventricle and
worsens prognosis, there is remarkably little evidence
that correcting chronic severe secondary MR prolongs
life or even improves symptoms for a prolonged period.
This paradox may result from the fact that mitral surgery
in ischemic MR does not prevent CAD from progress-
ing, nor does it prevent the continued idiopathic myo-
cardial deterioration in nonischemic chronic secondaryTable 18. Summary of Recommendations for Chronic Severe Secon
Recommendations
MV surgery is reasonable for patients with chronic severe secondary MR (stages C an
undergoing CABG or AVR
MV surgery may be considered for severely symptomatic patients (NYHA class III/IV)
severe secondary MR (stage D)
MV repair may be considered for patients with chronic moderate secondary MR (stag
undergoing other cardiac surgery
AVR indicates aortic valve replacement; CABG, coronary artery bypass graft; COR, Class of Recommend
NYHA, New York Heart Association.MR. Furthermore, when chronic severe secondary MR
is addressed surgically, it is not clear that repair, so
valuable in treating primary MR, is even preferred over
MVR in chronic severe secondary MR. Small RCTs
have demonstrated that mitral valve surgery reduces
chamber size and improves peak oxygen consumption in
chronic severe secondary MR. Deciding which patients
with chronic severe secondary MR will beneﬁt from
mitral surgery awaits the results of larger RCTs. Ischemic
or dilated cardiomyopathy presents different challenges
for mitral repair. Regurgitation is caused by annular
dilation as well as apical and lateral displacement of the
papillary muscles. New techniques have facilitated mitral
repair in this situation, but durability of the repair is
primarily dependent on regression or progression of
ventricular dilation. If the heart continues to dilate, long-
term durability of the repair is moot; the survival of the
patient is limited.
Supporting References: (434,435,439,448–458)
CLASS IIb
2. Mitral valve repair may be considered for patients with chronic
moderate secondary MR (stage B) who are undergoing other
cardiac surgery. (Level of Evidence: C)
Because MR tends to be a progressive disease, it may be
helpful to address moderate MR when other cardiac sur-
gery is being performed. Because adding MVR to other
valve surgery increases surgical risk, it seems logical that
repair would be preferred in such instances; however, there
are sparse data available at the time of publication to
support this concept.
Supporting Reference: (433)
See Online Data Supplement 18 for more information on
intervention.
8. Tricuspid Valve Disease
8.1. Stages of TR
Trace-to-mild degrees of TR of no physiological conse-
quence are commonly detected on TTE in subjects with
anatomically normal valves. Primary disorders of the
tricuspid apparatus that can lead to more signiﬁcant de-
grees of TR include rheumatic disease, prolapse, congenital
disease (Ebstein’s), IE, radiation, carcinoid, blunt chest
wall trauma, RV endomyocardial biopsyrelated trauma,dary MR
COR LOE References
d D) who are IIa C N/A
with chronic IIb B (439,448–458)
e B) who are IIb C N/A
ation; LOE, Level of Evidence; MR, mitral regurgitation; MV, mitral valve; N/A, not applicable; and
Figure 4. Indications for Surgery for MR
*Mitral valve repair is preferred over MVR when possible.
AF indicates atrial ﬁbrillation; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; ERO, effective regurgitant oriﬁce; HF, heart failure; LV, left ventricular; LVEF,
left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; MR, mitral regurgitation, MV, mitral valve; MVR, mitral valve replacement; NYHA, New York Heart
Association; PASP, pulmonary artery systolic pressure; RF, regurgitant fraction; RVol, regurgitant volume; and Rx, therapy.
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cardioverter-deﬁbrillator leads. Approximately 80% of
cases of signiﬁcant TR are functional in nature and
related to tricuspid annular dilation and leaﬂet tethering
in the setting of RV remodeling due to pressure and/or
volume overload. The tricuspid annulus is a saddle-
shaped ellipsoid that becomes planar and circular as it
dilates in an anterior-posterior direction and will often
not return to its normal size and conﬁguration after
relief of RV overload. Table 19 shows the stages (A
through D) of primary and functional TR as deﬁned for
other valve lesions. Severe TR (stages C and D) is
associated with poor prognosis independent of age, LV
and RV function, and RV size. Patients with signs or
symptoms of right HF would ﬁt into the stage D
category even if they do not meet other hemodynamic or
morphological criteria.
Supporting Reference: (460)8.2. Tricuspid Regurgitation
See Figure 5 for indications for surgery.
8.2.1. Diagnosis and Follow-Up: Recommendations
CLASS I
1. TTE is indicated to evaluate severity of TR, determine etiology,
measure sizes of right-sided chambers and inferior vena cava,
assess RV systolic function, estimate pulmonary artery systolic
pressure, and characterize any associated left-sided heart dis-
ease. (Level of Evidence: C)
Most TR is clinically silent. Advanced degrees of TR
may be detected on physical examination by the appearance
of elevated “c-V” waves in the jugular venous pulse, a
systolic murmur at the lower sternal border that increases
in intensity with inspiration, and a pulsatile liver edge. In
many patients, characteristic ﬁndings in the jugular venous
pulse are the only clues to the presence of advanced TR,
because a murmur may be inaudible even with severe
Table 19. Stages of TR
Stage Deﬁnition
Valve
Anatomy
Valve
Hemodynamics*
Hemodynamic
Consequences Symptoms
A At risk of TR Primary
 Mild rheumatic change
 Mild prolapse
 Other (e.g., IE with
vegetation, early
carcinoid deposition,
radiation)
 Intra-annular RV
pacemaker or ICD lead
 Postcardiac transplant
(biopsy related)
Functional
 Normal
 Early annular dilation
 No or trace TR  None  None or in relation to other
left heart or pulmonary/
pulmonary vascular disease
B Progressive TR Primary
 Progressive leaﬂet
deterioration/destruction
 Moderate-to-severe
prolapse, limited
chordal rupture
Functional
 Early annular dilation
 Moderate leaﬂet tethering
Mild TR
 Central jet area <5.0 cm2
 Vena contracta width not
deﬁned
 CW jet density and contour:
soft and parabolic
 Hepatic vein ﬂow: systolic
dominance
Moderate TR
 Central jet area 5–10 cm2
 Vena contracta width not
deﬁned but <0.70 cm
 CW jet density and contour:
dense, variable contour
 Hepatic vein ﬂow: systolic
blunting
Mild TR
 RV/RA/IVC size normal
Moderate TR
 No RV enlargement
 No or mild RA enlargement
 No or mild IVC enlargement
with normal respirophasic
variation
 Normal RA pressure
 None or in relation to other
left heart or pulmonary/
pulmonary vascular disease
C Asymptomatic,
severe TR
Primary
 Flail or grossly distorted
leaﬂets
Functional
 Severe annular dilation
(>40 mm or 21 mm/m2)
 Marked leaﬂet tethering
 Central jet area >10.0 cm2
 Vena contracta width
>0.7 cm
 CW jet density and contour:
dense, triangular with early
peak
 Hepatic vein ﬂow: systolic
reversal
 RV/RA/IVC dilated with
decreased IVC respirophasic
variation
 Elevated RA pressure with
“c-V” wave
 Diastolic interventricular
septal ﬂattening may be
present
 None, or in relation to other
left heart or pulmonary/
pulmonary vascular disease
D Symptomatic
severe TR
Primary
 Flail or grossly distorted
leaﬂets
Functional
 Severe annular dilation
(>40 mm or >21 mm/m2)
 Marked leaﬂet tethering
 Central jet area >10.0 cm2
 Vena contracta width
>0.70 cm
 CW jet density and contour:
dense, triangular with early
peak
 Hepatic vein ﬂow: systolic
reversal
 RV/RA/IVC dilated with
decreased IVC respirophasic
variation
 Elevated RA pressure with
“c-V” wave
 Diastolic interventricular
septal ﬂattening
 Reduced RV systolic function
in late phase
 Fatigue, palpitations,
dyspnea, abdominal
bloating, anorexia, edema
*Several valve hemodynamic criteria are provided for assessment of severity of TR, but not all criteria for each category will necessarily be present in every patient. Categorization of severity of TR as
mild, moderate, or severe also depends on image quality and integration of these parameters with clinical ﬁndings.
CW indicates continuous wave; ICD, implantable cardioverter-deﬁbrillator; IE, infective endocarditis; IVC, inferior vena cava; RA, right atrium; RV, right ventricle; and TR, tricuspid regurgitation.
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abdominal fullness, edema, and palpitations, particularly if
AF is also present. Progressive hepatic dysfunction may
occur due to the elevated right atrial pressure, and thus
assessment of liver function is useful in patients with
advanced degrees of TR.
TTE can distinguish primary from functional TR, deﬁne
any associated left-sided valvular and/or myocardial disease,
and provide an estimate of pulmonary artery systolic pres-
sure. Characterization of severity of TR (Table 19) relies on
an integrative assessment of multiple parameters as recom-
mended by the ASE and EAE. In cases of functional TR,the tricuspid annular diameter should be measured in the
apical 4–chamber view. There is a linear relationship be-
tween annular diameter and tricuspid regurgitant volume. A
diastolic diameter >40 mm (or >21 mm/m2) indicates
signiﬁcant annular dilation and an increased risk of persis-
tent or progressive TR after isolated mitral valve surgery.
With RV remodeling, tricuspid valve leaﬂet tethering
height and area also contribute to functional TR and may
predict the need for repair techniques other than annulo-
plasty to achieve an effective and durable operative result.
Pulmonary artery systolic pressure is estimated from the
maximal tricuspid valve regurgitant velocity using the
Figure 5. Indications for Surgery
*See Table 19 for deﬁnition of stages. TA dilation is deﬁned by >40 mm on TTE (>21 mm/m2) or >70 mm on direct intraoperative measurement.
LV indicates left ventricular; PHTN, pulmonary hypertension; RV, right ventricular; TA, tricuspid annular; TR, tricuspid regurgitation; TTE, transthoracic echocardiogram; TV,
tricuspid valve; and TVR, tricuspid valve replacement.
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can be compromised in severe TR due to the difﬁculty in
assessing right atrial pressure as well as potential inaccura-
cies of applying the simpliﬁed Bernoulli equation to lesions
with laminar ﬂow. Assessment of RV systolic function is
challenged by geometric and image acquisition constraints,
as well as by variability inRV loading conditions. Normal RV
systolic function is deﬁned by several parameters, including
tricuspid annular plane systolic excursion>16 mm, tricuspid
valve annular velocity (S’) >10.0 cm per second, and RV
end-systolic area<20.0 cm2 or fractional area change>35%.
TEE for tricuspid valve assessment can be considered when
TTE images are inadequate, although visualization of the
tricuspid valve with TEE can also be suboptimal.
Supporting References: (5,461–469,469–471)
CLASS IIa
1. Invasive measurement of pulmonary artery pressures and pul-
monary vascular resistance can be useful in patients with TR
when clinical and noninvasive data regarding their values are
discordant. (Level of Evidence: C)
When physical examination, ECG, and TTE data
regarding estimated pulmonary artery systolic pressure are
either discordant or insufﬁcient, including when the TR jet
velocity signal is inadequate or may underestimate pulmonaryartery systolic pressure, invasive measurement of pulmonary
artery pressures and pulmonary vascular resistance can be
helpful to guide clinical decision making in individual pa-
tients. Invasive data are essential for accurate diagnosis of
the cause of pulmonary hypertension and for the assessment
of pulmonary vascular reactivity following vasodilator chal-
lenge. Direct measurements of right atrial pressure may
also be useful for clinical decision making. Right ven-
triculography may further aid in the evaluation of the
severity of TR and the status of the right ventricle. Ther-
modilution cardiac output measurements may be inaccurate
with severe TR, and thus a Fick cardiac output should be
measured to apply to the calculation of pulmonary resistance.
CLASS IIb
1. CMR or real-time 3D echocardiography may be considered for
assessment of RV systolic function and systolic and diastolic
volumes in patients with severe TR (stages C and D) and sub-
optimal 2D echocardiograms. (Level of Evidence: C)
Assessment of RV systolic function in patients with TR
is a critical component of preoperative planning, especial-
ly in the context of reoperative isolated tricuspid valve
repair or replacement years after left-sided valve surgery.
Impaired RV systolic function negatively impacts early
functional, late functional, and survival outcomes following
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be suboptimal in some patients, due to poor acoustic win-
dows, the technical limitations of standard echocardio-
graphic and Doppler techniques, and dynamic changes in
RV loading conditions. Both CMR and real-time 3D
echocardiography may provide more accurate assessment
of RV volumes and systolic function, as well as annular
dimension and the degree of leaﬂet tethering. CMR may be
the ideal modality in young asymptomatic patients with se-
vere TR to assess initial and serial measurements of RV size
and systolic function. In addition, echocardiographic strain
imaging or CT scanning may be useful in assessing RV
function. These imaging modalities are not widely used at
the time of guideline publication, and outcome data are
needed to determine the incremental utility of these tests.
Supporting References: (472–481)
CLASS IIb
2. Exercise testing may be considered for the assessment of ex-
ercise capacity in patients with severe TR with no or minimal
symptoms (stage C). (Level of Evidence: C)
Patients with severe functional TR usually report
symptoms referable to the responsible left-sided valve or
myocardial abnormality. However, in some patients with
primary TR, symptoms may not emerge until relatively late
in the course of the disease. As is the case for left-sided
valve lesions, treadmill or bicycle testing may uncover
limitations to exercise not previously recognized by the
patient and prompt earlier evaluation for surgery. Although
some clinical experience has been reported for patients with
Ebstein’s anomaly, the effect on clinical outcomes of any
exercise-induced changes in RV size/function or pulmo-
nary artery pressures in patients with severe TR (stage C)
has not been prospectively studied.
Supporting Reference: (482)
8.2.2. Medical Therapy: Recommendations
CLASS IIa
1. Diuretics can be useful for patients with severe TR and signs of
right-sided HF (stage D). (Level of Evidence: C)
Patients with severe TR usually present with signs or
symptoms of right HF, including peripheral edema and
ascites. Diuretics can be used to decrease volume over-
load in these patients. Loop diuretics are typically provided
and may relieve systemic congestion, but their use can
be limited by worsening low-ﬂow syndrome. Aldosterone
antagonists may be of additive beneﬁt, especially in the
setting of hepatic congestion, which may promote sec-
ondary hyperaldosteronism.
CLASS IIb
1. Medical therapies to reduce elevated pulmonary artery pres-
sures and/or pulmonary vascular resistance might be consid-
ered in patients with severe functional TR (stages C and D).
(Level of Evidence: C)
Medical therapies for management of severe TR (stages
C and D) are limited. Attention should be focused on thecausative lesion in patients with functional TR. Reduc-
tion of pulmonary artery pressures and pulmonary vascu-
lar resistance with speciﬁc pulmonary vasodilators may
be helpful to reduce RV afterload and functional TR in
selected patients with pulmonary hypertension who dem-
onstrate acute responsiveness during invasive testing.
Medical treatment of conditions that elevate left-sided
ﬁlling pressures, such as systemic hypertension, should be
optimized.
Supporting References: (483,484)
8.2.3. Intervention: Recommendations
CLASS I
1. Tricuspid valve surgery is recommended for patients with se-
vere TR (stages C and D) undergoing left-sided valve surgery.
(Level of Evidence: C)
The indications for surgical correction of TR are most
often considered at the time of mitral or aortic valve sur-
gery. Severe TR of either a primary or functional nature
may not predictably improve after treatment of the left-
sided valve lesion and reduction of RV afterload; as such,
severe TR should be addressed as part of the index pro-
cedure. Reoperation for severe, isolated TR after left-sided
valve surgery is associated with a perioperative mortality
rate of 10% to 25%. Tricuspid valve repair does not add
appreciably to the risks of surgery and can be accomplished
with a clinically insigniﬁcant increase in ischemic time.
There has been a signiﬁcant increase in the number of
tricuspid valve repairs performed for this indication over
the past decade. Tricuspid valve repair is preferable to
replacement. When replacement is necessary for primary,
uncorrectable tricuspid valve disease, the choice of pros-
thesis is individualized, with the usual trade-offs between
thrombosis/anticoagulation with a mechanical valve and
durability with a tissue valve. Meta-analysis has shown no
difference in overall survival between mechanical and tissue
valves for patients undergoing tricuspid valve replacement.
The risks and beneﬁts of tricuspid valve operation should
be carefully considered in the presence of severe RV sys-
tolic dysfunction or irreversible pulmonary hypertension,
due to the possibility of RV failure after operation.
Supporting References: (485–494)
CLASS IIa
1. Tricuspid valve repair can be beneﬁcial for patients with mild,
moderate, or greater functional TR (stage B) at the time of left-
sided valve surgery with either 1) tricuspid annular dilation or 2)
prior evidence of right HF (464–466,495–501). (Level of
Evidence: B)
Left uncorrected at the time of left-sided valve sur-
gery, mild or moderate degrees of functional TR may
progress over time in approximately 25% of patients and
result in reduced long-term functional outcome and sur-
vival. Risk factors for persistence and/or progression of
TR include tricuspid annulus dilation (>40 mm diameter
or 21 mm/m2 diameter indexed to body surface area on
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operative measurement); degree of RV dysfunction/re-
modeling; leaﬂet tethering height; pulmonary artery
hypertension; AF; nonmyxomatous etiology of MR; and
intra-annular RV pacemaker or implantable cardioverter-
deﬁbrillator leads. The cut-off of >70 mm diameter on
direct intraoperative measurement originated from a sin-
gle center, performed with the patient on cardiopulmonary
bypass using a supple ruler, taken from the anteroseptal
commissure to the anteroposterior commissure. Echocar-
diography is usually performed on the beating heart and
examines a different plane of the tricuspid annulus. Nu-
merous observational studies and 1 prospective RCT attest
to the beneﬁt on several echocardiographic and functional
parameters of tricuspid repair at the time of mitral valve
surgery for mild-to-moderate TR (stage B) with tricuspid
annulus dilation. When surgery is performed for isolated
severe primary MR due to a degenerative etiology, less than
moderate TR is unlikely to progress if left untreated. A
prior recent history of right HF is also an indication for
tricuspid valve repair at the time of left-sided valve surgery.
A survival beneﬁt with tricuspid repair in this setting has
not been demonstrated. Management of indwelling pace-
maker or implantable cardioverter-deﬁbrillator leads may
require their removal with epicardial placement in selected
patients. Other approaches, such as sequestering the leads
in a commissure or placing them in an extra-annular po-
sition, may be used. Following repair with ring annulo-
plasty, residual TR is present in approximately 10% of
patients at 5 years.
Supporting References: (463–466,495–504)
CLASS IIa
2. Tricuspid valve surgery can be beneﬁcial for patients with
symptoms due to severe primary TR that are unresponsive to
medical therapy (stage D). (Level of Evidence: C)
Correction of symptomatic severe primary TR (stage D)
in patients without left-sided valve disease is preferentially
performed before onset of signiﬁcant RV dysfunction.
Replacement may be required because of the extent and
severity of the underlying pathology (e.g., carcinoid, radi-
ation, Ebstein’s anomaly). Reduction or elimination of the
regurgitant volume load can alleviate systemic venous and
hepatic congestion and decrease reliance on diuretics. Pa-
tients with severe congestive hepatopathy may also beneﬁt
from surgery to prevent irreversible cirrhosis of the liver.
Quality and duration of long-term survival are related to
residual RV function.
CLASS IIb
1. Tricuspid valve repair may be considered for patients with
moderate functional TR (stage B) and pulmonary artery hy-
pertension at the time of left-sided valve surgery. (Level of
Evidence: C)
When pulmonary artery hypertension is caused pre-
dominantly by left-sided valve disease, effective surgery on
the left-sided valve lesions usually leads to a fall in RVafterload and improvement in functional TR, especially in
the absence of signiﬁcant (i.e., >40 mm on TEE) tricuspid
annulus dilation. This observation dates to the early years
of mitral valve surgery. Prediction rules that account for the
relative contributions of pulmonary hypertension and only
mild-to-moderate degrees of tricuspid annulus enlarge-
ment for the risk of progressive TR are lacking. The beneﬁt
of routine tricuspid valve repair in this context is less clear
across broad populations but may be considered on an
individual basis.
Supporting References: (503,505,506)
CLASS IIb
2. Tricuspid valve surgery may be considered for asymptomatic or
minimally symptomatic patients with severe primary TR (stage
C) and progressive degrees of moderate or greater RV dilation
and/or systolic dysfunction. (Level of Evidence: C)
The optimal timing of tricuspid valve surgery for
asymptomatic or minimally symptomatic, severe primary
TR has not been established. Extrapolation from limited
experiences reported for patients with stable carcinoid
heart disease and patients with a ﬂail tricuspid leaﬂet and
application of the management principles adopted for
patients with severe MR suggest that serial assessments
of RV size and function might trigger consideration of
corrective surgery in selected patients with severe, primary
TR when a pattern of continued deterioration can be
established and the risks of surgery are considered ac-
ceptable. In otherwise healthy patients without other
comorbidities, such as the patient with severe TR due to
trauma, the risk of tricuspid valve operation is low (<1%
to 2%) in the absence of RV dysfunction or pulmonary
hypertension.
Supporting References: (507,508)
CLASS IIb
3. Reoperation for isolated tricuspid valve repair or replacement
may be considered for persistent symptoms due to severe TR
(stage D) in patients who have undergone previous left-sided
valve surgery and who do not have severe pulmonary hyper-
tension or signiﬁcant RV systolic dysfunction. (Level of
Evidence: C)
Isolated tricuspid valve surgery for severe TR has his-
torically been performed relatively late in the natural his-
tory of the disease and once patients have become
symptomatic with signs of right HF. Unadjusted mortality
rates for isolated tricuspid valve surgery have therefore
exceeded those reported for isolated aortic or mitral valve
surgery, and this trend has been even more pronounced
following reoperative tricuspid surgery late after left-sided
valve surgery. This high mortality is likely related to the
advanced nature of RV failure encountered at the time of
the second procedure, residual pulmonary hypertension,
LV dysfunction, and other valve abnormalities. Two Heart
Valve Centers of Excellence have reported perioperative
mortality rates with tricuspid valve reoperation of 4.2%
and 13.2%, respectively. Thus, the hazards imposed by
JACC Vol. 63, No. 22, 2014 Nishimura et al.
June 10, 2014:e57–185 2014 AHA/ACC Valvular Heart Disease Guideline
e113reoperation have inﬂuenced decision making for repair
of functional TR initially at the time of left-sided valve
surgery. The sobering results seen with tricuspid valve
repair at reoperation inject a note of caution into the
recommendations for its performance and may encour-
age replacement with an age-appropriate (mechanical or
biological) prosthesis. The presence of either severe and
uncorrectable pulmonary hypertension or signiﬁcant RV
dysfunction constitutes a relative contraindication to
reoperation.
Supporting References: (485–489,509–512)
See Online Data Supplement 19 for more information on
outcomes following tricuspid valve surgery.8.3. Stages of Tricuspid Stenosis
See Table 20 for the stages of severe tricuspid stenosis (TS).8.4. Tricuspid Stenosis
8.4.1. Diagnosis and Follow-Up: Recommendations
CLASS I
1. TTE is indicated in patients with TS to assess the anatomy of
the valve complex, evaluate severity of stenosis, and charac-
terize any associated regurgitation and/or left-sided valve dis-
ease. (Level of Evidence: C)
Rheumatic disease is the most common etiology of TS.
Its clinical manifestations are far overshadowed by those
attributable to the associated left-sided (particularly mitral)
valve disease. Because TS is often not detected during
bedside examination, TTE is essential for diagnosis and
characterization. TS is usually accompanied by TR of
varying severity. When valve and/or chordal thickening
and calciﬁcation are evident, additional ﬁndings indicative
of severe TS include mean pressure gradient >5 mm Hg,
pressure half-time 190 milliseconds, valve area 1.0 cm2
(continuity equation), and associated right atrial and
inferior vena cava enlargement. It is recognized that as-
sessment of TS severity with TTE is limited by several
technical factors; thus, these values are less well validated
than those reported for MS.
Supporting Reference: (8)
CLASS IIb
1. Invasive hemodynamic assessment of severity of TS may be
considered in symptomatic patients when clinical and nonin-
vasive data are discordant. (Level of Evidence: C)Table 20. Stages of Severe TS
Stage Deﬁnition Valve Anatomy Valve Hemodynamics H
C, D Severe TS  Thickened, distorted, calciﬁed
leaﬂets
 T 1/2 190 ms
 Valve area 1.0 cm2

The transtricuspid diastolic gradient is highly variable and is affected by heart rate, forward ﬂow, and p
10 mm Hg at heart rate 70 bpm.
bpm indicates beats per minute; IVC, inferior vena cava; RA, right atrium; T 1/2, pressure half-time; aHemodynamic assessment of TS is rarely undertaken
for patients with acquired disease but may be performed in
selected patients at the time of invasive study for another
indication, such as MS with pulmonary hypertension.
Direct assessment of the absolute right atrial and RV di-
astolic pressure may be useful in determining the contri-
bution of TS to the patient’s signs or symptoms.
8.4.2. Medical Therapy
As for patients with severe TR, loop diuretics may be
useful to relieve systemic and hepatic congestion in patients
with severe, symptomatic TS, although their use may be
limited by worsening low-ﬂow syndrome. Attention to
left-sided valve disease and AF, when present, is also
important.
8.4.3. Intervention: Recommendations
CLASS I
1. Tricuspid valve surgery is recommended for patients with se-
vere TS at the time of operation for left-sided valve disease.
(Level of Evidence: C)
Surgery for severe TS is most often performed at the
time of operation for left-sided valve disease, chieﬂy
rheumatic MS/MR. If repair is not adequate or feasible
due to valve destruction or multiple levels of pathological
involvement, replacement may be necessary. The choice of
prosthesis should be individualized. Perioperative mortal-
ity rates are higher for mitral plus tricuspid versus either
isolated mitral or tricuspid surgery alone.
Supporting Reference: (489)
CLASS I
2. Tricuspid valve surgery is recommended for patients with iso-
lated, symptomatic severe TS. (Level of Evidence: C)
Relief of severe stenosis should lower elevated right atrial
and systemic venous pressures and alleviate associated
symptoms. Tricuspid valve surgery is preferred over percu-
taneous balloon tricuspid commissurotomy for treatment
of symptomatic severe TS because most cases of severe
TS are accompanied by TR (rheumatic, carcinoid, other),
and percutaneous balloon tricuspid commissurotomy may
either create or worsen regurgitation. There is also a rela-
tive lack of long-term follow-up data on patients managed
with percutaneous balloon tricuspid commissurotomy for
this indication. Outcomes with surgery are dependent on
RV function.
Supporting References: (513,514)emodynamic Consequences Symptoms
RA/IVC enlargement  None or variable and dependent on severity
of associated valve disease and degree of
obstruction
hases of the respiratory cycle. However, severe TS usually has mean pressure gradients >5 to
nd TS, tricuspid stenosis. (8)
Table 21. Stages of Severe PR
Stage Deﬁnition Valve Anatomy Valve Hemodynamics Hemodynamic Consequences Symptoms
C, D Severe PR  Distorted or absent leaﬂets,
annular dilation
 Color jet ﬁlls RVOT
 CW jet density and contour:
dense laminar ﬂow with
steep deceleration slope;
may terminate abruptly
 Paradoxical septal motion
(volume overload pattern)
 RV enlargement
 None or variable and dependent
on cause of PR and RV function
CW indicates continuous wave; PR, pulmonic regurgitation; RV, right ventricular; and RVOT, right ventricular outﬂow tract. (515)
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1. Percutaneous balloon tricuspid commissurotomy might be
considered in patients with isolated, symptomatic severe TS
without accompanying TR. (Level of Evidence: C)
Isolated, symptomatic severe TS without accompanying
TR is an extremely rare condition for which percutaneous
balloon tricuspid commissurotomy might be considered,
recognizing its short-term limitations and the lack of long-
term outcome data.
See Online Data Supplement 19 for more information on
outcomes following tricuspid valve surgery.
9. Pulmonic Valve Disease
9.1. Stages of Pulmonic Regurgitation
See Table 21 for the stages of severe pulmonic regurgita-
tion (PR).
Mild-to-moderate PR seen on echocardiography is
common and does not require further follow-up or inter-
vention if asymptomatic with normal RV size and func-
tion. Signiﬁcant PR in patients is uncommon. Primary PR
that follows in the wake of childhood surgery for tetralogy
of Fallot or other congenital lesions may progress insidi-
ously and reach severe proportions that threaten RV
function without adequate clinical recognition. Its evalua-
tion and management, including indications for valve
replacement, are comprehensively reviewed in the “2008
ACC/AHA Guidelines for the Management of Patients
With Congenital Heart Disease.” The pulmonic valve is
rarely involved by IE or rheumatic disease but is susceptible
to carcinoid accretion because it also affects the tricuspid
valve and results in varying degrees of stenosis and regur-
gitation. Surgery is considered when symptoms or signs of
RV dysfunction have intervened and PR is severe. Sec-
ondary PR from long-standing pulmonary hypertension
and annular dilation is encountered less frequently in theTable 22. Stages of Severe Pulmonic Stenosis
Stage Deﬁnition Valve Anatomy Valve Hemodynam
C, D Severe PS  Thickened, distorted, possibly calciﬁed
leaﬂets with systolic doming and/or
reduced excursion
 Other anatomic abnormalities may
be present, such as narrowed RVOT
 Vmax >4 m/s; pe
instantaneous gra
>64 mm Hg
PA indicates pulmonary artery; PS, pulmonic stenosis; RA, right atrium; RV, right ventricle; RVH, right ventrmodern era. Treatment should focus on the cause(s) of
elevated pulmonary artery pressures.
Supporting Reference: (516)
9.2. Stages of Pulmonic Stenosis
See Table 22 for the stages of severe pulmonic stenosis.
Pulmonic stenosis is essentially a congenital disorder.
Less common etiologies include carcinoid and obstructing
vegetations or tumors. Assessment with TTE alone is
usually sufﬁcient for diagnosis and clinical decision mak-
ing. Indications for percutaneous balloon pulmonic valve
commissurotomy and valve replacement are contained in
the “2008 ACC/AHA Guidelines for the Management of
Patients With Congenital Heart Disease.”
Supporting Reference: (516)
10. Mixed Valve Disease
10.1. Mixed VHD
10.1.1. Diagnosis and Follow-Up
For the majority of patients with mixed valve disease, there
is usually a predominant valve lesion (i.e., stenosis or
regurgitation); further, the symptoms and pathophysiol-
ogy resemble those of a pure dominant lesion. However,
the presence of mixed valve disease poses limitations for
noninvasive and invasive techniques used to determine
severity. These limitations should be strongly considered in
the evaluation of patients with mixed valve disease. For
patients with mixed aortic disease and predominant AS, a
high gradient and small valve area will be present. Pressure
overload results in concentric LV myocardial hypertrophy,
usually without chamber enlargement except in late stages
of the disease. Symptoms may be present in patients with
predominant AS with or without alterations in chamber
morphology. Conversely, for patients with mixed aorticics Hemodynamic Consequences Symptoms
ak
dient
 RVH
 Possible RV, RA enlargement
 Poststenotic enlargement of
main PA
 None or variable and dependent
on severity of obstruction
icular hypertrophy; RVOT, right ventricular outﬂow; and Vmax, maximal pulmonic valve jet velocity. (8)
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gradient may be signiﬁcantly elevated due to regurgitation
in the setting of AS, but the aortic valve area is relatively
large. Patients with predominant AR will have both
pressure and volume overload, resulting in marked in-
creases in LV volume. In these patients, symptoms may be
relatively latent due to preload recruitment with compen-
satory hypertrophy. For patients with mixed mitral disease
and predominant MS, a high transmitral gradient and
small valve area will be present. Left atrial enlargement
occurs with relative preservation of the LV chamber size.
Conversely, in patients with mixed mitral disease and
predominant MR, LV remodeling will occur in addition to
left atrial enlargement. These patients frequently have high
transmitral gradients due to the regurgitant ﬂow, but the
valve area may be relatively large.
For patients with mixed valve disease, there is a paucity
of data on the natural history of such coexistent conditions.
Consequently, the appropriate timing for serial evaluations
of these patients remains uncertain. For patients with
predominant lesions (i.e., stenosis or regurgitation), serial
evaluations in accordance with recommendations for the
predominant valve lesion are generally recommended.
Nonetheless, it is important to recognize that the coexis-
tence of stenosis and regurgitation may have pathological
consequences that are incremental to the effects of either of
these disease states alone. As a result, patients with mixed
disease may require serial evaluations at intervals earlier
than recommended for single valve lesions.
Supporting References: (517–521)
10.1.2. Medical Therapy
Recommendations for medical therapy follow those for
single valve disease when there is a predominant valve
lesion and other management recommendations for
concomitant LV dysfunction. There are no other recom-
mendations for medical therapy speciﬁc to patients with
mixed valve disease.
10.1.3. Timing of Intervention
For patients with mixed valve disease and a predominant
lesion, the need for intervention should generally follow
recommendations for a pure dominant lesion. This con-
sideration should be undertaken with attention to symp-
toms, lesion severity, chamber remodeling, operative risk,
and the expected surgical outcome. Timing of intervention
must be individualized because coexistence of stenosis and
regurgitation may have pathological consequences that
are incremental to the effects of either lesion alone. For
example, patients with mixed aortic disease will have
increased afterload due to both the regurgitant volume and
the relatively small aortic valve area. Thus, patients with
dominant AR may develop symptoms and require sur-
gery before severe LV enlargement develops. For patients
with dominant AS, coexistent regurgitation may be poor-
ly tolerated by a ventricle that is noncompliant due topressure hypertrophy. An elevated left atrial pressure re-
sults from both MS and regurgitation in patients with
mixed mitral disease. Thus, patients with mixed mitral
disease may develop symptoms or pulmonary hypertension
at earlier intervals than has been demonstrated in patients
with pure stenosis or regurgitation. The alterations in
loading conditions due to mixed valve disease may also lead
to cardiac symptoms and chamber remodeling in patients
when there is not a predominant lesion (i.e., mixed mod-
erate valve disease). Patients with mixed moderate valve
disease present a special management challenge, as there is
a paucity of data to guide timing of intervention in these
patients.
For those patients with symptoms of uncertain origin,
valve intervention may be considered when there are
clinical ﬁndings or data supportive of signiﬁcant patho-
logical consequences of the mixed valve lesion. Suppor-
tive abnormalities include objective evidence of functional
limitation (e.g., severely reduced peak myocardial oxygen
consumption attributable to impaired cardiac output) and
signiﬁcantly elevated atrial or ventricular pressures. Exer-
cise hemodynamic studies should be considered for those
patients with symptoms that are out of proportion to he-
modynamic ﬁndings at rest. For example, patients with
mixed mitral disease and a relatively low mitral gradient
may be particularly susceptible to developing functionalMS
at higher transvalvular ﬂow rates due to the concomitant
regurgitant volume. In patients with mixed aortic disease,
the pathological contribution of aortic regurgitant volume
may lessen with exercise due to shortening of diastole.
Given the potential limitations of noninvasive assessments,
direct pressure measurement with cardiac catheterization
may be needed for assessing ventricular ﬁlling abnormal-
ities at rest and with exercise in patients with mixed valve
disease. Because the indications for intervention have not
been well studied in this patient population, the decision
to pursue surgical therapy should be individualized, with
consideration of patient symptoms, severity of hemody-
namic abnormalities, and risk of surgery.
Supporting References: (517–521)
10.1.4. Choice of Intervention
For patients with mixed valve disease, the appropriate
interventional therapy is determined by guidelines for the
predominant valve lesion with consideration of the severity
of the concomitant valve disease. For example, in a patient
with predominant AS, TAVR may be considered in pa-
tients with moderate but not severe AR, whereas con-
ventional AVR may be a therapeutic option regardless of
severity of mixed valve disease. Similarly, percutaneous
balloon mitral commissurotomy is a therapeutic option in
patients with MS and suitable anatomy if there is mild but
not moderate or severe regurgitation. Percutaneous aortic
balloon dilation should not be performed if there is
moderate or severe regurgitation due to the potential for
worsening of the regurgitation with the procedure.
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11.1. Evaluation and Selection of
Prosthetic Valves
11.1.1. Diagnosis and Follow-Up: Recommendations
Patients who have undergone valve replacement are not
cured but still have serious heart disease. Patients have
exchanged native valve disease for prosthetic valve disease
and must be followed with the same care as those with
native valve disease. The clinical course of patients with
prosthetic heart valves is inﬂuenced by several factors,
including LV dysfunction; progression of other valve
disease; pulmonary hypertension; concurrent coronary,
myocardial, or aortic disease; and complications of pros-
thetic heart valves. The interval between routine follow-up
visits depends on the patient’s valve type, residual heart
disease, comorbid conditions, and other clinical factors.
Management of anticoagulation should be supervised
and monitored frequently by an experienced healthcare
professional.
The asymptomatic uncomplicated patient is usually
seen at 1–year intervals for a cardiac history and physical
examination. ECG and chest x-ray examinations are not
routinely indicated but may be appropriate in individual
patients. Additional tests that may be considered include
hemoglobin and hematocrit in patients receiving chro-
nic anticoagulation. No further echocardiographic testing
is required after the initial postoperative evaluation in
patients with mechanical valves who are stable and who
have no symptoms or clinical evidence of prosthetic valve
or ventricular dysfunction or dysfunction of other heart
valves.
CLASS I
1. An initial TTE study is recommended in patients after pros-
thetic valve implantation for evaluation of valve hemodynamics
(522–525). (Level of Evidence: B)
An echocardiographic examination performed 6 weeks
to 3 months after valve implantation is an essential com-
ponent of the ﬁrst postoperative visit because it allows for
an assessment of the effects and results of surgery and
serves as a baseline for comparison should complications or
deterioration occur later. Doppler TTE provides accurate
measurements of transvalvular velocities and pressure gra-
dients as well as detection and quantitation of valvular and
paravalvular regurgitation. Normal Doppler transvalvular
velocities and gradients vary among different types and
sizes of prosthetic valves but are also affected by patient-
speciﬁc factors, including body size and cardiac output.
The postoperative study, recorded when the patient is
asymptomatic and in a stable hemodynamic state, provides
the normal Doppler ﬂow data for that valve in that patient.
In addition to imaging and Doppler ﬂow data for the
prosthetic valve, TTE provides assessment of other valvedisease(s), pulmonary hypertension, atrial size, LV and RV
hypertrophy, LV and RV size and function, and pericardial
disease.
Supporting References: (291,526,527)
CLASS I
2. Repeat TTE is recommended in patients with prosthetic heart
valves if there is a change in clinical symptoms or signs sug-
gesting valve dysfunction. (Level of Evidence: C)
Bioprosthetic valves are prone to tissue degeneration or
pannus formation with development of valve regurgita-
tion and/or stenosis. Bioprosthetic valve dysfunction typ-
ically presents with the insidious onset of exertional
dyspnea or with a louder systolic murmur (MR or AS) or
a new diastolic murmur (AR or MS) on physical exami-
nation. More abrupt and severe symptoms may occur
with bioprosthetic valve endocarditis or with degenerative
rupture of a valve cusp.
Patients with mechanical valve dysfunction present
with symptoms of HF, systemic thromboembolism,
hemolysis, or a new murmur on auscultation. Mechani-
cal valve dysfunction may be due to thrombosis, pannus
formation, or IE. Signs or symptoms of mechanical valve
dysfunction are often acute or subacute because of more
abrupt impairment of leaﬂet occluder opening or closing
by thrombus or pannus. Acute or chronic paravalvular
regurgitation may also be seen due to IE or suture
dehiscence.
TTE allows evaluation of valve dysfunction based on
imaging of leaﬂet structure and motion, vegetations, and
thrombus and Doppler evaluation for prosthetic valve
stenosis or regurgitation. Comparison with the baseline
postoperative echocardiogram is particularly helpful for
detection of prosthetic valve dysfunction.
Supporting References: (528,529)
CLASS I
3. TEE is recommended when clinical symptoms or signs suggest
prosthetic valve dysfunction. (Level of Evidence: C)
TTE is the preferred approach for initial assessment of
suspected prosthetic valve dysfunction because it allows
correct alignment of the Doppler beam with transvalvular
ﬂow for measurement of velocity, gradient, and valve area.
TTE also allows quantitation of LV volumes and LVEF,
an estimate of pulmonary pressures, and evaluation of right
heart function. However, the left atrial side of a prosthetic
mitral valve is obscured by acoustic shadowing from the
TTE approach, resulting in a low sensitivity for detection
of prosthetic MR and prosthetic mitral valve thrombus,
pannus, or vegetation. TEE provides superior images of
the left atrial side of the mitral prosthesis and is accurate
for diagnosis of prosthetic mitral valve dysfunction.
However, both TTE and TEE are needed for complete
evaluation in a patient with suspected prosthetic valve
dysfunction, particularly for those with prosthetic aortic
valves in whom the posterior aspect of the valve is
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the valve is shadowed on the TEE approach. With sus-
pected mechanical valve stenosis, ﬂuoroscopy or CT im-
aging of valve occluder motion is also helpful for detection
of reduced motion due to pannus or thrombus.
Supporting References: (530,531)
CLASS IIa
1. Annual TTE is reasonable in patients with a bioprosthetic valve
after the ﬁrst 10 years, even in the absence of a change in
clinical status. (Level of Evidence: C)
The incidence of bioprosthetic valve dysfunction is low
within 10 years of valve implantation but increases mark-
edly after that point; as such, routine annual evaluation is
a reasonable approach. Earlier evaluation may also be
prudent in selected patients at increased risk of early bio-
prosthetic valve degeneration, including those with renal
impairment, diabetes mellitus, abnormal calcium meta-
bolism, systemic inﬂammatory disease, and in patients <60
years of age. Patients typically remain asymptomatic until
valve dysfunction is severe enough to result in adverse
hemodynamic consequences, such as LV dilation and
systolic dysfunction, pulmonary hypertension, or AF. It
may be challenging to distinguish a murmur due to pros-
thetic MR or AS from the normal postoperative ﬂow
murmur, and the diastolic murmurs of prosthetic AR and
MS often are very soft and difﬁcult to hear on auscultation.
Depending on the valve type and mechanism of regurgi-
tation, some patients with asymptomatic signiﬁcant pros-
thetic valve regurgitation may require surgical intervention.
For example, if prosthetic regurgitation is due to a bio-
prosthetic leaﬂet tear, more severe acute regurgitation may
suddenly occur and cause clinical decompensation. Other
asymptomatic patients with less severe prosthetic valve
regurgitation or with stable valve anatomy can be moni-
tored for evidence of progressive LV dilation and systolic
dysfunction with the same criteria for timing of surgical
intervention as those for native valve regurgitation. With
prosthetic valve stenosis, echocardiographic diagnosis while
the patient is asymptomatic alerts the clinician to the need
for more frequent follow-up. Patients with asymptomatic
prosthetic valve stenosis should be educated about symp-
toms, the likely need for repeat valve intervention, and the
importance of promptly reporting new symptoms.
In patients with mechanical valve prostheses, routine
annual echocardiographic evaluation is not needed if the
postoperative baseline study is normal in the absence of
signs or symptoms of valve dysfunction. However, many of
these patients require TTE for other indications, such as
residual LV systolic dysfunction, pulmonary hypertension,
aortic disease, or concurrent valve disease.
Supporting References: (532,533)
11.1.2. Intervention: Recommendations
See Table 23 for a summary of recommendations for
prosthetic valve choice.CLASS I
1. The choice of valve intervention, that is, repair or replacement, as
well as type of prosthetic heart valve, should be a shared decision-
making process that accounts for the patient’s values and pref-
erences, with full disclosure of the indications for and risks of
anticoagulant therapy and the potential need for and risk of
reoperation. (Level of Evidence: C)
The choice of valve prosthesis in an individual patient is
based on consideration of several factors, including valve
durability, expected hemodynamics for a speciﬁc valve type
and size, surgical or interventional risk, the potential need
for long-term anticoagulation, and patient preferences.
Speciﬁcally, the tradeoff between risk of reoperation for
bioprosthetic valve degeneration and the risk associated
with long-term anticoagulation should be discussed in
detail with the patient. Surgical or interventional risk for an
individual patient is estimated by using the STS PROM
score with the online calculator (Section 3.2.4). This in-
formation is discussed with the patient and family to allow
for shared decision making about the timing and type of
intervention. In a patient with a small aortic annulus,
patient-prosthesis mismatch of the implanted prosthetic
aortic valve may be avoided or reduced by consulting tables
of prosthetic valve hemodynamics for the valve types and
sizes being considered. Aortic annular enlarging pro-
cedures may be used when patient-prosthesis mismatch
cannot be avoided with any available valve substitute.
Bioprosthetic valves avoid the need for long-term anti-
coagulation with VKA, such as warfarin, but have limited
durability. The risk of need for reoperation with a bio-
prosthetic valve is inversely related to the patient’s age at the
time of implantation, with a rate of structural deterioration
15 to 20 years after implantation of only 10% in patients 70
years of age at the time of implantation compared with 90%
in those 20 years of age at the time of implantation. Me-
chanical valves are durable in patients of any age with a low
risk of reoperation, and current VKA therapeutic manage-
ment strategies are associated with a low risk of thrombo-
embolism and bleeding. Some patients prefer to avoid repeat
surgery and are willing to accept the risks and inconvenience
of lifelong anticoagulant therapy. A mechanical valve might
be prudent for patients in whom a second surgical procedure
would be high risk; for example, those with prior radiation
therapy or a porcelain aorta. Other patients are unwilling to
consider long-term VKA therapy due to the inconvenience
of monitoring, the attendant dietary and medication in-
teractions, and the need to restrict participation in some
types of athletic activity. In women who desire subsequent
pregnancy, the issue of anticoagulation during pregnancy is a
consideration (Section 13).
In patients who are being treated with long-term VKA
anticoagulation before valve surgery, a mechanical valve
may be appropriate, given its greater durability compared
with a bioprosthetic valve and the need for continued VKA
anticoagulation even if a bioprosthetic valve is implanted.
However, if interruption of VKA therapy is necessary for
Table 23. Summary of Recommendations for Prosthetic Valve Choice
Recommendations COR LOE References
Choice of valve intervention and prosthetic valve type should be a shared decision process I C N/A
A bioprosthesis is recommended in patients of any age for whom anticoagulant therapy is
contraindicated, cannot be managed appropriately, or is not desired
I C N/A
A mechanical prosthesis is reasonable for AVR or MVR in patients <60 y of age who do not
have a contraindication to anticoagulation
IIa B (534–536)
A bioprosthesis is reasonable in patients >70 y of age IIa B (537–540)
Either a bioprosthetic or mechanical valve is reasonable in patients between 60 y and 70 y of age IIa B (541,542)
Replacement of the aortic valve by a pulmonary autograft (the Ross procedure), when performed
by an experienced surgeon, may be considered in young patients when VKA anticoagulation is
contraindicated or undesirable
IIb C N/A
AVR indicates aortic valve replacement; COR, Class of Recommendation; LOE, Level of Evidence; MVR, mitral valve replacement; N/A, not applicable; and VKA, vitamin K antagonist.
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coagulants may be needed if a mechanical valve is present,
whereas stopping and restarting VKA therapy for other
indications may be simpler. Speciﬁc clinical circumstances,
comorbid conditions, and patient preferences should be
considered when deciding between a bioprosthetic and
mechanical valve in patients receiving VKA therapy for
indications other than the prosthetic valve itself.
Supporting References: (532,533,543–545)
CLASS I
2. A bioprosthesis is recommended in patients of any age for whom
anticoagulant therapy is contraindicated, cannot be managed
appropriately, or is not desired. (Level of Evidence: C)
Anticoagulant therapy with VKA is necessary in all
patients with a mechanical valve to prevent valve throm-
bosis and thromboembolic events. If anticoagulation is
contraindicated or if the patient refuses VKA therapy, an
alternate valve choice is appropriate.
CLASS IIa
1. A mechanical prosthesis is reasonable for AVR or MVR in pa-
tients less than 60 years of age who do not have a contraindi-
cation to anticoagulation (534–536). (Level of Evidence: B)
In a prospective randomized study of 575 patients un-
dergoing older-generation mechanical versus bioprosthetic
valve replacement, overall survival was similar at 15 years in
both groups. However, in patients <65 years of age un-
dergoing AVR, primary valve failure occurred in 26% of
those with a bioprosthetic valve compared with 0% of pa-
tients with a mechanical valve. Similarly, in those<65 years
of age undergoing MVR, primary valve failure occurred in
44% of patients with a bioprosthetic mitral valve compared
with 4% with a mechanical mitral valve (p¼0.0001). In a
propensity scorematched comparison of 103 patients<60
years of age undergoing mechanical versus biological AVR,
those with amechanical valve had lowermortality rates (HR:
0.243; 95% CI: 0.054 to 0.923; p¼0.038) despite similar
rates of valve-related complications. This is possibly related
to better valve hemodynamics and the beneﬁcial effects of
anticoagulant therapy in those with a mechanical valve.
Overall, patients <60 years of age at the time of valve
implantation have a higher incidence of primary structuraldeterioration and a reoperation rate as high as 40% for pa-
tients 50 years of age, 55% for patients 40 years of age, 75%
for patients 30 years of age, and 90% for patients 20 years
of age. Anticoagulation with VKA has an acceptable risk
of complications in patients <60 years of age, particularly
in compliant patients with appropriate monitoring of INR
levels. Thus, the balance between valve durability versus
risk of bleeding and thromboembolic events favors the
choice of a mechanical valve in patients <60 years of age.
Supporting References: (533,536,546)
CLASS IIa
2. A bioprosthesis is reasonable in patients more than 70 years of
age (537–540). (Level of Evidence: B)
In patients >70 years of age at the time of bioprosthetic
valve implantation, the likelihood of primary structural
deterioration at 15 to 20 years is only about 10%. In
addition, older patients are at higher risk of bleeding
complications related to VKA therapy and more often
require interruption of VKA therapy for noncardiac sur-
gical and interventional procedures. In the United States,
the expected number of remaining years of life at 70 years
of age is 13.6 years for a man and 15.9 years for a woman;
at 80 years of age the expected number of remaining years
of life is 7.8 years for men and 9.3 years for women. Thus,
it is reasonable to use a bioprosthetic valve in patients >70
years of age to avoid the risks of anticoagulation because
the durability of the valve exceeds the expected years of life.
Data from 41,227 patients in the Society for Cardiotho-
racic Surgery in the Great Britain and Ireland National
database between 2004 and 2009 show that the proportion
of patients >70 years of age who receive a biological
prosthesis at the time of valve replacement has increased
from 87% to 96%, with no evidence for an increase in
adverse events.
Supporting References: (41,533,546)
CLASS IIa
3. Either a bioprosthetic or mechanical valve is reasonable in pa-
tients between 60 and 70 years of age (541,542). (Level of
Evidence: B)
Outcomes are similar with implantation of either a
bioprosthetic or mechanical valve for patients between 60
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burgh Heart Valve Study of 533 patients (mean age
54.410.4 years) undergoing valve surgery, there was no
difference in long-term survival between those random-
ized to a Bjork-Shiley mechanical prosthesis or a porcine
prosthesis (log-rank test: p¼0.39). In a prospective ran-
domized Italian study of 310 patients between 55 and 70
years of age, there was no difference in overall survival at
13 years between those receiving a mechanical valve
compared with those who received a bioprosthetic valve.
The linearized rates of thromboembolism, bleeding, IE,
and major adverse prosthesis-related events were no dif-
ferent between the 2 valve types, but valve failures and
reoperations were more frequent in the bioprosthetic
valve group compared with the mechanical valve group
(p¼0.0001 and p¼0.0003, respectively).
Although the evidence supports the use of either a
mechanical or bioprosthetic valve in patients 60 to 70 years
of age, patient preferences should also be considered. Ac-
cording to data on 41,227 patients in the Society for
Cardiothoracic Surgery in the Great Britain and Ireland
National database collected between 2004 and 2009, the
proportion of patients 60 to 65 years of age who received a
bioprosthesis at the time of valve replacement increased
from 37% to 55%; in those 65 to 70 years of age, the
proportion increased from 62% to 78%.
Supporting References: (532,533,543,546)
CLASS IIb
1. Replacement of the aortic valve by a pulmonary autograft (the
Ross procedure), when performed by an experienced surgeon,
may be considered in young patients when VKA anticoagulation
is contraindicated or undesirable. (Level of Evidence: C)
Replacement of the aortic valve with a pulmonary
autograft (the Ross procedure) is a complex operation
intended to provide an autologous substitute for the pa-
tient’s diseased aortic valve by relocating the pulmonic
valve into the aortic position and subsequently replacing
the pulmonic valve with a homograft. It is a surgical
challenge and requires an experienced surgical team with
exceptional surgical expertise. In the most experienced
hands, hospital mortality can be similar to mortality for a
simple bioprosthetic or mechanical valve replacement.
Expansion of the Ross procedure to a broader group of
surgeons with less focused experience has been difﬁcult.
The failure mode of the Ross procedure is most often due
to regurgitation of the pulmonary autograft (the neoaortic
valve) in the second decade after the operation. Regurgi-
tation typically is due to leaﬂet prolapse if the autograft is
implanted in the subcoronary position or to aortic sinus
dilation if the autograft is implanted starting at the aortic
sinuses. Surgical reinforcement techniques have been used
to prevent dilation of the neoaortic sinuses. Some surgeons
have advocated placing the pulmonic valve within a Dacron
conduit. Still others have returned to placing the neoaortic
valve in a subcoronary position with a reinforced nativeaorta. The outcome of these new procedures, with data
extending into the second decade after operation, is not yet
available.
In a small (n¼228) RCT comparing pulmonary auto-
grafts with aortic valve allografts, the HR for death at 10
years was 4.61 (p¼0.006) in those receiving an allograft
compared with those with a pulmonary autograft AVR,
with survival in the autograft group similar to an age-
matched general population. Freedom from reoperation
for the aortic sinuses and ascending aorta was 99% in the
autograft group and 82% in the allograft group. Freedom
from severe regurgitation of the neoaortic valve was 94%
at 10 years. However, these outstanding results have not
been generally replicated. In addition, an allograft valve is
not the ideal comparator, given current outcomes with
bioprosthetic valves.
In addition to reoperation for neoaortic valve regurgi-
tation, at least half of the new pulmonic homograft valve
implants will require intervention during the second
decade. This is obviously a concern for young patients who
began with single valve disease and then face a lifetime of
dealing with both pulmonic homograft and neoaortic valve
disease. Calciﬁcation of the homograft and adhesions be-
tween the homograft and neoaorta may increase the difﬁ-
culty of reoperation.
The Ross procedure is an effective procedure in the
hands of a small group of focused and experienced sur-
geons. It is a risky procedure in the hands of surgeons who
perform it only occasionally. The procedure should be
reserved for patients in whom anticoagulation is either
contraindicated or very undesirable, and it should be per-
formed only by surgeons experienced in complex surgery
involving the aortic valve, sinuses, and ascending aorta.
Supporting References: (547–549)
See Online Data Supplement 20 for more information on
choice of valve prosthesis.
11.2. Antithrombotic Therapy for
Prosthetic Valves
11.2.1. Diagnosis and Follow-Up
Effective antithrombotic therapy in patients with me-
chanical heart valves requires continuous effective VKA
anticoagulation with an INR in the target range. It is
preferable to specify a single INR target in each patient,
recognizing that the acceptable range is 0.5 INR units on
each side of this target; this is preferable because it avoids
patients having INR values consistently near the upper or
lower edge of the range. In addition, ﬂuctuations in INR
are associated with increased incidence of complications in
patients with prosthetic valves, so patients and caregivers
should strive to attain the single INR value. The effects of
VKA anticoagulation vary with the speciﬁc medication,
absorption of medication, effects of various foods and
medications, and changes in liver function. Most of the
published studies on VKA therapy used warfarin, although
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clinical practice, a program of patient education and close
surveillance by an experienced healthcare professional
with periodic monitoring of the INR is necessary. Patient
monitoring by hospital-based anticoagulation clinics re-
sults in lower complication rates compared with standard
care and is cost-effective due to lower rates of bleeding
and hemorrhagic complications. Periodic direct patient
contact and telephone encounters with the anticoagu-
lation clinic pharmacists are equally effective in reducing
complication rates. Self-monitoring with home INR
measurement devices is another option for educated and
motivated patients.
Supporting References: (550–555)
11.2.2. Medical Therapy: Recommendations
CLASS I
1. Anticoagulation with a VKA and INR monitoring is recommended
in patients with a mechanical prosthetic valve (556–558).
(Level of Evidence: A)
All patients with mechanical valves require anticoagu-
lant therapy. In addition to the thrombogenicity of the
intravascular prosthetic material, mechanical valves im-
pose abnormal ﬂow conditions, with zones of low ﬂow
within their components, as well as areas of high-shear
stress, which can cause platelet activation, leading to
valve thrombosis and embolic events. Life-long therapy
with an oral VKA at an INR goal appropriate for the co-
morbidity of the patient and the type and position of the
mechanical valve prosthesis is recommended to decrease
the incidence of thromboembolism and the associated
morbidity (e.g., ischemic stroke, cerebrovascular accident,
and peripheral systemic embolism). Cumulative data show
that anticoagulation with a VKA is protective against valve
thrombosis (OR: 0.11; 95% CI: 0.07 to 0.2) and throm-
boembolic events (OR: 0.21; 95% CI: 0.16 to 0.27).
Many centers initiate heparin early after surgery for
anticoagulation until the INR reaches the therapeutic
range. Bridging anticoagulation is typically started once
postoperative bleeding is no longer an issue. Some centers
use subcutaneous low-molecular-weight heparin (LMWH)
or unfractionated heparin (UFH), whereas other centers
continue to prefer intravenous UFH.
Supporting References: (12,556,559,560)
CLASS I
2. Anticoagulation with a VKA to achieve an INR of 2.5 is re-
commended in patients with a mechanical AVR (bileaﬂet or
current-generation single tilting disc) and no risk factors for
thromboembolism (561–563). (Level of Evidence: B)
The intensity of anticoagulation in a patient with a
mechanical aortic valve prosthesis should be optimized so
that protection from thromboembolism and valve throm-
bosis is achieved without excess risk of bleeding. The rate
of thromboembolism in patients with bileaﬂet mechanical
AVR on VKA and antiplatelet regimen is estimated to be0.53% per patient-year over the INR range of 2.0 to 4.5.
In a large retrospective study, adverse events increased if
the INR was >4.0 in patients with mechanical AVR. In
patients with the new-generation AVR without other risk
factors for thromboembolism, the risk of thromboembolic
events was similar, but the risk of hemorrhage was lower
in the group with an INR of 2.0 to 3.0 versus the group
with an INR of 3.0 to 4.5 (p<0.01). In a study comparing
an INR target of 1.5 to 2.5 with the conventional 2.0 to
3.0 in 396 patients with low-risk mechanical aortic pros-
thetic valves and no other risk factors, the lower INR
target was noninferior, but the quality of the evidence was
low. Thus, for bileaﬂet and current-generation single
tilting disc valve prostheses in the aortic position, an INR
of 2.5 (between 2.0 and 3.0) provides a reasonable balance
between optimal anticoagulation and a low risk of
bleeding for mechanical aortic valves with a low throm-
boembolic risk.
Supporting Reference: (12)
CLASS I
3. Anticoagulation with a VKA is indicated to achieve an INR of 3.0
in patients with a mechanical AVR and additional risk factors for
thromboembolic events (AF, previous thromboembolism, LV
dysfunction, or hypercoagulable conditions) or an older-
generation mechanical AVR (such as ball-in-cage) (564).
(Level of Evidence: B)
In patients with an aortic mechanical prosthesis who
are at higher risk of thromboembolic complications, INR
should be maintained at 3.0 (range 2.5 to 3.5). These pa-
tients include those with AF, previous thromboembolism,
and a hypercoagulable state. Many would also include pa-
tients with severe LV dysfunction in this higher-risk group.
Supporting Reference: (12)
CLASS I
4. Anticoagulation with a VKA is indicated to achieve an INR of 3.0
in patients with a mechanical MVR (564,565). (Level of
Evidence: B)
In patients with mechanical prostheses, the incidence of
thromboembolism is higher for the mitral than the aortic
position, and the rate of thromboembolism is lower in
patients with a higher INR goal compared with those with
a lower target INR. In the GELIA (German Experience
With Low Intensity Anticoagulation) study of patients
with a mechanical mitral prosthesis, a lower INR (2.0 to
3.5) was associated with lower survival rates than a higher
target INR range (2.5 to 4.5) in those with a second me-
chanical valve. Patient compliance may be challenging with
higher INR goals. In 1 study, patients with a target INR
between 2.0 and 3.5 were within that range 74.5% of the
time. In contrast, patients with a target INR of 3.0 to 4.5
were within range only 44.5% of the time. An INR target
of 3.0 (range 2.5 to 3.5) provides a reasonable balance
between the risks of under- or overanticoagulation in pa-
tients with a mechanical mitral valve.
Supporting References: (12,562)
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5. Aspirin 75 mg to 100 mg daily is recommended in addition to
anticoagulation with a VKA in patients with a mechanical valve
prosthesis (566,567). (Level of Evidence: A)
Aspirin is recommended for all patients with prosthetic
heart valves, including those with mechanical prosthetic
valves receiving VKA therapy. Even with the use of VKA,
the risk of thromboemboli is 1% to 2% per year.
The addition of aspirin 100 mg daily to oral VKA
anticoagulation decreases the incidence of major embo-
lism or death (1.9% versus 8.5% per year; p<0.001), with
the stroke rate decreasing to 1.3% per year versus 4.2%
per year (p<0.027) and overall mortality to 2.8% per year
versus 7.4% per year (p<0.01). The addition of low-
dose aspirin (75 mg to 100 mg per day) to VKA ther-
apy (INR 2.0 to 3.5) also decreases mortality due to other
cardiovascular diseases. The combination of low-dose
aspirin and VKA is associated with a slightly increased
risk of minor bleeding such as epistaxis, bruising, and
hematuria, but the risk of major bleeding does not differ
signiﬁcantly between those who received aspirin (8.5%)
versus those who did not (6.6%; p¼0.43). The risk of GI
irritation and hemorrhage with aspirin is dose dependent
over the range of 100 mg to 1,000 mg per day, but the
antiplatelet effects are independent of dose over this
range. The addition of aspirin (75 mg to 100 mg per day)
to VKA should be strongly considered unless there is
a contraindication to the use of aspirin (i.e., bleeding or
aspirin intolerance). This combination is particularly
appropriate in patients who have had an embolus while
on VKA therapy with a therapeutic INR, those with
known vascular disease, and those who are known to be
particularly hypercoagulable.
Supporting References: (12,568–571)
CLASS IIa
1. Aspirin 75 mg to 100 mg per day is reasonable in all patients
with a bioprosthetic aortic or mitral valve (572–575). (Level of
Evidence: B)
The risk of a clinical thromboembolism is on average
0.7% per year in patients with biological valves in sinus
rhythm; this ﬁgure is derived from several studies in which
the majority of patients were not undergoing therapy with
VKA. Among patients with bioprosthetic valves, those
with mitral prostheses have a higher rate of thrombo-
embolism than those with aortic prostheses in the long
term (2.4% per patient-year versus 1.9% per patient-year,
respectively). In a prospective study of bioprosthetic
valves in patients with AVR who were in sinus rhythm
and had no other indications for anticoagulation, the
incidence of thromboembolic events, bleeding, and death
was similar between those who received aspirin or aspirin-
like antiplatelet agents only versus those who received
VKA. There are no studies examining the long-term effect
of antiplatelet agents in patients with bioprosthetic MVR
or mitral valve repair, but the beneﬁcial effects seen withbioprosthetic aortic valves are presumed to apply to mitral
valves as well.
Supporting Reference: (12)
CLASS IIa
2. Anticoagulation with a VKA is reasonable for the ﬁrst 3 months
after bioprosthetic MVR or repair to achieve an INR of 2.5
(576). (Level of Evidence: C)
The risk of ischemic stroke after all types of mitral valve
surgery is about 2% at 30 days, 3% at 180 days, and 8% at
5 years. This is observed even with routine use of early
heparin followed by VKA in patients with a mechanical
valve or other indications for long-term anticoagulant ther-
apy. The risk of ischemic stroke at 5 years is lower with
mitral valve repair (6.1%0.9%) compared with bio-
prosthetic (8.0%2.1%) and mechanical valve replacement
(16.1%2.7%). In 1 study, patients with a bioprosthetic
MVR who received anticoagulation had a lower rate of
thromboembolism than those who did not receive therapy
with VKA (2.5% per year with anticoagulation versus
3.9% per year without anticoagulation; p¼0.05). However,
another study showed that even with routine anticoagu-
lation early after valve surgery, the incidence of ischemic
stroke within the ﬁrst 30 postoperative days was higher
after replacement with a biological prosthesis (4.6%1.5%;
p<0.0001) than after mitral valve repair (1.5%0.4%) or
replacement with a mechanical prosthesis (1.3%0.8%;
p<0.001). Thus, anticoagulation with a target INR of 2.5
(range 2.0 to 3.0) is reasonable early after bioprosthetic
mitral valve implantation.
Many centers start heparin as soon as the risk of surgical
bleeding is acceptable (usually within 24 to 48 hours), with
maintenance of a therapeutic partial thromboplastin time.
After an overlap of heparin and VKA for 3 to 5 days,
heparin may be discontinued when the INR reaches 2.5.
After 3 months, the tissue valve can be treated like native
valve disease, and VKA can be discontinued in more than
two thirds of patients with biological valves. In the
remaining patients with associated risk factors for throm-
boembolism, such as AF, previous thromboembolism, or
hypercoagulable condition, lifelong VKA therapy is indi-
cated to achieve an INR of 2 to 3.
Supporting References: (572–574,577–582)
CLASS IIb
1. Anticoagulation, with a VKA, to achieve an INR of 2.5 may be
reasonable for the ﬁrst 3 months after bioprosthetic AVR (583).
(Level of Evidence: B)
Patients with a bioprosthetic aortic valve are at a higher
risk of ischemic stroke or peripheral embolism than the
normal population, particularly in the ﬁrst 90 days after
valve replacement. Anticoagulation early after valve im-
plantation is intended to decrease the risk of thrombo-
embolism until the prosthetic valve is fully endothelialized.
The potential beneﬁt of anticoagulation therapy must be
weighed against the risk for bleeding, particularly in pa-
tients who are at low risk for thromboembolism (e.g., those
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thromboembolism, or history of hypercoagulable condi-
tions). Small RCTs have not established beneﬁt for anti-
coagulation after implantation of a bioprosthetic AVR;
however, a large observational registry demonstrated ben-
eﬁt without a signiﬁcantly increased bleeding risk. In 4,075
patients undergoing isolated bioprosthetic AVR with a
median duration of follow-up of 6.57 person-years, the
estimated rate of strokes per 100 person-years was 7.00
(95% CI: 4.07 to 12.06) in patients not treated with VKA
versus 2.69 (95% CI: 1.49 to 4.87) in those treated with
VKA (HR: 2.46; 95% CI: 1.09 to 5.55). The lower event
rates in those on VKA persisted at 6 months, with a car-
diovascular death rate of 6.50 per 100 person-years (95%
CI: 4.67 to 9.06) in those not on VKA therapy compared
with 2.08 (95% CI: 0.99 to 4.36) in those on VKA therapy
(adjusted internal rate of return: 3.51; 95% CI: 1.54 to
8.03) for events within 90 to 179 days after surgery. Thus,
anticoagulation with an INR target of 2.5 (range 2.0 to
3.0) may be reasonable for at least 3 months, and perhaps
as long as 6 months, after bioprosthetic AVR.
Supporting References: (572,574,583–586)
CLASS IIb
2. Clopidogrel 75 mg daily may be reasonable for the ﬁrst 6
months after TAVR in addition to life-long aspirin 75 mg to 100
mg daily. (Level of Evidence: C)
During TAVR, a biological prosthesis mounted on a
metallic expandable frame is inserted transcutaneously
within the native aortic valve with stenosis. In prospective
RCTs of balloon-expandable TAVR for treatment of AS,
the research protocol included dual antiplatelet therapy
with aspirin and clopidogrel for the ﬁrst 6 months to
minimize the risk of thromboembolism. The current re-
commendation is based on outcomes in these published
studies, although the issue of antiplatelet therapy was not
assessed. A small prospective, RCT, single-center study of
79 patients receiving self-expanding TAVR did not show a
difference in the composite of major adverse cardiac and
cerebrovascular events, deﬁned as death from any cause,
MI, major stroke, urgent or emergency conversion to sur-
gery, or life-threatening bleeding between aspirin and
clopidogrel versus aspirin alone at both 30 days (13%
versus 15%; p¼0.71) and 6 months (18% versus 15%;
p¼0.85).
Supporting References: (79,170,587,588)
CLASS III: Harm
1. Anticoagulant therapy with oral direct thrombin inhibitors or
anti-Xa agents should not be used in patients with mechanical
valve prostheses (589–591). (Level of Evidence: B)
The U.S. Food and Drug Administration has approved
new anticoagulants that are direct thrombin inhibitors or
factor Xa inhibitors (dabigatran, apixaban, and rivarox-
aban) for anticoagulant prophylaxis in patients with AF not
caused by VHD. Several case reports have demonstrated
thrombosis on mechanical heart valves despite therapeuticdosing with dabigatran. The RE-ALIGN (Randomized,
Phase II Study to Evaluate the Safety and Pharmacoki-
netics of Oral Dabigatran Etexilate in Patients after Heart
Valve Replacement) trial was stopped prematurely for
excessive thrombotic complications in the dabigatran arm.
After enrollment of 252 patients, ischemic or unspeciﬁed
stroke occurred in 9 patients (5%) randomized to dabiga-
tran compared with no patients treated with warfarin. In
the dabigatran group, 15 patients (9%) reached the com-
posite endpoint of stroke, transient ischemic attack, sys-
temic embolism, MI, or death compared with 4 patients
(5%) in the warfarin group (HR in the dabigatran group:
1.94; 95% CI: 0.64 to 5.86; p¼0.24). In addition, a major
bleeding episode occurred in 7 patients (4%) in the dabi-
gatran group and 2 patients (2%) in the warfarin group,
and bleeding of any type occurred in 45 patients (27%) and
10 patients (12%), respectively (HR: 2.45; 95% CI: 1.23 to
4.86; p¼0.01). The Food and Drug Administration has
issued a speciﬁc contraindication for use of this product in
patients with mechanical heart valves. These agents are also
not recommended, due to lack of data on their safety and
effectiveness, in patients with bioprosthetic valves who
require anticoagulation.
Supporting References: (591–594)11.3. Bridging Therapy for Prosthetic Valves
11.3.1. Diagnosis and Follow-Up
The management of patients with mechanical heart valves
in whom interruption of anticoagulation therapy is needed
for diagnostic or surgical procedures should take into ac-
count the type of procedure, risk factors, and type, location,
and number of heart valve prosthesis(es).
11.3.2. Medical Therapy: Recommendations
CLASS I
1. Continuation of VKA anticoagulation with a therapeutic INR is
recommended in patients with mechanical heart valves under-
going minor procedures (such as dental extractions or cataract
removal) where bleeding is easily controlled. (Level of Evidence: C)
Management of antithrombotic therapy must be indi-
vidualized, but some generalizations apply. Antithrombotic
therapy should not be stopped for procedures in which
bleeding is unlikely or would be inconsequential if it oc-
curred (i.e., surgery on the skin, dental cleaning, or simple
treatment for dental caries). Eye surgery, particularly for
cataracts or glaucoma, is usually associated with very little
bleeding and thus is frequently performed without alter-
ations to antithrombotic treatment.
CLASS I
2. Temporary interruption of VKA anticoagulation, without bridging
agents while the INR is subtherapeutic, is recommended in
patients with a bileaﬂet mechanical AVR and no other risk
factors for thrombosis who are undergoing invasive or surgical
procedures. (Level of Evidence: C)
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formed with a patient receiving antithrombotic therapy
has to be weighed against the increased risk of a throm-
boembolism caused by stopping the therapy. In patients
with a bileaﬂet mechanical aortic valve and no other risk
factors for thromboembolism, the risk of stopping VKA
is relatively slight if the drug is withheld for only a few
days. In these low-risk patients, the inconvenience and
expense of bridging anticoagulation can be avoided. When
it is necessary to interrupt VKA therapy, VKA is stopped
2 to 4 days before the procedure (so the INR falls to <1.5
for major surgical procedures) and restarted as soon as
bleeding risk allows, typically 12 to 24 hours after surgery.
Supporting References: (595,596)
CLASS I
3. Bridging anticoagulation with either intravenous UFH or sub-
cutaneous LMWH is recommended during the time interval
when the INR is subtherapeutic preoperatively in patients who
are undergoing invasive or surgical procedures with a 1) me-
chanical AVR and any thromboembolic risk factor, 2) older-
generation mechanical AVR, or 3) mechanical MVR. (Level of
Evidence: C)
In patients at higher risk of thromboembolism during
interruption of VKA anticoagulation, the risk of an adverse
event can be minimized by anticoagulation with alternative
agents that can be stopped right before and restarted right
after the surgical procedure (e.g., “bridging therapy”). Pa-
tients at high risk of thrombosis include all patients with
mechanical MVR or tricuspid valve replacements and
patients with an AVR and any risk factors for thrombo-
embolism. Such risk factors include AF, previous throm-
boembolism, hypercoagulable condition, older-generation
mechanical valves, LV systolic dysfunction (LVEF <30%),
or >1 mechanical valve.
When interruption of VKA therapy is needed, VKA is
stopped 2 to 4 days before the procedure (so the INR falls
to <1.5 for major surgical procedures) and restarted as
soon as bleeding risk allows, typically 12 to 24 hours after
surgery. Bridging anticoagulation with intravenous UFH
or subcutaneous LMWH is started when INR is <2.0
(usually about 48 hours before surgery) and stopped 4 to
6 hours (for intravenous UFH) or 12 hours (for subcu-
taneous LMWH) before the procedure. When LMWH is
used, therapeutic weight-adjusted doses are given twice
daily. One study of bridging therapy for interruption of
VKA included 215 patients with mechanical valves. In the
total group of 650 patients, the risk of thromboembolism
(including possible events) was 0.62%, with 95% CI:
0.17% to 1.57%. Major bleeding occurred in 0.95% (0.34%
to 2.0%). Most studies using LMWH used enoxaparin for
therapy. The use of bridging heparin after surgery must be
individualized, depending on risk of bleeding and risk of
thrombosis.
The acceptable level of anticoagulation in patients un-
dergoing cardiac catheterization depends on the speciﬁcprocedure being performed. For procedures with a low
bleeding risk, such as coronary angiography from the
radial approach, only slight modiﬁcation in VKA dos-
ing is needed. With interventional procedures at higher
risk, many clinicians prefer to stop VKA anticoagulation
and use bridging therapy as is done for other surgical
procedures.
Supporting References: (597–599)
CLASS IIa
1. Administration of fresh frozen plasma or prothrombin complex
concentrate is reasonable in patients with mechanical valves
receiving VKA therapy who require emergency noncardiac sur-
gery or invasive procedures. (Level of Evidence: C)
Because VKA inhibits production of several proteins
involved in the coagulation cascade, the anticoagulant ef-
fect persists until adequate levels of these proteins are
achieved after stopping warfarin therapy, a process that
takes at least 48 to 72 hours. In patients with mechanical
valves on long-term warfarin therapy who require emer-
gency surgery or invasive procedures, anticoagulation can
be reversed by administration of fresh frozen plasma or
intravenous prothrombin complex concentrate. Adminis-
tration of low-dose (1 mg to 2 mg) oral vitamin K may be
added because the effect of fresh frozen plasma or pro-
thrombin complex has a shorter half-life than the effects of
VKA therapy. Higher doses of vitamin K are discouraged
to avoid difﬁculty in achieving a therapeutic INR after the
procedure.
Supporting References: (600–602)
See Online Data Supplement 21 for more information on
bridging therapy.
11.4. Excessive Anticoagulation and
Serious Bleeding With Prosthetic Valves:
Recommendation
See Figure 6 for anticoagulation for prosthetic valves.
CLASS IIa
1. Administration of fresh frozen plasma or prothrombin complex
concentrate is reasonable in patients with mechanical valves
and uncontrollable bleeding who require reversal of anti-
coagulation (601,602). (Level of Evidence: B)
Excessive anticoagulation (INR5) greatly increases the
risk of hemorrhage. However, a rapid decrease in the INR
that leads to INR falling below the therapeutic level in-
creases the risk of thromboembolism. High-dose vitamin
K should not be given routinely, because this may create
a hypercoagulable condition. In most patients with an
INR of 5 to 10, excessive anticoagulation can be managed
by withholding VKA and monitoring the level of anti-
coagulation with serial INR determinations. In patients
with an INR >10 who are not bleeding, it is prudent to
administer 1 mg to 2.5 mg of oral vitamin K1 (phytona-
dione) in addition to holding VKA therapy. When the
INR falls to a safe level, VKA therapy is restarted with the
dose adjusted as needed to maintain therapeutic
Figure 6. Anticoagulation for Prosthetic Valves
Risk factors include AF, previous thromboembolism, LV dysfunction, hypercoagulable condition, and older-generation mechanical AVR.
AF indicates atrial ﬁbrillation; ASA, aspirin; AVR, aortic valve replacement; INR, international normalized ratio; LMWH, low-molecular-weight heparin; MVR, mitral valve
replacement; PO, by mouth; QD, every day; SC, subcutaneous; TAVR, transcatheter aortic valve replacement; UFH, unfractionated heparin; and VKA, vitamin K antagonist.
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trollable bleeding, administration of fresh frozen plasma or
prothrombin complex concentrate is reasonable because
the onset of action of vitamin K is very slow.
Supporting References: (600,603)
11.5. Thromboembolic Events With
Prosthetic Valves
11.5.1. Diagnosis and Follow-Up
The annual risk of thromboembolic events in patients with
a mechanical heart valve is 1% to 2% versus 0.7% with a
bioprosthetic valve, even with appropriate antithrombotic
therapy. Many complications are likely related to subop-
timal anticoagulation; even in clinical trials, the time in
therapeutic range for patients on VKA varies from only
60% to 70%. However, embolic events do occur even in
patients who are in the therapeutic range at every testing
interval. Annual follow-up in patients with prosthetic heart
valves should include review of the adequacy of anti-
coagulation and any issues related to compliance withmedical therapy. Screening questions for symptoms that
may be related to embolic events are especially important if
anticoagulation has been suboptimal. Patients should be
educated about symptoms related to embolic events and
instructed to promptly report to a healthcare provider
should symptoms occur. TTE is the ﬁrst step in evaluation
of suspected prosthetic valve thromboembolism to evaluate
valve hemodynamics in comparison to previous studies,
and TEE often is needed, particularly for mitral prosthetic
valves. However, the prosthetic valve should be considered
the source of thromboembolism even if echocardiographic
ﬁndings are unchanged.
11.5.2. Medical Therapy
In patients on VKA anticoagulation and aspirin 75 mg to
100 mg daily for a mechanical valve who have a deﬁnite
embolic episode, it is important to document the adequacy
of the anticoagulation, including the time within thera-
peutic range. If there have been periods in which the INR
has been documented to be subtherapeutic, appropriate
steps to ensure adequate anticoagulation should be taken.
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when other contraindications are not present, a prudent
approach to antithrombotic therapy is:
 Increase the INR goal from 2.5 (range 2.0 to 3.0) to
3.0 (range 2.5 to 3.5) for patients with an AVR; or,
increase the INR goal from 3.0 (range 2.5 to 3.5) to
4.0 (range 3.5 to 4.5) for patients with an MVR.
In patients with a bioprosthetic valve with embolic events
who are only on aspirin 75 mg to 100 mg daily, a possible
approach includes consideration of anticoagulation with
a VKA.
11.5.3. Intervention
Embolic events in patients with prosthetic heart valves
should be managed by ensuring optimal anticoagulation
and antiplatelet therapy. Measures to improve patient
compliance, including patient education and more frequent
monitoring, should be instituted. Studies show that pa-
tients on anticoagulation with VKA who are managed by a
dedicated pharmacist-led anticoagulation clinic have lower
rates of bleeding and thromboembolism compared with
conventional monitoring by a clinician’s ofﬁce. Surgical
intervention is rarely needed for recurrent thromboembolic
events but might be considered in some situations. In
patients with degenerated bioprosthetic valves, calciﬁc
emboli may complicate thrombotic embolism, often in
association with prosthetic valve stenosis and/or regurgi-
tation. In patients with mechanical valves who have
recurrent serious adverse effects of over- or underanti-
coagulation despite all efforts to improve compliance,
replacement of the mechanical valve with a bioprosthetic
valve might be considered after a discussion of the potential
risks and beneﬁts of this approach.
11.6. Prosthetic Valve Thrombosis
See Figure 7 for evaluation and management of suspected
valve thrombosis.
11.6.1. Diagnosis and Follow-Up: Recommendations
CLASS I
1. TTE is indicated in patients with suspected prosthetic valve
thrombosis to assess hemodynamic severity and follow resolu-
tion of valve dysfunction (604,605). (Level of Evidence: B)
Obstruction of prosthetic heart valves may be caused by
thrombus formation, pannus ingrowth, or a combination
of both. Mechanical prosthetic heart valve thrombosis has a
prevalence of only 0.3% to 1.3% per patient-year in
developed countries but is as high as 6.1% per patient-year
in developing countries. Bioprosthetic valve thrombosis is
less common. Differentiation of valve dysfunction due to
thrombus versus ﬁbrous tissue ingrowth (pannus) is chal-
lenging because the clinical presentations are similar.
Thrombus is more likely when there is a history of inad-
equate anticoagulation and with more acute onset of valve
dysfunction and symptoms. Although ﬂuoroscopy or CTimaging can be used to evaluate the leaﬂet motion of an
obstructed mechanical prosthesis, the etiology and hemo-
dynamic impact are best evaluated by echocardiography.
TTE allows evaluation of valve hemodynamics and
detection of valve stenosis or regurgitation. Leaﬂet motion
and thrombus may be visualized in some patients, but
TEE is more sensitive for detection of valve thrombosis,
especially of the mitral valve. Transthoracic imaging also
allows measurement of LV size and systolic function, left
atrial size, right heart function, and an estimation of pul-
monary pressures.
Clinical evaluation, including auscultation of dimin-
ished or abolished clicks together with new systolic or
diastolic murmurs, is the ﬁrst step in the routine assess-
ment of patients with a prosthetic heart valve but is un-
reliable for detection of valve thrombosis. TTE allows
detection of prosthetic valve dysfunction and quantita-
tion of stenosis and regurgitation but is inadequate for
evaluation of the presence and size of thrombus or valve
occluder motion.
CLASS I
2. TEE is indicated in patients with suspected prosthetic
valve thrombosis to assess thrombus size and valve motion
(605–607). (Level of Evidence: B)
TEE allows direct imaging of mechanical valve
thrombosis, particularly for thrombi on the left atrial
side of the mitral valve, which is obscured by shadowing
on TTE imaging. Compared with chronic ﬁbrous in-
growth or pannus, thrombi tend to be larger, less dense,
and more mobile than pannus on ultrasound imaging.
Thrombus size, measured on TEE, is a signiﬁcant inde-
pendent predictor of outcome after thrombolysis of an
obstructed prosthetic heart valve. Multivariate analysis
of 107 patients with thrombosed heart valve prostheses
revealed that prior history of stroke (OR: 4.55; 95%
CI: 1.35 to 15.38) and thrombus area by TEE (OR: 2.41
per 1.0 cm2; CI: 1.12 to 5.19) were independent predic-
tors of complications after thrombolysis. A thrombus
area <0.8 cm2 identiﬁed patients at lower risk for com-
plications from thrombolysis, irrespective of NYHA clas-
siﬁcation. TEE should be used to identify lower-risk
patients for thrombolysis.
Supporting References: (605–607)
CLASS IIa
1. Fluoroscopy or CT is reasonable in patients with suspected valve
thrombosis to assess valve motion. (Level of Evidence: C)
Fluoroscopy and CT are alternative imaging techniques
for evaluation of mechanical valve “leaﬂet” motion, par-
ticularly in patients with prosthetic aortic valves, which
are difﬁcult to image by either TTE or TEE. CT is best
suited for measurement of valve opening angles because
3D image acquisition allows postacquisition analysis from
multiple views. CT imaging may also allow visualization
of pannus or thrombus in patients with mechanical or
bioprosthetic valves.
Figure 7. Evaluation and Management of Suspected Prosthetic Valve Thrombosis
*See text for dosage recommendations.
CT indicates computed tomography; IV, intravenous; NYHA, New York Heart Association; Rx, therapy; TEE, transesophageal echocardiography; and TTE, transthoracic
echocardiography.
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CLASS IIa
1. Fibrinolytic therapy is reasonable for patients with a throm-
bosed left-sided prosthetic heart valve, recent onset (<14 days)
of NYHA class I to II symptoms, and a small thrombus (<0.8 cm2)
(605,608). (Level of Evidence: B)
Although ﬁbrinolytic therapy of a left-sided obstructed
prosthetic heart valve is associated with an overall rate of
thromboembolism and bleeding of 17.8%, the degree of
risk is directly related to thrombus size. When thrombus
area is measured in the 2D TEE view showing the largest
thrombus size, an area of 0.8 cm2 provides a useful
breakpoint for clinical decision making. A mobile throm-
bus or a length >5 mm to 10 mm is also associated with
increased embolic risk. Patients with a small thrombus
(<1.0 cm in diameter or 0.8 cm2 in area) have fewerthrombolysis-related complications, whereas those with
a large thrombus (>1.0 cm diameter or 0.8 cm2 in area)
have a 2.4–fold higher rate of complications per 1.0 cm2
increase in size. Factors that identify patients at risk for
adverse outcomes of ﬁbrinolytic therapy include active
internal bleeding, history of hemorrhagic stroke, recent
cranial trauma or neoplasm, diabetic hemorrhagic reti-
nopathy, large thrombi, mobile thrombi, systemic hy-
pertension (>200 mm Hg/120 mm Hg), hypotension or
shock, and NYHA class III to IV symptoms.
With mild symptoms due to aortic or mitral valve
thrombosis with a small thrombus burden, it is prudent to
reassess after several days of intravenous UFH. If valve
thrombosis persists, ﬁbrinolysis with a recombinant tissue
plasminogen activator dose of a 10 mg IV bolus followed
by 90 mg infused IV over 2 hours is reasonable. Heparin
and glycoprotein IIb/IIIa inhibitors are held, but aspirin
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dose of a 20 mg IV bolus followed by 10 mg per hour
for 3 hours may be appropriate in some situations. Alter-
natively, streptokinase may be used with a loading dose of
500,000 IU in 20 minutes followed by 1,500,000 IU over
10 hours. Urokinase is less effective than tissue plasmin-
ogen activator or streptokinase. If ﬁbrinolytic therapy is
successful, it is followed by intravenous UFH until VKA
achieves an INR of 3.0 to 4.0 for aortic prosthetic valves
and 3.5 to 4.5 for mitral prosthetic valves. A structured
institutional protocol with indications, contraindications,
and a speciﬁc timeline for medication administration and
patient monitoring is recommended.
After treatment of the acute thrombotic event, it is
important to always determine the adequacy of anti-
coagulation before the event and ensure that there is
meticulous follow-up after the event. The anticoagulation
regimen can be increased as outlined in Section 11.5.2.
Supporting References: (609,610)
CLASS IIa
2. Fibrinolytic therapy is reasonable for thrombosed right-sided
prosthetic heart valves (611,612). (Level of Evidence: B)
In nonrandomized, retrospective cohorts of thrombosed
mechanical or biological tricuspid valve prostheses, ﬁbri-
nolysis was as successful in normalization of hemody-
namics as surgical intervention. With ﬁbrinolysis of
right-sided valve thrombosis, the resultant small pulmo-
nary emboli appear to be well tolerated and systemic
emboli are uncommon.
See Online Data Supplement 22 for more information on
ﬁbrinolytic therapy.
11.6.3. Intervention: Recommendations
CLASS I
1. Emergency surgery is recommended for patients with a throm-
bosed left-sided prosthetic heart valve with NYHA class III to IV
symptoms (610,611,613). (Level of Evidence: B)
Prompt surgical treatment of a thrombosed prosthetic
heart valve is an effective treatment to ameliorate clinical
symptoms and restore normal hemodynamics, with a
success rate close to 90% in patients who do not have a
contraindication to surgical intervention. In contrast, a
meta-analysis of 7 studies that included 690 episodes of
left-sided prosthetic valve thrombosis showed a success
rate for restoring normal valve function of only about
70% in 244 cases treated with ﬁbrinolytic therapy. There
was no difference in mortality between surgical and
ﬁbrinolytic therapy for left-sided prosthetic valve
thrombosis, but in addition to a higher success rate for
restoring normal valve function, surgery was associated with
lower rates of thromboembolism (1.6% versus 16%), major
bleeding (1.4% versus 5%), and recurrent prosthetic valve
thrombosis (7.1% versus 25.4%). Although RCTs have
not been performed, the weight of the evidence favors
surgical intervention for left-sided prosthetic valve thrombosisunless the patient is asymptomatic and the thrombus
burden is small.
Supporting References: (605,613,614)
CLASS IIa
1. Emergency surgery is reasonable for patients with a throm-
bosed left-sided prosthetic heart valve with a mobile or large
thrombus (>0.8 cm2) (605,607,610). (Level of Evidence: C)
Prompt surgical treatment of a thrombosed prosthetic
heart valve is associated with a relatively low rate of mor-
tality. In a retrospective study of 106 surgeries for
obstructed left-sided prosthetic heart valves, the mortality
rate was 17.5% for patients with NYHA class IV symp-
toms and 4.7% in those patients with NYHA class I to III
symptoms. Mortality was similar for removing the
thrombus or replacing the entire prosthetic valve. Patients
with large, mobile clots that extend beyond the prosthesis
are better suited for surgical intervention than ﬁbrinolysis,
which is associated with signiﬁcant risk of systemic em-
bolism. In 1 report, in which patients with small throm-
bus burden (<0.8 cm2 on TEE imaging) had minimal
thrombolysis-related complications, those with large
thrombus burden (0.8 cm2) had a 2.4–fold higher rate of
complications per 1.0 cm2 increase in size, making surgery
the optimal intervention. In patients with recent hemor-
rhagic stroke, surgery is a better choice because of the
bleeding risks associated with ﬁbrinolysis.11.7. Prosthetic Valve Stenosis
11.7.1. Diagnosis and Follow-Up
Reoperation to replace a prosthetic heart valve is a serious
clinical event. It is usually required for moderate-to-
severe prosthetic dysfunction (structural and nonstruc-
tural), dehiscence, and prosthetic valve endocarditis
(PVE). Causes of prosthetic valve stenosis that might
require reoperation with a mechanical valve include
chronic thrombus or pannus impinging on normal leaf-
let occluder motion; for a bioprosthetic valve, leaﬂet
ﬁbrosis and calciﬁcation are the most common causes.
Reoperation may also be needed for recurrent thrombo-
embolism, severe intravascular hemolysis, severe recurrent
bleeding from anticoagulant therapy, and thrombosed
prosthetic valves.
In some patients, the size of the prosthetic valve that
can be implanted results in inadequate blood ﬂow to meet
the metabolic demands of the patient, even when the
prosthetic valve itself is functioning normally. This situa-
tion, called “patient-prosthesis mismatch” (deﬁned as an
indexed effective oriﬁce area 0.85 cm2/m2 for aortic valve
prostheses), is a predictor of a high transvalvular gradient,
persistent LV hypertrophy, and an increased rate of cardiac
events after AVR. The impact of a relatively small valve
area is most noticeable with severe patient-prosthesis
mismatch, deﬁned as an oriﬁce area <0.65 cm2/m2.
Patient-prosthesis mismatch is especially detrimental in
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hood of resolution of symptoms and improvement in
LVEF. Patient-prosthesis mismatch can be avoided or
reduced by choosing a valve prosthesis that will have an
adequate indexed oriﬁce area, based on the patient’s
body size and annular dimension. In some cases, annular
enlargement or other approaches may be needed to
allow implantation of an appropriately sized valve or
avoidance of a prosthetic valve. With bileaﬂet mechanical
valves, patterns of blood ﬂow are complex and signiﬁcant
pressure recovery may be present; this may result in a high
velocity across the prosthesis that should not be mis-
taken for prosthetic valve stenosis or patient-prosthesis
mismatch.
In patients with bioprosthetic valves who show evidence
of prosthetic valve stenosis, TTE is used to monitor the
appearance of the valve leaﬂets, valve hemodynamics, LV
size, and systolic function, and to estimate pulmonary
pressures. Transthoracic imaging is usually adequate, with
TEE imaging reserved for patients with poor-quality im-
ages. In patients with mechanical valves, ﬂuoroscopy or
CT imaging can be helpful for showing disc motion.
CT may also visualize paravalvular pannus formation
with either bioprosthetic or mechanical valves.
Supporting References: (527,528,544,615,616)
11.7.2. Medical Therapy
There are no medical therapies known to prevent bio-
prosthetic valve degeneration other than those integrated
into the valve design. Medical therapy is not effective for
treatment of symptoms due to signiﬁcant prosthetic valve
stenosis, except with valve thrombosis, but standard
medical therapy may help stabilize patients before surgical
intervention and may be used for palliative care in patients
who are not surgical candidates.
11.7.3. Intervention: Recommendation
CLASS I
1. Repeat valve replacement is indicated for severe symptomatic
prosthetic valve stenosis. (Level of Evidence: C)
The indications for surgical intervention for prosthetic
valve stenosis are the same as those for native stenosis of
the aortic or mitral valve. Surgery is primarily needed for
bioprosthetic valve degeneration. In this situation, the
choice of a new valve prosthesis depends on the same
factors as those for patients undergoing a ﬁrst valve
replacement. The use of transcatheter valve prostheses to
treat bioprosthetic valve stenosis with a “valve-in-valve”
approach is promising but not yet fully validated.
Mechanical valve stenosis is rare and typically due to
valve thrombosis or pannus formation. If patient non-
compliance contributed to valve thrombosis, it is prudent
to consider a bioprosthetic valve at the time of reopera-
tion. With attention to optimal valve selection, a second
surgical procedure for signiﬁcant patient-prosthesis mismatchis rarely needed and should be considered only if a larger
prosthetic valve or a valve type with better hemodynamics
can be implanted.
11.8. Prosthetic Valve Regurgitation
11.8.1. Diagnosis and Follow-Up
In patients with bioprosthetic valves who show evidence of
prosthetic valve regurgitation, TTE is used to monitor the
appearance of the valve leaﬂets, valve hemodynamics, LV
size, and systolic function, and to estimate pulmonary
pressures. The initial approach is TTE for evaluation of
antegrade valve velocities and pressure gradients. However,
TEE is essential for evaluation of suspected or known
prosthetic mitral valve regurgitation. On TTE imaging, the
LA is shadowed by the valve prosthesis, obscuring evi-
dence of prosthetic regurgitation. TEE imaging provides
clear images of the left atrial side of the mitral prosthesis
and is particularly useful for delineation of the site and
severity of paravalvular regurgitation, evaluation of suit-
ability for a percutaneous approach, and guidance during
percutaneous closure procedures.
11.8.2. Medical Therapy
Bioprosthetic valve regurgitation is typically due to leaﬂet
degeneration and calciﬁcation. There are no medical
therapies known to prevent bioprosthetic valve degenera-
tion other than those integrated into the valve design.
Pathological regurgitation of a mechanical prosthetic valve
is typically due to a paravalvular leak or pannus limiting
normal occluder closure. Medical therapy is not effective
for treatment of symptoms due to signiﬁcant prosthetic
valve regurgitation, but standard approaches may help
stabilize patients before surgical intervention and may be
used for palliative care in patients who are not surgical
candidates.
11.8.3. Intervention: Recommendations
CLASS I
1. Surgery is recommended for operable patients with mechanical
heart valves with intractable hemolysis or HF due to severe
prosthetic or paraprosthetic regurgitation (617,618). (Level of
Evidence: B)
The indications for surgical intervention for prosthetic
valve regurgitation include the same indications for native
regurgitation of the aortic or mitral valve. Speciﬁcally, in-
dicators are evidence of LV systolic dysfunction, including
a low LVEF or progressive LV dilation; the same cut-off
points should be used as deﬁned for native valve disease.
Paravalvular regurgitation may also result in hemolytic
anemia; often this is mild and is managed medically but
may be refractory in some patients. Paravalvular regurgi-
tation may be treated by replacing the dysfunctional valve
with a new valve or by repairing the paravalvular defect.
Supporting Reference: (619)
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1. Surgery is reasonable for operable patients with severe symp-
tomatic or asymptomatic bioprosthetic regurgitation. (Level of
Evidence C)
Bioprosthetic valve degeneration results in regurgitation
due to leaﬂet calciﬁcation and noncoaptation or leaﬂet
degeneration with a tear or perforation. Even in asymp-
tomatic patients with severe bioprosthetic regurgitation,
valve replacement is reasonable due to the risk of sudden
clinical deterioration if further leaﬂet tearing occurs. The
choice of type of valve prosthesis in a patient undergoing
reoperation depends on the same factors as those for pa-
tients undergoing a ﬁrst valve replacement. The use of
transcatheter valve prostheses to treat bioprosthetic valve
regurgitation with a “valve-in-valve” approach is prom-
ising but is not yet fully validated. Paravalvular regurgi-
tation can also occur with a bioprosthetic valve. New
paravalvular regurgitation may be due to IE or suture
disruption from mechanical causes. Blood cultures should
be obtained when new paravalvular regurgitation is
detected.
CLASS IIa
2. Percutaneous repair of paravalvular regurgitation is reasonable
in patients with prosthetic heart valves and intractable hemo-
lysis or NYHA class III/IV HF who are at high risk for surgery and
have anatomic features suitable for catheter-based therapy
when performed in centers with expertise in the procedure
(620–622). (Level of Evidence B)
Surgery is a viable therapeutic option in many patients
with symptomatic paravalvular prosthetic regurgitation.
However, in some patients, surgery to replace a prosthetic
valve with signiﬁcant paravalvular regurgitation may carry
signiﬁcant operative risk due to the need for reoperation
and patient comorbidity. Recent studies have demon-
strated clinical success with percutaneous approaches, in
which operators use complex catheter techniques and a
variety of occluder devices to reduce paravalvular regurgi-
tation. Procedural success rates with percutaneous closure,
typically deﬁned by no more than mild residual regurgi-
tation and the absence of death and major complications,
have been reported to be 80% to 85% in centers with
expertise in the procedure. Major complications, none-
theless, occur in 9% of patients, mainly due to vascular
injury, cardiac perforation, and bleeding (procedural
death, <2%). The degree of residual regurgitation directly
affects symptom improvement and survival free of adverse
events. Treatment of HF symptoms is more successful
than treatment of hemolysis. Due to the complexity of
these procedures, consideration should be given to their
performance in centers of expertise under the guidance of
a multidisciplinary team.
Supporting References: (620–629)
See Online Data Supplement 23 for more information on
paravalvular regurgitation.12. Infective Endocarditis
See Online Data Supplement 24 for more information
on surgical outcomes.
12.1. IE: Overview
IE has a high mortality rate, even with appropriate
antibiotic therapy and surgical intervention, with an in-
hospital mortality rate of 15% to 20% and a 1–year mor-
tality rate approaching 40%. The overall incidence of IE is
3 to 10 per 100,000 patient-years, with a higher prevalence
in older patients. In underdeveloped countries, IE is most
often associated with rheumatic heart disease. In developed
countries, IE is increasingly associated with prosthetic
valve and intracardiac devices, with a risk of IE 50 times
higher in patients with a prosthetic valve compared with
the general population. IE also may be associated with
intravenous drug use, diabetes mellitus, or immunosup-
pression. Despite differences in associated risk factors
and clinical outcomes, there are few differences in the
recommendations for diagnosis and treatment of NVE
versus PVE. In this guideline, there is 1 set of recom-
mendations for diagnosis and management of all types of
IE. Recommendations for prevention of IE are included in
Section 2.
Antimicrobial therapy is the cornerstone of therapy for
IE. The speciﬁc antimicrobial agents and duration of ther-
apy should be guided by the susceptibility proﬁle of the
causative organism. Temporal and geographic variability
in causative organisms and antimicrobial susceptibility
proﬁles mandate concomitant management with an in-
fectious disease specialist. Details of speciﬁc antimicrobial
regimens have previously been published by the AHA,
European Society of Cardiology, and British Society for
Antimicrobial Chemotherapy and are not repeated in this
guideline.
In addition to antibiotic therapy, early surgical inter-
vention is often needed for effective treatment of infec-
tion and to manage the sequelae of valve leaﬂet and
paravalvular tissue destruction. Decisions about whether
surgical intervention is needed and the optimal timing of
intervention are complex. Most of the indications for
surgical intervention are the same for NVE and PVE and
are included in 1 recommendation for both when
possible. Appropriate management of patients with IE
requires a Heart Valve Team approach, initiated as soon
as a diagnosis of probable or deﬁnite IE is conﬁrmed,
with specialists in cardiology, cardiothoracic surgery, and
infectious disease all involved in patient care and decision
making.
Supporting References: (52,278,630–635)
12.2. Infective Endocarditis
See Online Data Supplement 24 for more information on
surgical outcomes.
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See Figure 8 for recommendations for imaging studies in
NVE and PVE.
CLASS I
1. At least 2 sets of blood cultures should be obtained in patients
at risk for IE (e.g., those with congenital or acquired VHD,
previous IE, prosthetic heart valves, certain congenital or heri-
table heart malformations, immunodeﬁciency states, or injec-
tion drug users) who have unexplained fever for more than 48
hours (636) (Level of Evidence: B) or patients with newly diag-
nosed left-sided valve regurgitation. (Level of Evidence: C)
Blood cultures are positive in 90% of patients with IE.
In patients with a chronic (or subacute) presentation, 3 sets
of blood cultures should be drawn >6 hours apart at pe-
ripheral sites before initiation of antimicrobial therapy.
However, this is not feasible or safe in patients with severe
sepsis or septic shock. In this situation, 2 cultures at
separate times should allow for a secure microbiological
diagnosis before initiation of antimicrobial therapy. More
important than the time interval of the cultures is the
observance of strict aseptic technique, avoiding sam-
pling from intravascular lines, and ensuring adequate vol-
ume of blood for culture sample. Routine incubation of
blood cultures for >7 days is no longer necessary in the
era of continuous-monitoring blood culture systems and
nonculture-based technology. In the 10% of patients with
culture-negative endocarditis, serologic testing to identify
the etiologic agent is appropriate.
Supporting References: (52,637–641)Figure 8. Recommendations for Imaging Studies in NVE and PVE
*Repeat TEE and/or TTE re-commended for re-evaluation of patients with IE and a change
CT indicates computed tomography; IE, infective endocarditis; NVE, native valve endocard
transesophageal echocardiography; and TTE, transthoracic echocardiography.CLASS I
2. The Modiﬁed Duke Criteria should be used in evaluating a pa-
tient with suspected IE (Tables 24 and 25) (642–645). (Level of
Evidence: B)
The Modiﬁed Duke Criteria (Tables 24 and 25) have
been well validated in comparison to surgical or autopsy
ﬁndings and in clinical outcomes in numerous studies in a
wide spectrum of patients, including children, the elderly,
prosthetic valve recipients, injection drug users, and non-
drug users, as well as patients in both primary and tertiary
care settings. Clinical judgment and infectious disease
specialty guidance are essential when deciding on the type
and duration of antibiotic therapy when these criteria
suggest possible IE and in patients with unusual clinical
presentations or culture-negative endocarditis. About three
fourths of patients with IE are diagnosed within 30 days
of the onset of infection, so classic clinical features, such
as embolic or vasculitic skin lesions, renal disease due to
immune complex deposition, and immunologic abnor-
malities of IE, are often absent. In these cases, maintaining
a high level of clinical suspicion to the possibility of IE in
patients who are susceptible is paramount.
Supporting References: (644,646–650)
CLASS I
3. Patients with IE should be evaluated and managed with
consultation of a multispecialty Heart Valve Team including an
infectious disease specialist, cardiologist, and cardiac surgeon.
In surgically managed patients, this team should also include a
cardiac anesthesiologist (651). (Level of Evidence: B)in clinical signs or symptoms and in patients at high risk of complications.
itis; PVE, prosthetic valve endocarditis; S. aureus, Staphylococcus aureus; TEE,
Table 24. Diagnosis of IE According to the Proposed
Modiﬁed Duke Criteria
Deﬁnite IE
Pathological criteria
 Microorganisms demonstrated by culture or histologic examination of
a vegetation, a vegetation that has embolized, or an intracardiac
abscess specimen; or
 Pathological lesions: vegetation or intracardiac abscess conﬁrmed by
histological examination showing active endocarditis
Clinical criteria
 2 major criteria; or
 1 major criterion and 3 minor criteria; or
 5 minor criteria
Possible IE
 1 major criterion and 1 minor criterion; or
 3 minor criteria
Rejected
 Firm alternate diagnosis explaining evidence of IE; or
 Resolution of IE syndrome with antibiotic therapy for <4 d; or
 No pathological evidence of IE at surgery or autopsy, with antibiotic
therapy for <4 d; or
 Does not meet criteria for possible IE as listed above
IE indicates infective endocarditis. (642,644)
Table 25. Major and Minor Criteria in the
Modiﬁed Duke Criteria for the Diagnosis of IE
Major Criteria
1. Blood culture positive for IE
Typical microorganisms consistent with IE from 2 separate blood cultures:
 Viridans streptococci, Streptococcus bovis, HACEK group
(Haemophilus spp., Actinobacillus actinomycetemcomitans,
Cardiobacterium hominis, Eikenella spp., and Kingella kingae),
Staphylococcus aureus; or community-acquired enterococci,
in the absence of a primary focus; or
Microorganisms consistent with IE from persistently positive blood cultures,
deﬁned as follows:
 At least 2 positive cultures of blood samples drawn 12 h apart; or
 All of 3 or a majority of 4 separate cultures of blood (with ﬁrst
and last samples drawn at least 1 h apart)
 Single positive blood culture for Coxiella burnetii or antiphase
I IgG antibody titer >1:800
2. Evidence of endocardial involvement
 Echocardiogram positive for IE deﬁned as follows:
 Oscillating intracardiac mass on valve or supporting structures, in
the path of regurgitant jets, or on implanted material in the absence
of an alternative anatomic explanation;
 Abscess; or
 New partial dehiscence of prosthetic valve
 New valvular regurgitation (worsening or changing of pre-existing
murmur not sufﬁcient)
Minor Criteria
1. Predisposition, predisposing heart condition, or injection drug use
2. Fever, temperature >38 C (100.4 F)
3. Vascular phenomena, major arterial emboli, septic pulmonary infarcts,
mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages,
and Janeway lesions
4. Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth’s
spots, and rheumatoid factor
5. Microbiological evidence: positive blood culture but does not meet
a major criterion as noted above* or serological evidence of active
infection with organism consistent with IE
*Excludes single positive cultures for coagulase-negative staphylococci and organisms that do
not cause IE.
C indicates Celsius; F, Fahrenheit; IE, infective endocarditis; spp, species; TEE, trans-
esophageal echocardiography; and TTE, transthoracic echocardiography. (642,644)
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delayed, which may cause progressive and potentially
irreparable structural damage to the heart and other organ
systems secondary to vascular-embolic and immunologically
mediated events. The in-hospital mortality rate for patients
with IE remains high (15% to 20%), with 1–year mortality,
even in the current therapeutic era, approaching 40%.
Additionally, stroke (16.9%), embolization other than
stroke (22.6%), HF (32.3%), intracardiac abscess (14.4%),
and the need for surgical therapy (48.2%) remain common.
The optimal treatment and potential timing of invasive
strategies in these patients can be quite challenging in the
individual patient. Patients with suspected IE are most
optimally managed in an environment that coordinates
management of specialists well attuned to various organ
systems, pathological processes, and potential treatment
modalities involved. Cardiologists provide expertise in
diagnosis, imaging, and clinical management; infectious
disease specialists provide expertise in identiﬁcation of
the causative organism and the choice and duration of
antimicrobial therapy; cardiac surgeons are essential for
decisions about timing of surgical intervention as well
as the procedure itself; and anesthesiologists are essential
for peri- and intraoperative diagnosis and management.
Because the urgent/emergency need for surgical interven-
tion can arise rapidly, it is strongly recommended that
these patients be cared for in centers with immediate access
to cardiac surgery during the initial observation stages of
the disease. With the emerging use of telemedicine, it
may be reasonable to manage patients with lower-acuity
IE in a center without on-site multispecialty care by tele-
communication with a Heart Valve Team and infectious
disease specialists. Rapid transfer of the patient should alsobe available if the need arises. IE is a disease that is contin-
ually changing with new high-risk patients, new diagnostic
procedures, the involvement of new micro-organisms, and
new therapeutic approaches. Despite knowledge of these
changes and considerable improvements in diagnostic and
therapeutic strategies, IE is still a potentially debilitating or
fatal disease. Patients affected by the disease are often older
and sicker, and the comorbidity rate is high.
Supporting References: (652–654)
CLASS I
4. TTE is recommended in patients with suspected IE to identify
vegetations, characterize the hemodynamic severity of valvular
lesions, assess ventricular function and pulmonary pressures,
and detect complications (655–659). (Level of Evidence: B)
The presence of valvular vegetation is a major criterion
in the diagnosis of IE. TTE has a sensitivity of between
50% and 90% and a speciﬁcity >90% for detection of
vegetations in NVE. TTE has a sensitivity of only 36% to
69% in PVE, but TTE still has a role in these patients for
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challenging situation of regurgitation in the mechanical
prosthetic mitral valve, for which a proximal convergence
zone may provide important evidence for a paravalvular
leak), evaluation of ventricular size and systolic function,
and estimation of pulmonary pressures. TTE exhibits su-
perior imaging over TEE for the anterior aspect of a
prosthetic aortic valve, which is commonly shadowed by
the valve on TEE. TTE also allows measurement of aortic
transvalvular velocity/gradient, which is not always possible
on TEE. Although TTE will not deﬁnitely exclude veg-
etations or abscesses in IE, it can identify very high-risk
patients and establish the diagnosis as well as guide early
treatment decisions (Figure 8).
Supporting References: (655,660–664)
CLASS I
5. TEE is recommended in all patients with known or suspected IE
when TTE is nondiagnostic, when complications have developed
or are clinically suspected, or when intracardiac device leads
are present (662,665–672). (Level of Evidence: B)
The sensitivity of TEE in NVE ranges from 90% to
100%, with sensitivity ranges slightly lower in PVE. The
positive predictive value for TEE in both NVE and PVE
is 90%. TEE is superior to TTE in the visualization
of both vegetations and perivalvular complications, which
can be anatomic or hemodynamic in nature. Examples of
such complications include valve perforation, abscesses,
and pericardial effusion. Hemodynamic complications
may include valve regurgitation, ﬁstulae, and intracardiac
thrombi. TEE is now considered the most reliable
noninvasive test for deﬁning this disease. However, it may
not differentiate between active and healed vegetations and
may not discriminate between thickened valves or valvular
nodules and vegetations. TTE and TEE are complemen-
tary for the comprehensive evaluation of hemodynamics
and anatomy in patients with IE. Because TEE has a
higher sensitivity in detecting anatomic complications, it
should be used as an adjunct in patients with echocardio-
graphic features of IE on TTE to rule out the presence of
ﬁndings such as abscesses, which may alter the therapeutic
approach to the management of the patient. TEE also
serves a vital role in reassessment of patients with known
IE with suspected clinical complications as well as a
guiding tool in the intraoperative assessment and man-
agement of the IE patient.
The number, type, and timing of repeat examinations
depend on the clinical presentation and course as well as the
virulence of the microorganism. Vegetation size at diagnosis
has clearly identiﬁed a higher risk of death in prospective
studies. Additionally, 1 study has shown that failure to
decrease vegetation size with antibiotic treatment was asso-
ciated with an increased risk of embolism. Another study
demonstrated that most vegetations (83.8%) remain constant
in size under therapy and that this does not worsen prog-
nosis. In this study, both increase of vegetation size underantibiotic therapy (observed in 10.5% of patients with IE)
and reduction of vegetation size under therapy were associ-
ated with an increased embolic risk. Thus, increasing vege-
tation size under therapy must be considered a risk factor for
new embolic events, whereas unchanged or reduced vege-
tation size under therapy may be more difﬁcult to interpret.
Compared with TTE, TEE is more sensitive for
detection of vegetations and thrombi associated with de-
vice leads. There are emerging data that intracardiac
echocardiography may be an increasingly useful tool to
diagnose vegetations that may be present on right-sided
pacemaker leads. It has shown superior sensitivity over
TEE in identifying these lesions.
Supporting References: (664,670,673–681)
CLASS I
6. TTE and/or TEE are recommended for re-evaluation of patients
with IE who have a change in clinical signs or symptoms (e.g.,
new murmur, embolism, persistent fever, HF, abscess, or
atrioventricular heart block) and in patients at high risk of
complications (e.g., extensive infected tissue/large vegetation
on initial echocardiogram or staphylococcal, enterococcal,
fungal infections) (679,682). (Level of Evidence: B)
HF, perivalvular extension, and embolic events represent
the 3 most frequent and severe complications of IE. They
are also the 3 main indications for early surgery, which is
performed in almost 50% of cases. If signs or symptoms
consistent with any of these complications exist, there
should be a very low threshold for repeat imaging in these
patients. TEE may miss initial paravalvular abscesses,
particularly when the study is performed early in the pa-
tient’s illness. In such cases, the incipient abscess may be
seen only as nonspeciﬁc paravalvular thickening, which on
repeat imaging across several days may become recogniz-
able as it expands and cavitates. Similarly, paravalvular
ﬁstulae and pseudoaneurysms develop over time, and
negative early TEE images do not exclude the potential for
their development. For patients who have IE that was
diagnosed by clinical, microbiological, or surgical criteria
but for whom results of initial TEE were false-negative,
repeated TEE has often demonstrated vegetative IE.
Thus, it appears that a single negative TEE study cannot
rule out underlying IE and that a repeat TEE study should
be performed when a suspicion of persistence of infection
remains or if complications ensue. Conversely, in the
absence of clinical deterioration or new signs/symptoms,
routine follow-up echocardiography is probably of only
limited clinical utility.
Supporting References: (52,630,665,683–685)
CLASS I
7. Intraoperative TEE is recommended for patients undergoing
valve surgery for IE (686,687). (Level of Evidence: B)
Intraoperative TEE during cardiac surgery plays an
important role in the evaluation and quality control of
a large variety of pathologies. Clinical and echocardio-
graphic characteristics may change during an episode of
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course of this disease. Even if preoperative TEE has been
performed, the possibility of vegetation change/emboli-
zation or extension of the infectious process beyond the
valve tissue may occur. In addition, other valves may
become involved as the disease timeline progresses. In-
traoperative TEE has been invaluable for baseline reas-
sessment of anatomical/hemodynamic changes that may
occur in the interval between the diagnostic echocardio-
gram and the time of surgery. TEE is also an important
monitoring tool for evaluation of operative complications
such as air emboli and an important adjunct to ensure the
quality of the intended surgical result.
Supporting References: (688,689)
CLASS IIa
1. TEE is reasonable to diagnose possible IE in patients with
Staphylococcal aureus (S. aureus) bacteremia without a known
source (690–692). (Level of Evidence: B)
IE in patients with S. aureus bacteremia frequently in-
volves normal cardiac valves and is seldom accompanied by
the physical stigmata of IE, rendering the diagnosis of the
disease difﬁcult. Reliance on physical examination ﬁndings
and clinical stigmata is likely to result in underdiagnosis of
S. aureus IE in a large number of cases. TEE is cost-
effective to guide duration of therapy in patients with
intravascular catheter-associated S. aureus bacteremia, pa-
tients with intracardiac electronic devices, or other patients
at higher risk for IE (including those with previous pros-
thetic valve surgery) or associated complications.
Despite early diagnosis and appropriate therapy, IE
following S. aureus bacteremia is frequently associated with
disabling and life-threatening sequelae. The overall mor-
tality of S. aureus IE ranges from 19% to 65%. Other
complications include HF (20% to 50%), paravalvular
cardiac abscesses (30% to 40%), neurological manifesta-
tions (30%), and systemic embolization (40%).
Supporting References: (652,677,693,694)
CLASS IIa
2. TEE is reasonable to diagnose IE of a prosthetic valve in the
presence of persistent fever without bacteremia or a new
murmur (695,696). (Level of Evidence: B)
When compared with NVE, PVE is characterized by
a lower incidence of vegetations (especially in mechanical
prostheses) and a higher incidence of annular abscess and
other paravalvular complications. Because cardiac auscul-
tation may also be less revealing in PVE and because
ordinarily less virulent organisms may cause more anatomic
destruction before culture or serological detection, it is
important to use TEE early in these high-risk patients.
TEE has a lower sensitivity in detecting prosthetic IE
when compared with TEE detection rates in NVE, so the
importance of comparing serial echocardiographic studies
is paramount to making the diagnosis.
Supporting References: (697,698)CLASS IIa
3. Cardiac CT is reasonable to evaluate morphology/anatomy in
the setting of suspected paravalvular infections when the
anatomy cannot be clearly delineated by echocardiography
(678,699–701). (Level of Evidence: B)
Electrocardiographic-synchronized, multidetector-row
CT is emerging as an important tool for noninvasive car-
diac assessment and may be helpful in evaluating compli-
cations of IE. CT may also be indicated in right-sided
IE to demonstrate the presence of septic pulmonary in-
farcts and abscesses. Although CT is less accurate than
TTE and TEE for identifying valvular vegetation and
valvular perforations, CT is useful for evaluating patients
with equivocal ﬁndings on TEE and for evaluating com-
plications in patients with suspected myocardial, pericar-
dial, and coronary sinus extension of the infectious process.
CT can also more sensitively detect paravalvular abscess
involvement and evaluate extent and anatomic conse-
quences of pseudoaneurysms and their relationship to
adjacent structures. CT imaging is particularly useful in
preoperative evaluation of patients with aortic valve IE to
evaluate coronary artery and aortic involvement.
In suspected PVE, cardiac CT is less affected by the
shadowing of mechanical valves or bioprosthetic valve
sewing rings than ultrasound. CT also allows evaluation of
motion of mechanical valve occluders and provides visu-
alization of thrombus or infective material limiting valve
occluder motion. Additional imaging modalities such as
cardiac valvular ﬂuoroscopy can be an adjunct to other
clinical and imaging information to detect the presence of
obstructive disease of mechanical prosthetic valves affected
by IE. Normative values for the opening and closing angles
are known for the common valves available for patient use.
A combination of cineradiography and echocardiography
makes it possible to provide an accurate and detailed
determination of the degree and extent of valvular
obstruction that may accompany mechanical PVE.
Supporting References: (699,702–706)
CLASS IIb
1. TEE might be considered to detect concomitant staphylococcal
IE in nosocomial S. aureus bacteremia with a known portal of
entry from an extracardiac source (663,707,708). (Level of
Evidence: B)
Because the frequency of IE among patients with
S. aureus bacteremia is reported to be approximately 30%,
with many cases not being clinically suspected, TEE
should generally be pursued in the setting of S. aureus
bacteremia to rule out IE. Even in S. aureus bacteremia
from a known extracardiac source, such as an infected joint
or joint prosthesis, TEE might be considered. given
known cases of seeding of valve tissue in this type of
setting. Possible exceptions are patients who have no un-
derlying cardiac predisposing conditions or clinical signs
of IE whose fever and bacteremia resolve within 72 hours
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lar catheter removal). In the absence of 1) prolonged
bacteremia >4 days, 2) a permanent intracardiac device,
3) hemodialysis dependency, and 4) spinal infection or
nonvertebral osteomyelitis, the risk of IE is relatively low,
and routine TEE may not be necessary.
Supporting References: (663,691,692,709)12.2.2. Medical Therapy: Recommendations
See Online Data Supplement 24 for more information on
surgical outcomes.
CLASS I
1. Appropriate antibiotic therapy should be initiated and continued
after blood cultures are obtained with guidance from antibiotic
sensitivity data and infectious disease consultants (636).
(Level of Evidence: B)
Optimal treatment of IE is based on the appropriately
timed initiation of antimicrobial therapy that is effective
against the speciﬁc infective organism involved. Empirical
therapy may be necessary in patients with septic shock or
who show high-risk signs on presentation; however, tar-
geted antimicrobial therapy guided by minimum inhibitory
concentration is the goal. The minimum inhibitory con-
centration is used to determine the antibiotic dosage that
the patient will receive and the type of antibiotic used and
can lower the opportunity for microbial resistance to spe-
ciﬁc antimicrobial agents. Prompt use of antibiotics
signiﬁcantly reduces the incidence of emboli in patients
with IE. Duration of therapy needs to be guided by those
with expertise in the ﬁeld of antibiotic therapy. Although
no RCTs have been performed with the use of antibiotic
therapy in IE, the mortality rate before the antibiotic age
neared 100%. Despite advances in knowledge of mecha-
nism of therapeutic approaches to treating infections and
despite a signiﬁcant expansion of the antimicrobial arma-
mentarium, the emergence of resistant organisms has led to
continued complexity in the approach to patients with
systemic infections. Antimicrobial therapy for NVE and
PVE should be guided by the susceptibility proﬁle of the
causative organism. Speciﬁc antimicrobial regimens,
depending on the causative microorganism, have been
published by the British Society for Antimicrobial
Chemotherapy and the AHA. Given the ever-changing
spectrum of antimicrobial sensitivity, as well as regional
and site-speciﬁc differences in antimicrobial susceptibility
proﬁles, concomitant management with the assistance of a
consultant thoroughly familiar with these patterns is
imperative.
Supporting References: (633,634,636,710–713)
CLASS IIa
1. It is reasonable to temporarily discontinue anticoagulation in
patients with IE who develop central nervous system symptoms
compatible with embolism or stroke regardless of the other in-
dications for anticoagulation (714–719). (Level of Evidence: B)There are several potential mechanisms of stroke in
patients with IE, including hemorrhagic transformation of
an ischemic infarct, septic erosion of an arteritic vessel
without aneurysm formation, and rupture of a mycotic
aneurysm. Approximately 15% to 35% of all patients with
IE develop clinically evident systemic emboli. If more
sensitive tests such as cerebral magnetic resonance imaging
are used, a much higher proportion of patients with IE
have evidence of emboli (30%). The most common cause
of stroke in patients with IE in the modern antimicrobial
era is a septic embolus resulting in ischemia, often followed
by hemorrhagic transformation. Anticoagulant therapy
may increase the risk of an embolic infarct converting to a
hemorrhagic infarct. Hemorrhagic transformations can
occur up to 11 days after an initial infarct. On the other
hand, the longer anticoagulation is withheld, the higher
the chance of recurrent embolization or valve dysfunction
in patients with PVE. The beneﬁcial or deleterious effect
of anticoagulation in patients with IE is determined by
a multitude of clinical, bacteriologic, radiological, and
echocardiographic variables that may tilt the balance of the
risk toward early recurrent stroke or intracranial hemor-
rhage. Patients with IE and a cerebral embolism or stroke
should be referred to a center with a multispecialty Heart
Valve Team. A specialist in the ﬁeld of neurology and/or
neuroradiology should be added to this team when the
complication of stroke arises in IE. The risk of bleeding
complications should be included in the assessment of
patients with IE receiving anticoagulation treatment.
Supporting References: (12,720–726)
CLASS IIb
1. Temporary discontinuation of VKA anticoagulation might be
considered in patients receiving VKA anticoagulation at the
time of IE diagnosis (715,727–730). (Level of Evidence: B)
In patients with NVE, routine use of VKA is not rec-
ommended unless a separate indication exists. There is no
conclusive evidence that prophylactic use of VKA anti-
coagulation reduces the incidence of emboli in patients
with NVE who have no other indication for
anticoagulation.
Alternatively, for patients already receiving anti-
coagulation with VKA or aspirin for other evidence-based
indications at the time of diagnosis with IE, there is little
information on the risks and beneﬁts of continued anti-
coagulation therapy. Continuing anticoagulant therapy
in the face of IE potentially increases the risk of hemor-
rhagic transformation of an embolic stroke or accentuation
of bleeding from septic arteritis or mycotic aneurysms
should they occur. The evidence and propensity of expert
consensus would suggest that VKAs be discontinued at the
time of initial presentation with IE secondary to the
combined risk of bleeding from potentially urgent invasive
procedures and the risk of developing hemorrhagic stroke.
Early surgery is required in roughly 50% of patients with
PVE. Although there is no evidence regarding the use of
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coagulant therapy while patients are off VKAs, studies
indicate that there is increased risk of hemorrhagic stroke
in patients on intravenous UFH during the acute phase
of acute IE. It should be noted that the strength of this
evidence is low, and some institutional practices continue
VKA anticoagulation until an invasive procedure is
deemed a deﬁnitive necessity or until a neurological
complication develops or is noted on imaging studies.
Decisions about continued anticoagulation and antiplatelet
therapy should ultimately be directed by the patient’s
consulting cardiologist and cardiothoracic surgeon in con-
sultation with a neurology specialist if neurological ﬁndings
are clinically present or noted on imaging. Although there
is no strong evidence base for screening neurological im-
aging studies and their potential impact on management,
the data are strong that subclinical neurological abnor-
malities are common, occurring in 25% of patients with
IE and S. aureus and up to 55% of critically ill patients with
IE. In patients with valvular or nonvalvular indications
for continued use of VKAs, strong consideration should
be given to cerebral magnetic resonance imaging to eval-
uate for subclinical cerebrovascular complications to help
guide anticoagulation management. Novel oral anticoagu-
lants have no indication for VHD.
In patients with IE, routine antiplatelet therapy is not
recommended unless a separate indication exists. There
is no evidence that routine use of aspirin in the setting of
IE reduces risk of embolic stroke in patients who are
already receiving antibiotic therapy. However, large retro-
spective studies have suggested that embolism associated
with IE occurs less frequently among patients who have
received continuous daily antiplatelet therapy for other
indications before the diagnosis of IE.
Supporting References: (12,728–735)
CLASS III: Harm
1. Patients with known VHD should not receive antibiotics before
blood cultures are obtained for unexplained fever. (Level of
Evidence: C)
Two sets of blood cultures are the minimum for a secure
microbiological diagnosis of IE. The leading cause of “cul-
ture-negative IE,” which can be a signiﬁcant clinical
conundrum, is the use of antibiotics before blood cultures
are obtained.Negative blood cultures in the setting of IE can
delay diagnosis by slowing other serological and polymerase
chain reaction assessments; therefore, it can delay deﬁnitive
treatment of the patient as well as impair determination of
antimicrobial treatment duration. The identiﬁcation of the
causative pathogen will improve the speciﬁcity of the ther-
apeutic regimen and may signiﬁcantly improve patient
outcome. S. aureus is the most common pathogen respon-
sible for PVE but still accounts for only 23% of cases.
Antibiotic therapy is most effective if the identity and
sensitivities of the responsible organism are known.
Supporting References: (724,736,737)12.2.3. Intervention: Recommendations
See Figure 9 for diagnosis and treatment of IE and Online
Data Supplement 24 for more information on surgical
outcomes.
CLASS I
1. Decisions about timing of surgical intervention should be made
by a multispecialty Heart Valve Team of cardiology, cardiotho-
racic surgery, and infectious disease specialists (651). (Level of
Evidence: B)
The in-hospital mortality rate for IE is high, at 15% to
20%, with 1–year mortality approaching 40%. Given those
rates and the complexities and uncertainties about surgical
timing/indications related to comorbid conditions in many
of these patients, it is recommended that patients with IE
be managed in an environment with ready access to spe-
cialists in the ﬁelds of cardiology, cardiothoracic surgery,
and infectious disease. Cardiothoracic surgical consultation
should be obtained rapidly after the diagnosis of IE. A
risk-scoring system using the STS database has been
developed to predict risk of surgery in patients with IE to
help better counsel patients and more objectively deﬁne
risks of surgery. One trial noted that even when surgery is
indicated, women were less likely to undergo a surgical
procedure than men (26% versus 47%) and that women
had higher in-hospital and 1–year mortality rates than men
despite similar comorbidities. To prevent subjective bias in
decision making for patients, it is recommended that
hospitals use system policies to ensure best practices in
patients with IE.
Supporting References: (738–740)
CLASS I
2. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) is indicated in patients
with IE who present with valve dysfunction resulting in symp-
toms of HF (741–746). (Level of Evidence: B)
Death may occur suddenly in patients with endocarditis-
induced HF, particularly if the aortic valve is involved. The
ICE-PCS (International Collaboration on Endocarditis-
Prospective Cohort Study) has reported a 21% in-
hospital mortality rate in patients with IE with HF
treated with surgery versus a 45% mortality rate in those
who were medically treated. One-year mortality in this
study was 29.1% in patients undergoing valvular surgery
versus 58.4% in those not undergoing surgery. In
complicated left-heart NVE, 4 baseline features have
been independently associated with 6–month mortality:
abnormal mental status, moderate-to-severe HF, bacterial
etiology other than Viridans streptococci, and medical ther-
apy without valve surgery. This risk stratiﬁcation system
has been validated in a separate cohort, and similar ﬁndings
have been reproduced in both retrospective propensity
studies and prospective studies. Prompt surgical consulta-
tion should be obtained in all cases of IE to assist with
assessment of the need for surgical treatment and to
Figure 9. Diagnosis and Treatment of IE
*Early surgery deﬁned as during initial hospitalization before completion of a full therapeutic course of antibiotics.
HF indicates heart failure; ICD, implantable cardioverter-deﬁbrillator; IE, infective endocarditis; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; Rx, therapy;
S. aureus, Staphylococcus aureus; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography; and VKA, vitamin K antagonist.
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e136help judge the timing of surgery. Further prospective
randomized studies with large study populations are
necessary to more precisely evaluate the optimal timing
of surgery in patients with NVE.
Reinfection after prosthetic valve surgery (which occurs
in 5% to 10% of patients, with a signiﬁcant percentage
of these being injectable drug users) is low relative to the
risk of no surgery in patients with hemodynamic and
microbial indications for surgery. Repair rather than
replacement of a valve is always best; however, such re-
pairs are possible in only a minority of cases, such as when
a leaﬂet perforation occurs without extensive leaﬂet
destruction or annular involvement. PVE is clearly as-
sociated with both higher mortality rates (especially if
associated with a new murmur, HF, or severe valvular
dysfunction or if the infectious microbe is staphylococ-
cal or fungal) and higher post-treatment HF-related
disability. Most surgical series report a surgical rate of
nearly 50% in patients with PVE. Up to 20% more would
beneﬁt from surgery if it were not for an already developed
catastrophic complication. Surgical debridement andreplacement of the infected prosthetic valve lead to
signiﬁcantly lower mortality (23%) compared with med-
ical therapy alone (56%). Improved outcome was seen for
the surgical group even when controlling for severity of
illness at time of diagnosis. In a series of 1,025 patients
with PVE, early surgery did not reduce in-hospital or 1–
year mortality when adjusted for the propensity to operate
and the effect of survivor bias. However, subgroup analysis
indicated that patients with the strongest indications for
surgery (new left-sided valve regurgitation, paravalvular
abscess or ﬁstula, prosthetic valve dehiscence, or HF) did
have a lower 1–year mortality rate with early surgery
(27.9% versus 50.0%; p¼0.007).
PVE is classiﬁed into “early-,” “intermediate-,” and
“late-” onset PVE. Early-onset PVE is deﬁned as occur-
ring within the ﬁrst 60 days of surgery and is typically
associated with healthcareacquired infection, with the
most common microbe during this time frame being
S. aureus. Intermediate-onset PVE occurs between 60 and
365 days after surgery and is associated with a mix of both
healthcareacquired infection and community-acquired
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intermediate-onset PVE is coagulase-negative Staphylo-
coccus. Two thirds of all reported cases of PVE occur within
the ﬁrst year of valve surgery. Late-onset PVE is deﬁned as
occurring >1 year after surgery. Although S. aureus and
coagulase-negative Staphylococcus remain important infect-
ing agents, the late-onset PVE microbial spectrum more
closely resembles that of NVE.
Supporting References: (635,724,747–751)
CLASS I
3. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) is indicated in patients
with left-sided IE caused by S. aureus, fungal, or other highly
resistant organisms (746,752–758). (Level of Evidence: B)
In the United States, 34% of NVE cases are due to
S. aureus. Compared with patients with IE due to other
organisms, patients with S. aureus IE were signiﬁcantly
more likely to die (20% versus 12%), experience an embolic
event (60% versus 31%), have a central nervous system
event (20% versus 13%), and not undergo surgery (26%
versus 39%). Although mortality rates are lower in patients
with methicillin-sensitive S. aureus, the rate of embolic
events is even higher than that of methicillin-resistant
S. aureus. Factors involved in the higher modern rates of
S. aureus IE are a low prevalence of rheumatic heart disease
(therefore an older, less immunocompetent population
with underlying degenerative VHD), a larger population of
hemodialysis patients, an increasing diabetic population,
and a higher rate of prolonged use of an intravascular de-
vice. In hospital-acquired IE, the mortality rate has been
reported to be 2 times that of community-acquired IE,
largely due to resistant staphylococcal and enterococcal
species. Certain pathogens, such as Pseudomonas aerugi-
nosa, Brucella, fungi, and gram-positive cocci (especially
those that are resistant to beta-lactam antibiotics or van-
comycin) are extremely difﬁcult to cure with medical
therapy alone. Many of these organisms are also prone to
abscess/ﬁstula formation and other cardiac tissue destruc-
tion, which cannot be effectively treated with medical
therapy alone. Despite high-quality imaging using 2D and
even 3D TEE, false-negative ﬁndings for intracardiac
abscess are as high as 60%. Similar to studies in S. aureus
IE, the mortality rate is signiﬁcantly lower in patients
treated with antifungal agents combined with surgery
compared with those treated with antifungal agents alone
(42% versus 59%).
An important distinction is made for injectable drug
users. When Staphylococcus is the bacteria, death occurs
in <5% of patients with right-sided NVE; however, in
left-sided NVE with the same organism, death ensues
in 20% to 30% of cases. In injectable drug users with
NVE, Enterococcus sp carries a mortality rate of 15% to
25%. Pseudomonas aeruginosa, Enterobacteriaceae, and
fungi, though rare, carry an overall mortality rate of
>50% in this population. Coexisting conditions thatincrease mortality in injectable drug users include HF,
neurological events, renal failure, and symptomatic HIV
infection. Given the high nonsurgical cure rates of right-
sided IE combined with the signiﬁcant concern of rein-
fection of prosthetic material in surgical intervention,
an even more coordinated effort of surgical and nonsurgi-
cal experts in management of NVE is necessary for
injectable drug users.
Staphylococcal PVE has been associated with a mor-
tality rate as high as 70%. Given the difﬁculty in eradi-
cating Staphylococcus spp when foreign and avascular
material are involved in the infection, survival rates are
signiﬁcantly higher in patients who undergo surgical
debridement and have the infected valve removed and
replaced. Mortality rates remain higher in this group of
patients whether treated surgically or not when compared
with every other category of IE aside from fungal in-
fections. Pseudomonas aeruginosa and multiresistant en-
terococci, for which there is no synergistic bactericidal
regimen, are also less amenable to medical therapy.
Supporting References: (652,724,747,753,759–766)
CLASS I
4. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) is indicated in patients
with IE complicated by heart block, annular or aortic abscess,
or destructive penetrating lesions (746,767–771). (Level of
Evidence: B)
Abscess of the native valves or paravalvular structures
with or without extension to the cardiac conduction system
is a life-threatening complication that cannot be cured
with antibiotic therapy alone. Early recognition and
institution of appropriate medical and surgical therapy is
necessary for patient survival. Complete heart block in IE
usually occurs secondary to extension of infection into the
atrioventricular node. Heart block is most commonly
associated with aortic valve IE, given the high prevalence
of paravalvular extension and the proximity of the con-
duction system to the valve (although it has also been re-
ported in mitral and tricuspid valve IE) and is associated
with an increased risk for sudden cardiac death and more
severe anatomical destruction of cardiac tissues. Extensive
perivalvular infections (to include annular/aortic abscesses
and destructive penetrating lesions/ﬁstulae) respond
poorly to medical therapy and are associated with a mor-
tality rate of 40%. Patients with paravalvular abscess are
typically very ill by the time they are referred for surgery.
Even so, the long-term results of surgery are very satis-
factory, with an actuarial survival rate of 75%6% at 5
years. Freedom from recurrent IE has been reported to be
76% at 8 years. The 2 primary objectives of surgery are total
removal of infected tissues and reconstruction of functional
anatomy. Surgical series have shown that the surgical re-
sults are more related to a surgeon’s ability to remove all
infected tissues than to the type of valve used for a
replacement.
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as manifested by intracardiac abscesses, ﬁstulae, or heart
block, experience high mortality rates and are rarely cured by
medical treatment alone. By contrast, surgical series have
reported surgical survival rates of 71% in this high-risk group.
Supporting References: (724,772–775)
CLASS I
5. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) for IE is indicated in
patients with evidence of persistent infection as manifested by
persistent bacteremia or fevers lasting longer than 5 to 7 days
after onset of appropriate antimicrobial therapy (746,756,
757,776–778). (Level of Evidence: B)
Blood cultures will typically become negative after 48
hours of appropriate antimicrobial therapy; however, in
methicillin-resistant S. aureus and other resistant organ-
isms, it may take up to a week for cultures to become
negative. An ongoing infection despite antibiotic therapy
is common with aggressive micro-organisms, abscess for-
mation, or large vegetations. In some patients, the only
evidence of persistent infection is an elevated white blood
cell count or fevers that persist longer than 5 to 7 days. In
patients with persistent bacteremia despite appropriate
susceptibility-based therapy, the clinician must consider
surgical adjunctive therapy based on multispecialty input
and guidance from serial TEE and other imaging data.
Detection of abscess by TEE can be missed in the presence
of calciﬁcation in the posterior mitral annulus or because of
echocardiography artifact from prosthetic material. CT
imaging may be helpful in this situation. Early surgery has
been shown to improve outcome in patients with an ab-
scess. Additionally, patients with persistent sepsis are at
high risk of developing multiorgan failure, and surgery may
be needed in these patients to debride infected/necrotic
tissues to effectively eradicate the infection. Predictors of
in-hospital mortality in patients with PVE include older
age, healthcare-associated infection, S. aureus infection,
HF, stroke, intracardiac abscess, and persistent bacteremia.
Some caution is advised in patients who develop recurrent
fever after an initially successful response to antibiotics,
because the fever could be explained by other reasons than
the endocarditic valve.
Supporting References: (724,746,747,777,779)
CLASS I
6. Surgery is recommended for patients with PVE and relapsing
infection (deﬁned as recurrence of bacteremia after a complete
course of appropriate antibiotics and subsequently negative
blood cultures) without other identiﬁable source for portal of
infection. (Level of Evidence: C)
TEE has a reduced sensitivity for detection of abscess in
patients with prosthetic valves. If there is suspicion by a
team of cardiologists, cardiothoracic surgeons, and infec-
tious disease specialists that relapsing infections may be
due to incomplete sterilization of valvular or paravalvulartissue secondary to a deep tissue infection, it is reasonable
to consider surgery in this situation. In the absence of
other indications for intervention, such as severe valve
dysfunction or a resistant organism, the timing of surgi-
cal intervention cannot be strictly deﬁned in these situa-
tions. Because the possibility of “reseeding” a prosthetic
valve has been reported in the setting of infection from
an origin separate from the heart, careful assessment for
the possibility of reintroduction of an infectious microbe
from another portal should be thoroughly ruled out in
these instances before consideration of cardiac surgical
reintervention.
Supporting Reference: (746)
CLASS I
7. Complete removal of pacemaker or deﬁbrillator systems,
including all leads and the generator, is indicated as part of
the early management plan in patients with IE with docu-
mented infection of the device or leads (780–783). (Level of
Evidence: B)
Complete device and lead removal is recommended
for all patients with cardiac device infection, even if evi-
dence for infection appears to be limited to the generator
pocket site. A prospective cohort study using data from
ICE-PCS showed that among patients with cardiac de-
vice IE, the rates of both concomitant valve infection and
mortality are high, particularly if there is valve dys-
function. Optimal therapy for cardiac device IE combines
complete device extraction and a prolonged course of
parenteral antibiotics. A proportional hazards regression
analysis showed a survival beneﬁt at 1 year for device
removal during the initial hospitalization; 28 of 141 pa-
tients (19.9%) who underwent device removal during
the index hospitalization had died at 1 year versus 13 of
34 (38.2%) who did not undergo device removal (HR:
0.42; 95% CI: 0.22 to 0.82).
Supporting References: (681,784–786)
CLASS IIa
1. Complete removal of pacemaker or deﬁbrillator systems,
including all leads and the generator, is reasonable in patients
with valvular IE caused by S. aureus or fungi, even without
evidence of device or lead infection (780–783). (Level of
Evidence: B)
The likelihood of underlying cardiac device infection in
a patient with S. aureus bacteremia is relatively high
(approximately 30% to 40%) and is also likely in patients
with fungal valvular IE. In patients with a normal pocket
site, it is difﬁcult to determine if the device should be
removed. If there is evidence of valvular endocarditis on
TEE, then the device should be removed. If there is a lead
mass without a valve lesion, device removal has been
advocated by some based on “lead endocarditis.” However,
the writing committee noted that the likelihood of ﬁnding
a clot on a lead in noninfected patients can range from 1%
to 50% of patients undergoing TEE.
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electronic device infection in someone with bacteremia due
to gram-negative bacilli is much less. Therefore, if the
pocket site appears normal, device removal is generally not
required for an initial episode of bacteremia.
Supporting References: (781,785,787)
CLASS IIa
2. Complete removal of pacemaker or deﬁbrillator systems,
including all leads and the generator, is reasonable in patients
undergoing valve surgery for valvular IE. (Level of Evidence: C)
In patients with an intracardiac lead who are undergoing
prosthetic valve replacement for valvular IE, the device and
lead might serve as a nidus for recurrent infection because
infection of the leads may be present even without visible
vegetations. Removal of the entire device and leads reduces
the risk of reinfection.
CLASS IIa
3. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) is reasonable in patients
with IE who present with recurrent emboli and persistent veg-
etations despite appropriate antibiotic therapy (655,788,789).
(Level of Evidence: B)
Early surgery is associated with a reduction in the rate
of embolic complications in patients who present with
left-sided IE, severe VHD, and large vegetations (>10
mm). Embolic events are a frequent and life-threatening
complication of IE. Embolism is associated with an in-
creased morbidity and mortality in IE and occurs in 20%
to 40% of patients with IE. Embolic incidence decreases
to 9% to 21% after initiation of antibiotic treatment.
Factors associated with a new embolic event are vegeta-
tion size >10 mm in length and marked vegetation
mobility (especially when associated with the anterior
leaﬂet of the mitral valve). The risk of embolism is highest
during the ﬁrst days after initiation of antibiotic treatment
and decreases after 2 weeks.
Patients with PVE who are most likely to beneﬁt from
medical therapy without surgery are those with non-
Staphylococcal PVE without complications or prosthetic
valve dysfunction, aswell as thosewho remain clinically stable
and who show clinical improvement on antibiotic treatment.
Surgical intervention is especially beneﬁcial in patients with
StaphylococcalPVEand complicatedPVE, ofwhich recurrent
embolization is identiﬁed as a common type of major
complication (>20% of patients in all PVE studies).
Supporting References: (679,783,789–791)
CLASS IIb
1. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) may be considered in
patients with NVE who exhibit mobile vegetations greater than
10 mm in length (with or without clinical evidence of embolic
phenomenon) (655,788,789). (Level of Evidence: B)
With NVE, large vegetation size is associated with
a markedly higher rate of embolic phenomenon. Embolicevents are also known to be causally associated with
higher rates of mortality in IE. In an RCT of surgical
intervention in patients with severe left-sided valve
dysfunction and vegetations >10 mm in length (even
in the absence of clinically apparent embolic events or
HF), there was no signiﬁcant difference in all-cause
mortality at 6 months in the early-surgery versus the
conventional-treatment groups (3% and 5%, respectively;
p¼0.59); however, there was a marked reduction in the
number of embolic events, 0% in the early-surgery group
compared with 21% in the conventional-treatment
group (p¼0.005). Additionally, 77% of the conventional
group required surgery in the initial hospitalization or
during the follow-up phase secondary to HF, paravalvular
extension, and heart block.
Supporting References: (652,789)13. Pregnancy and VHD
13.1. Native Valve Stenosis: Recommendations
CLASS I
1. All patients with suspected valve stenosis should undergo a clin-
ical evaluation and TTE before pregnancy. (Level of Evidence: C)
Patients with severe valve stenosis tolerate the hemo-
dynamic changes of pregnancy poorly. The increased car-
diac output, increased heart rate, and decreased afterload
that occur during pregnancy may all contribute to hemo-
dynamic decompensation in the presence of severe valve
stenosis. Thus, it is critical to identify patients who may
have suspected valve stenosis before pregnancy, because
this ﬁnding may have important implications for therapy
before conception as well as management during preg-
nancy and delivery. The most common etiology of AS in
women of childbearing age in developed countries is a
congenitally abnormal unicuspid or bicuspid valve, which
can be associated with an aortopathy. In these patients, it
is important to determine the size of the aorta before
pregnancy, because those with a dilated aorta may be at
increased risk for further dilation during pregnancy. A
comprehensive TTE and Doppler echocardiogram should
be performed before pregnancy to diagnose the presence
of valve stenosis, severity of stenosis, and hemodynamic
consequence of the stenosis.
Supporting References: (792–794)
CLASS I
2. All patients with severe valve stenosis (stages C and D) should
undergo prepregnancy counseling by a cardiologist with exper-
tise in managing patients with VHD during pregnancy. (Level of
Evidence: C)
The management of patients with valve stenosis should
ideally begin before conception. A complete assessment of
functional capacity, severity of stenosis, and the status of
the left ventricle and pulmonary pressures are necessary to
determine the risk of pregnancy and delivery in patients
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with pregnancy must be fully discussed with the patient.
Interventions before pregnancy, such as valve replacement,
valve repair, or percutaneous aortic or mitral balloon dila-
tion should be considered, particularly in those patients
with severe stenosis, regardless of symptoms. Drugs with
potential harmful effects on the fetus must be identiﬁed.
If pregnancy is contemplated, arrangements should be
made for the patient to be monitored in a tertiary care
center with a dedicated Heart Valve Team of cardiologists,
surgeons, anesthesiologists, and obstetricians who have
expertise in managing high-risk cardiac patients. Coun-
seling regarding all these areas should be performed by a
cardiologist with expertise in managing patients with
VHD during pregnancy.
Supporting References: (792–794)
CLASS I
3. All patients referred for a valve operation before pregnancy
should receive prepregnancy counseling by a cardiologist with
expertise in managing patients with VHD during pregnancy
about the risks and beneﬁts of all options for operative in-
terventions, including mechanical prosthesis, bioprosthesis,
and valve repair. (Level of Evidence: C)
All prosthetic valve types pose major problems during
pregnancy. Patients with mechanical prostheses require
continued anticoagulation throughout pregnancy to pre-
vent valve thrombosis and systemic embolism. However,
anticoagulation has risks for both the mother and the fetus.
Bioprostheses have a limited life span, particularly in the
younger patient, and controversy persists as to whether
there is acceleration of valve degeneration during preg-
nancy. Patients of childbearing age who undergo valve
surgery should be informed of the maternal and fetal risks
of anticoagulation, risk of mechanical valve thrombosis and
embolism, and risk of bioprosthetic valve degeneration
during pregnancy.
Supporting References: (793,795)
CLASS I
4. Pregnant patients with severe valve stenosis (stages C and D)
should be monitored in a tertiary care center with a dedicated
Heart Valve Team of cardiologists, surgeons, anesthesiologists,
and obstetricians with expertise in the management of high-risk
cardiac patients during pregnancy. (Level of Evidence: C)
Patients with severe stenosis are at high risk during
pregnancy. The risk increases throughout pregnancy, given
the continued hemodynamic changes, including increased
intravascular volume, decreased afterload, and increased
heart rate. Pulmonary edema, arrhythmias, and even
maternal death may occur. The presence of severe valve
stenosis is also associated with an increased risk to the
fetus. Management of pregnant patients with VHD re-
quires that clinicians have knowledge and experience in
caring for these patients. Cardiac diagnostics, hemody-
namic monitoring, and prevention of cardiovascular com-
plications require expertise beyond the standard obstetricalscope of practice. Timing and mode of delivery should be
discussed jointly and carried out by the Heart Valve Team,
with close hemodynamic monitoring during and up to 24
hours after delivery.
Supporting References: (792–794)
13.1.1. Diagnosis and Follow-Up: Recommendation
CLASS IIa
1. Exercise testing is reasonable inasymptomaticpatientswith severe
AS (aortic velocity ‡4.0 m per second or mean pressure gradient
‡40 mm Hg, stage C) before pregnancy. (Level of Evidence: C)
Patients with severe ASdparticularly those who are
symptomaticdhave an increased risk of sudden clinical
deterioration and even death during pregnancy. Exercise
testing is reasonable in asymptomatic patients with severe
AS before pregnancy to obtain an objective assessment of
exercise tolerance. Patients with symptoms provoked by
exercise testing should be considered symptomatic, espe-
cially if the clinical history is equivocal. These patients
should be treated for symptomatic severe AS and cautioned
against pregnancy or should undergo an intervention such
as AVR or percutaneous aortic balloon dilation before
conception. Although there are no data on the prognostic
value of other ﬁndings on exercise testing before pregnancy,
high-risk parameters on exercise testing for nonpregnant
patients include a limited exercise tolerance or a drop in BP.
Supporting References: (46,47,117,793,794)
13.1.2. Medical Therapy: Recommendations
CLASS I
1. Anticoagulation should be given to pregnant patients with MS
and AF unless contraindicated. (Level of Evidence: C)
Systemic embolization may occur in up to 10% to 20%
of patients with MS, with the highest risk in patients
with AF. One third of embolic events occur within the
ﬁrst month of the onset of AF. Anticoagulation will result
in a 4– to 15–fold decrease in the incidence of embolic
events in nonpregnant patients. Pregnancy is associated
with a hypercoagulable state and is expected to further
increase the risk of thromboembolic events. Therefore, all
patients with MS and AF should receive antithrombotic
therapy. Warfarin is the most effective anticoagulant
regimen in the second and third trimester. These patients
should then be converted to continuous infusion of UFH
before planned delivery. The optimal anticoagulation
regimen during the ﬁrst trimester remains controversial
and is discussed further in the prosthetic valve and preg-
nancy section (Section 13.3.2).
Supporting References: (310,316,796,797)
CLASS IIa
1. Use of beta blockers as required for rate control is reasonable
for pregnant patients with MS in the absence of contraindica-
tion if tolerated. (Level of Evidence: C)
In patients with MS, the shortening of the diastolic
ﬁlling period with the increased heart rate of pregnancy
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mitral valve level. If stenosis is only mild to moderate, the
increase in cardiac output further exacerbates the rise in
LA pressure. If MS is severe, the normal rise in cardiac
output may be blunted due to the short diastolic ﬁlling
period across a small mitral oriﬁce. Therapy targeted at
reducing heart rate allows a longer diastolic ﬁlling period
with an improvement in forward cardiac output and re-
duction in LA pressure. After the ﬁrst trimester, restricting
physical activity helps with heart rate control. In addition,
beta-blocker medications are relatively safe for both the
mother and the fetus. The use of beta blockers with beta-1
selectivity is preferred because the beta-2 effects on uterine
relaxation are avoided. Metoprolol has a lower incidence
of fetal growth retardation than atenolol and is the pre-
ferred beta blocker for use in pregnancy.
Supporting References: (794,798–801)
CLASS IIb
1. Use of diuretics may be reasonable for pregnant patients with
MS and HF symptoms (stage D). (Level of Evidence: C)
Diuretics may be helpful in reducing elevated LA
pressure in patients with MS who become symptomatic.
However, they should be used with caution due to the
potential for reducing placental perfusion.
Supporting Reference: (793)
CLASS III: Harm
1. ACE inhibitors and ARBs should not be given to pregnant patients
with valve stenosis (802–804). (Level of Evidence: B)
ACE inhibitors and ARBs are contraindicated during
pregnancy due to fetal toxicity, including renal or tubular
dysplasia, oligohydramnios, growth retardation, ossiﬁca-
tion disorders of the skull, lung hypoplasia, and intra-
uterine fetal death. If a patient with valve stenosis is taking
1 of these medications for any reason, it should be dis-
continued or replaced with an alternate medication before
conception.
Supporting References: (802–804)
13.1.3. Intervention: Recommendations
CLASS I
1. Valve intervention is recommended before pregnancy for
symptomatic patients with severe AS (aortic velocity ‡4.0 m
per second or mean pressure gradient ‡40 mm Hg, stage D).
(Level of Evidence: C)
Patients with severe AS are at high risk for complica-
tions during the hemodynamic stress of pregnancy. Early
studies demonstrated a very poor outcome for patients
with severe AS who become pregnant, with a maternal
mortality rate of 17% and fetal and neonatal mortality rate
of 32%. Subsequent studies reported better outcomes, but
there is still a 3% to 10% risk of complication of HF and
up to a 25% risk of arrhythmia. In addition, sudden
deterioration and even death may occur, despite meticu-
lous medical care during pregnancy and delivery. Fetalcomplications, including preterm birth, intrauterine
growth retardation, and low birth weight occur in up to
25% of pregnant women with moderate and severe AS.
The severity of stenosis and presence of symptoms are
predictors of poor outcomes during pregnancy in patients
with AS. Valve intervention is recommended for all pa-
tients with severe symptomatic AS, regardless of whether
or not pregnancy is being contemplated. Women with
symptomatic severe AS who wish to become pregnant
should have a valve intervention before conception to
prevent the possible devastating consequences of progres-
sive or sudden deterioration during pregnancy and delivery.
Percutaneous aortic balloon dilation may be considered in
patients with noncalciﬁed bicuspid aortic valves, with the
understanding that restenosis may occur within several
years of the procedure. AVR may also be considered before
pregnancy, after a detailed discussion with the patient
about the risks and beneﬁts of a bioprosthetic versus a
mechanical valve.
Supporting References: (792,805–810)
CLASS I
2. Valve intervention is recommended before pregnancy for
symptomatic patients with severe MS (mitral valve area £1.5
cm2, stage D). (Level of Evidence: C)
Patients with severe MS (mitral valve area 1.5 cm2)
are at increased risk for complications during pregnancy.
The increased blood volume, heart rate, and cardiac
output will more than double the transmitral gradient,
signiﬁcantly increasing LA pressure. Up to 74% of pa-
tients with severe MS will have clinical deterioration
during pregnancy, manifested primarily by HF symptoms
and atrial arrhythmias. The predictors of poor outcome
are severity of the stenosis and symptoms before preg-
nancy. Maternal mortality is uncommon but does occur
with severe symptoms and critical MS. Fetal outcome is
also dependent on the severity of stenosis and symptoms.
The rate of premature delivery is 14% in patients with
mild MS and up to 33% in patients with severe MS. If
severe symptoms develop, there is a 30% risk of fetal
mortality. These complications can be minimized by
relief of MS before pregnancy. When valve morphology
is favorable, percutaneous mitral balloon commissur-
otomy is the preferred intervention. In patients with
calciﬁed immobile valves and subvalvular fusion, the
choice between therapeutic intervention using percuta-
neous mitral balloon commissurotomy, surgical commis-
surotomy, or MVR should be made based on institutional
experience.
Supporting References: (792,809–813)
CLASS I
3. Percutaneous mitral balloon commissurotomy is recommended
before pregnancy for asymptomatic patients with severe MS
(mitral valve area £1.5 cm2, stage C) who have valve
morphology favorable for percutaneous mitral balloon commis-
surotomy. (Level of Evidence: C)
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performed with a high rate of success and low rate of
complications in patients with valve anatomy amenable to
this procedure. There is a high rate of clinical deteriora-
tion that occurs in patients with severe MS during the
hemodynamic changes of pregnancy. There is also a high
rate of compromised fetal outcome, including growth
retardation, prematurity, and low birth weight, which
has subsequent consequences on infant morbidity, infant
mortality, and patient cardiovascular disease. If valve
anatomy is suitable for commissurotomy, percutaneous
mitral balloon commissurotomy should be performed in
patients with severe MS before conception, even in the
absence of symptoms.
Supporting References: (809–814)
CLASS IIa
1. Valve intervention is reasonable before pregnancy for asymp-
tomatic patients with severe AS (aortic velocity ‡4.0 m per
second ormean pressure gradient‡40mmHg, stageC). (Level of
Evidence: C)
Most patients with mild-to-moderate AS can tolerate the
hemodynamic changes of pregnancy without adverse car-
diovascular events. However, patients with severe AS are at
an increased risk for complications, with HF developing in
10% to 44% of patients and arrhythmias in up to 25%, even if
they were asymptomatic before pregnancy. Progressive as
well as sudden deterioration may occur in patients with se-
vere AS during pregnancy and delivery. There is also an
increased incidence of hypertensive emergencies that occur
during pregnancy in patients with severeAS, possibly related
to poor placental perfusion. Fetal outcomes are also worse in
patients with severe AS. These adverse outcomes can be
minimized by relief of AS. Percutaneous aortic balloon
dilation may be considered in patients with noncalciﬁed
congenital AS, with the understanding that restenosis may
occur within several years of the procedure. When anatomy
is not suitable for balloon aortic dilation, AVR may be
considered before pregnancy, after a detailed discussion with
the patient about the risks and beneﬁts of a bioprosthetic
versus a mechanical valve.
Supporting References: (805–810)
CLASS IIa
2. Percutaneous mitral balloon commissurotomy is reasonable for
pregnant patients with severe MS (mitral valve area £1.5 cm2,
stage D) with valve morphology favorable for percutaneous
mitral balloon commissurotomy who remain symptomatic with
NYHA class III to IV HF symptoms despite medical therapy
(157,815–818). (Level of Evidence: B)
Patients with severe MS have a high probability of
developing progressive symptoms during the hemody-
namic changes of pregnancy, particularly during the second
and third trimesters. Percutaneous mitral balloon com-
missurotomy has been performed successfully in pregnant
patients with severe MS, primarily in those who have ananatomy that is amenable to this intervention. Although
the risk of complications is low, there is still a risk of severe
MR requiring urgent MVR. This procedure should be
reserved only for those patients who remain symptomatic
with NYHA class III to IV HF symptoms after initial
therapy with bed rest, beta blockade, and diuretics.
Percutaneous mitral balloon commissurotomy should
preferably be performed after 20 weeks of gestation, the
period safest for the fetus. Percutaneous mitral balloon
commissurotomy during pregnancy should only be per-
formed by experienced operators who have a demonstrated
low complication rate, minimizing radiation dose to the
mother and fetus. The procedure should also be done with
back-up cardiac surgery, anesthesiology, and high-risk
obstetrics services in place.
Supporting References: (157,815–818)
CLASS IIa
3. Valve intervention is reasonable for pregnant patients with se-
vere MS (mitral valve area £1.5 cm2, stage D) and valve
morphology not favorable for percutaneous mitral balloon com-
missurotomy only if there are refractory NYHA class IV HF
symptoms. (Level of Evidence: C)
Patients with severe MS and unfavorable valve
morphology (i.e., severe leaﬂet calciﬁcation, leaﬂet thick-
ening, immobility, subvalvular fusion, and commissural
calciﬁcation) are at high risk for percutaneous mitral
balloon commissurotomy. In these patients, the percuta-
neous approach may be complicated by severe MR
requiring emergency MVR. Although percutaneous
balloon mitral commissurotomy remains an option, MVR
under controlled surgical conditions is the safest approach
in this subgroup of patients. However, valve operation
during pregnancy is high risk, with a 30% to 40% fetal
mortality rate and up to 9% maternal mortality rate. Sur-
gery for MS during pregnancy should be reserved for those
with refractory NYHA class IV HF symptoms that are not
responsive to medical therapy. The operation needs to be
carefully planned with a Heart Valve Team of cardiologists,
cardiovascular anesthesiologists, surgeons, and obstetri-
cians specializing in high-risk obstetrics to determine
optimal timing and sequence of therapies. High pump
ﬂows and normothermic perfusion should be used to
protect the fetus during cardiopulmonary bypass, with the
shortest pump time possible. Continued monitoring of the
fetus should be performed. There is no ideal time during
pregnancy to perform open heart surgery, so timing is
based on the combination of the clinical status of the
mother and the fetus. The period between the 20th and
28th weeks of pregnancy appears to be safest for the fetus
in terms of risk of malformation and premature delivery. If
the mother can carry the fetus to full maturity, a combined
cesarean section followed by cardiac surgery can be
planned.
Supporting References: (816,819–822)
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4. Valve intervention is reasonable for pregnant patients with se-
vere AS (mean pressure gradient ‡40 mm Hg, stage D) only if
there is hemodynamic deterioration or NYHA class III to IV HF
symptoms (805,823–828). (Level of Evidence: B)
Patients with severe AS may develop progressive HF or
sudden hemodynamic deterioration during the hemody-
namic stress of pregnancy. Medical therapy is of limited
efﬁcacy, as the AS is a ﬁxed mechanical obstruction. Both
open heart surgery and percutaneous aortic balloon dilation
are high-risk procedures during pregnancy for both the
mother and the fetus and should only be performed
if there is hemodynamic deterioration or severe NYHA
class III to IV HF symptoms. The type of intervention
(AVR or percutaneous aortic balloon dilation) will be
dependent on the expertise of the center but the inter-
vention should always be performed in a center with a
multidisciplinary group of cardiologists, interventionalists,
cardiac anesthesiologists, and obstetricians specializing in
high-risk obstetrics.
There have been reports of successful percutaneous
aortic balloon dilation during pregnancy. This procedure
has better results in patients with the noncalciﬁed bicuspid
aortic valve but may result in severe AR due to a tear in an
aortic valve cusp. Limited ﬂuoroscopy time with appro-
priate lead shielding of the fetus is necessary. Intervention
is preferable after 20 weeks of gestation because it is safer
for the fetus. Percutaneous aortic balloon dilation should
only be performed by highly experienced operators in
centers with a competent team of cardiologists and car-
diovascular anesthesiologists, with back-up cardiac surgery
and high-risk obstetrics services in place.
AVR may also be considered. High pump ﬂows and
normothermic perfusion should be used to protect the fetus
during cardiopulmonary bypass, with the shortest pump
time possible. Continued monitoring of the fetus should be
performed. There is no ideal time during pregnancy to
perform open heart surgery, so timing is based on the
combination of the clinical status of the mother and the
fetus. The period between the 20th and 28th weeks of
pregnancy appears to be safest for the fetus in terms of risk
of malformation and premature delivery. If the mother can
carry the fetus to full maturity, a combined cesarean section
followed by cardiac operation can be planned.
Percutaneous aortic balloon dilation and AVR pro-
cedures need to be carefully planned with a Heart Valve
Team of cardiologists, cardiovascular anesthesiologists,
surgeons, and obstetricians specializing in high-risk ob-
stetrics to determine optimal timing and sequence of
therapies.
Supporting References: (805,816,819–828)
CLASS III: Harm
1. Valve operation should not be performed in pregnant patients
with valve stenosis in the absence of severe HF symptoms.
(Level of Evidence: C)Valve surgery during pregnancy is high risk, with a 30%
to 40% fetal mortality rate and up to 9% maternal mortality
rate reported. It should be reserved only for patients with
severe, intractable symptoms unresponsive to bed rest and
medical therapy.
Supporting References: (816,819–822)13.2. Native Valve Regurgitation
13.2.1. Diagnosis and Follow-Up: Recommendations
CLASS I
1. All patients with suspected valve regurgitation should undergo a
clinical evaluation and TTE before pregnancy. (Level of Evidence: C)
Patients with valve regurgitation tolerate pregnancy
better than do patients with valve stenosis because the
decrease in afterload that occurs throughout pregnancy
allows an appropriate increase in cardiac output without a
rise in ventricular ﬁlling pressures. However, patients with
severe regurgitation who are already symptom limited or
have a reduced LVEF or pulmonary hypertension may
develop HF symptoms because of the volume load of
pregnancy. Clinical and TTE evaluation before pregnancy
allow determination of the cause of regurgitation, quanti-
tation of regurgitant severity, measurement of LVEF, and
estimation of pulmonary pressures so that patients at high
risk can be identiﬁed.
Supporting References: (792–794,810,829–834)
CLASS I
2. All patients with severe valve regurgitation (stages C and D)
should undergo prepregnancy counseling by a cardiologist with
expertise in managing patients with VHD during pregnancy.
(Level of Evidence: C)
The management of patients with valve regurgitation
should ideally begin before conception. A complete
assessment of functional capacity, severity of regurgita-
tion, pulmonary pressures, and LV size and function are
necessary to determine the risk of pregnancy and delivery
in patients with valve regurgitation. The risks and ben-
eﬁts of proceeding with pregnancy must be fully dis-
cussed with the patient. Interventions before pregnancy
may be considered in the patient with severe regurgita-
tion who is at high risk for developing HF during
pregnancy, particularly if the valve can be repaired
instead of replaced. Drugs with potential harmful effects
on the fetus must be identiﬁed. If pregnancy is
contemplated, arrangements should be made for the
patient to be monitored in a tertiary care center with a
dedicated Heart Valve Team of cardiologists, surgeons,
anesthesiologists, and obstetricians with expertise in
managing high-risk cardiac patients. Counseling
regarding all these areas should be performed by a
cardiologist with expertise in managing patients with
VHD during pregnancy.
Supporting References: (792–794,810,834)
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3. All patients referred for a valve operation before pregnancy
should receive prepregnancy counseling by a cardiologist with
expertise in managing patients with VHD during pregnancy
regarding the risks and beneﬁts of all options for operative in-
terventions, including mechanical prosthesis, bioprosthesis,
and valve repair. (Level of Evidence: C)
When intervention is indicated, valve repair is preferred
for the treatment of valve regurgitation in women of child-
bearing age. However, not all valves can be adequately
repaired, and the decision to proceed with implantation of a
prosthetic valve is sometimes made at the time of operation.
All prosthetic valve types pose major problems during
pregnancy. Mechanical prostheses require continued anti-
coagulation throughout pregnancy, with risks to both the
mother and the fetus. Bioprostheses have a limited life span,
particularly in the younger patient, and controversy persists
as to whether there is acceleration of valve degeneration
during pregnancy. All patients of childbearing age being
considered for a valve operation should receive prepregnancy
counseling by a cardiologist with expertise in managing
patients with VHD during pregnancy to discuss the risks
and beneﬁts of available treatment options.
Supporting References: (793,795,810,834)
CLASS I
4. Pregnant patients with severe regurgitation (stages C and D)
should be monitored in a tertiary care center with a dedicated
Heart Valve Team of cardiologists, surgeons, anesthesiologists,
and obstetricians with expertise in managing high-risk cardiac
patients. (Level of Evidence: C)
Patients with severe regurgitation may be at high risk
during pregnancy. The risk increases throughout pregnancy,
given the continued physiological hemodynamic changes,
including increased volume, decreased afterload, and
increased heart rate. Pulmonary edema, arrhythmias, and
even maternal death may occur. The presence of severe valve
regurgitation is also associated with an increased risk to the
fetus. Timing and mode of delivery should be discussed and
carried out by the Heart Valve Team, with close hemody-
namic monitoring during and up to 24 hours after delivery.
Management at a tertiary care center with a dedicated Heart
Valve Team of cardiologists, surgeons, anesthesiologists, and
obstetricians who have expertise in the care of high-risk
cardiac patients will ensure optimal maternal and fetal out-
comes in women with severe valve regurgitation.
Supporting References: (792–794,810,834)
CLASS IIa
1. Exercise testing is reasonable in asymptomatic patients with
severe valve regurgitation (stage C) before pregnancy. (Level of
Evidence: C)
Asymptomatic patients with severe valve regurgitation
usually tolerate the hemodynamic changes of pregnancy,
unless there is concurrent ventricular systolic dysfunction
or pulmonary hypertension. Exercise testing may identify
apparently asymptomatic patients at higher risk ofcomplications during pregnancy. Exercise parameters
suggesting a higher risk include limited exercise tolerance,
exercise-induced pulmonary hypertension, or abnormal
symptoms. Patients with symptoms provoked by exercise
testing should be considered symptomatic.
Supporting References: (793,810,834)
13.2.2. Medical Therapy: Recommendation
CLASS III: Harm
1. ACE inhibitors and ARBs should not be given to pregnant pa-
tients with valve regurgitation (802–804). (Level of Evidence: B)
ACE inhibitors and ARBs are contraindicated during
pregnancy due to fetal toxicity, including renal or tubular
dysplasia, oligohydramnios, growth retardation, ossiﬁca-
tion disorders of the skull, lung hypoplasia, and intra-
uterine fetal death. If a patient with valvular regurgitation
is taking 1 of these medications for any reason, it should be
discontinued or replaced with an alternate medication
before conception.
Supporting References: (802–804)
13.2.3. Intervention: Recommendations
CLASS I
1. Valve repair or replacement is recommended before pregnancy for
symptomatic women with severe valve regurgitation (stage D).
(Level of Evidence: C)
Symptomatic women with severe valve regurgitation are
at high risk for developing HF during pregnancy. All pa-
tients with symptomatic severe valve regurgitation should
undergo surgery to repair or replace the valve, regardless of
whether they wish to become pregnant. The operation will
improve long-term outcomes and prevent progressive
ventricular dysfunction from the long-standing volume
overload. Although the ideal operation would be valve
repair, not all valves can be successfully repaired. Potential
problems associated with the different types of prosthetic
valves during pregnancy must be discussed in detail with all
women before operation.
Supporting References: (793,810,834)
CLASS IIa
1. Valve operation for pregnant patients with severe valve regur-
gitation is reasonable only if there are refractory NYHA class IV
HF symptoms (stage D). (Level of Evidence: C)
Valve operation during pregnancy is high risk for both
the mother and the fetus, with a 30% to 40% fetal mor-
tality rate and up to 9% maternal mortality rate reported.
Thus, it should be reserved for the very rare patient with
severe valve regurgitation who has severe refractory HF
symptoms. The operation needs to be carefully planned
with the multidisciplinary Heart Valve Team of cardiol-
ogists, cardiovascular anesthesiologists, surgeons, and
high-risk obstetricians to determine optimal timing and
sequence of therapies. High pump ﬂows and normo-
thermic perfusion should be used to protect the fetus
during cardiopulmonary bypass, with the shortest pump
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be performed. There is no ideal time during pregnancy to
perform open heart surgery, so timing is based on the
combination of the clinical status of the mother and the
fetus. The period between the 20th and 28th weeks of
pregnancy appears to be safest for the fetus in terms of
risk of malformation and premature delivery. If the
mother can carry the fetus to full maturity, a combined
cesarean section followed by cardiac operation can be
planned.
Supporting References: (819–822)
CLASS IIb
1. Valve repair before pregnancy may be considered in the
asymptomatic patient with severe MR (stage C) and a valve
suitable for valve repair, but only after detailed discussion with
the patient about the risks and beneﬁts of the operation and
its outcome on future pregnancies. (Level of Evidence: C)
The threshold for valve operation for valve regurgitation
should be higher in the asymptomatic patient who wants
to become pregnant as opposed to conventional criteria in
patients who are not likely to become pregnant. Although
a successful mitral valve repair will result in a low-risk
pregnancy and delivery, not all valves can be successfully
repaired with complete certainty. If surgery is undertaken
and valve repair is unsuccessful, the implantation of a
mitral valve prosthesis increases the risks during preg-
nancy, regardless of whether a mechanical or bioprosthetic
valve is used. Most patients with asymptomatic severe MR
tolerate pregnancy, and there is no evidence for accelera-
tion of LV dysfunction during pregnancy. Thus, it may be
prudent to manage these patients medically rather than
recommending valve surgery before pregnancy. In patients
with MR who are at higher risk for the development of
HF during pregnancy, including those with depressed LV
systolic function or pulmonary hypertension (pulmonary
artery systolic pressure >50 mm Hg), the decision to
operate before pregnancy should take into consideration
the mitral valve morphology, chance of successful repair in
the institution, estimated surgical risk, and issues related
to possible MVR. This may require referral to a Heart
Valve Center of Excellence if the expected rate of a suc-
cessful and durable valve repair at the institution does not
exceed 95%.
Supporting References: (793,810,834)
CLASS III: Harm
1. Valve operations should not be performed in pregnant patients
with valve regurgitation in the absence of severe intractable HF
symptoms. (Level of Evidence: C)
Valve surgery during pregnancy is high risk, with a 30%
to 40% fetal mortality rate and up to 9% maternal mortality
rate reported. It should be reserved only for patients with
severe, intractable symptoms unresponsive to bed rest and
medical therapy.
Supporting References: (819–822)13.3. Prosthetic Valves in Pregnancy
13.3.1. Diagnosis and Follow-Up: Recommendations
CLASS I
1. All patients with a prosthetic valve should undergo a clinical eval-
uation and baseline TTE before pregnancy. (Level of Evidence: C)
Major complications can occur during pregnancy in pa-
tients with prosthetic valves. The increased hemodynamic
burden of pregnancy can lead to HF if there is prosthetic
valve thrombosis, stenosis, regurgitation, or patient-
prosthesis mismatch. Clinical evaluation and baseline
TTE allow determination of valve function and hemody-
namics under normal loading conditions and help identify
valve dysfunction that might require treatment before
pregnancy. In addition, there is an increased risk of valve
thrombosis in patients with a mechanical prosthesis due
to the hypercoagulable state of pregnancy. The baseline
TTE serves as the reference standard for the patient if
valve thrombosis is suspected during pregnancy.
Supporting References: (793,795)
CLASS I
2. All patients with a prosthetic valve should undergo prepreg-
nancy counseling by a cardiologist with expertise in managing
patients with VHD during pregnancy. (Level of Evidence: C)
The management of the pregnant patient with a pros-
thetic valve may signiﬁcantly differ from that of the patient
who is not pregnant, speciﬁcally in relation to antith-
rombotic therapy. There is a much higher risk of valve
thrombosis for patients with a mechanical prosthesis due
to the hypercoagulable state of pregnancy. Certain drugs
are contraindicated during pregnancy. Prepregnancy coun-
seling by a cardiologist with expertise in managing patients
with VHD during pregnancy should be performed to
determine the risk of pregnancy, discuss potential com-
plications, and outline an approach for anticoagulation at
the time of conception.
Supporting References: (793,795)
CLASS I
3. TTE should be performed in all pregnant patients with a pros-
thetic valve if not done before pregnancy. (Level of Evidence: C)
Although it is preferable to perform a baseline echo-
cardiogram before pregnancy in women with prosthetic
heart valves, if a baseline study is not available during the
time the patient has been clinically stable, TTE during
pregnancy still provides evaluation of prosthetic valve
function, as well as ventricular function and pulmonary
pressures. Due to an increase in cardiac output that
occurs during pregnancy, the mean pressure gradient
across all prostheses will increase throughout the ﬁrst
and second trimesters and remain elevated in the third
trimester. Other hemodynamic parameters such as dia-
stolic half-time (for a mitral prosthesis) and dimen-
sionless index (the ratio of the LV outﬂow time velocity
divided by the peak aortic valve velocity for an aortic
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prosthesis.
Supporting References: (793,795)
CLASS I
4. Repeat TTE should be performed in all pregnant patients with a
prosthetic valve who develop symptoms. (Level of Evidence: C)
If there are changes in clinical status with either the
onset of symptoms of dyspnea or change in the clinical
examination, a repeat echocardiogram is indicated to look
for changes in ventricular function and in the hemody-
namics of the prosthetic valve. Bioprosthetic valves are at
risk for tissue degeneration; bioprosthetic valve stenosis
typically develops slowly, but bioprosthetic regurgitation
may be acute due to a leaﬂet tear adjacent to an area of
calciﬁcation. Mechanical valves are prone to acute stenosis
or regurgitation during pregnancy due to valve thrombosis
limiting disc opening or closure. TTE should be performed
initially because both aortic and mitral transvalvular ﬂows
can be recorded from this approach. However, TEE is
needed if prosthetic MR is suspected. Although radiation
exposure should be minimized, ﬂuoroscopy of mechanical
valves may be helpful in evaluating disc motion.
Supporting References: (793,795)
CLASS I
5. TEE should be performed in all pregnant patients with a me-
chanical prosthetic valve who have prosthetic valve obstruction
or experience an embolic event. (Level of Evidence: C)
If thrombotic obstruction is suspected or if an embolic
event occurs in a pregnant patient with a mechanical
prosthesis, TEE is indicated to look at valve function
and disc motion and to determine the thrombus burden.
Subsequent therapeutic decisions will depend on the
clinical state of the patient, gestational age of the child,
degree of valve dysfunction, and thrombus burden. TEE
is especially important for detection of prosthetic mitral
valve dysfunction, and an apparently normal trans-
thoracic study should not dissuade clinicians from pro-
ceeding with TEE. With a prosthetic aortic valve, both
TTE and TEE are needed for a complete examination.
Chest CT imaging can also diagnose prosthetic valve
thrombosis and limitations of mechanical valve motion
but should be avoided during pregnancy due to radiation
exposure.
Supporting References: (605,793,795,835–837)
CLASS I
6. Pregnant patients with a mechanical prosthesis should be
monitored in a tertiary care center with a dedicated Heart Valve
Team of cardiologists, surgeons, anesthesiologists, and obste-
tricians with expertise in the management of high-risk cardiac
patients. (Level of Evidence: C)
Women with mechanical valves are at high risk of
devastating complications during pregnancy. There is an
increased risk for thrombosis of mechanical valves due
to the hypercoagulable state of pregnancy, particularlythose with a prosthetic valve in the mitral position. Anti-
coagulation regimens to prevent valve thrombosis require
in-depth knowledge of the risks and beneﬁts of each
approach. Valve thrombosis may result in acute, severe HF
and/or embolic events, with a high-resultant maternal and
fetal mortality. The occurrence of valve thrombosis during
pregnancy constitutes a medical and sometimes surgical
emergency. Integrated care by a Heart Valve Team of
cardiologists, surgeons, anesthesiologists, and obstetricians
with expertise in the management of high-risk cardiac
patients is needed.
Supporting References: (793,795)
13.3.2. Medical Therapy: Recommendations
See Figure 10 for anticoagulation of pregnant patients with
mechanical valves.
CLASS I
1. Therapeutic anticoagulation with frequent monitoring is rec-
ommended for all pregnant patients with a mechanical pros-
thesis (838,839). (Level of Evidence: B)
There is a high risk of valve thrombosis in patients with
mechanical prostheses who are pregnant due to the hy-
percoagulable state that occurs during pregnancy. All
anticoagulant regimens carry an increased risk to the fetus,
with fetal abnormalities, an increased risk of miscarriage,
and hemorrhagic complications, including retroplacental
bleeding, leading to premature birth and fetal death.
However, without any anticoagulation, maternal mortality
is high (up to 5%), and there is a high risk of thrombo-
embolic events (up to 24%) and valve thrombosis. Because
of the physiological effects of pregnancy, there are con-
stantly changing requirements for antithrombotic regi-
mens. Effective anticoagulation with frequent monitoring
of its systemic effect is critical throughout the pregnancy.
Supporting References: (838,839)
See Online Data Supplement 25 for more information on
pregnancy.
CLASS I
2. Warfarin is recommended in pregnant patients with a mechanical
prosthesis to achieve a therapeutic INR in the second and third
trimesters (840–845). (Level of Evidence: B)
Warfarin is the most effective anticoagulant for pre-
venting maternal thromboembolic events during preg-
nancy. Although warfarin has potential fetal teratogenic
effects in the ﬁrst trimester, there is little teratogenic effect
in the second and third trimesters. Use of UFH
throughout pregnancy has the highest risk of thrombo-
embolic events and maternal death in patients with a
mechanical prosthesis, with reported instances of mas-
sive thrombosis of prosthetic valves. Although there are
no RCTs comparing the different antithrombotic regi-
mens, the risk of thromboembolic events using warfarin
throughout pregnancy is <4%, compared with 33% with
the use of UFH throughout pregnancy. Use of UFH
throughout pregnancy is also associated with maternal
Figure 10. Anticoagulation of Pregnant Patients With Mechanical Valves
aPTT indicates activated partial thromboplastin time; ASA, aspirin; INR, international normalized ratio; LMWH, low-molecular-weight heparin; QD, once daily; and UFH,
unfractionated heparin.
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LMWH given at a ﬁxed dose has resulted in fatal valve
thrombosis. When monitored with anti-Xa levels, LMWH
has a lower rate of valve thrombosis compared with UFH.
Even with meticulous monitoring of anti-Xa levels, there
have been cases of valve thrombosis with LMWH used
throughout pregnancy. There is no ideal anticoagulant
regimen for pregnant women with mechanical valves.
However, during the second and third trimesters of preg-
nancy, the beneﬁts of warfarin for the mother appear
to outweigh the slightly increased risk to the fetus.
Supporting References: (838,840–847)
See Online Data Supplements 25 and 26 for more infor-
mation on pregnancy.
CLASS I
3. Discontinuationofwarfarinwith initiation of intravenousUFH (with
an activated partial thromboplastin time [aPTT] >2 times control)
is recommended before planned vaginal delivery in pregnant
patients with a mechanical prosthesis. (Level of Evidence: C)Warfarin crosses the placental barrier and results in
anticoagulation of the fetus as well as the mother. There is a
higher risk of intracranial hemorrhage for the fetus if the
mother is fully anticoagulated during vaginal delivery. It is
recommended that the mother be hospitalized before plan-
ned delivery with discontinuation of warfarin and initiation
of intravenous continuous infusion of UFH to keep aPTT
>2 times control levels. Then heparin is stopped just before
delivery. Patients with mechanical prostheses are at
increased risk for premature labor, so careful planning with a
Heart Valve Team of cardiologists, anesthesiologists, and
obstetricians is required before anticipated delivery. Alter-
native approaches to delivery include elective cesarean sec-
tion after a shorter cessation of warfarin.
Supporting References: (848,849)
CLASS I
4. Low-doseaspirin (75mg to100mg)onceper day is recommended
for pregnantpatients in the secondand third trimesterswitheither
a mechanical prosthesis or bioprosthesis. (Level of Evidence: C)
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aspirin to anticoagulation in pregnant patients with pros-
thetic valves, the addition of aspirin is effective in lowering
the thromboembolic risk in nonpregnant patients. Aspirin
is safe in the second and third trimesters of pregnancy from
the obstetric standpoint.
Supporting References: (567,568,850)
CLASS IIa
1. Continuation of warfarin during the ﬁrst trimester is reasonable
for pregnant patients with a mechanical prosthesis if the dose
of warfarin to achieve a therapeutic INR is 5 mg per day or less
after full discussion with the patient about risks and beneﬁts
(838,839,844,845,848,851). (Level of Evidence: B)
The optimal anticoagulant used during the ﬁrst
trimester in pregnant patients with mechanical prosthetic
valves remains controversial. Oral anticoagulation with
warfarin is the safest regimen for the mother, but there is
an increased risk of embryopathy. Anticoagulation with
UFH or LMWH has been recommended to avoid the risk
of embryopathy, but it is not as effective as warfarin in
preventing thromboembolic events. The risk of embryop-
athy is dose dependent, with a low risk (<3%) if the
dose of warfarin is 5 mg per day. The risk of abortion
and fetal loss are increased with any anticoagulant regimen
but may be similar in women exposed to oral anticoagu-
lants versus heparin in the ﬁrst trimester, especially at low
doses of warfarin. Continuation of warfarin during the ﬁrst
trimester is reasonable after a full discussion with the pa-
tient and family about the risks and beneﬁts when a
therapeutic INR can be maintained with a daily warfarin
dose of 5 mg.
Supporting References: (838,839,844,845,848,851–854)
See Online Data Supplements 25 and 26 for more infor-
mation on pregnancy.
CLASS IIa
2. Dose-adjusted LMWH at least 2 times per day (with a target
anti-Xa level of 0.8 U/mL to 1.2 U/mL, 4 to 6 hours post-
dose) during the ﬁrst trimester is reasonable for pregnant
patients with a mechanical prosthesis if the dose of warfarin
is greater than 5 mg per day to achieve a therapeutic INR
(840–843,855,856). (Level of Evidence: B)
In patients whose dosage of warfarin is >5 mg per day,
the risk of embryopathy is >8% (compared with <3%
with a warfarin dosage of 5 mg per day). It is reasonable
to consider heparin anticoagulation instead of warfarin
during the ﬁrst trimester of pregnancy, because heparin
does not cross the placental barrier and is not associated
with fetal embryopathy. LMWH may be a better alter-
native than UFH with potential advantages of better
subcutaneous absorption and bioavailability, longer half-
life, and a more predictable anticoagulation response.
Anti-Xa levels should be monitored because dosage re-
quirements may increase by as much as 50% over the
course of pregnancy. The target anti-Xa level should be0.8 U/mL to 1.2 U/mL, measured 4 to 6 hours after in-
jection. With use of this meticulous dosing regimen, the
incidence of valve thrombosis is lower than with UFH,
but there are still reports of valve thrombosis, even with
the newer-generation mechanical prostheses. The data
for use of LMWH in pregnancy are incomplete, with
unresolved questions to be addressed, including optimal
anti-Xa levels, use of peak and trough levels, optimal
timing of dosage, and compliance issues with dosing
2 times a day and sometimes 3 times a day. If the patient
chooses not to be on an oral anticoagulant in the ﬁrst
trimester, dose-adjusted LMWH is a reasonable choice of
anticoagulation.
Supporting References: (840–843,846,855–857)
See Online Data Supplements 25 and 26 for more infor-
mation on pregnancy.
CLASS IIa
3. Dose-adjusted continuous intravenous UFH (with an aPTT at
least 2 times control) during the ﬁrst trimester is reasonable for
pregnant patients with a mechanical prosthesis if the dose of
warfarin is greater than 5 mg per day to achieve a therapeutic
INR (838,839,848). (Level of Evidence: B)
If the decision is made to use UFH during the ﬁrst
trimester of pregnancy, it is reasonable that the patient
receive a continuous infusion of heparin, with carefully
monitoring of aPTT and a goal of at least 2 times control.
Prior studies have shown that the use of subcutaneous
UFH is associated with a high incidence of valve throm-
bosis, especially with older-generation valve prostheses.
Disadvantages of intravenous UFH include an increased
risk of serious infection and a risk of osteoporosis.
Supporting References: (838,839,848)
See Online Data Supplements 25 and 26 for more infor-
mation on pregnancy.
CLASS IIb
1. Dose-adjusted LMWH at least 2 times per day (with a target
anti-Xa level of 0.8 U/mL to 1.2 U/mL, 4 to 6 hours postdose)
during the ﬁrst trimester may be reasonable for pregnant pa-
tients with a mechanical prosthesis if the dose of warfarin is 5
mg per day or less to achieve a therapeutic INR (840–843,855–
857). (Level of Evidence: B)
The choice of type of anticoagulation during the ﬁrst
trimester requires a detailed discussion with the patient
about the risks and beneﬁts of the different regimens. The
use of warfarin during the ﬁrst trimester is associated
with an increased risk of warfarin embryopathy, but the
risk is low (<3%) if the daily dose of warfarin is 5 mg.
The use of heparin will avoid the risk of embryopathy
but is associated with an increased risk of valve thrombo-
sis and embolic events. If the patient decides not to
continue warfarin during the ﬁrst trimester, after a full
discussion of the risks and beneﬁts of the different regi-
mens, dose-adjusted LMWH appears to be the safest
choice in terms of prevention of thromboembolic events.
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Xa levels, as dosing requirements change throughout
pregnancy. The recommended target is an anti-Xa level of
0.8 U/mL to 1.2 U/mL at 4 to 6 hours postdose, given at
least 2 times a day.
Supporting References: (840–843,846,855–857)
See Online Data Supplements 25 and 26 for more infor-
mation on pregnancy.
CLASS IIb
2. Dose-adjusted continuous infusion of UFH (with aPTT at least 2
times control) during the ﬁrst trimester may be reasonable for
pregnant patients with a mechanical prosthesis if the dose of
warfarin is 5 mg per day or less to achieve a therapeutic INR
(838,839,848). (Level of Evidence: B)
If the patient on a dose of warfarin 5 mg per day
decides not to continue warfarin during the ﬁrst trimester,
after a full discussion of the risks and beneﬁts of the
different regimens, dose-adjusted LMWH appears to be
the safest choice in terms of prevention of thromboembolic
events. If the decision is made to use UFH during the ﬁrst
trimester of pregnancy, it is reasonable that the patient
receive a continuous infusion of heparin, with careful
monitoring of aPTT with a goal of at least 2 times control.
Subcutaneous UFH is associated with a high incidence
of valve thrombosis, especially with the older-generation
valve prostheses. Intravenous UFH is associated with an
increased risk of infection from the prolonged use of
intravenous catheters and a risk of osteoporosis.
Supporting References: (838,839,848)
See Online Data Supplements 25 and 26 for more infor-
mation on pregnancy.
CLASS III: Harm
1. LMWH should not be administered to pregnant patients with
mechanical prostheses unless anti-Xa levels are monitored 4 to
6 hours after administration (841,842,847,855,856). (Level of
Evidence: B)
Initial studies using subcutaneous LMWH at a ﬁxed
dose without monitoring of anti-Xa levels in pregnant
patients with a mechanical prosthesis were associated
with a high risk of valve thrombosis, leading to maternal
deaths. Since the requirements of LMWH increase
throughout pregnancy, there should be meticulous mon-
itoring of anti-Xa levels 4 to 6 hours after administration
if dose-adjusted administration of LMWH is to be used.
Supporting References: (841,842,847,855,856)
14. Surgical Considerations
14.1. Evaluation of Coronary Anatomy:
Recommendations
See Figure 11 for evaluation and management of CAD in
patients undergoing valve surgery.
Screening coronary angiography to assess associated
CAD should be considered in selected patients beforecardiac surgery or transcatheter intervention for VHD.
Invasive selective coronary angiography remains the gold
standard. Fractional ﬂow reserve may better delineate
the physiological signiﬁcance of a coronary lesion, but
there are no outcome data for its utility in patients
undergoing valve surgery. Due to its high negative
predictive value, coronary CT angiography to exclude
CAD may be an option in patients with low or inter-
mediate pretest probability of CAD. If signiﬁcant
epicardial CAD is present, concomitant CABG should
be considered at the time of valve surgery. The presence
of severe CAD may also be helpful in determining
whether a surgical or transcatheter approach is optimal
in patients with AS.
CLASS I
1. Coronary angiography is indicated before valve intervention in
patients with symptoms of angina, objective evidence of
ischemia, decreased LV systolic function, history of CAD, or
coronary risk factors (including men age >40 years and post-
menopausal women). (Level of Evidence: C)
Knowledge of the coronary anatomy contributes to risk
stratiﬁcation and determines if concomitant coronary
revascularization is indicated. Coronary angiography can
be avoided in young patients (men <40 years of age and
premenopausal women) with no atherosclerotic risk fac-
tors and in patients in whom the risks outweigh the
beneﬁts, such as in patients with acute aortic dissection,
large aortic valve vegetation, or occlusive prosthetic
thrombosis.
Supporting References: (858–871)
CLASS I
2. Coronary angiography should be performed as part of the eval-
uation of patients with chronic severe secondary MR. (Level of
Evidence: C)
In patients with chronic secondary MR, the valve leaﬂets
and chordae are structurally normal and theMR results from
the geometrical distortion of the mitral apparatus. This is
due to multiple factors that can cause displacement of the
papillary muscles, tethering of the leaﬂets, annular dilation,
and decreased closing forces from reduced contractility.
Because CAD and accompanying myocardial ischemia may
contribute to chronic secondary MR, the assessment of
coronary anatomy status is necessary to complete the diag-
nosis and allow evaluation of revascularization options.
Supporting References: (309,872–875)
CLASS IIa
1. Surgery without coronary angiography is reasonable for patients
having emergency valve surgery for acute valve regurgitation,
disease of the aortic sinuses or ascending aorta, or IE. (Level of
Evidence: C)
Assessment of coronary artery anatomy is rarely required
in patients undergoing emergency valve surgery for acute
AR, aortic dissection, or IE with hemodynamic instability.
Supporting References: (188,876–879)
Figure 11. Evaluation and Management of CAD in Patients Undergoing Valve Surgery
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; CT, computed tomography; IE, infective endocarditis; LV, left ventricular; and PCI, percutaneous
coronary intervention.
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2. CT coronary angiography is reasonable to exclude the presence
of signiﬁcant obstructive CAD in selected patients with a low/
intermediate pretest probability of CAD. A positive coronary CT
angiogram (the presence of any epicardial CAD) is conﬁrmed
with invasive coronary angiography (880–886). (Level of
Evidence: B)
In select patients who are at low-to-intermediate pretest
probability of CAD and who are being considered for
angiography before valve surgery, coronary CT angiog-
raphy is a reasonable alternative. This does not include
patients who have active symptoms of angina, those with
documented ischemia, or those with a prior history of
CAD, all of whom should have selective coronary angi-
ography. Several small studies have reported high diag-
nostic accuracy of coronary CT angiography in select
patients with VHD. One study of 98 consecutive patients
with signiﬁcant VHD and guideline-based indications for
coronary angiography underwent CT coronary angiog-
raphy if their coronary calcium score was <1,000. Invasive
coronary angiography was performed in patients with at
least 1 of the following: >50% stenosis, calcium artifacts,or motion artifacts. CT coronary angiography excluded the
presence of signiﬁcant CAD in 80.6% of patients without
the need for invasive angiography. Conventional coronary
angiography was required in 19.4% of patients because of
>50% stenosis in 13.3%, calcium artifact in 2%, and mo-
tion artifact in 1%. In another study of 70 patients, 31 had
AS (44%), 24 had MR (34%), 9 had AR (13%), and the
remainder had other valvular or congenital lesions. On a
per-patient basis, sensitivity was 100% (18 of 18 patients
with signiﬁcant CAD) and speciﬁcity was 92% (48 of 52
patients without signiﬁcant CAD). The corresponding
negative likelihood ratio is 0.01, which means a negative
test would be associated with a very low posttest probability
of disease for patients with low and intermediate pretest
probabilities. Assuming that all patients would have pre-
viously been referred for invasive angiography, coronary
CT angiography allowed the 48 patients (69%) in the study
cohort with negative CT ﬁndings to avoid this procedure.
However, a positive coronary CT angiogram, deﬁned as
the presence of epicardial CAD, requires conﬁrmation
with invasive coronary angiography to establish the need
for and extent of CABG. The risk of radiation exposure
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taken into consideration.
Supporting References: (880–887)
14.2. Concomitant Procedures
14.2.1. Intervention for CAD: Recommendation
In patients undergoing AVR who also have signiﬁcant
CAD, the combination of CABG and AVR reduces the
rates of perioperative MI, perioperative mortality, late
mortality, and morbidity when compared with patients not
undergoing simultaneous CABG, even though the com-
bined operation carries a small but real increased risk of
mortality. The alternative in some patients of a hybrid
approach of surgical valve replacement and PCI is attractive,
but there are no data at this time to support this approach.
Supporting References: (859,888)
CLASS IIa
1. CABG or PCI is reasonable in patients undergoing valve repair or
replacement with signiﬁcant CAD (‡70% reduction in luminal
diameter in major coronary arteries or ‡50% reduction in luminal
diameter in the left main coronary artery). (Level of Evidence: C)
Several studies have reported the outcomes of patients
undergoing combined CABG and valve operation. Al-
though combined myocardial revascularization and valve
operation increases cross-clamp time and has the potential
to increase perioperative MI and early postoperative mor-
tality compared with patients without CAD undergoing
isolated valve surgery, in several series, combined CABG
had little or no adverse effect on operative mortality.
Moreover, combined CABG and valve operation reduces
the rates of perioperative MI, operative mortality and late
mortality, and morbidity compared with patients with
signiﬁcant CAD who do not undergo revascularization at
the time of valve operation. Incomplete revascularization
is associated with greater postoperative LV systolic dys-
function and reduced survival rates after surgery compared
with patients who receive complete revascularization. For
more than a decade, improved myocardial preservation
techniques have been associated with reduced overall
operative mortality, and it has become standard practice
to bypass all signiﬁcant coronary artery stenoses when
possible in patients undergoing valve surgery. In patients
with a signiﬁcant stenosis of the left anterior descending
artery, a left internal thoracic artery graft should be
used if possible. No RCTs fully support the use of con-
comitant coronary revascularization in all patients with
asymptomatic CAD undergoing valve operation.
Supporting References: (889–895)
14.2.2. Intervention for AF: Recommendations
CLASS IIa
1. A concomitant maze procedure is reasonable at the time of
mitral valve repair or replacement for treatment of chronic,
persistent AF. (Level of Evidence: C)The addition of arrhythmia surgery to valve procedures
has been advocated on the basis of evidence that persistent
AF is an independent risk factor for cerebrovascular acci-
dent and mortality following surgery for VHD. When AF
has been present for >1 year, stable sinus rhythm is un-
likely with mitral repair alone. Arrhythmia procedures
span a spectrum from pulmonary vein isolation to the full
maze and a variety of intermediate procedures. The term
“maze procedure” properly refers to a speciﬁc biatrial pro-
cedure creating a deﬁned set of conduction block lesions
performed “cut and sew” (“maze III”) or with tissue abla-
tion technologies including cryoablative or radio-
frequency (“maze IV”). The requisite lesions or incisions
include complete encirclement of the pulmonary veins en
bloc, an incision or lesion to the mitral annulus from this
encircling lesion, and a lesion to the stump of the ligated or
amputated left atrial appendage on the LA. On the right
atrium, an ablation line or incision extends in the tubular
portion from superior vena cava to inferior vena cava and
along the right atrial free wall from this lateral incision
across the body of the right atrium to the tricuspid annulus.
A separate incision or lesion extends across the right atrial
appendage down to the tricuspid annulus. As originally
described, the septum is opened into the fossa ovalis,
although this lesion or incision is increasingly omitted in
current practice. When performed in this manner, com-
bined with mitral valve repair or replacement, RCTs have
shown that the surgical maze procedure affords superior
freedom from AF at discharge and at 1 year (with success
rates ranging from 75% to 95% with ablation versus 10%
to 40% without ablation). Combining the maze proce-
dure with a mitral valve procedure adds little complexity
because the LA is already open. As such, the procedure
does not appear to signiﬁcantly increase operative risk of
mortality in properly selected patients. In RCTs, long-
term survival and stroke risk have not been improved by
addition of the maze procedure.
Ligation or amputation of the left atrial appendage is
commonly performed in patients with AF with or without
such arrhythmia procedures with the aim of reducing the
risk of thromboembolic events, although no RCTs have
demonstrated a beneﬁcial impact.
Supporting References: (420,896–912)
CLASS IIa
2. A full biatrial maze procedure, when technically feasible, is
reasonable at the time of mitral valve surgery, compared with a
lesser ablation procedure, in patients with chronic, persistent
AF (907,908). (Level of Evidence: B)
A large variety of less extensive procedures, commonly
referred to as “mini-maze” procedures, have been devel-
oped and promulgated, ranging from pulmonary vein
isolation alone to single atrial procedures. The clinical
efﬁcacy of these procedures falls below that of the full
maze procedure, although the full maze procedure may be
associated with more bradycardia requiring pacemaker
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procedure may be preferable in speciﬁc circumstances in
which one is willing to trade efﬁcacy for invasiveness, when
feasible, the full maze is preferable. These less extensive
procedures are more often advocated when the AF is
paroxysmal, rather than persistent, and when combined
with procedures other than those on the mitral valve.
Supporting References: (907,908)
CLASS IIb
1. A concomitant maze procedure or pulmonary vein isolation may
be considered at the time of mitral valve repair or replacement
in patients with paroxysmal AF that is symptomatic or associ-
ated with a history of embolism on anticoagulation. (Level of
Evidence: C)
RCTs have shown that the surgical maze procedure
affords superior freedom from AF at discharge and at
1 year, deﬁned as sinus rhythm at last follow-up (75% to
95% with ablation versus 10% to 40% without ablation).
When the maze procedure is added to mitral valve
procedures, it adds little complexity because the LA is
already open. As such, this procedure does not appear to
increase operative risk of mortality in properly selected
patients. In RCTs, neither long-term survival nor stroke
risk appears to be improved by addition of the procedure.
Several nonrandomized studies, however, have suggested a
reduction in stroke risk with the addition of the maze
procedure to mitral valve repair or MVR even when a
mechanical prosthesis is used.
Other surgical approaches to prevention of recurrent
AF, including less extensive procedures such as pulmo-
nary vein isolation or a left-sided-only maze, have been
less successful than the full maze procedure in conver-
ting the patient to sinus rhythm. Although less effective,
these less extensive procedures are also less invasive
and, accordingly, are more often advocated when the
AF is paroxysmal rather than persistent and when com-
bined with procedures other than those on the mitral
valve.
Supporting References: (898,900–902,904–906,913,914)
CLASS IIb
2. Concomitant maze procedure or pulmonary vein isolation may
be considered at the time of cardiac surgical procedures other
than mitral valve surgery in patients with paroxysmal or
persistent AF that is symptomatic or associated with a history
of emboli on anticoagulation. (Level of Evidence: C)
The addition of arrhythmia surgery to valve proce-
dures other than mitral valve disease has been advocated
on the basis of evidence that persistent AF is an inde-
pendent risk factor for cerebrovascular accident and
mortality following surgery for mitral VHD. Limited data
suggest an increased risk of HF and stroke after AVR
as well. When combined with aortic valve surgery, the
addition of the maze procedure has been shown in
observational studies to improve conversion to sinus
rhythm over aortic valve surgery alone. This occurs in thesetting of chronic AF without a statistically signiﬁcant
increase in operative risk of mortality, although the po-
tential impact of selection bias cannot be ignored. Limited
evidence suggests pulmonary vein isolation is equivalent to
maze in the presence of paroxysmal AF.
Supporting References: (420,896,897,915)
CLASS III: No Beneﬁt
1. Catheter ablation for AF should not be performed in patients
with severe MR when mitral repair or replacement is antici-
pated, with preference for the combined maze procedure plus
mitral valve repair (916). (Level of Evidence: B)
A single randomized study of patients with rheumatic
mitral valve disease compared catheter ablation with sur-
gical maze and demonstrated superior conversion to sinus
rhythm (82% versus 55%) in the surgical group. Accord-
ingly, if surgical repair or replacement of the mitral valve
is anticipated, catheter ablation should be deferred in favor
of surgical maze.
Supporting References: (916)
See Online Data Supplement 27 for more information on
the maze procedure.15. Noncardiac Surgery in Patients With VHD
15.1. Diagnosis and Follow-Up
The risk of noncardiac surgery is increased in patients
with signiﬁcant VHD. AS is present in 1% to 2% of all
patients >65 years of age and 3% to 8% of all patients
>75 years of age. Severe AS is associated with an in-
creased risk for noncardiac surgery, depending on the
speciﬁc degree of valve narrowing, LV systolic function,
concurrent CAD, and other risk factors for surgery. The
estimated rate of cardiac complications in patients with
undiagnosed severe AS undergoing noncardiac surgery
is 10% to 30%. Thus, TTE is appropriate in patients being
evaluated for noncardiac surgery when a systolic murmur
suggestive of AS is present for evaluation of stenosis
severity and LV systolic function to allow optimization
of perioperative management. Evaluation for concurrent
CAD in patients with AS is problematic, and standard
ECG exercise testing is not adequate. A stress echocar-
diographic or nuclear imaging study may be helpful if
resting LV systolic function is normal and AS is only mild
to moderate in severity. With severe AS, coronary angi-
ography may be necessary if risk factors or symptoms
that might be due to coronary disease are present.
MS may also be poorly tolerated with the altered he-
modynamics of anesthesia and noncardiac surgery. Left-
sided regurgitant lesions are better tolerated but still
convey increased risk, particularly if the anesthesiologist
and surgeon are unaware of the diagnosis or severity
of valve disease. Thus, whenever the clinical history or
physical examination suggests valve disease might be pre-
sent, TTE is helpful to detect valve dysfunction and
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echocardiographic data useful in operative planning in-
clude LV systolic function and an estimate of pulmonary
artery systolic pressure.
Supporting References: (917–923)15.2. Medical Therapy
Anesthetic management of patients with VHD undergo-
ing noncardiac surgery should take into account the un-
derlying valvular abnormality, its effect on the systolic and
diastolic function of the heart, and any comorbidities, such
as CAD or pulmonary hypertension. In noncardiac surgical
patients with AS, the reduced LV compliance that results
from the chronic pressure overload makes ventricular ﬁlling
dependent on preload and atrial contraction. In the patient
with AS, arrhythmias are poorly tolerated. Speciﬁcally,
tachycardia should be particularly avoided, because the
combination of a shortened diastolic ﬁlling period and a
stiff left ventricle results in inadequate LV ﬁlling and a fall
in cardiac output. If possible, sinus rhythm should be
maintained and the ventricular rate controlled. A typical
example is the patient with AS with acute onset supra-
ventricular tachycardia or AF, in whom synchronized
cardioversion should be applied immediately if the patient
becomes hypotensive. The atrial contribution to LV ﬁlling
is often signiﬁcant, particularly with AS and diastolic
dysfunction. Intravascular volume should be titrated at a
level that ensures an adequate forward cardiac output
without an excessive rise in left atrial pressure. This can be
achieved by ensuring adequate volume replacement with
guidance from central venous or pulmonary pressures or
dynamic pulsatility indices, and monitoring LV chamber
size with intraoperative TEE may be particularly useful. A
drop in systemic vascular resistance may reduce diastolic
BP and coronary blood ﬂow, leading to myocardial
ischemia, and this may be particularly detrimental in the
patient with coexisting CAD or peripheral artery disease.
The anesthetic approach and anesthetic agents should be
chosen to avoid systemic hypotension. Potential detri-
mental effects of the anesthetic approach should be
considered, such as acute increases in afterload-induced
laryngoscopy, tracheal intubation, or surgical stimulation.
Either phenylephrine or norepinephrine can be used to
raise the BP; both were found to not adversely affect LV
systolic and diastolic function. Instances of systemic hy-
pertension should be treated preferentially with arterial
dilators, such as short-acting calcium channel blockers
instead of preload-reducing agents such as nitroglycerin.
General anesthetics are well tolerated, and the choice of
anesthetic agents should be carefully titrated to maintain
normotension and sinus rhythm. It is equally important to
modify epidural or spinal anesthetic interventions so that
systemic pressure changes do not occur or occur gradually.
For example, only high-dilution neuraxial local anesthetic
agents in combination with opioids should be used.The patient with MS undergoing noncardiac surgery
should be treated in a manner similar to the patient
with AS, because the pathophysiology of the disease and
its implications are similar. Maintenance of normal
LV preload and sinus rhythm, and avoidance of tachy-
cardia and systemic hypotension should be the targets in
the perioperative period. Of particular concern is judicious
intravenous ﬂuid administration so as to avoid increases in
the left atrial pressure and pulmonary capillary pressure
that may precipitate acute pulmonary edema.
Patients with AR or MR present with chronic LV
volume overload. In either disease, a decrease in systemic
afterload will augment the systemic LV output and reduce
the regurgitant volume. Patients with regurgitant valve
lesions are better suited to receive a regional anesthetic,
because the combination of neuraxial local anesthetics and
opioids produces a favorable systemic vasodilation. How-
ever, preload should be maintained, particularly in the
chronic regurgitation lesions, because there is a larger LV
volume and increase in diastolic compliance. Monitoring
of central venous or pulmonary pressures and size and
function of the left ventricle should be done with invasive
catheters or echocardiography.
Changes in ﬂuid balance continue to occur postop-
eratively, so these intraoperative considerations are appli-
cable in the 48– to 72–hour postoperative period as well
as during the procedure.
Supporting References: (924–929)15.3. Intervention: Recommendations
When VHD is diagnosed in patients being considered
for elective noncardiac surgery, the ﬁrst step is to review
the standard criteria for intervention of the speciﬁc valve
lesion. If the patient meets standard criteria for interven-
tion, it is usually prudent to defer the elective noncardiac
procedure and proceed to valve intervention instead.
In patients with signiﬁcant asymptomatic valve disease
who do not meet standard criteria for intervention, the risk
of the noncardiac procedure can be minimized by 1) having
an accurate diagnosis of the type and severity of valve
dysfunction, 2) choosing an anesthetic approach appro-
priate to the valve lesion, and 3) ensuring a higher level of
intraoperative monitoring.
In emergency situations, noncardiac surgery may be
necessary in the presence of uncorrected severe valve dis-
ease. In patients with severe AS or MS, volume shifts and
rhythm disturbances associated with the surgical stress and
cardiovascular side effects of the anesthetic medications
may lead to hypovolemia and tachycardia and further
hemodynamic compromise. Thus, patients with severe
left-sided valve stenosis requiring emergency noncardiac
surgery should be managed by a cardiovascular anesthesi-
ologist with invasive hemodynamic or TEE imaging
monitoring intraoperatively and remain in an intensive
monitoring setting for 48 to 72 hours postoperatively.
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1. Moderate-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring is
reasonable to perform in patients with asymptomatic severe AS
(917,920–922). (Level of Evidence: B)
The hemodynamic effects of anesthesia and surgery are
poorly tolerated in patients with severe AS. AVR is rec-
ommended in all patients with symptomatic severe AS and
should be performed before other surgical interventions to
avoid hemodynamic instability during, as well as after,
noncardiac surgery.
In patients with moderate-to-severe AS, 30–day mor-
tality is higher for patients with AS (2.1%) compared
with propensity scorematched controls (1.0%) with a
higher risk of postoperative MI in patients with AS.
Predictors of adverse outcomes include severity of AS,
high-risk surgery, cardiac symptoms, coexisting MR, and
CAD. However, these comorbidities also increase the
risk of AVR. The risk–beneﬁt ratio continues to favor
managing patients with severe AS undergoing moderate-
risk noncardiac surgery with hemodynamic monitoring
and optimization of loading conditions rather than con-
sidering prophylactic AVR.
Adverse outcomes in the setting of aortic valve
obstruction are due to the combination of the anesthetic
procedure (general, regional, or monitored anesthesia care)
and surgical stress. Systemic hypotension and tachycardia
may result in decreased coronary perfusion pressure, de-
velopment of arrhythmias or ischemia, myocardial injury,
cardiac failure, and death. These complications can be
avoided by periprocedural hemodynamic monitoring with
a right-heart catheter or intraoperative TEE to allow
continuous optimization of loading conditions. Intra- and
postoperative monitoring of BP and intracardiac volume
are implemented starting in the preoperative period and
continuing until hemodynamics are stable, which may be
as long as 24 to 48 hours after the procedure. Mainte-
nance of normal coronary perfusion pressure with the
administration of alpha-adrenergic agents, such as
phenylephrine, may be helpful early in the procedure
to avoid the detrimental consequences of myocardial
hypoperfusion.
Supporting References: (917,920–922)
CLASS IIa
2. Moderate-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring is
reasonable to perform in patients with asymptomatic severe
MR. (Level of Evidence: C)
In patients with severe MR undergoing noncardiac
surgery, the overall hemodynamic goals are avoidance of
both increased afterload and bradycardia by choosing the
appropriate anesthetic scheme. Invasive hemodynamic
and/or TEE monitoring allows for continuous optimiza-
tion of loading conditions during and after the operative
procedure, with these patients admitted to an intensivemonitoring setting for up to 24 to 48 hours after the
procedure.
Supporting Reference: (930)
CLASS IIa
3. Moderate-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring is
reasonable to perform in patients with asymptomatic severe AR
and a normal LVEF. (Level of Evidence: C)
Patients with severe AR are prone to hemodynamic
instability because of the detrimental effects of increased
volume on myocardial wall stress. The perioperative stress
associated with noncardiac surgery may lead to hypoten-
sion, arrhythmias, HF, or even death. It is especially
important to avoid bradycardia when AR is present due to
the increase in total diastolic time. These patients should
be monitored with invasive systemic arterial and venous
catheters and/or TEE and admitted postoperatively to an
intensive monitoring setting. Patients with severe AR and
a decreased LVEF, elevated serum creatinine >2 mg/dL,
or who are undergoing intermediate- to high-risk
noncardiac surgery have the highest risk of cardiopulmo-
nary complications and death.
Supporting Reference: (931)
CLASS IIb
1. Moderate-risk elective noncardiac surgery in patients with appro-
priate intraoperative and postoperative hemodynamic monitoring
may be reasonable to perform in asymptomatic patients with se-
vere MS if valve morphology is not favorable for percutaneous
balloon mitral commissurotomy. (Level of Evidence: C)
Patients with asymptomatic severe MS and valve anat-
omy favorable for percutaneous balloon mitral commis-
surotomy who are undergoing elective noncardiac surgery
should be evaluated and treated pursuant to the recom-
mendations for MS (Section 6.2.3). If valve anatomy is not
favorable or if there are other contraindications to percu-
taneous balloon mitral commissurotomy, elective noncar-
diac surgery may be considered with invasive hemodynamic
monitoring to optimize loading conditions. Preload should
be maintained high enough to allow an adequate forward
cardiac output across the stenotic mitral valve but low
enough to avoid pulmonary edema. Maintaining preload in
this narrow range can be challenging and requires mea-
surement of cardiac output and pulmonary wedge pressure.
Tachycardia should be avoided due to the shortened dia-
stolic LV ﬁlling time across the stenotic mitral valve,
resulting in an increase in left atrial pressure.
Supporting References: (924,932)
See Online Data Supplement 28 for more information on
noncardiac surgery.
16. Evidence Gaps and Future Directions
Current recommendations for evaluation and manage-
ment of VHD are largely based on clinical experience
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We recommend that research on valve disease span the
spectrum from basic science to prospective randomized
trials and that studies focus on each stage of the disease
process from the patient at risk to the patient with end-
stage disease.
16.1. Prevention of Valve DiseasedStage A
On a worldwide basis, rheumatic fever remains the primary
cause of VHD; global health systems outcomes studies
are needed to identify impediments to successful primary
and secondary prevention of rheumatic heart disease.
Other approaches to prevention (such as vaccine develop-
ment) and delaying disease progression once valve damage
is present should also be explored. Disease prevention
in patients at risk of other types of valve disease is needed.
Some subgroups at risk of calciﬁc AS can be identiﬁed,
such as those with a congenital bicuspid aortic valve or
elevated lipoprotein(a) levels. However, there are no known
therapies to prevent valve dysfunction in these patients.
Basic science studies on the genetic and pathobiological
causes of valve dysfunction will provide insight into
mechanisms of disease initiation and progression that
might be amenable to medical therapy.
Supporting References: (933–938)
16.2. Medical Therapy to Treat or Prevent
Disease ProgressiondStage B
In patients with early VHD, including those with calciﬁc
or myxomatous disease, there are currently no therapies to
prevent disease progression in the valve leaﬂets. Instead,
our recommendations are all directed toward patient mon-
itoring with the intent to intervene once severe disease is
present that results in symptoms or abnormal cardiovas-
cular function. Again, basic science studies are needed to
identify potential targets for prevention of progressive
VHD that then can be translated into prospective clinical
trials. Additional studies are needed for therapies that
might prevent the adverse consequences of VHD, such as
LV dysfunction and pulmonary hypertension.
Supporting Reference: (939)
16.3. Optimal Timing of InterventiondStage C
Current approaches to identifying the optimal timing of
intervention in patients with progressive valve disease are
suboptimal. Symptom onset is a subjective measure and
may occur too late in the disease course for optimal long-
term outcomes. Despite the availability of sophisticated
approaches for measurement of LV volumes, systolic
function, diastolic function, and other measures of myo-
cardial performance, recommendations rely only on simple
linear dimensions used in published series with data that
may not reﬂect contemporary clinical outcomes. We ur-
gently need studies evaluating the value of newer measures
of LV size, function, and myocardial structure in predict-
ing outcomes after valve intervention. However, LVenlargement and dysfunction are late consequences of valve
dysfunction; as more durable approaches to restoring
normal valve function are developed, the balance of ben-
eﬁtrisk for intervention will shift to earlier in the disease.
Studies examining the role of earlier markers of myocar-
dial dysfunction such as strain and strain-rate imaging,
diastolic dysfunction, serum markers, and other novel ap-
proaches to deﬁning the optimal timing of intervention
also are needed.
Few studies have included adequate numbers of older
adults to make speciﬁc recommendations for this group of
patients in whom particular concerns, such as cognitive
function, frailty, and mobility challenges, may change the
decision algorithms.
Given the relatively low risk of intervention in other-
wise healthy patients and the improved options for valve
repair or replacement, RCTs of intervention for severe
asymptomatic VHD are needed. Examples of speciﬁc
conditions where clinical equipoise exists are asymptom-
atic severe AS in otherwise healthy patients, asymptom-
atic severe AR with normal LV systolic function, and
severe primary MR with normal LV function and a high
likelihood of valve repair. Data from large, carefully
designed registries are also needed for deﬁning and
improving quality of care.
16.4. Better Options for InterventiondStage D
We need better options for valve repair and replacement.
The timing of intervention is based on the balance between
outcomes with native valve disease and the risk and long-
term durability of the valve after intervention. As valve
repair and replacement options improve, the balance will
shift toward earlier intervention. We need a valve substi-
tute that can be safely and reliably implanted, is non-
thrombogenic, has hemodynamics similar to a normal
native valve, and is durable. Transcatheter valve procedures
offer the promise of safe implantation and excellent he-
modynamics, but long-term durability is not yet known. In
patients who require mechanical valve replacement, we
need oral therapy that provides effective anticoagulation
with a low risk of complications and no negative impact on
quality of life.
Moderate-to-severe VHD is present in 2.5% of the U.S.
population and increases in prevalence with age. The dis-
ease affects between 4% and 9% of those 65 to 75 years of
age and 12% to 13% of those >75 years of age. Many of
these patients require surgical or interventional procedures.
However, even with intervention, overall survival is lower
than expected, and the risk of adverse outcomes due to
VHD is high, both because of limited options for restoring
normal valve function and failure to intervene at the
optimal time point in the disease course. We urgently need
research on almost every aspect of VHD to ensure that
patients who already have VHD receive optimal therapy
and to prevent VHD in those at risk. Approaches to
improving outcomes in patients with VHD include
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continuous evaluation of outcomes data at each Heart
Valve Center of Excellence, and 3) a focus on patient-
centric care with involvement of the patient in the
decision-making process.
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e185Appendix 3. Abbreviations2D ¼ 2-dimensional
3D ¼ 3-dimensional
ACE ¼ angiotensin-converting enzyme
AF ¼ atrial ﬁbrillation
ARB ¼ angiotensin-receptor blocker
aPTT ¼ activated partial thromboplastin time
AR ¼ aortic regurgitation
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
BP ¼ blood pressure
CABG ¼ coronary artery bypass graft
CAD ¼ coronary artery disease
CMR ¼ cardiac magnetic resonance
COR ¼ Class of Recommendation
CT ¼ computed tomography
ECG ¼ electrocardiogram
HF ¼ heart failure
HIV ¼ human immunodeﬁciency virus
IE ¼ infective endocarditis
INR ¼ international normalized ratio
LA ¼ left atrium
LMWH ¼ low-molecular-weight heparin
LOE ¼ Level of EvidenceLV ¼ left ventricular
LVEF ¼ left ventricular ejection fraction
LVESD ¼ left ventricular end-systolic dimension
MI ¼ myocardial infarction
MR ¼ mitral regurgitation
MS ¼ mitral stenosis
MVR ¼ mitral valve replacement
NYHA ¼ New York Heart Association
NVE ¼ native valve endocarditis
PR ¼ pulmonic regurgitation
PROM ¼ predicted risk of mortality
PVE ¼ prosthetic valve endocarditis
RCT ¼ randomized controlled trial
RV ¼ right ventricular
TAVR ¼ transcatheter aortic valve replacement
TR ¼ tricuspid regurgitation
TS ¼ tricuspid stenosis
TEE ¼ transesophageal echocardiography
TTE ¼ transthoracic echocardiography/echocardiogram
UFH ¼ unfractionated heparin
VHD ¼ valvular heart disease
VKA ¼ vitamin K antagonist
